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ABSTRACT    
Induced pluripotent stem cells (iPSCs) are an intriguing approach for neurological 
disease modeling, because neural lineage-specific cell types that retain the donors’ complex 
genetics can be established in vitro. The statistical power of these iPSC-based models, however, 
is dependent on accurate diagnoses of the somatic cell donors; unfortunately, many 
neurodegenerative diseases are commonly misdiagnosed in live human subjects. Postmortem 
histopathological examination of a donor’s brain, combined with premortem clinical criteria, is 
often the most robust approach to correctly classify an individual as a disease-specific case or 
unaffected control. We describe the establishment of primary dermal fibroblasts cells lines from 
28 autopsy donors. These fibroblasts were used to examine the proliferative effects of 
establishment protocol, tissue amount, biopsy site, and donor age.  As proof-of-principle, iPSCs 
were generated from fibroblasts from a 75-year-old male, whole body donor, defined as an 
unaffected neurological control by both clinical and histopathological criteria. To our knowledge, 
this is the first study describing autopsy donor-derived somatic cells being used for iPSC 
generation and subsequent neural differentiation.  This unique approach also enables us to 
compare iPSC-derived cell cultures to endogenous tissues from the same donor. We utilized 
RNA sequencing (RNA-Seq) to evaluate the transcriptional progression of in vitro-differentiated 
neural cells (over a timecourse of 0, 35, 70, 105 and 140 days), and compared this with donor-
identical temporal lobe tissue. We observed in vitro progression towards the reference brain 
tissue, supported by (i) a significant increasing monotonic correlation between the days of our 
timecourse and the number of actively transcribed protein-coding genes and long intergenic non-
coding RNAs (lincRNAs) (P < 0.05), consistent with the transcriptional complexity of the brain,   
(ii) an increase in CpG methylation after neural differentiation that resembled the epigenomic 
signature of the endogenous tissue, and (iii) a significant decreasing monotonic correlation 
between the days of our timecourse and the percent of in vitro to brain-tissue differences (P < 
0.05) for tissue-specific protein-coding genes and all putative lincRNAs. These studies support 
the utility of autopsy donors’ somatic cells for iPSC-based neurological disease models, and 
provide evidence that in vitro neural differentiation can result in physiologically progression.   
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CHAPTER 1 
ESTABLISHMENT AND BANKING OF PRIMARY DERMAL FIBROBLAST CELL LINES FROM 
NEUROPATHOLOGICALLY-EXAMINED AUTOPSY DONORS 
Introduction 
Human dermal fibroblasts (HDFs) are a valuable resource for both primary cell research 
and stem cell-based, in vitro disease modeling because fibroblasts are typically easy to establish 
in cell culture and exhibit robust in vitro proliferation (Mansbridge).  Moreover, these primary cells 
are permissive to a variety of reprogramming techniques, including nuclear transfer, cell fusion 
and transcription factor transduction (i.e., induced pluripotent stem cells) (Yamanaka and Blau).  
Because of these advantages, HDFs have become the most widely used somatic cell type for the 
generation of human induced pluripotent stem cells (iPSCs) (Lowry and Quan).  In fact, the first 
human iPSCs described in the scientific literature were generated by lentiviral integration of the 
Yamanaka (POU5F1, SOX2, KLF4, MYC) or Thomson (POU5F1, SOX2, NANOG, LIN28) factors 
using HDFs as the somatic (or genetic) donor (Takahashi et al.; Yu et al.).   
It has been hypothesized, however, that fibroblasts may not be the optimal somatic cell 
type for the generation of clinical-grade pluripotent stem cells and their derivatives (Lowry and 
Quan).  Fibroblast-derived iPSCs exhibit epigenetic modifications slightly dissimilar to human 
embryonic stem cells (hESCs) and elegant studies with murine iPSCs suggest those derived from 
tail-tip fibroblasts are significantly more likely to produce tumors following neurosphere 
engraftment (Miura et al.; Kim et al.).  For these reasons, much of the reprogramming field is 
shifting towards using primary cells derived from whole blood for generating iPSCs from living 
donors (Mack et al.; Rajesh et al.; Brown et al.). Despite the disadvantages fibroblast-derived 
iPSCs may have for use in regenerative medicine, these cells still retain immense value for 
creating donor-specific, in vitro disease/toxicity/genetic models, many examples having already 
been published (Dimos et al.; Park et al.; Ebert et al.; Ghodsizadeh et al.; Somers et al.; Raya et 
al.; Lee et al.).  
Studies that aim to use primary human cells lines for genetic disease models of both rare 
diseases, and diseases that have either late-onset or complex genetic etiology, will likely continue 
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to use HDFs as the somatic cell source; living donors may either be difficult to obtain, or it may be 
beneficial to obtain cell lines from a biobank that has additional genetic information about the 
donors’ disease, respectively.  One primary example of a biobank that stores primary HDFs from 
individuals with a variety of genetic disorders is the Coriell Cell Repository, a part of the Coriell 
Institute for Medical Research.  This biobank includes HDFs from diseases such as amyotrophic 
lateral sclerosis (ALS; mutations or repeats: SOD1, FUS, TARDBP (TDP-43), ANG, FIG4 and 
C9orf72), familial early-onset Alzheimer’s disease (AD; mutation PSEN1), frontotemporal 
dementia (FTD; mutations MAPT and PGRN), Huntington’s disease (HD; repeats HD (CAG)), 
Parkinson’s disease (PD; mutations or repeats LRRK2, PARK2, GBA, MAPT, CACNA1A, 
DCTN1, PINK1, PLA2G6, C9orf72, and SNCA), as well as countless rare disorders with and 
without clear Mendelian inheritance (http://ccr.coriell.org/).  However, many of the 
neurodegenerative diseases mentioned are dominated by sporadic cases where no known causal 
mutation or repeat has been identified, and many of these diseases are not mutually exclusive 
(i.e., an affected individual may actually have pathological features of multiple disorders).  Due to 
these complications in both sensitivity and specificity, robust classification of an individual as a 
specific disease case or unaffected neurological control is often strengthen by the additional 
information obtained from a postmortem neuropathological exam (Beach, Monsell, et al.; Beach, 
Sue, et al.; Corneveaux et al.; Hamilton; Joseph et al.; Nelson et al.; Piguet et al.; Tolosa, 
Wenning and Poewe). 
We aimed to establish a cell line cohort of primary dermal fibroblasts from autopsy 
donors that had been clinically diagnosed with a neurodegenerative disorder and were further 
evaluated by a postmortem neuropathological examination.  Likewise, we aimed to establish 
HDFs from autopsy donors with no known neurological impairments, but upon postmortem 
examination may or may not show neuropathological features of disease (e.g., beta amyloid 
plaques).   Meske et al. have demonstrated that HDFs can be established in cell culture from 
autopsy donors up to 48h postmortem and from individuals up to 99-years-old (Meske et al.).  
These studies additionally demonstrated that (in a rat model) fibroblast viability/proliferation was 
negatively affected by longer post mortem intervals (PMIs). 
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We collaborated with Dr. Thomas Beach and Lucia Sue of the Brain and Body Donation 
Program at Banner Sun Health Research Institute (BSHRI) to obtain skin biopsies for the 
purposes of fibroblast cell line establishment and protocol optimization.  
“The Brain and Body Donation Program (BBDP) is an autopsy-based, research-
devoted brain bank, biobank and biospecimen bank that derives its human 
donors from the Arizona Study of Aging and Neurodegenerative Disease 
(AZSAND), a longitudinal clinicopathological study of the health and diseases of 
elderly volunteers living in Maricopa county and metropolitan Phoenix, Arizona” 
(https://www.brainandbodydonationprogram.org/). 
 
Donors enrolled in this study are usually evaluated by autopsy and have their brain removed after 
a short postmortem interval (< 3h), thereby preserving sensitive molecules like RNA that are 
subject to rapid degradation following death (Beach, Sue, et al.; Birdsill et al.).  Here, we describe 
the establishment of over 200 low-passage, primary HDF cell lines from 28 autopsy donors 
enrolled in the Brain and Body Donation Program at BSHRI.  
Materials and Methods 
Whole Body Donation 
Tissue was collected after a postmortem interval (PMI) of approximately three to seven 
hours during the rapid autopsies of 33 whole-body donors (ages 44-97).  Although 33 autopsies 
were attended and biopsied, 5 donors had positive test results for Hepatitis B or C antibodies; 
these cell lines were not established due to safety concerns, resulting in successful cell line 
establishment for 28 autopsy donors. The subjects were enrolled as whole body donors in the 
Banner Sun Health Research Institute (BSHRI) Brain and Body Donation Program and had 
previously signed informed consent approved by the BSHRI Institutional Review Board (IRB) 
(Beach, Sue, et al.).  Most fibroblast cell lines were established as previously described by 
Villegas and McPhaul, with minor modifications (Villegas and McPhaul).   Fibroblast cell lines 
established by explant protocol were generated as previously described by Keira et al. (Keira). 
Skin Biopsies and Fibroblast Cell Line Establishment 
A small area (~ 20cm2) of the anterior side of the forearm, leg, and/or torso was sterilized 
with Betadine (Purdue Pharma L.P., Stamford, CT, USA) and rinsed with sterile Dulbecco’s 
Phosphate Buffered Saline (DPBS; Invitrogen, Carlsbad, CA, USA). 3mm and 5mm punch 
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biopsies (Acuderm, Ft. Lauderdale, FL, USA) were dissected from these areas and placed into 
50ml conical tubes containing 25ml ice-cold Primary Fibroblast Media (PFM; Minimal Essential 
Media (MEM; Invitrogen), 18% Fetal Bovine Serum (FBS; ATCC, Manassas, VA, USA), 
100units/ml penicillin, 100µg/ml streptomycin (Sigma Aldrich, St. Louis, MO, USA), 0.25ug/ml 
amphotericin (Sigma Aldrich), and 5µg/ml Plasmocin prophylactic (Invivogen, San Diego, CA, 
USA).  Skin biopsies were dissected into pieces, distributing approximately 0.7cm2 to 1.9cm2 
dermal tissue per 25cm2 flask (BD Biosciences, Bedford, MA, USA).  Any adipose tissue 
identified was removed with dissecting scissors prior to cell culture establishment. Dissociation 
Protocol: tissue pieces in 1ml cold PFM were dissociated into pinhead-sized pieces with a scalpel 
and were further frayed by pressure with the blunt-end of a 1ml tuberculin syringe (BD 
Biosciences, San Jose, CA, USA).  Mechanically dissociated tissue and media were introduced 
into a BD Primaria 25cm2 flask with a 1ml tuberculin syringe (BD Biosciences) and were then 
evenly distributed.  Explant Protocol: tissue pieces in 1ml cold PFM were placed into flask with 
non-dermal side of tissue pieces facing the flask’s adherent surface.  For both protocols, flasks 
were placed at room temperature in a vertical laminar flow hood for 2 hours to allow for tissue 
adherence, then 10ml warm PFM was introduced into the flask prior to its placement in a 37°C 
5% CO2 cell culture incubator.  Media was exchanged every five days until the first passage (Day 
18), at which time the cells were counted manually with a hemocytometer and these numbers 
were recorded. Autopsy donor-derived fibroblast cell lines were banked in freezing media (PFM 
with 10% dimethyl sulfoxide (DMSO; Sigma Aldrich) at passage 3 (P:3) and were stored in a -
130°C liquid nitrogen freezer.   
Statistical Analysis 
A One-way Analysis of Variance (ANOVA) and Tukey’s HSD Post-hoc test was 
performed on the cell counts at passage 1 (P:1) from 30 primary fibroblast cell lines established 
from 3 autopsy donors to determine the effect of biopsy site.  A One-way ANOVA was performed 
on the cell counts from 34 primary fibroblast cell lines (all obtained from the same biopsy site 
(arm)) established from 18 autopsy donors to determine the effect of age (binned into 4-year 
groups).  Data sets met the parametric assumptions of normality and homogeneity of variances.  
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All statistics were performed using IBM SPSS Statistics, Version 19 software.  Graphs were 
generated using Microsoft Excel 2008.  In addition, one donor was used to evaluate the efficacy 
of the two protocols (Dissociation vs. Explant) and the amount of tissue needed; however, 
conclusions from these tests were based on gross observations and not statistics because the 
individual groups were not repeated and several of the cell lines started by Explant Protocol did 
not result in positive establishment (i.e., no viable cells at first passage). 
Results 
Primary dermal fibroblasts cell lines were successfully established from all 28 donors.  An 
example of an autopsy donor-derived fibroblast cell line at the beginning of the establishment 
(i.e., 5 days after biopsy and cell seeding) and after two passages prior to cryopreservation are 
shown (Fig. 1).   
The cohort of 28 autopsy donors included several neurodegenerative disorders and 
unaffected neurological controls.  Details regarding the diseases and relevant, non-identifying 
information about the autopsy donors are listed (Table 1).  Also shown are the donor(s) used to 
test variables for protocol optimization (Table 1).  A summary of how many cell lines were 
established and cryopreserved for each donor is also shown (Table 2). 
Although it was not tested by statistical analysis, it was apparent by gross observations that 
fibroblast cell line establishment was more successful using the dissociation protocol than the 
explant protocol (Fig. 2).  Eight cell lines were started with each protocol, both using different 
biopsy sites and using different amounts of tissue.  All eight cell lines started with the dissociation 
protocol resulted in cell proliferation and viable cells by the first passage (Day 18).  In addition, 
75% of these cell lines (6/8) contained > 4x105 cells, suggesting the established lines had robust 
cell proliferation.  Conversely, only five cell lines started with the explant protocol resulted in 
viable cells at the first passage (Day 18). None of the cell lines established by explant protocol 
(0/8) had > 4x105 cells, suggesting their proliferative potential was poorer than cells established 
by dissociation (Fig. 2). 
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Table 1. 
Autopsy Donors and Variables Tested for Proliferation Effects. 
    Variables Tested for Proliferation Effects 
TGen Donor ID Age Sex Disease Protocol Biopsy Site Donor Age 
F01 ≥ 90* F Control Yes Yes Yes 
F02 75 M Control No Yes Yes 
F03 80 M Control No Yes Yes 
F04 ≤ 50* M ALS No No No 
F05 81 M PD / AD No No Yes 
F06 79 F AD + LB No No Yes 
F07 ≥ 90* F Control No No Yes 
F08 86 F Control / MCI No No Yes 
F09 80 M AD + LB No No Yes 
F10 67 M FTLD No No Yes 
F11 73 M PD / AD No No Yes 
F12 78 M PD + dem No No Yes 
F13 84 F Control / MCI No No Yes 
F14 ≤ 50* M Control No No No 
F15 ≥ 90* M Control No No Yes 
F16 89 M FTLD / AD No No Yes 
F18 ≥ 90* M Control / MCI No No Yes 
F19 89 M AD + VD No No Yes 
F20 78 M AD No No Yes 
F21 74 M Control No No Yes 
F22 88 F AD + LB No No Yes 
F23 79 M Control / MCI No No No 
F24 85 M PD No No No 
F25 79 F PD / AD No No No 
F26 ≥ 90* M Control / MCI No No No 
F30 88 F AD No No No 
F31 83 M AD + LB No No No 
F32 83 F PD / AD No No No 
ID: F = Fibroblast; Age: * = exact age not shown so donor cannot be identified; Sex: M = Male, F = Female;                          
Disease: AD = Alzheimer’s disease; PD = Parkinson’s disease; ALS = amyotrophic lateral sclerosis;                           
FTLD = frontotemporal lobar dementia; LB = Lewy bodies; dem = dementia; VD = vascular dementia;                             
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Table 2. 
Summary of Fibroblast Cell Lines Cryo-Banked from 28 Autopsy Donors. 
TGen Donor ID # Cell Lines Started # Cell Lines Established % Success 
F01 28 23 82.1% 
F02 16 14 87.5% 
F03 16 11 68.8% 
F04 8 8 100% 
F05 8 8 100% 
F06 8 8 100% 
F07 8 8 100% 
F08 8 5 62.5% 
F09 8 8 100% 
F10 8 5 62.5% 
F11 8 6 75.0% 
F12 8 7 87.5% 
F13 8 8 100% 
F14 8 8 100% 
F15 8 5 62.5% 
F16 8 8 100% 
F18 8 5 62.5% 
F19 8 8 100% 
F20 8 7 87.5% 
F21 8 7 87.5% 
F22 8 8 100% 
F23 8 6 75.0% 
F24 8 7 87.5% 
F25 8 8 100% 
F26 8 8 100% 
F30 8 5 62.5% 
F31 8 6 75.0% 
F32 8 8 100% 
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The primary dermal fibroblast cell counts were analyzed to determine if biopsy site or age 
affected proliferation.  Three biopsy sites (arm, leg, and torso) were evaluated, from which all cell 
lines were established using the same amount of tissue and procedures.  A One-Way ANOVA 
demonstrated a significant difference in fibroblast proliferation between biopsy sites (ANOVA: F= 
9.616, v1=2, v2=27, P=0.001).  A Tukey’s HSD Post-hoc test subsequently revealed the arm 
biopsy site had statistically greater fibroblast proliferation than either the leg (P=0.003) or torso 
(P=0.004) sites, while there was no significant difference between the leg and torso (P=0.998) 
(Fig. 3).  Donor age (age range 72-97) was also analyzed statistically and the One-Way ANOVA 
showed there was no significant difference in fibroblast proliferation based on donor age (within 
an elderly cohort) (ANOVA: F=1.756, v1=5, v2=28, P=0.155) (Fig. 4).   
Discussion 
 This study aimed to establish primary dermal fibroblast cell lines from autopsy donors 
diagnosed with and without neurodegenerative disorders.  In addition, we aimed to evaluate 
several variables involved in the cell line establishment process.  Many of these tests have likely 
not been performed as most fibroblast cell lines are generated from living donors, and protocol 
optimization is not a justifiable reason for the procurement of additional skin biopsies.  In addition, 
we wanted to create a cell line cohort for potential use in iPSC reprogramming, so it was 
important that these cell lines were established under optimal conditions, thereby increasing our 
chances of cryobanking a large number (~40 cryovials) of low-passage (P:3) fibroblasts.  We 
were able to successfully establish primary dermal fibroblast cell lines for all 28 autopsy donors. 
 We concluded that the Dissociation protocol was more successful than the Explant 
protocol.   We hypothesize that this may be due to an increase in tissue-to-flask surface contact 
created after the tissue is minced, or that dissociated tissue may allow more cells to easily access 
the available nutrients provided in the cell culture media.   
  We additionally evaluated the effects of biopsy site and autopsy donor age on fibroblast 
proliferation and cell line establishment.  Interestingly, the results showed a significantly greater 
number of viable cells by the first passage (Day 18) when using the arm biopsy site, compared to 
the leg or torso.  It is important to note that while the same site and tissue amounts were used for  




Figure 1.   
 
Brightfield Images of Primary Dermal Fibroblasts During Cell Line Establishment. (A) Primary 
dermal fibroblasts adhering to BD Primaria tissue culture-treated flask five days after tissue 
dissociation and seeding. (B) Primary dermal fibroblasts (Wright-Giemsa stain for contrast) after 


















Figure 2.  
 
Fibroblast Cell Line Establishment is More Successful using Dissociation Protocol. Number of 
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Figure 3.  
 
Fibroblast Proliferation is Significantly Effected by Biopsy Site.  Number of viable cells  (y-axis) 
was recorded 18 days post biopsy (Passage 1).  Graph represents results of One-Way ANOVA 
and Tukey’s HSD Post-hoc test results, demonstrating biopsies obtained from the arm result in a 
significant increase in fibroblast proliferation as compared to biopsies obtained from the leg or 
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Fig. 2. Fibroblast proliferation is affected by biopsy site but not autopsy donor age
(within an elderly cohort). Number of cells counted (y-axis) in both graphs was
recorded 18 days post biopsy (Passage 1). (A) Graphical representation of One-Way
ANOVA and Tukey’s HSD Post hoc test results, demonstrating biopsies obtained from
the arm result in a significant increase in fibroblast proliferation as compared to
biopsies obtained from the leg or torso. (B) Graphical representation of One-Way
ANOVA results, demonstrating fibroblast proliferation is not significantly affected
by autopsy donor age.
torso (P = 0.998) (Fig. 2A). Donor age, within an elderly cohort (ages
72–97), was also analyzed statistically and the One-Way ANOVA
showed there was no significant difference in fibroblast prolifera-
tion based on donor age (ANOVA: F = 1.756, v1 = 5, v2 = 28, P = 0.155)
(Fig. 2B). While these biopsies were collected within a short PMI of
3–7 h, Meske et al. additionally demonstrated that (in a rat model)
fibroblast viability/proliferation was negatively affected by longer
PMIs [13]. Collectively, these results suggest that researchers aim-
ing to successfully establish fibroblast cell lines from non-optimal
biopsy sites or after extended PMIs should collect and use more
tissue per cm2 of tissue culture surface.
Efficient translation of the Yamanaka factor proteins in the
described iPSCs was  confirmed by western blot (Fig. 3A). All four
factors were strongly expressed in the two  iPSC clones evaluated
as compared to the autopsy donor-derived fibroblasts. Expression
of pluripotency markers was  also evaluated by ICC (Fig. 3B). The
Yamanaka factor Oct3/4 and the hESC antigens SSEA4, TRA-1-60,
and NANOG were all expressed and appropriately localized in the
iPSCs.
DNA extracted from fibroblast cell line F02AA1 and IPSC clone
2–21 was  used for analyzing genotype concordance and CNVs (see
Supplementary data). A percent concordance of 99.9625% verified
that the IPSC clone had originated from the autopsy donor cell line.
In addition, no IPSC-specific CNVs spanned regions greater than
100 kilobases, suggesting that no large chromosomal segments or
whole chromosomes had become aneuploid during the reprogram-
ming process.
The two  iPSC clones (2–13 and 2–21) characterized in this study
were differentiated into derivatives of the neural lineage. ICC assays
identified neurons after 14 (Figs. 1D and 4A and B) and 28 (Fig. 4C
and D) days of differentiation. TUBB3 and NRXN IV were utilized as
terminal neuronal markers; both antigens co-localized specifically
to cells exhibiting a neuronal phenotype (Fig. 4A–D). ICC assays
also identified glial subtypes, including astrocytes and oligoden-
drocytes, after 35 days of differentiation (Fig. 4E and F). GFAP was
expressed in the majority of the differentiated, non-neuronal cells,
while a small subset of this population expressed MOG  (Fig. 4E and
F). This data suggests that the majority of the glia were astrocytic
in nature, while a small minority was becoming oligodedrocytic.
These results provide evidence that postmortem human tis-
sue can be successfully reprogrammed to a pluripotent state.
This approach may  be significantly useful for studies investi-
gating diseases and/or drugs that may  cause sudden death and
for neurodegenerative disease research. The ability to combine
both clinical diagnostic criteria and postmortem histopathologi-
cal observations can greatly increase neurodegenerative diagnostic
accuracy; this may  subsequently increase the statistical power for
donor-specific in vitro disease models. Human iPSC-based disease
models generated from postmortem tissue may  provide additional
confidence for researchers investigating these conditions, and pro-
Fig. 3. Western blot analysis and immunocytochemistry of hESC markers. (A) IPSCs generated from autopsy donor fibroblasts express the Yamanka factor proteins. Lanes:
(1)  iPSC clone 2-13, (2) iPSC clone 2–21, and (3) autopsy donor-derived dermal fibroblast (F02AA1). (B) Confocal microscopy images of IPSCs show expression of nuclear and
surface  pluripotency antigens. Each row of images displays localization of DAPI and two  hESC markers within the same field of view. Top panel: 1 !m optical section; DAPI,
Oct3/4, SSEA4. Bottom panel: 3D reconstruction of 16 !m × 1 !m optical sections through the Z-axis; DAPI, TRA-1-60, and NANOG. Scalebars = 50 !m.

















Figure 4.  
 
Fibroblast Proliferation is Not Significantly Effected by Donor Age (within an Elderly Cohort). 
Number of viable cells (y-axis) was recorded 18 days post biopsy (Passage 1).  Graph represents 
results of One-Way ANOVA and Tukey’s HSD Post-hoc test results, demonstrating fibroblast 
proliferation is not significantly affected by autopsy donor age (within an elderly cohort) (Hjelm, 
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Fig. 2. Fibroblast proliferation is affected by biopsy site but not autopsy donor age
(within an elderly cohort). Number of cells counted (y-axis) in both graphs was
recorded 18 days post biopsy (Passage 1). (A) Graphical representation of One-Way
ANOVA and Tukey’s HSD Post hoc test results, demonstrating biopsies obtained from
the arm result in a significant increase in fibroblast proliferation as compared to
biopsies obtained from the leg or torso. (B) Graphical representation of One-Way
ANOVA results, demonstrating fibroblast proliferation is not significantly affected
by autopsy donor age.
torso (P = 0.998) (Fig. 2A). Donor age, within an elderly cohort (ages
72–97), was also analyzed statistically and the One-Way ANOVA
showed there was no significant difference in fibroblast prolifera-
tion based on donor age (ANOVA: F = 1.756, v1 = 5, v2 = 28, P = 0.155)
(Fig. 2B). While these biopsies were collected within a short PMI of
3–7 h, Meske et al. additionally demonstrated that (in a rat model)
fibroblast viability/proliferation was negatively affected by longer
PMIs [13]. Collectively, these results suggest that researchers aim-
ing to successfully establish fibroblast cell lines from non-optimal
biopsy sites or after extended PMIs should collect and use more
tissue per cm2 of tissue culture surface.
Efficient translation of the Yamanaka factor proteins in the
described iPSCs was  confirmed by western blot (Fig. 3A). All four
factors were strongly expressed in the two  iPSC clones evaluated
as compared to the autopsy donor-derived fibroblasts. Expression
of pluripotency markers was  also evaluated by ICC (Fig. 3B). The
Yamanaka factor Oct3/4 and the hESC antigens SSEA4, TRA-1-60,
and NANOG were all expressed and appropriately localized in the
iPSCs.
DNA extracted from fibroblast cell line F02AA1 and IPSC clone
2–21 was  used for analyzing genotype concordance and CNVs (see
Supplementary data). A percent concordance of 99.9625% verified
that the IPSC clone had originated from the autopsy donor cell line.
In addition, no IPSC-specific CNVs spanned regions greater than
100 kilobases, suggesting that no large chromosomal segments or
whole chromosomes had become aneuploid during the reprogram-
ming process.
The two  iPSC clones (2–13 and 2–21) characterized in this study
were differentiated into derivatives of the neural lineage. ICC assays
identified neurons after 14 (Figs. 1D and 4A and B) and 28 (Fig. 4C
and D) days of differentiation. TUBB3 and NRXN IV were utilized as
terminal neuronal markers; both antigens co-localized specifically
to cells exhibiting a neuronal phenotype (Fig. 4A–D). ICC assays
also identified glial subtypes, including astrocytes and oligoden-
drocytes, after 35 days of differentiation (Fig. 4E and F). GFAP was
expressed in the majority of the differentiated, non-neuronal cells,
while a small subset of this population expressed MOG  (Fig. 4E and
F). This data suggests that the majority of the glia were astrocytic
in nature, while a small minority was becoming oligodedrocytic.
These results provide evidence that postmortem human tis-
sue can be successfully reprogrammed to a pluripotent state.
This approach may  be significantly useful for studies investi-
gating diseases and/or drugs that may  cause sudden death and
for neurodegenerative disease research. The ability to combine
both clinical diagnostic criteria and postmortem histopathologi-
cal observations can greatly increase neurodegenerative diagnostic
accuracy; this may  subsequently increase the statistical power for
donor-specific in vitro disease models. Human iPSC-based disease
models generated from postmortem tissue may  provide additional
confidence for researchers investigating these conditions, and pro-
Fig. 3. Western blot analysis and immunocytochemistry of hESC markers. (A) IPSCs generated from autopsy donor fibroblasts express the Yamanka factor proteins. Lanes:
(1)  iPSC clone 2-13, (2) iPSC clone 2–21, and (3) autopsy donor-derived dermal fibroblast (F02AA1). (B) Confocal microscopy images of IPSCs show expression of nuclear and
surface  pluripotency antigens. Each row of images displays localization of DAPI and two  hESC markers within the same field of view. Top panel: 1 !m optical section; DAPI,
Oct3/4,  SSEA4. Bottom panel: 3D reconstruction of 16 !m × 1 !m optical sections through the Z-axis; DAPI, TRA-1-60, and NANOG. Scalebars = 50 !m.
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all comparisons, only one specific site was tested per body region and it is possible that other 
areas of the arm, leg, or torso may exhibit effects that are more/less pronounced. 
Another important issue is that we did not test the biopsied tissue (or original ‘starting 
material’) for the number of viable cells.  As such, we do not know if the difference in fibroblast 
proliferation per biopsy site is because the cells from these regions are healthier, demonstrate 
greater postmortem viability, exist at a greater density in vivo, or really are just different (beyond a 
level that can be identified morphologically).  Another possibility is that the leg and torso areas 
contain more adipose tissue, and fat cells appear to inhibit fibroblast proliferation when co-
introduced in cell culture (observation during cohort establishment, data not shown).  Lastly, it 
was observed that the arm biopsies often resulted in blood loss at the site, while this did not occur 
for the leg or torso biopsy sites.  While these biopsies were collected postmortem, it is not 
surprising that there may be blood loss given that these are warm-body autopsies occurring after 
a short postmortem interval.  However, perhaps the site-specific blood loss is also indicative of 
the proximity the fibroblast cells are to larger capillaries or nutrient sources, thereby prolonging 
their life in vivo, premortem and/or postmortem.   
 Finally, we found that donor age (within an elderly cohort) did not significantly affect 
fibroblast proliferation and cell line establishment.  This is encouraging for future studies aiming to 
create fibroblast cell line cohorts from donation programs specific to diseases of late-onset. It 
should be noted, however, that our results can only be concluded for a cohort of elderly donors, 
and there may be (and likely would be) a difference in fibroblast proliferation if testing samples 
from a larger developmental range (e.g., fetal through adult tissues). 
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CHAPTER 2 
INDUCTION OF PLURIPOTENT STEM CELLS FROM AUTOPSY DONOR-DERIVED  
SOMATIC CELLS 
Introduction 
Traditional in vitro disease modeling approaches rely on primary or immortalized somatic 
cells that are either obtained from a diseased individual, or are genetically modified to exhibit a 
disease phenotype in vitro (Li and Zhou). Unfortunately, these models require a physiologically 
relevant cell line, which may not be easily available, and genetic modification may not recapitulate 
the etiology of complex diseases. Human induced pluripotent stem cells (iPSCs) can overcome 
these shortcomings, because genetically identical, tissue-specific cell types that are disease-
applicable can be generated in vitro (Li and Zhou; Marchetto, Winner and Gage; Takahashi et al.; 
Yu et al.). Donor-specific iPSC models are particularly intriguing for the study of neurological and 
neurodegenerative diseases, because unlike other tissues of the human body, live brain tissue 
often cannot be obtained from living subjects without undue risk of cognitive or functional 
impairment (Fitzgerald). 
Previous studies have demonstrated that neural progenitor cells can be successfully 
isolated, cultured and differentiated from adult postmortem brain tissue (Palmer et al.).   However, 
these adult stem cell populations can only be expanded in vitro through a limited number of 
population doublings before undergoing cellular senescence, unlike hESCs or iPSCs, which can 
theoretically be cultured indefinitely (Palmer et al.; Zeng and Rao; Carpenter, Rosler and Rao). 
The statistical power of iPSC-based neurological models is dependent on the diagnostic 
accuracy of the diseased (case) and unaffected (control) somatic cell donors. For many 
neurological diseases, premortem clinical criteria do not provide sufficient information for the 
subject to be given a definite diagnosis, but rather a possible or probable diagnosis (Beach, Sue, 
et al.; Corneveaux et al.; Gelpi et al.; Hamilton; Joseph et al.; Mueller et al.; Nelson et al.; Piguet 
et al.; Tolosa, Wenning and Poewe). For example, Alzheimer’s disease can be identified through 
clinical evaluations as the possible or probable cause of dementia; however, the definite 
diagnosis of this pathology cannot currently be confirmed until clinical criteria are combined with 
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postmortem histopathological observations of the subject’s brain (Beach, Sue, et al.; Corneveaux 
et al.; Joseph et al.; Mueller et al.). Because clinical phenotypes like dementia can be shared by 
multiple neuropathies, postmortem brain banking programs have become an exceptional 
resource for providing neuropathy-associated brain tissue that has been subjected to the most 
robust diagnostic methods. In fact, much of what is known about many neurological and 
neurodegenerative diseases has been from analyses (histological, biochemical, molecular, etc.) 
on autopsy donor-derived brain tissue (Beach, Sue, et al.; Gelpi et al.; Hamilton; Joseph et al.; 
Marchetto, Winner and Gage; Nelson et al.; Piguet et al.). 
Meske et al. have demonstrated that human dermal fibroblasts (HDFs) can be 
established in cell culture from autopsy donors up to 48 hours postmortem and from individuals 
up to 99-years-old (Meske, Albert and Ohm). To our knowledge, however, there are no published 
reports of autopsy donor-derived somatic cells being used for human iPSC generation.  Because 
somatic cell senescence has been identified as a potential barrier in iPSC reprogramming, our 
group sought to investigate whether autopsy donor-derived fibroblasts could be induced to a 
pluripotent state (Banito et al.; Utikal et al.; Chan et al.; Liu et al.).  In addition, we chose to 
examine if these iPSCs could be differentiated in vitro into derivatives of the neural lineage, since 
this approach may be particularly valuable for neurological disease research.       
Materials and Methods 
Lentiviral Transduction and Feeder-Free iPSC Generation/Maintenance 
IPSCs were generated from one autopsy donor, a 75-year-old male identified by clinical 
studies and histopathological examination as being suitable as a "control" subject as he was 
negative for major neurological and neuropathological conditions (non-demented, without clinical 
parkinsonism and without diagnostic levels of histopathology for any major neuropathological 
condition). Autopsy donor-derived fibroblast cell line F02AA1 was selected for induced 
pluripotency experiments.   
Human iPSCs were generated in a feeder-free culture system by lentiviral transduction of 
the Yamanaka factors (Takahashi et al.; Chan et al.).  Autopsy donor-derived fibroblasts 
(F02AA1) were seeded in 6-well tissue culture-treated plates (BD Biosciences, San Jose, CA, 
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USA) at 1.5x105 cells/well.  Cells were infected at a multiplicity of infection (MOI) of 20 with 
prepackaged lentiviral particles, premixed with the reprogramming factors Oct3/4, Sox2, Klf4, c-
Myc on individual vectors (Human OSKM Set; Allele Biotech, San Diego, CA, USA).  To increase 
transduction efficiency, the Viraductin Lentivirus Transduction Kit was used according to the 
manufacturer’s instructions (Cell Biolabs Inc., San Diego, CA, USA), and the virus complex was 
removed from the cells after 24 hours.  Seven days post transduction, the 5x104 infected 
fibroblasts were transferred to a single well of a 6-well tissue culture-treated plate pre-coated 
overnight at 37°C with 1ml/well of BD Matrigel hESC-qualified matrix (BD Biosciences), diluted 
one aliquot Matrigel per 20ml of DMEM/F12 (Invitrogen, Carlsbad, CA, USA) (Xu et al.; Nakahara 
et al.).  One day following the transfer to Matrigel matrix, the PFM was replaced by hESC/iPSC 
media (mTeSR1; Stem Cell Tech., Vancouver, BC, Canada), supplemented with 100units/ml 
penicillin, 100µg/ml streptomycin (Sigma Aldrich, St. Louis, MO, USA), and 5µg/ml Plasmocin 
prophylactic (Invivogen, San Diego, CA, USA).  Complete mTeSR1 media (2.5ml/well) was 
exchanged every other day until iPSC colony selection (days 25 and 32 post transduction) 
(Ludwig et al.).  IPSC clones were selected based on morphology, and colonies were picked with 
a 23-gauge needle (BD Biosciences) and a 200µl pipette.  IPSC lines were passaged once a 
week by pipette disruption and mild treatment with 1mg/ml collagenase IV (Sigma) in DMEM/F12 
(Invitrogen) and cells were split 1:6 onto freshly coated Matrigel-coated plates. IPSC lines 
(through P:10) were frozen in cryopreservation media (mFreSrR; Stem Cell Tech.) and stored at -
130°C prior to characterization and differentiation experiments, which were performed using iPSC 
clones 2-13 and 2-21 at passage 8 (P:8).   
Embryoid Body Formation and Neural Differentiation 
Embryoid Bodies (EBs), with approximately 400 cells per EB, were generated using 
Aggrewell 400 Plates (Stem Cell Tech) according to the manufacturer’s instructions.  EBs were 
transferred in suspension to low adherence, non-treated 6-well plates (BD Biosciences) with 
approximately 500 EBs per well.    
Inductive loss of pluripotency (LOP) was performed as previously described with minor 
modifications (S. M. Kang et al.; Schwartz et al.).  Briefly, EBs were cultured in suspension for 5 
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days in hESC media without basic fibroblast growth factor (bFGF) (DMEM/F12 (Invitrogen), 20% 
Knockout Serum Replacement (Invitrogen), 1mM L-Glutamine (Invitrogen), 0.1mM non-essential 
amino acids (NEAA; Invitrogen), 0.0007% 2-Mercaptoethanol (Sigma Aldrich), 100units/ml 
penicillin, 100µg/ml streptomycin (Sigma Aldrich), and 5µg/ml Plasmocin prophylactic (Invivogen 
San Diego, CA, USA)), and the media was exchanged every other day.  The LOP media was 
then replaced with NeuroCult NS-A Proliferation media (Stem Cell Tech), supplemented with 
20ng/ml recombinant human epidermal growth factor (rhEGF; Stem Cell Tech), 10ng/ml bFGF 
(Stemgent, Cambridge, MA, USA), 2µg/ml Heparin (Stem Cell Tech), 100units/ml penicillin, 
100µg/ml streptomycin (Sigma Aldrich), and 5µg/ml Plasmocin prophylactic (Invivogen, San 
Diego, CA, USA), and the EBs were cultured in suspension for an additional 5 days.  EBs were 
plated in complete NeuroCult NS-A Proliferation media onto 6-well tissue culture-treated plates 
(BD Biosciences) pre-coated with 1ml/well hESC-qualified Matrigel matrix (BD Biosciences), 
diluted 1 aliquot per 10ml DMEM/F12 (Invitrogen).  EBs were allowed to collapse onto the matrix, 
and adherent cells were further cultured in complete NeuroCult NS-A Proliferation media for 14 
days.  Neural precursors were collected by bulk enzymatic passage with 1mg/ml Collagenase IV 
(Sigma Aldrich) in DMEM/F12 (Invitrogen) as previously described (Schwartz et al.).  Cells were 
seeded for differentiation experiments at 5x103 cells/cm2 on glass coverslips (VWR, West 
Chester, PA, USA) pre-coated with 1ml/coverslip of hESC-qualified Matrigel matrix (BD 
Biosciences), diluted 1:10 as described above. 
Cells plated onto glass coverslips were maintained in NeuroCult NS-A Differentiation 
media supplemented with 100units/ml penicillin, 100µg/ml streptomycin (Sigma Aldrich), and 
5µg/ml Plasmocin prophylactic (Invivogen), and the media was exchanged every other day.  Cells 
were allowed to differentiate for 14, 21, 28 or 35 days, at which time the coverslips were fixed in 
4% paraformaldehyde (Thermo Fisher Scientific, Waltham, MA, USA) in DPBS (Invitrogen) for 15 
minutes at room temperature.  The coverslips were then rinsed and stored in DPBS (Invitrogen) 
at 4°C for later use in immunocytochemistry (ICC) experiments (see below). 
Immunocytochemistry and Microscopy 
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Cells cultured on Matrigel-coated glass coverslips and fixed with 4% paraformaldehyde 
were used for all ICC assays.  Cells were permeabilized for 10 minutes with 0.1% Triton X-100 
(Thermo Fisher Scientific, Waltham, MA, USA) in DPBS  (Invitrogen), followed by a 30-minute 
incubation with blocking solution (2.5% bovine serum albumin (BSA) in DPBS with 0.1% Tween 
20 (Sigma)). All primary antibodies were incubated overnight at 4°C and fluorophore-conjugated 
secondary antibodies were incubated for 2 hours at room temperature.  The primary antibodies 
used for this study were directed against the following antigens: Oct3/4, 1:100 (Stemgent, 
Cambridge, MA, USA), SSEA4, 1:100 (Stemgent), TRA-1-60, 1:100 (Stemgent), Nanog, 1:100 
(Santa Cruz Biotech, Santa Cruz, CA, USA), Neurexin IV (NRXN IV), 1:100 (Santa Cruz Biotech), 
Neuron-specific Beta III Tubulin (TUBB3), 1:2000 (Abcam, Cambridge, MA, USA), glial fibrillary 
acidic protein (GFAP), 1:500 (Abcam), and myelin/oligodendrocyte-specific protein (MOG), 1:500 
(Millipore, Bedford, MA, USA).  Alexa Fluor-conjugated secondary antibodies (1:2000, excitations 
488, 594, and 647; Invitrogen) were used for all experiments.  In addition, 0.1ug/ml 4'-6-
Diamidino-2-phenylindole (DAPI) was used as a nuclear counterstain.   All brightfield, phase 
contrast and fluorescence images were obtained using the Leica DM IL inverted microscope with 
the Leica DFC 290 digital camera and Leica Application Suite software (version 2.8.1).  All 
confocal microscopy images were obtained using an Olympus Fluoview FV1000 confocal 
microscope and the Olympus FV10-ASW 1.7 imaging analysis software.  
Protein Extractions and Western Blots 
 Total soluble protein (TSP) was extracted from autopsy donor-derived fibroblasts 
(F02AA1, P:4), and two iPSC clones (2-13 and 2-21, P:8) using ice-cold RIPA buffer 
supplemented with a protease inhibitor cocktail and EDTA as per the manufacturer’s instructions 
(Thermo Fisher Scientific).  Protein extracts were concentrated approximately 10-fold with 
Microcon Centrifugal Filter Devices (30,000 nominal molecular weight limit; Millipore, Billerica, 
MA, USA), and TSP was quantified using the Pierce BCA Protein Assay Kit (Thermo Fisher 
Scientific).   
 Approximately 25µg TSP/lane was separated using 4-12% Bis-Tris precast gels and 
NuPage electrophoresis system (Invitrogen).  Protein was transferred onto Invitrolon PVDF 
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membranes (Invitrogen) that were subsequently incubated in blocking solution consisting of 5% 
nonfat dry milk (Safeway, Pleasanton, CA, USA) in tris-buffered saline with 0.1% Tween (TBST; 
Thermo Fisher Scientific). All primary antibodies were incubated overnight at 4°C and horseradish 
peroxidase (HRP)-conjugated secondary antibodies were incubated for 1 hour at room 
temperature.  The primary antibodies used for this study were directed against the following 
antigens: Oct3/4, 1:500 (Stemgent), Sox2, 1:150 (Invitrogen), Klf4, 1:100 (Stemgent), c-Myc, 
1:100 (Stemgent), and GAPDH, 1:60,000 (Millipore).  The HRP-conjugated secondary antibodies 
used were as follows: Goat anti-rabbit HRP, 1:5,000 (Upstate/Millipore), goat anti-mouse, 1:1000 
(Millipore), and rabbit anti-chicken, 1:10,000 (Millipore).  Western blots were developed using the 
Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific) and the chemiluminescence 
was detected on x-ray film (Kodak, Rochester, NY, USA).  
Single Nucleotide Polymorphism (SNP) Genotyping 
Genomic DNA was extracted from fibroblast cell line F02AA1 and IPSC clone 2-21 using 
the Qiagen Blood & Cell Culture DNA Mini Kit as per the manufacturer’s instructions (Qiagen, 
Valencia, CA, USA).  Concentration and purity of both DNA extracts were analyzed using a 
NanoDrop ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, USA) and Quant-iT 
PicoGreen Kit (Invitrogen).  DNA aliquots were prepared at a concentration of 50ng/µl in a total 
volume of 10µl for use in the Affymetrix Genome-Wide Human SNP Array 6.0, performed as per 
the manufacturer’s instructions (Affymetrix, Santa Clara, CA, USA).  Array images were collected 
using the GeneChip Scanner 3000 (Affymetrix) and raw data image files were generated using 
the GeneChip Operating System (GCOS) software (Affymetrix), after which a .CEL file was 
produced from each image file.  Contrast quality control (QC) and other QC metrics were 
analyzed using the Genotyping Console 2.1 software (Affymetrix).  Genotyping calls were 
generated in the Genotyping Console using the Birdseed version 2 SNP genotyping algorithm.  
Genotyping calls for 909,622 SNPs were exported into Microsoft Excel 2008 for further review.  
SNPs that were not called from one or both samples (fibroblast and IPSC) were manually 
removed, reducing the total number of SNPs called to 900,680. 
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The number of matching and mismatching SNP calls between the two samples were 
extrapolated in Microsoft Excel 2008 and this was used to calculate the percent concordance.  In 
addition, Affymetrix Genome-Wide Human SNP Array 6.0 results were used for copy number 
variation (CNVs) analysis.  CNVs were initially detected for both the fibroblast and IPSC samples 
using the free software tool PennCNV (www.openbioinformatics.org/penncnv) (Wang et al.).  The 
log R Ratio (LRR) and B Allele Frequency (BAF) plots were manually inspected using the 
visualize_cnv.pl program available in the PennCNV package, and any identified CNVs that 
appeared as potential false-positives were systematically removed.  
Results 
The primary aim of this study was to examine if autopsy donor-derived dermal fibroblasts 
could be reprogrammed to a pluripotent state, for potential use in iPSC-based disease modeling.   
A visual summary of the various cell types used and generated in this proof-of-principle study are 
illustrated (Fig.5).  IPSC clones from several additional autopsy donors have been generated 
using the same procedures as described, demonstrating this approach to iPSC generation is 
reproducible (data not shown). 
Efficient translation of the Yamanaka factor proteins in the described iPSCs was 
confirmed by western blot (Fig.6, A).  All four factors were strongly expressed in the two iPSC 
clones evaluated as compared to the autopsy donor-derived fibroblasts.  Expression of 
pluripotency markers was also evaluated by ICC (Fig.6, B).  The Yamanaka factor Oct3/4 and the 
hESC antigens SSEA4, TRA-1-60, and NANOG were all expressed and appropriately localized in 
the iPSCs.  
DNA extracted from fibroblast cell line F02AA1 and IPSC clone 2-21 was used for 
analyzing genotype concordance and CNVs (Table 3). A percent concordance of 99.9625% 
verified that the IPSC clone had originated from the autopsy donor cell line.  In addition, no IPSC-
specific CNVs spanned regions greater than 100 kilobases, suggesting that no large 
chromosomal segments or whole chromosomes had become aneuploid during the 
reprogramming process.     
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Figure 5.  
 
IPSC Induction and Neural Differentiation from Autopsy Donor-Derived Fibroblasts. Brightfield, 
phase contrast, and immunofluorescence images of (A) autopsy donor-derived dermal fibroblasts 
(F02AA1; Wright-Giemsa contrast stain), (B) iPSC colony arising from feeder-free conditions 21 
days post transduction, (C) EBs generated from iPSC clone 2-13, and (D) neurons after 14 days 
of in vitro differentiation (neuron-specific beta III tubulin antibody stained).    Scalebar = 50µm 
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entific). All primary antibodies were incubated overnight at 4 ◦C
and horseradish peroxidase (HRP)-conjugated secondary antibod-
ies were incubated for 1 h at room temperature. The primary
antibodies used for this study were directed against the following
antigens: Oct3/4, 1:500 (Stemgent), Sox2, 1:150 (Invitrogen), Klf4,
1:100 (Stemgent), c-Myc, 1:100 (Stemgent), and GAPDH, 1:60,000
(Millipore). The HRP-conjugated secondary antibodies used were
as follows: Goat anti-rabbit HRP, 1:5000 (Upstate/Millipore), goat
anti-mouse, 1:1000 (Millipore), and rabbit anti-chicken, 1:10,000
(Millipore). Western blots were developed using the Pierce ECL
Western Blotting Substrate (Thermo Fisher Scientific) and the
chemiluminescence was detected on X-ray film (Kodak, Rochester,
NY, USA).
Genomic DNA was extracted from fibroblast cell line F02AA1
and IPSC clone 2–21 using the Qiagen Blood & Cell Culture DNA
Mini Kit as per the manufacturer’s instructions (Qiagen, Valencia,
CA, USA). Concentration and purity of both DNA extracts were ana-
lyzed using a NanoDrop ND-1000 spectrophotometer (Nanodrop,
Wilmington, DE, USA) and Quant-iT PicoGreen Kit (Invitrogen).
DNA aliquots were prepared at a concentration of 50 ng/!l in a total
volume of 10 !l for use in the Affymetrix Genome-Wide Human
SNP Array 6.0, performed as per the manufacturer’s instructions
(Affymetrix, Santa Clara, CA, USA) (see Supplementary methods).
The number of matching and mismatching SNP calls between
the two samples were extrapolated in Microsoft Excel 2008 and
this was used to calculate the percent concordance. In addition,
Affymetrix Genome-Wide Human SNP Array 6.0 results were used
for copy number variation (CNVs) analysis. CNVs were initially
detected for both the fibroblast and IPSC samples using the free soft-
ware tool PennCNV (www.openbioinformatics.org/penncnv) [22].
The log R Ratio (LRR) and B Allele Frequency (BAF) plots were man-
ually inspected using the visualize cnv.pl program available in the
PennCNV package, and any identified CNVs that appeared as poten-
tial false-positives were systematically removed.
The primary aim of this study was to examine if autopsy donor-
derived dermal fibroblasts could be reprogrammed to a pluripotent
state, for potential use in iPSC-based disease modeling. A visual
summary of the various cell types used and generated in this proof-
of-principle study are illustrated (Fig. 1). iPSC clones from several
additional autopsy donors have been generated using the same
procedures as described, demonstrating this approach to iPSC gen-
eration is reproducible (data not shown).
The primary dermal fibroblast cell counts were analyzed to
determine if biopsy site or age affected proliferation. Three biopsy
sites (arm, leg, and torso) were evaluated, from which all cell
lines were established using the same amount of tissue and pro-
cedures. A One-Way ANOVA demonstrated a significant difference
in fibroblast proliferation between biopsy sites (ANOVA: F = 9.616,
v1 = 2, v2 = 27, P = 0.001). A Tukey’s HSD Post hoc test subsequently
revealed the arm biopsy site had statistically greater fibroblast pro-
liferation than either the leg (P = 0.003) or torso (P = 0.004) sites,
while there was  no significant difference between the leg and
Fig. 1. IPSC induction and neural differentiation from autopsy donor-derived fibroblasts. Brightfield, phase contrast, and immunofluorescence images of (A) autopsy donor-
derived dermal fibroblasts (F02AA1; Wright-Giemsa contrast stain), (B) iPSC colony arising from feeder-free conditions 21 days post transduction, (C) EBs generated from
iPSC  clone 2–13, and (D) neurons after 14 days of in vitro differentiation (neuron-specific beta III tubulin antibody stained). Scalebar = 50 !m.
























Figure 6.  
 
Western Blot Analysis and Immunocytochemistry of Embryonic Stem Cell Markers. (A) IPSCs 
generated from autopsy donor fibroblasts express the Yamanka factor proteins. Lanes: (1) iPSC 
clone 2-13, (2) iPSC clone 2-21, and (3) autopsy donor-derived dermal fibroblast (F02AA1).  (B) 
Confocal microscopy images of IPSCs show expression of nuclear and surface pluripotency 
antigens.  Each row of images displays localization of DAPI and two hESC markers within the 
same field of view.  Top panel: 1µm optical section; DAPI, Oct3/4, SSEA4.  Bottom panel: 3D 
reconstruction of 16x 1µm optical sections through the Z-axis; DAPI, TRA-1-60, and NANOG.  
Scalebars = 50µm (Hjelm, Rosenberg, et al.). 
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Fig. 2. Fibroblast proliferation is affected by biopsy site but not autopsy donor age
(within an elderly cohort). Number of cells counted (y-axis) in both graphs was
recorded 18 days post biopsy (Passage 1). (A) Graphical representation of One-Way
ANOVA and Tukey’s HSD Post hoc test results, demonstrating biopsies obtained from
the arm result in a significant increase in fibroblast proliferation as compared to
biopsies obtained from the leg or torso. (B) Graphical representation of One-Way
ANOVA results, demonstrating fibroblast proliferation is not significantly affected
by autopsy donor age.
torso (P = 0.998) (Fig. 2A). Donor age, within an elderly cohort (ages
72–97), was also analyzed statistically and the One-Way ANOVA
showed there was no significant difference in fibroblast prolifera-
tion based on donor age (ANOVA: F = 1.756, v1 = 5, v2 = 28, P = 0.155)
(Fig. 2B). While these biopsies were collected within a short PMI of
3–7 h, Meske et al. additionally demonstrated that (in a rat model)
fibroblast viability/proliferation was negatively affected by longer
PMIs [13]. Collectively, these results suggest that researchers aim-
ing to successfully establish fibroblast cell lines from non-optimal
biopsy sites or after extended PMIs should collect and use more
tissue per cm2 of tissue culture surface.
Efficient translation of the Yamanaka factor proteins in the
described iPSCs was  confirmed by western blot (Fig. 3A). All four
factors were strongly expressed in the two  iPSC clones evaluated
as compared to the autopsy donor-derived fibroblasts. Expression
of pluripotency markers was  also evaluated by ICC (Fig. 3B). The
Yamanaka factor Oct3/4 and the hESC antigens SSEA4, TRA-1-60,
and NANOG were all expressed and appropriately localized in the
iPSCs.
DNA extracted from fibroblast cell line F02AA1 and IPSC clone
2–21 was  used for analyzing genotype concordance and CNVs (see
Supplementary data). A percent concordance of 99.9625% verified
that the IPSC clone had originated from the autopsy donor cell line.
In addition, no IPSC-specific CNVs spanned regions greater than
100 kilobases, suggesting that no large chromosomal segments or
whole chromosomes had become aneuploid during the reprogram-
ming process.
The two  iPSC clones (2–13 and 2–21) characterized in this study
were differentiated into derivatives of the neural lineage. ICC assays
identified neurons after 14 (Figs. 1D and 4A and B) and 28 (Fig. 4C
and D) days of differentiation. TUBB3 and NRXN IV were utilized as
terminal neuronal markers; both antigens co-localized specifically
to cells exhibiting a neuronal phenotype (Fig. 4A–D). ICC assays
also identified glial subtypes, including astrocytes and oligoden-
drocytes, after 35 days of differentiation (Fig. 4E and F). GFAP was
expressed in the majority of the differentiated, non-neuronal cells,
while a small subset of this population expressed MOG  (Fig. 4E and
F). This data suggests that the majority of the glia were astrocytic
in nature, while a small minority was becoming oligodedrocytic.
These results provide evidence that postmortem human tis-
sue can be successfully reprogrammed to a pluripotent state.
This approach may  be significantly useful for studies investi-
gating diseases and/or drugs that may  cause sudden death and
for neurodegenerative disease research. The ability to combine
both clinical diagnostic criteria and postmortem histopathologi-
cal observations can greatly increase neurodegenerative diagnostic
accuracy; this may  subsequently increase the statistical power for
donor-specific in vitro disease models. Human iPSC-based disease
models generated from postmortem tissue may  provide additional
confidence for researchers investigating these conditions, and pro-
Fig. 3. Western blot analysis and immunocytochemistry of hESC markers. (A) IPSCs generated from autopsy donor fibroblasts express the Yamanka factor proteins. Lanes:
(1)  iPSC clone 2-13, (2) iPSC clone 2–21, and (3) autopsy donor-derived dermal fibroblast (F02AA1). (B) Confocal microscopy images of IPSCs show expression of nuclear and
surface  pluripotency antigens. Each row of images displays localization of DAPI and two  hESC markers within the same field of view. Top panel: 1 !m optical section; DAPI,
Oct3/4, SSEA4. Bottom panel: 3D reconstruction of 16 !m × 1 !m optical sections through the Z-axis; DAPI, TRA-1-60, and NANOG. Scalebars = 50 !m.
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Fig. 2. Fibroblast proliferation is affected by biopsy site but not autopsy donor age
(within an elderly cohort). Number of cells counted (y-axis) in both graphs was
recorded 18 days post biopsy (Passage 1). (A) Graphical representation of One-Way
ANOVA and Tukey’s HSD Post hoc test results, demonstrating biopsies obtained from
the arm result in a significant increase in fibroblast proliferation as compared to
biopsies obtained from the leg or torso. (B) Graphical representation of One-Way
ANOVA results, demonstrating fibroblast proliferation is not significantly affected
by autopsy donor age.
torso (P = 0.998) (Fig. 2A). Donor age, within an elderly cohort (ages
72–97), was also analyzed statistically and the One-Way ANOVA
showed there was no significant difference in fibroblast prolifera-
tion based on donor age (ANOVA: F = 1.756, v1 = 5, v2 = 28, P = 0.155)
(Fig. 2B). While these biopsies were collected within a short PMI of
3–7 h, Meske et al. additionally demonstrated that (in a rat model)
fibroblast viability/proliferation was negatively affected by longer
PMIs [13]. Collectively, these results suggest that researchers aim-
ing to successfully establish fibroblast cell lines from non-optimal
biopsy sites or after extended PMIs should collect and use more
tissue per cm2 of tissue culture surface.
Efficient translation of the Yamanaka factor proteins in the
described iPSCs was  confirmed by western blot (Fig. 3A). All four
factors were strongly expressed in the two  iPSC clones evaluated
as compared to the autopsy donor-derived fibroblasts. Expression
of pluripotency markers was  also evaluated by ICC (Fig. 3B). The
Yamanaka factor Oct3/4 and the hESC antigens SSEA4, TRA-1-60,
and NANOG were all expressed and appropriately localized in the
iPSCs.
DNA extracted from fibroblast cell line F02AA1 and IPSC clone
2–21 was  used for analyzing genotype concordance and CNVs (see
Supplementary data). A percent concordance of 99.9625% verified
that the IPSC clone had originated from he autopsy donor cell line.
In addition, no IPSC-specific CNVs spanned regions greater than
100 kilobases, suggesting that no large chromosomal segments or
whole chromosomes had become aneuploid during the reprogram-
ming process.
The two  iPSC clones (2–13 and 2–21) characterized in this study
were differentiated into derivatives of the neural lineage. ICC assays
identified neurons after 14 (Figs. 1D and 4A and B) and 28 (Fig. 4C
and D) days of differentiation. TUBB3 and NRXN IV were utilized as
terminal neuronal markers; both antigens co-localized specifically
to cells exhibiting a neuronal phenotype (Fig. 4A–D). ICC assays
also identified glial subtypes, including astrocytes and oligoden-
drocytes, after 35 days of differentiation (Fig. 4E and F). GFAP was
expressed in the majority of the differentiated, non-neuronal cells,
while a small subset of this population expressed MOG  (Fig. 4E and
F). This data suggests that the majority of the glia were astrocytic
in nature, while a small minority was becoming oligodedrocytic.
These results provide evidence that postmortem human tis-
sue can be successfully reprogrammed to a pluripotent state.
This approach may  be significantly useful for studies investi-
gating diseases and/or drugs that may  cause sudden death and
for neurodegenerative disease research. The ability to combine
both clinical diagnostic criteria and postmortem histopathologi-
cal observations can greatly increase neurodegenerative diagnostic
accuracy; this may  subsequently increase the statistical power for
donor-specific in vitro disease models. Human iPSC-based disease
models generated from postmortem tissue may  provide additional
confidence for researchers investigating these conditions, and pro-
Fig. 3. Western blot analysis and immunocytochemistry of hESC markers. (A) IPSCs generated from autopsy donor fibroblasts express the Yamanka factor proteins. Lanes:
(1)  iPSC clone 2-13, (2) iPSC clone 2–21, and (3) autopsy donor-derived dermal fibroblast (F02AA1). (B) Confocal microscopy images of IPSCs show expression of nuclear and
surface  pluripotency antigens. Each row of images displays localization of DAPI and two  hESC markers within the same field of view. Top panel: 1 !m optical section; DAPI,
Oct3/4, SSEA4. Bottom panel: 3D reconstruction of 16 !m × 1 !m optical sections through the Z-axis; DAPI, TRA-1-60, and NANOG. Scaleba s = 50 !m.
A. 
B. 
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Table 3. 
Genome-Wide Human SNP Array: Percent Concordance and Copy Number Variation (Hjelm, 
Rosenberg, et al.). 
 
Genotype Concordance 
Total SNPs called 900,680 
# Matches a 900,342 
# Mismatches a 338 
% Concordance a 99.9625% 
 
Copy Number Variants (CNVs) 
Total CNVs called 42 % of CNVs 
Autopsy Donor-specific b 30 71.4% 
IPSC-specific c 12 28.6% 
Fibroblast-specific d 0 0.0% 
                            
                           a Fibroblast cell line (FO2AA1) vs. IPSC (clone 2-21) 
                           b CNV called in both fibroblast and IPSC 
                           c  CNV called in IPSC, but not in fibroblast  










































Figure 7.  
 
IPSCs Generated from Autopsy Fibroblasts Can Be Differentiated into Neurons and Glia. 
Confocal microscopy images shown are from 1µm optical sections through the Z-axis of cells 
fixed after 14 (A), 28 (B) and 35 (C) days of differentiation. iPSC clone 2-13: (A, B) Neurexin IV 
(NRXN IV) (red), co-localization of Neurexin IV (NRXN IV) and neuron-specific beta III tubulin 
(TUBB3) (yellow), and the nuclear counterstain DAPI (blue). (C) Glial fibrillary acidic protein 
(GFAP) (red), myelin/oligodendrocyte-specific protein (MOG) (green), and the nuclear 
counterstain DAPI (blue).  Scalebars = 50µm (Hjelm, Rosenberg, et al.). 
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Fig. 4. IPSCs generated from autopsy donor fibroblasts can be differentiated into neurons and glia. Confocal microscopy images shown are from 1 !m optical sections through
the  Z-axis of cells fixed after 14 (A and B), 28 (C and D) and 35 (E and F) days of differentiation. Left panel: iPSC clone 2–13; Right panel: iPSC clone 2–21. (A, B, C, D) Neurexin
IV  (NRXN IV) (red), co-localization of Neurexin IV (NRXN IV) and neuron-specific beta III tubulin (TUBB3) (yellow), and the nuclear counterstain DAPI (blue). (E and F) Glial
fibrillary acidic protein (GFAP) (red), myelin/oligodendrocyte-specific protein (MOG) (green), and the nuclear counterstain DAPI (blue). Scalebars = 50 !m.
vides an avenue for comparing differentiated in vitro cell ty es to
endogenous adult tissu  from the same individ al.
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The two iPSC clones (2-13 and 2-21) characterized in this study were differentiated into 
derivatives of the neural lineage.  ICC assays identified neurons after 14 and 28 days of 
differentiation (Fig. 7).  TUBB3 and NRXN IV were utilized as terminal neuronal markers; both 
antigens co-localized specifically to cells exhibiting a neuronal phenotype (Fig. 7).  ICC assays  
also identified expression of glial markers, specific to both astrocytes and oligodendrocytes, after 
35 days of differentiation (Fig. 7).  GFAP was expressed in the majority of the differentiated, non-
neuronal cells, while a small subset of this population expressed MOG (Fig. 7).  This data 
suggests that the majority of the glia were astrocytic in nature, while a small minority was 
becoming oligodedrocytic.       
Discussion 
The is the first known published study to use autopsy donor-derived somatic cells for the 
generation of induced pluripotent stem cells (iPSCs).  Since this publication, however, others 
have additionally shown that this platform can be employed successfully.  Specifically, Bliss et al. 
demonstrated that autopsy donor-derived fibroblasts obtained from the scalp, in addition to 
human dura mater from autopsy-derived brain tissue, can both be successfully reprogrammed to 
a pluripotent state (Bliss et al.).  These are additionally important avenues for future research, 
particularly for donation programs that only procure the brain (as opposed to whole-body 
donation).   
One important technical note is that while we know autopsy donor-derived fibroblasts can 
be reprogrammed to a pluripotent state, we do not know if this process is as efficient as 
fibroblasts isolated from living donors.  Future studies may include transduction experiments 
where fibroblasts derived from autopsy and living donors are tested for reprogramming efficiency 
side-by-side. In addition, we don’t know if elderly or autopsy donors are more likely to possess 
somatic cell mutations in their fibroblasts that could potentially be amplified in the cell population 
during iPSC clonal selection and cell line establishment.   
These results provide evidence that postmortem human tissue can be successfully 
reprogrammed to a pluripotent state. This approach may be significantly useful for studies 
investigating diseases and/or drugs that may cause sudden death and for neurodegenerative 
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disease research.  The ability to combine both clinical diagnostic criteria and postmortem 
histopathological observations can greatly increase neurodegenerative diagnostic accuracy; this 
may subsequently increase the statistical power for donor-specific in vitro disease models.  
Human iPSC-based disease models generated from postmortem tissue may provide additional 
confidence for researchers investigating these conditions, and provides an avenue for comparing 
differentiated in vitro cell types to endogenous adult tissue from the same individual.
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       CHAPTER 3 
IN VITRO-DIFFERENTIATED NEURAL CELL CULTURES PROGRESS TOWARDS  
DONOR-IDENTICAL BRAIN TISSUE 
Introduction 
Disease models for human genetic disorders exist in many forms, including transgenic 
animals (Chaible et al.; Pandey and Nichols), primary or immortalized human cell lines (Li and 
Zhou; Birney et al.), or the more recently described induced pluripotent stem cells (iPSCs) 
(Takahashi et al.; Yu et al.; Stadtfeld and Hochedlinger; Park et al.).  IPSCs are particularly 
intriguing tools for modeling human genetic disorders, because tissue-specific and disease-
applicable cell types that retain the donor’s complex genetics can be generated in vitro 
(Takahashi et al.; Yu et al.; Stadtfeld and Hochedlinger; Park et al.).  However, with any disease 
model system, there may be initial concerns about the physiological or pathological relevance of 
the model, and how subsequent drug screening or toxicity trials will correlate with clinical 
responses (Allen et al.; Marchetto, Winner and Gage; Han, Williams and Eggan; Murry and 
Keller; Hanna, Saha and Jaenisch; Wichterle and Przedborski; Stadtfeld and Hochedlinger; 
Patterson et al.). Potential challenges exist as to which iPSC-derived disease models will be able 
to produce a pathological phenotype, and how observed in vitro pathologies will correlate with in 
vivo disease onset, severity, progression and/or drug response (Wichterle and Przedborski; 
Marchetto, Winner and Gage; Han, Williams and Eggan; Hanna, Saha and Jaenisch; Stadtfeld 
and Hochedlinger; Patterson et al.).   
Neurodegenerative disorders are commonly misdiagnosed in live human patients; often, 
a diagnosis can only be confirmed or refuted with the additional observations of a postmortem 
neuropathological exam (Hjelm, Rosenberg, et al.; Beach, Sue, et al.; Nelson et al.; Rohrer et al.; 
Beach, Monsell, et al.).  Autopsy donors that have been subjected to these rigorous diagnostic 
criteria are especially useful for iPSC generation, because subsequent in vitro disease models 
can be produced with increased confidence that the donor was a neurological control (true 
negative; greater specificity) or possessed a specific neurological disease (true positive; greater 
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sensitivity) (Hjelm, Rosenberg, et al.).  In addition, this approach enables us to compare iPSC-
derived cell cultures to endogenous tissues from the same donor. 
In this study, we compared iPSC-derived neural cell cultures to donor-identical brain 
tissue.  This particular donor was a 75-year-old male, defined by both clinical criteria and 
postmortem neuropathological observations as a neurological control.  Data regarding the 
establishment of fibroblast cell lines, iPSC generation, and initial neural differentiation tests can 
be found in the Materials and Methods section of Chapter 2 (Hjelm, Rosenberg, et al.).  For this 
study, we differentiated iPSC-derived neural precursor cells (NPC) over a timecourse of 0, 35, 70, 
105, and 140 days (i.e., in 5-week intervals over a period of 20 weeks) and compared this to 
temporal lobe tissue from the same autopsy donor.  The neural differentiation protocol used in 
these studies was specific to the development of forebrain, cortical neurons (and glia), or what is 
commonly referred to as the “default” neural differentiation pathway when no additional 
morphogens are included in culture (Zeng et al.; Brennand et al.; Shi, Kirwan and Livesey; 
Mariani et al.).  As our endogenous tissue reference for these initial studies, we chose the 
temporal lobe because this brain region is part of the forebrain/cerebral cortex, and is 
pathologically relevant to multiple neurological conditions (including several late-onset diseases 
that are diagnostically aided by neuropathological confirmation) (Rohrer et al.; Beach, Sue, et al.; 
Nelson et al.; Scharfman; Whalley et al.).  The brain tissue used in this study was collected and 
frozen after a short postmortem interval (3.33hrs), thereby preserving the RNA integrity (Beach, 
Sue, et al.; Birdsill et al.), and allowing us to use RNA sequencing (RNA-Seq) analyses for our in 
vitro to brain tissue comparisons. 
RNA-Seq is a set of methods based upon next-generation sequencing technology that 
allows one to evaluate the transcriptome, effectively permitting single-transcript resolution of the 
expressed RNA transcripts at a particular snapshot in time, regardless of the transcript’s function 
or protein-coding potential (Trapnell, Pachter and Salzberg; Trapnell, Roberts, et al.; Trapnell, 
Williams, et al.).  This is a powerful tool because it allows us to study expression levels without 
any a priori hypotheses about which genes or regulatory features may be differentially expressed.  
In this study, we focused on differential expression (in vitro vs. brain tissue) of both well-
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annotated protein-coding genes, as well as long intergenic noncoding RNAs (lincRNAs), both of 
which have been shown to exhibit tissue-specificity and are considered developmentally 
important (Krupp et al.; Ponten et al.; Cabili et al.; Ashburner et al.; Guttman et al.).  Unlike other 
types of noncoding RNAs, lincRNAs do not overlap with well-annotated protein-coding genes 
allowing both features to be computationally tractable (Cabili et al.; Guttman et al.; Mercer, Dinger 
and Mattick).  
In addition to transcriptome analyses, we also analyzed a subset of our samples for 
differences in genome-wide CpG methylation using an array-based platform (Bibikova et al.).  
CpG methylation has been linked to differential gene expression, in both developmental and 
pathological contexts, and has been extensively studied in human cancer (Salhia et al.; Irizarry et 
al.; Feinberg and Tycko; Deaton and Bird). In addition, previous studies have shown that CpG 
methylation can distinguish cell types in a tissue-specific manner (Irizarry et al.; Doi et al.), and 
that methylation patterns vary between different regions of the brain (Ladd-Acosta et al.).  
Likewise, the specific methylation states of various loci have been shown to exhibit dynamic 
changes in the brain during development and aging (Siegmund et al.; Sharma, Gavin and 
Grayson).      
This study describes the transcriptional and methylation effects of in vitro neural 
differentiation and prolonged neural cell culture as it relates to the physiological levels exhibited 
by the endogenous brain tissue.  We hope that our donor-identical comparisons will provide a 
valuable resource for those interested in the physiological or pathological relevance of iPSC-
derived neurological disease models and the specific transcriptional progression of protein-coding 
genes and lincRNAs we observed in vitro. 
Materials and Methods 
Autopsy Donor and Brain Tissue Collection 
A 75-year-old male autopsy donor was identified as a neurological control (i.e., non-
demented, without histological diagnostic levels of any major neurological disease) by both 
clinical criteria and a postmortem pathology exam.  This subject was enrolled in the Banner Sun 
Health Research Institute (BSHRI) Brain and Body Donation Program as a whole-body donor and 
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had previously signed informed consent approved by the BSHRI Institutional Review Board (IRB) 
(Beach, Sue, et al.).  The brain of this autopsy donor was removed and specific regions or 
hemispheres were frozen after a short postmortem interval (PMI) (3.33hrs) and were stored at -
80°C for available use in future studies.  Frozen brain tissue from the temporal lobe, specifically 
the medial temporal gyrus, was selected as this region is pathological relevant to multiple 
neurological conditions.  One piece of temporal lobe brain tissue containing both white and gray 
matter was divided into three pieces that were all of approximate size (1cm x 1cm x 0.2cm).  Two 
of these pieces were subjected to RNA extraction and RNA-Seq, and were combined as 
replicates later during analysis (i.e., using Cuffdiff from the Cufflinks analysis package).  The third 
piece was used for DNA extraction and subsequent CpG methylation array studies. 
In Vitro Sample Collection and Neural Differentiation  
Autopsy donor-derived dermal fibroblasts were used for iPSC generation and subsequent 
neural differentiation studies.  Detailed methods regarding skin biopsies, fibroblast cell line 
establishment, iPSC generation, embryoid body (EB) formation and neural precursor cell (NPC) 
selection can be found in the Materials and Methods section of Chapter 2 (Hjelm, Rosenberg, et 
al.).  For review, iPSCs were generated using a lentiviral cocktail (Allele Biotechnology, San 
Diego, CA, USA) of the Yamanaka Factors (Oct3/4, Sox2, Klf4, c-Myc) under feeder-free 
conditions using mTeSR1 growth media (STEMCELL Technologies, Vancouver, BC, Canada) 
and Matrigel hESC-qualified adherent matrix (BD Biosciences, San Jose, CA, USA) (Ludwig et 
al.; Xu et al.; Takahashi et al.; Chan et al.).  EBs were generated using AggreWell 400 Plates 
(STEMCELL Technologies), followed by inductive loss of pluripotency (LOP), and NPCs were 
propagated and expanded in monolayer cultures using NeuroCult NS-A Proliferation media 
(STEMCELL Technologies) and Matrigel matrix (BD Biosciences) (Hjelm, Rosenberg, et al.; 
Schwartz et al.; Ma et al.).   
Early-passage (p3), IPSC-derived NPCs were differentiated into neurons and glia as 
previously described (Hjelm, Rosenberg, et al.), except that in these studies, NPCs were seeded 
at a lower cell density (2x103/cm2) so that a longer differentiation timecourse could be examined.  
NPCs were generated and maintained using the NeuroCult NS-A Proliferation Kit supplemented 
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with bFGF (10ng/ml), rhEGF (20ng/ml), Heparin (2µg/ml) (STEMCELL Technologies), 100 
units/ml penicillin, 100µg/ml streptomycin (Sigma Aldrich), and 5µg/ml Plasmocin prophylactic 
(Invivogen, San Diego, CA, USA). NPCs were expanded and passaged as monolayer cultures in 
wells pre-coated with BD Matrigel (BD Biosciences). NPCs were differentiated into forebrain, 
cortical neurons (and glia) on adherent Matrigel matrix using the Neurocult NS-A Differentiation 
Kit (STEMCELL Technologies) supplemented with 100 units/ml penicillin, 100µg/ml streptomycin 
(Sigma Aldrich), and 5µg/ml Plasmocin prophylactic (Invivogen).  Neural cell cultures were 
allowed to differentiate for 35, 70, 105, or 140 days, at which time the RNA was extracted and 
frozen at -80°C for RNA-Seq studies. Two independent experiments were performed at different 
times, and replicates from each independent timepoint were RNA extracted, library prepped, and 
sequenced separately.  Replicates were later combined during analysis (i.e., using Cuffdiff from 
the Cufflinks analysis package). The undifferentiated NPC sample and last differentiation 
timepoint (D140) were also used for DNA extractions and subsequent CpG methylation array 
analysis. 
Copy Number Variation (CNV) Analysis 
DNA was extracted from the IPSC line (2-13) and parental fibroblast (FO2AA1). DNA was 
extracted from both samples using the Qiagen Blood & Cell Culture DNA Mini Kit according to the 
manufacturer’s instructions (Qiagen, Valencia, CA, USA).  Genomic DNA was quantified using 
the Quant-iT PicoGreen dsDNA Assay (Life Technologies, Carlsbad, CA, USA). DNA quality was 
analyzed with both a 2% agarose gel and by evaluation of absorbance spectra from the ND-1000 
Spectrophotometer (NanoDrop, Wilmington, DE, USA).   
3.0µg genomic DNA per sample was used for next-generation sequencing library 
preparation, similar to our previously published methods (except that samples were not bar-coded 
for this study) (Craig, Pearson, et al.).  See RNA-Seq library prep methods section following 
cDNA conversion for more details.   
WGS libraries were sequenced across 13 lanes (IPSC, 8 lanes; fibroblast, 5 lanes) using 
the Illumina HiSeq 2000 (Bennett).  High quality (> Q30), paired-end sequencing reads (104 
cycles x 2) were obtained for both WGS samples.  Base calling and bcl to qseq conversion was 
   32 
performed using the Off-Line Basecaller (OLB), and qseq to fastq conversion was performed 
using the Consensus Assessment of Sequence and Variation (CASAVA) software (Illumina, San 
Diego, CA, USA).  Fastq files were aligned to build 37 of the human genome provided by the 
Genome Reference Consortium (GRCh37). Sequence alignment was performed using the 
Burrows-Wheeler Aligner (BWA), version 0.5.9-r16.  PCR duplicates were removed during WGS 
analysis, and only uniquely mapped read numbers are reported. 
CNV Analysis was performed using normalized sequencing coverage as previously 
described (Craig, O'Shaughnessy, et al.).  The methods for this type of analysis have been 
recently described by our group for the identification of CNVs in cancer using WGS from tumor-
normal pairs (Craig, O'Shaughnessy, et al.).  Analysis was performed with both the raw data, as 
well as data masked for repetitive regions (RepeatMasker).  CNV “hits” that were detected in both 
analyses were further evaluated by visual inspection.  Only small focal amplifications (4x) and 
deletions (2x) were detected between the iPSC and parental fibroblast; however, both deletions 
identified have been previously detected in other somatic studies and are likely also false-
positives.  This analysis demonstrated the iPSC line used in this study had a normal, diploid 
karyotype and did not contain any major chromosomal aberrations.   
Immunocytochemistry (ICC) Analysis 
 Differentiated neural cell cultures were grown on Matrigel-coated coverslips for 35 days 
(D35), at which point they were fixed in a solution of 4% paraformaldehyde (Thermo Scientific) in 
PBS (Invitrogen Carlsbad, CA, USA)) for 15min at RT, and were rinsed (and stored at 4°C) in 
PBS for later use.  Coverslips were permeabilized with a PBS solution of 0.1% Triton X-100 
(Sigma, St. Louis, MO, USA) for 10min, then were blocked in a solution of 2.5% BSA (Sigma) in 
PBS-T (PBS with 0.01% Tween 20 (VWR)) for 30min at room temperature (RT).  Primary 
antibodies were all incubated overnight on a rotating shaker at 4°C.  Primary antibodies included 
the following: TUBB3 (1:2000; Abcam ab18207), MAP2 (1:1000; EnCor Biotech. CPCA-MAP2), 
VGLUT1 (1:1000; Synaptic Systems 135-303), and GAD67 (1:300; Abcam ab26116).  Coverslips 
were then washed 3X for 20min each in 2X PBS-T (PBS with 0.02% Tween 20), followed by 
another 30min blocking step.  Alexa Fluor-conjugated secondary antibodies (1:2000; Alexa Fluor 
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488 or 647 (Invitrogen)) were then incubated on the coverslips for 1hr at RT.  The coverslips were 
washed 3X again, and were then counterstained with DAPI (1µg/ml) for 10min.  Coverslips were 
mounted onto slides with SlowFade Gold antifade reagent (Invitrogen) and were sealed with clear 
nail polish.  All confocal microscopy images were obtained using an Olympus Fluoview FV1000 
confocal microscope and the Olympus FV10-ASW 1.7 imaging analysis software.  All confocal 
micrographs displayed are 3-D reconstructions from 10-15 1µm optical sections through the Z-
axis.   
RNA-Seq Library Preparation and Next-Generation Sequencing  
 RNA was extracted from both the in vitro neural samples and the endogenous brain 
tissue using TRIzol (Ambion, Life Technologies, Carlsbad, CA, USA) and the PureLink RNA Mini 
Kit along with an on-column DNase treatment (Life Technologies, Carlsbad, CA, USA) according 
to the manufacturer’s instructions.  Extracted RNA was quantified and qualified using Agilent RNA 
6000 Nano kits and the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).  
All samples had an RNA Integrity Number (RIN) between 8.5 and 10.  100ng total RNA was 
linearly amplified and converted to double-stranded cDNA using the Ovation RNA-Seq System 
(NuGEN, San Carlos, CA, USA) as per the manufacturer’s instructions (Tariq et al.).  Double-
stranded cDNA was quantified using the Quant-iT PicoGreen dsDNA Assay (Life Technologies). 
 Between 1.8µg and 3.0µg cDNA per sample was used for next-generation sequencing 
library preparation, similar to our previously published methods (except that samples were not 
bar-coded for this study) (Craig, Pearson, et al.).  cDNA was fragmented by sonication in 
6x16mm glass microtubes (Covaris #520045) using the Covaris S2 instrument (Covaris, Woburn, 
MA, USA).   Settings for fragmentation included a duty of 5%, intensity = 3, 200 cycles/burst, and 
two 30 second cycles.  The majority of the cDNA was between 200-650bp after sonication.  
Fragmented cDNA was subjected to end repair using the NEBNext end repair buffer and enzyme 
(New England BioLabs, Ipswich, MA, USA), followed by purification using Agencourt Ampure 
Beads (Beckman Coulter, Brea, CA, USA).  End-repaired cDNA was subjected to A-tailing using 
the NEBNext dA-Tailing buffer and Klenlow Fragment (New England BioLabs), followed by 
purification using Agencourt Ampure Beads (Beckman Coulter).  Samples were then quantified 
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using the Quant-iT PicoGreen dsDNA Assay (Life Technologies).   Illumina-compatible adapters 
(IDT) were ligated onto A-tailed samples at a 10:1 molar ratio (adaptor:DNA) using the NEBNext 
Quick T4 DNA Ligase and Quick Ligation buffer (New England BioLabs).  Samples were ran on a 
3% agarose gel containing GelStar (Lonza) for approximately 3hrs and DNA/gel was cut out of 
each lane at approximately 400bp and extracted using the Quantum Prep Freeze ‘N  Squeeze 
DNA extraction spin columns according to the manufacturer’s instructions (Bio-Rad).  Ligated 
samples were amplified by enrichment PCR (10 cycles) using primers specific to the adapter 
sequences.  Amplified samples were isolated using a 2.5% agarose gel and Freeze N’ Squeeze 
purification as previously described.  Extracted libraries were further purified by ethanol 
precipitation and were resuspended in 50µl sterile H2O. Libraries were quantified and qualified 
using the Agilent High Sensitivity DNA Kit, and RNA-Seq libraries had a final size distribution of 
230-350bp.  RNA-Seq libraries were sequenced with one sample per lane using the Illumina 
HiSeq 2000 (Bennett).  High quality (> Q30), paired-end sequencing reads (104 cycles x 2) were 
obtained for all RNA-Seq samples.  
Sequence Alignment and RNA-Seq Analysis  
 Base calling and bcl to qseq conversion was performed using the Off-Line Basecaller 
(OLB), and qseq to fastq conversion was performed using the Consensus Assessment of 
Sequence and Variation (CASAVA) software (Illumina, San Diego, CA, USA).  Eight nucleotides 
were computationally trimmed off of the 5’ end of each paired-end read, to avoid poor alignment 
due to the possible incorporation of the SPIA primer used during RNA-Seq library preparation 
(i.e., in Ovation RNA-Seq System).  Fastq files were aligned to build 37 of the human genome 
provided by the Genome Reference Consortium (GRCh37).  Transcript alignment was performed 
using TopHat (version 1.3.2) as previously described (Trapnell, Pachter and Salzberg). 
 Analysis of differential expression and transcript abundance was performed using Cuffdiff 
from the Cufflinks analysis package (version 1.3.0) (Trapnell, Roberts, et al.; Trapnell, Williams, 
et al.).  All replicates from independent experiments or tissue pieces were combined analytically 
during Cuffdiff analysis.  Cuffdiff run included the same reference as was previously used for 
TopHat alignment (GRCh37.62), and any transcript associated with ribosomal RNA (rRNA) genes 
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or pseudogenes, transfer RNA (tRNA) genes or pseudogenes, or mitochondrial (mt) genes were 
ignored during analysis (using MASK file specific to these features created from the same 
genome reference).  All samples were normalized to both the compatible-hits and upper-quartile.  
For Cuffdiff analysis on genes, data was annotated using the Human gtf file from Ensembl 
(release 63); for Cuffdiff analysis on lincRNAs, data was annotated to the lincRNA gtf file provided 
in the supplemental section of Cabili et al. (Cabili et al.). 
 For expression analysis on genes, a list was obtained from the Consensus CDS (CCDS) 
project (release 9/7/11) that originally contained 27,816 CCDS IDs.  This list was limited to only 
“public” genes; any IDs “withdrawn,” “pending,” or “under review” were manually removed.  This 
list was further limited to those with unique gene IDs and those that were present in our Cuffdiff 
output file, resulting in 18,062 CCDS genes that were used for transcriptome analysis.  Lists of 
GO Processes specific to “Brain Development Genes” (443) and “Non-Brain Development 
Genes” (avg. 132) were obtained from the MetaCore search engine from GeneGo Inc. as 
previously described (Ashburner et al.).  For expression analysis on lincRNAs, a list of 8,262 
putative lincRNAs was obtained from the annotation file provided by Cabili et al. (Cabili et al.).  
Likewise, tissue-classified lists of lincRNAs specific to the brain (183) and other non-brain tissues 
(avg. 130) were obtained from the online supplemental data of Cabili et al. (Cabili et al.).  
Additional details about tissue-specific lists can be found in the Results section of this chapter. 
CpG Methylation Array and Analysis   
 DNA was extracted from the NPC and D140 in vitro neural samples, along with the brain 
tissue sample (i.e., BRAIN).  In vitro neural samples were treated with Proteinase K for 1hr prior 
to DNA extraction, and the frozen brain tissue sample was treated with Proteinase K for 24hr prior 
to DNA extraction.  DNA was extracted from all samples using the Qiagen Blood & Cell Culture 
DNA Mini Kit according to the manufacturer’s instructions (Qiagen).  Genomic DNA was 
quantified using the Quant-iT PicoGreen dsDNA Assay (Life Technologies). DNA quality was 
analyzed with both a 2% agarose gel and by evaluation of absorbance spectra from the ND-1000 
Spectrophotometer (NanoDrop).   
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 1µg genomic DNA per sample was used for the Illumina Infinium HumanMethylation450 
Bead Chip, and the chip was prepared and ran according to the manufacturer’s instructions 
(Illumina) (Bibikova et al.).  This array had a total of 485,577 probe sites.  Any probe with a 
detection p-value > 0.01 for any of the three samples was manually removed, resulting in 485,261 
probes that were evaluated for differential methylation.  Differential methylation was defined as a 
site that had a beta value difference of at least 20% (i.e., ≥ 0.2).  Analysis of differential 
methylation for all methylation sites, as well as those specific to CpG Islands, shore or shelves, 
was performed using Microsoft Excel.   
Data Access 
 Sequencing data will be deposited in the NIH database of Genotypes and Phenotypes 
(dbGaP).   
Graphical Analysis and Figures  
For the primary figures, density plots (Fig. 11) and heatmaps (Fig. 19) were created using 
R Studio.  Brightfield images (Fig. 8) were taken using a Leica DM IL inverted microscope with 
the Leica DFC 290 digital camera and Leica Application Suite software (version 2.8.1).  Confocal 
micrographs were obtained using an Olympus Fluoview FV1000 confocal microscope and the 
Olympus FV10-ASW 1.7 imaging analysis software (Fig. 10).  Rank-order scatter plots (Fig. 11), 
line graphs (Fig. 14), and bar graphs (Figs. 16, 17, 18) were created using Microsoft Excel.  
Schematic diagram (Fig. 8) and figures were prepared using Microsoft Powerpoint. Scatter plots 
and rank correlations (Spearman’s rank correlation tests; Figs. 12,13) were produced using R 
Studio.  The number of mapped reads per chromosome was calculated using the flagstat 
command in SAMTools, and table was generated using Microsoft Word (Table 4).  CNV plots 
were generated using R Studio (Fig. 9). Venn diagrams (Fig. 15) were created in Microsoft 
Powerpoint.  List of genes found to be upregulated or downregulated in vitro in the published 
study of Patterson et al. were obtained from their heatmap figure, and those available for analysis 
in our dataset were evaluated further (Table 5) (Patterson et al.).  Binomial distribution tests for 
overlap between our data and those of Patterson et al. were performed in Microsoft Excel (Table 
5).  
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Results 
Samples and Experimental Design 
We selected a 75-year-old, male autopsy-donor with no neurological conditions for these 
initial in vitro to brain tissue comparisons. This donor was cognitively normal, and the postmortem 
neuropathological exam revealed he had a Braak score (Stage 1) and a CERAD Neuritic Plaque 
score (0) consistent with an unaffected neurological control.  A schematic diagram of our 
experimental design, along with samples selected for both RNA-Seq and CpG methylation 
analyses are shown (Fig. 8A).  Briefly, early-passage (p3), iPSC-derived neural precursor cells 
(NPC) were used for two independent experiments, and were differentiated in vitro for a period of 
35, 70, 105, or 140 days. Sample acronyms used for the neural differentiated samples in this 
study are listed (D35, D70, D105, D140) (Fig. 8A).   
Differentiated neural samples were only selected for analysis in the case where at least 
80% of the cells appeared neuronal by the first differentiation timepoint (D35) (i.e., exhibited 
neuritic cell-to-cell processes distinguishable by brightfield microscopy as shown in D140 sample) 
(Fig. 8B).  A representative image of a piece of temporal lobe tissue used for RNA-Seq and CpG 
methylation analysis is also shown; all three tissue pieces had approximately the same amount of 
white matter (wm) and grey matter (gm) (Fig. 8B).  
An average of 33.2 ± 11.7-million quality reads per sample library (mapped to GRCh37) 
were used for RNA-Seq analysis, and the number of sequencing reads for each RNA-Seq sample 
and replicate can be found in Table 4.  The number of unique whole genome sequencing (WGS) 
reads (for both the iPSC and parental fibroblast) used for CNV analysis can also be found in 
Table 4.  The CNV analysis demonstrated the iPSC line used in this study had a normal, diploid 
karyotype and did not contain any major chromosomal aberrations (Fig. 9). 
Differentiated neural cell cultures that met our selection criterion were further evaluated 
by immunocytochemistry (ICC) for verification of neuronal identity and population architecture 
(Fig. 10).  The differentiated neural cell cultures contained a mixed population of both immature 
(TUBB3+/MAP2-) and mature (TUBB3+/MAP2+) neurons at the first differentiation timepoint 
(D35) (Fig. 10).  As a whole, the in vitro cell populations were mostly (≥ 85%) neurons (TUBB3+),  






















Figure 8.   
 
In Vitro and Tissue-Derived Neural Samples. (A) Schematic diagram of experimental design, 
comparing in vitro iPSC-derived neural cell populations to donor-identical brain tissue. Samples 
used for RNA-Seq and CpG methylation analyses are displayed, along with the corresponding 
sample acronyms that are used in subsequent figures (i.e., NPC, D35-D140, BRAIN).  (B) 
Brightfield images of neural cell cultures at the beginning (NPC) and end (D140) of the 
experimental timecourse.  NPC images show clusters of undifferentiated cell populations, while 
D140 images show differentiated neurons with abundant neuritic processes. Photographic image 
of the frozen, temporal lobe brain tissue sample is also shown (in dashed circle).  All tissue 
pieces used for RNA-Seq and CpG methylation analyses were approximately the same size and 
had the same proportion of white matter (wm) and gray matter (gm) (Hjelm, Salhia, et al.).  
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Table 4.  
 
RNA-Seq and WGS Reads per Chromosome. The number of mapped reads for each autosome 
and sex chromosome, as well as the combined total, is shown for all samples sequenced by (A) 
transcriptome sequencing (RNA-Seq) and (B) whole genome sequencing (WGS). All read 








   Whole Genome Sequencing (WGS)                                             Transcriptome Sequencing (RNA-Seq) 
   # (millions) Mapped Reads - Duplicates                                                                                                   # (millions) Mapped Reads 
 Chromosome    Fibroblast        iPSC                              Chromosome        NPC        D35a        D35b        D70a        D70b        D105a      D105b      D140a      D140b      BRAINa    BRAINb 
            1                    22.4              49.9            1                3.3           2.1           1.9           6.3           3.8            3.0           3.7           3.5          3.9             2.8          3.3 
            2                    21.4              52.2            2                2.9           1.7           1.5           5.3           3.4            2.8           2.7           2.7          2.9             2.6          3.0 
            3                    16.7       42.6            3                2.0           1.4           1.3           4.7           2.7            2.3           2.3           2.4          2.3             2.2          2.4 
            4                    14.2       41.4                           4                1.5           1.0           0.9           3.3           2.1            1.7           1.5           1.6          1.5             1.7          2.0 
            5                    15.1       33.8            5                2.3           1.4           1.3           4.5           2.8            2.2           2.3           2.3          2.5             2.0          2.1 
            6                    14.5       37.1            6                1.8           1.0           0.9           3.3           2.1            1.7           1.8           1.8          1.8             1.7          1.8 
            7                    14.1       33.9            7                1.7           0.9           0.9           3.3           1.9            1.5           1.8           1.8          1.8             1.7          1.7 
            8                    12.9       31.6            8                1.2           0.8           0.7           2.6           1.7            1.2           1.3           1.3          1.4             1.2          1.5 
            9                    11.2       26.0            9                1.3           0.7           0.6           2.4           1.5            1.2           1.2           1.3          1.4             1.3          1.4 
          10                    13.1       29.1                                           10                1.4           0.7           0.6           2.4           1.4            1.1           1.2           1.2          1.4             1.4          1.5 
          11                    12.4       28.1                                           11                1.7           1.9           1.5           5.7           3.0            2.6           1.9           2.4          2.4             1.9          2.2  
          12                    12.0       28.4                                           12                2.1           1.0           0.9           3.2           2.1            1.7           1.7           1.6          1.9             1.2          1.5 
          13                      7.4       20.7                                           13                1.2           0.7           0.7           2.1           1.4            1.1           1.3           1.1          1.2             1.3          1.3 
          14                      8.1       19.2                                           14                1.0           0.6           0.5           2.0           1.1            0.9           0.9           1.0          1.1             1.1          1.2 
          15                      8.3       17.8                                           15                1.0           0.5           0.5           1.8           1.1            0.8           0.9           1.0          1.1             1.0          1.0 
          16                      9.7       18.2          16                0.8           0.4           0.4           1.5           0.8            0.7           1.1           0.9          1.1             0.7          0.8 
          17                      9.0       16.6          17                1.2           0.7           0.5           1.9           1.2            0.9           1.3           1.1          1.5             0.8          0.9 
          18                      6.6       16.4          18                0.5           0.3           0.3           1.0           0.6            0.5           0.5           0.6          0.6             0.7          0.7 
          19                      7.0       11.4          19                0.6           0.3           0.3           0.9           0.5            0.5           0.8           0.6          0.9             0.4          0.5 
          20                      6.7       12.8          20                0.7           0.3           0.3           1.1           0.6            0.5           0.7           0.7          0.7             0.5          0.5 
          21                      3.5         8.6          21                0.3           0.2           0.2           0.6           0.4            0.3           0.4           0.4          0.4             0.3          0.3 
          22                      4.4         7.2          22                0.3           0.2           0.1           0.6           0.3            0.3           0.4           0.4          0.5             0.2          0.3 
           X                       6.9       17.1                          X                 0.9           0.6           0.6           2.2           1.3            1.0           1.2           1.1          1.3             1.1          1.1 
           Y                       1.6         3.9           Y                 0.1           0.0           0.0           0.2           0.1            0.1           0.1           0.1          0.1             0.1          0.1 
      TOTAL               259.5           604.0                                       TOTAL          31.7         19.6         17.3         62.9         37.9          30.6         33.1         32.9        35.7           30.0        33.2 
    Coverage   10X      22X                               a, b = biological replicates from independent experiments or tissue pieces (combined as replicates during Cuffdiff analysis) 
 
 
                                                                     
                                                                                        
    
  
           
 
B.  A.  
Supplemental Table S1.  Whole Genome Sequencing (WGS) and Transcriptome (RNA-Seq) Read Counts and Coverage.  (A) Uniquely mapped reads (no 
duplicates) for parental fibroblast (FIB) and induced pluripotent stem cell (iPSC) line 2-13.  Mapped reads are shown for each autosome and sex chromosome, as well 
as the whole genome (Total).  Average genome-wide coverage is also shown for both samples. (B) Mapped reads for all in vitro and in vivo neural samples used for 
RNA-Seq analyses.  All differentiated in vitro and in vivo samples were collected as biological replicates (independent experiments or separate tissue pieces), which 
were prepared as unique libraries and sequenced separately.  Mapped reads are shown for each autosome and sex chromosome, as well as the whole transcriptome  







   Whole Genome Sequencing (WGS)                                             Transcriptome Sequencing (RNA-Seq) 
   # (millions) Mapped Reads - Duplicates                                                                                                   # (millions) Mapped Reads 
 Chromosome    Fibroblast        iPSC                              Chromosome        NPC        D35a        D35b        D70a        D70b        D105a      D105b      D140a      D140b      BRAINa    BRAINb 
            1                    22.4              49.9            1                3.3           2.1           1.9           6.3           3.8            3.0           3.7           3.5          3.9             2.8          3.3 
            2                    21.4              52.2            2                2.9           1.7           1.5           5.3           3.4            2.8           2.7           2.7          2.9             2.6          3.0 
            3                    16.7       42.6            3                2.0           1.4           1.3           4.7           2.7            2.3           2.3           2.4          2.3             2.2          2.4 
            4                    14.2       41.4                           4                1.5           1.0           0.9           3.3           2.1            1.7           1.5           1.6          1.5             1.7          2.0 
            5                    15.1       33.8            5                2.3           1.4           1.3           4.5           2.8            2.2           2.3           2.3          2.5             2.0          2.1 
            6                    14.5       37.1            6                1.8           1.0           0.9           3.3           2.1            1.7           1.8           1.8          1.8             1.7          1.8 
            7                    14.1       33.9            7                1.7           0.9           0.9           3.3           1.9            1.5           1.8           1.8          1.8             1.7          1.7 
            8                    12.9       31.6            8                1.2           0.8           0.7           2.6           1.7            1.2           1.3           1.3          1.4             1.2          1.5 
            9                    11.2       26.0            9                1.3           0.7           0.6           2.4           1.5            1.2           1.2           1.3          1.4             1.3          1.4 
          10                    13.1       29.1                                           10                1.4           0.7           0.6           2.4           1.4            1.1           1.2           1.2          1.4             1.4          1.5 
          11                    12.4       28.1                                           11                1.7           1.9           1.5           5.7           3.0            2.6           1.9           2.4          2.4             1.9          2.2  
          12                    12.0       28.4                                           12                2.1           1.0           0.9           3.2           2.1            1.7           1.7           1.6          1.9             1.2          1.5 
          13                      7.4       20.7                                           13                1.2           0.7           0.7           2.1           1.4            1.1           1.3           1.1          1.2             1.3          1.3 
          14                      8.1       19.2                                           14                1.0           0.6           0.5           2.0           1.1            0.9           0.9           1.0          1.1             1.1          1.2 
          15                      8.3       17.8                                           15                1.0           0.5           0.5           1.8           1.1            0.8           0.9           1.0          1.1             1.0          1.0 
          16                      9.7       18.2          16                0.8           0.4           0.4           1.5           0.8            0.7           1.1           0.9          1.1             0.7          0.8 
          17                      9.0       16.6          17                1.2           0.7           0.5           1.9           1.2            0.9           1.3           1.1          1.5             0.8          0.9 
          18                      6.6       16.4          18                0.5           0.3           0.3           1.0           0.6            0.5           0.5           0.6          0.6             0.7          0.7 
          19                      7.0       11.4          19                0.6           0.3           0.3           0.9           0.5            0.5           0.8           0.6          0.9             0.4          0.5 
          20                      6.7       12.8          20                0.7           0.3           0.3           1.1           0.6            0.5           0.7           0.7          0.7             0.5          0.5 
          21                      3.5         8.6          21                0.3           0.2           0.2           0.6           0.4            0.3           0.4           0.4          0.4             0.3          0.3 
          22                      4.4         7.2          22                0.3           0.2           0.1           0.6           0.3            0.3           0.4           0.4          0.5             0.2          0.3 
           X                       6.9       17.1                          X                 0.9           0.6           0.6           2.2           1.3            1.0           1.2           1.1          1.3             1.1          1.1 
           Y                       1.6         3.9           Y                 0.1           0.0           0.0           0.2           0.1            0.1           0.1           0.1          0.1             0.1          0.1 
      TOTAL               259.5           604.0                                       TOTAL          31.7         19.6         17.3         62.9         37.9          30.6         33.1         32.9        35.7           30.0        33.2 
    Coverage   10X      22X                               a, b = biological replicates from independent experiments or tissue pieces (combined as replicates during Cuffdiff analysis) 
 
 
                                                                     
                                                                                        
    
  
           
 
B.  A.  
Supplemental Table S1.  Whole Genome Sequencing (WGS) and Transcriptome (RNA-Seq) Read Counts and Coverage.  (A) Uniquely mapped reads (no 
duplicates) for parental fibroblast (FIB) and induced pluripotent stem cell (iPSC) line 2-13.  Mapped reads are shown for each autosome and sex chromosome, as well 
as the whole genome (Total).  Average genome-wide coverage is also shown for both samples. (B) Mapped reads for all in vitro and in vivo neural samples used for
RNA-Seq analyses.  All differentiated in vitro and in vivo samples were collected as biological replicates (independent experiments or separate tissue pieces), which
were prepared as unique libraries and sequenced separately.  Mapped reads are shown for each autosome and sex chromosome, as well as the whole transcriptome  
(Total).  Overall, RNA-Seq libraries had an average of 33.2 million mapped reads per sample.    
A
B




Figure 9.   
 
Copy Number Variation (CNV) Analysis using Whole Genome Sequencing (WGS) Data.  
Chromosomal aberration plots comparing induced pluripotent stem cells (iPSC) line 2-13 to 
parental fibroblast cell line (F02AA1). Copy number variations (CNVs) were defined as regions or 
loci that had a log2 fold change (iPSC/FIB) > +0.75 (i.e., gain in iPSC) or < -0.75 (i.e., loss in 
iPSC) using normalized coverage comparisons obtained by whole genome sequencing (WGS).  
All detected CNVs were manually inspected at high resolution for false positives prior to 
annotation. Focal regions amplified (gain) are circled in red, while deletions (loss) are circled in 
green; any gene localized to a detected CNV is shown alongside the event in the corresponding 
color.  The results from this analysis support that the iPSC line in these studies had a normal, 
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Figure 10.   
 
Immunocytochemistry analysis of in vitro neural cell cultures at the first differentiation timepoint 
(D35).  The neuronal marker TUBB3, glutamatergic marker VGLUT1, and GABAergic marker 
GAD67 (all green; Alexa Fluor 488) were counterstained against the mature neuronal marker 
MAP2 (red; Alexa Fluor 647).  DAPI (blue) is shown in all images as a nuclear counterstain.  All 
scale bars = 100 µm.  All images (confocal micrographs) and are 3-D reconstructions from 10-15 
1µm optical sections through the Z-axis.  Region of interest (white box) in merged image (left 
most) is shown at higher magnification (2nd from left most).  TUBB3/MAP2 image sets 
demonstrate regional heterogeneity of areas with both immature (TUBB3+/MAP2-) and mature 
(TUBB3+/MAP2+) neurons (1st row), and areas dominated by mature (TUBB3+/MAP2+) neurons 
(2nd row).  VGLUT1 staining demonstrated vesicular-like localization in immature neurons and 
localization to both the cell body and neuritic processes in mature neurons (3rd row).  GAD67 was 
only detected in mature neurons (4th row).  See results section for population percentages (Hjelm, 
Salhia, et al.).  
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and about one third (30-35%) of these neurons were mature (MAP2+).  Both glutamatergic 
(VGLUT1+) and GABAergic (GAD67+) neurons were identified (Fig. 10).  VGLUT1 expression 
was detected in the majority (70-75%) of neurons, regardless if they were mature (MAP2+) or not.  
However, VLGUT1 expression in immature neurons appeared as strong, punctate staining in the 
cell body, consistent with a vesicular localization, while mature neurons (MAP2+) expressed 
VGLUT1 all along the neuritic processes in addition to the cell body.  GAD67 expression was only 
detected in a subset (15-20%) of mature (MAP2+) neurons.  ICC analyses were performed 
across three iPSC clones from the same donor, including the clone used for these RNA-Seq 
studies, verifying that the neural differentiation efficiency and percent of neuronal subtype 
markers evaluated were both reproducible.  ICC analyses, previous studies, and our currently 
described RNA-Seq data, demonstrate a small proportion (≤ 5%) of the cell population was 
astrocytic glia (Hjelm, Rosenberg, et al.).   
In Vitro Neural Cells Undergo Progressive Activation of Transcription and CpG Methylation 
Studies using gene expression microarrays and RNA-Seq have demonstrated there are 
an increased number of actively transcribed genes in the brain compared to most other tissues, 
although there are exceptions (Ramskold et al.; Jongeneel et al.).  This observation of increased 
transcriptional activation is presumably due to a high level of cell population complexity within the 
brain (Ramskold et al.; Jongeneel et al.; H. J. Kang et al.).  In addition, functional features like 
postsynaptic membranes have been predicted to contain hundreds to thousands of proteins, and 
these numbers have been shown to increase during neuronal differentiation and subsequent 
equilibrium (Sugiyama et al.; Bayes and Grant).  
Due to the possible added effects of population and functional complexity in the brain or 
cortex, we detected a high number of actively transcribed genes in our temporal lobe tissue 
sample (i.e., BRAIN).  Specifically, out of 18,062 consensus CDS (CCDS) protein-coding genes 
evaluated, 82.9% (14,971) had detectable transcript expression values, or FPKM (i.e., Fragments 
Per Kilobase of exon per Million fragments mapped) above our cutoff (FPKM > 0.01), and 63.9% 
(11,538) had a FPKM > 1.  Previous studies using RNA-Seq or gene expression arrays have 
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reported a similar percentage of expressed genes (e.g., 71%, 76%, 82%, 86%) within the 
developing or adult brain (Ramskold et al.; H. J. Kang et al.; Johnson et al.).  Differences in 
technologies used for transcript abundance estimations, in addition to differences in the total 
number of sequencing reads, may affect the total number of expressed transcripts detected; as 
such, these published values may not be directly comparable with our data. 
An initial inspection of transcript data showed an increase in the number of actively 
transcribed, protein-coding genes as the in vitro neural samples progressed through our 
differentiation timecourse.  Specifically and for comparison, 73.1% (13,199), 75.6% (13,661), 
78.8% (14,239), 77.5% (14,003), and 82.0% (14,811) of CCDS genes had an FPKM > 0.01, for 
our NPC, D35, D70, D105, and D140 samples, respectively.  Likewise, 50.2% (9,060), 53.5% 
(9,662), 56.2% (10,146), 56.9% (10,269), and 61.3% (11,066) of CCDS genes had an FPKM > 1 
in these samples (listed in order).  Statistical analysis showed a significant increasing monotonic 
correlation between the days of our timecourse and the percent (or number) of actively 
transcribed genes as determined by a one-tailed non-parametric Kendall’s tau correlation test.  
This significant correlation was observed for both the cutoffs used to evaluate transcriptional 
activation (FPKM > 0.01, p < 0.05; FPKM > 1, p < 0.01). 
In order to better characterize the transcript diversity, we conducted a density analysis of 
all transcripts under varying FPKM values.  Density plots can be used for meta-analysis and 
visualization of the FPKM distributions, and have been previously described by Trapnell et al. in 
their published methods regarding RNA-Seq analysis and the CummeRbund analysis package 
(Trapnell, Roberts, et al.).  For clarification, a pseudo-count of 0.01 was added to all FPKM values 
so that density plots could be displayed on a log10 scale.  As such, density plots exhibit a bimodal 
distribution, whereby the first peak shows the density of inactive, non-expressed or ‘off’ genes, 
while the second peak shows the density and distribution of actively transcribed, expressed or 
‘on’ genes in that sample.  Density plots show a decrease in inactive genes (shrinkage in first 
peak) and an increase in actively transcribed genes (augmentation in second peak) as our 
differentiation timecourse progressed (Fig. 11A). The temporal lobe also showed a higher density 
of actively transcribed genes and is plotted alongside the in vitro samples as a reference        
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(Fig. 11A).  In summation, the density plots and rank-ordered scatter plots show a systematic 
increase of area under the second curve, consistent with transcriptional activation of CCDS 
genes (Fig. 11A,D).           
 In addition to the progressive increase in the number of actively transcribed CCDS 
genes, we also observed a progressive increase in the number of lincRNA transcripts expressed, 
although this trend was less linear than that of protein-coding genes (R2≅0.75 vs. R2≅0.91) (data 
not shown).  Out of 8,262 putative lincRNAs previously described by Cabili et al. (Cabili et al.), the 
temporal lobe sample (BRAIN) had 31.7% (2,623) of lincRNA actively expressed at an FPKM > 
0.01, and 31.2% (2,581) had an FPKM > 1 in this sample.  Comparatively, the in vitro neural 
samples showed 16.0% (1,318), 18.7% (1,544), 25.3% (2,087), 22.5% (1,855), and 25.4% 
(2,097) of lincRNAs had an FPKM > 0.01, for our NPC, D35, D70, D105, and D140 samples, 
respectively.  Likewise, 15.5% (1,280), 18.1% (1,496), 24.0% (1,986), 21.5% (1,775) and 24.4% 
(2,020) of lincRNAs had an FPKM > 1 (listed in order).  Statistical analysis showed a significant 
increasing monotonic correlation between the days of our timecourse and the percent (or 
number) of actively transcribed lincRNAs as determined by a one-tailed non-parametric Kendall’s 
tau correlation test.  This significant correlation was observed for both the cutoffs used to 
evaluate transcriptional activation (FPKM > 0.01, p < 0.05; FPKM > 1, p < 0.05). 
There was a smaller percentage of lincRNAs expressed in both the in vitro neural 
samples and the endogenous brain tissue than there were protein-coding genes.  These 
observations have been previously reported by others and are likely, in part, due to the high level 
of tissue-specificity in lincRNAs and a lower level that are constitutively active compared to 
protein-coding genes (Cabili et al.).   On average, 23.2% to 22.5% of lincRNAs were expressed in 
our neural samples, for FPKM > 0.01 and > 1, respectively.  In contrast, 78.3% to 57% of protein-
coding genes were expressed (on average) in our neural samples, for FPKM > 0.01 and > 1. 
Density plots and rank-ordered scatter plots demonstrate this increase in transcriptional activation 
of lincRNAs, as previously described for CCDS genes (Fig. 11B,E).  Interestingly, for both 
protein-coding genes (18,062) and putative lincRNAs (8,262), we saw an activation rate or slope 
of ≅2.2% per timepoint, or ≅0.4% per week, as determined by linear equation tests for our in vitro 
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samples (data not shown).  We also observed increased variation between our replicates (for 
both CCDS genes and lincRNAs) as our timecourse progressed, and more variability in 
progressive transcriptional activation at the middle stages of our timecourse, as determined by 
Spearman’s correlation coefficients of the FPKM rankings (Figs. 12, 13). 
As a final measure of the global differences between our in vitro samples and the 
endogenous brain tissue, we performed density analysis on methylation sites (485,261) with 
varying levels of methylation (i.e., beta values) obtained from a genome-wide methylation array. 
We observed an increased number of methylated CpG sites in the last neural differentiation 
timepoint (D140) compared to the methylated sites at the beginning or our timecourse (NPC), and 
this correlated with increased methylation in the tissue (BRAIN) (Fig. 11C).  Beta value bins of < 
0.2 (unmethylated) and > 0.8 (methylated) have been previously described by Illumina 
publications describing these arrays (Bibikova et al.).  From the 485,261 methylation sites 
examined, the temporal lobe tissue sample (BRAIN) had 30.8% (149,561) of these sites with a 
beta value > 0.8. In comparison, the two in vitro samples examined had 17.6% (85,259) and 
29.3% (142,285) of sites with a beta value > 0.8, for the NPC and D140 samples respectively.  
Conversely, 44.3% (215,021), 33.3% (161,552) and 35.8% (173,711) of these sites had a beta 
value < 0.2, for the NPC, D140, and BRAIN samples, respectively. Density plots and rank-order 
scatter plots demonstrate this increase in genome-wide DNA methylation (Fig. 11C,F). 
The Percent of In Vitro to Tissue Differences Decreases During Differentiation, but Demonstrates  
Variation Dependent on Tissue-Specificity (Genes and lincRNAs) and Proximal Relation to CpG 
Islands (Methylation)   
 In order to stratify in vitro to brain tissue comparisons into more specific and informative 
datasets, statistical analysis of differential expression was performed between each in vitro neural 
sample (NPC, D35, D70, D105, D140) and the endogenous brain tissue (BRAIN), for all CCDS 
genes (18,062) and putative lincRNAs (8,262) using Cuffdiff from the Cufflinks analysis package 
(Trapnell, Williams, et al.).  Specifically, genes and lincRNAs that had both a log2 fold-change > 
+2 and a p-value < 0.01 were defined as significantly upregulated in vitro, and those that had both 
a log2 fold-change < -2 and a p-value < 0.01 were defined as significantly downregulated in vitro.  
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Figure 11.   
Global Transcription and CpG Methylation. Density plots of RNA expression (i.e., FPKM(log10)) 
for (A) CCDS genes (N=18,062) and (B) lincRNAs (N=8,262).  First plot (top left) displays the 
overlay of all samples.  Subsequent plots display the overlay of each individual in vitro sample 
along with the endogenous brain tissue. (C) Density plots of CpG methylation (i.e., beta values) 
for all sites on the Illumina Infinium HumanMethylation450 Bead Chip (N=485,261).  First plot 
(left) displays overlay of the three samples analyzed for CpG methylation differences (NPC, 
D140, BRAIN).  Subsequent plots display overlay of the two in vitro samples along with the brain 
tissue.  Rank-order scatter plots for (D) CCDS genes, and (E) lincRNAs.  First plot (top left) 
displays the overlay of all samples’ RNA expression (y-axis: FPKM(log10)), along with the Rank-
order of each sample (x-axis: rank-order of FPKM, smallest to largest).  Subsequent plots display 
the overlay of each individual in vitro sample along with the endogenous brain tissue, while using 
the BRAIN rank-order as the x-axis. (F) Rank-order scatter plots of 50,000 randomly selected 
CpG methylation sites.  First plot (left) displays the overlay of the three analyzed samples’ 
methylation (y-axis: beta values), along with the Rank-order of each sample (x-axis: rank-order of 
beta values, smallest to largest). Subsequent plots display the overlay of the two in vitro samples 
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Figure 12.  
 
Rank Correlations of Gene Expression between Replicates and Sample Groups.  FPKM 
correlation scatter plots and Spearman’s rank correlation coefficients, or rho(ρ), for (A) each set 
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Figure 13.  
 
Rank Correlations of lincRNA Expression between Replicates and Sample Groups.  FPKM 
correlation scatter plots and Spearman’s rank correlation coefficients, or rho(ρ), for (A) each set 
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Likewise, differential methylation between a subset of in vitro neural samples (NPC and D140) 
and the endogenous brain tissue (BRAIN) were evaluated for all methylation sites (485,261).  
Specifically, methylation sites that had a beta value difference ≤ -0.2 were defined as 
hypomethylated in vitro, and those that had a beta value difference ≥ +0.2 were defined as 
hypermethylated in vitro. The results of these comparisons provide the basis for our remaining 
figures (Figs. 14, 15, 16, 17, 18, 19). 
We first looked at both the percentage of genes and the percentage of lincRNAs with 
significant differential expression, assessing all CCDS genes (18,062) and putative lincRNAs 
(8,262) along with tissue-specific gene lists (Fig. 14A,B).  For brain tissue-specific gene lists, a list 
of “Brain Development Genes” (443) was obtained from the GO processes network using the 
MetaCore search engine from GeneGo Inc. (Ashburner et al.).  As a negative control, lists of 
“Non-Brain Development Genes” were examined, using lists of GO processes from 8 different 
tissues (i.e., skin, eye, heart, bone, kidney, liver, lung, and pancreas development) (avg. 132), 
and the average number of differential genes was evaluated (Fig. 14A) (Ashburner et al.).  For 
lincRNAs, a list of “Brain Tissue-specific lincRNAs” (183) was obtained from the annotated 
resource provided by Cabili et al., who separated lincRNAs into tissue-specific classes (Cabili et 
al.).  As a negative control, “Non-Brain Tissue-specific lincRNAs” were examined, using lists of 8 
different tissues (i.e., skeletal muscle, heart, placenta, liver, kidney, colon, lung, and testes) (avg. 
130) also provided by Cabili et al., and the average number of differential lincRNAs was 
evaluated (Fig. 14B) (Cabili et al.).   
 Trends in differential gene expression showed that the percentage of in vitro to brain 
tissue differences declined as our timecourse progressed; however, only the “Brain Development 
Genes” (443) showed a significant decreasing monotonic correlation as determined by a one-
tailed non-parametric Kendall’s tau correlation test.  This significant correlation was observed for 
both the total percentage of differences (p < 0.01), as well as the percentage of genes 
downregulated in vitro (p < 0.05), but was not significant for genes that were upregulated in vitro 
(Fig. 14A).  Likewise, these trends were not significant for all CCDS genes (18,062) or “Non-Brain 
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Development Genes” (avg. 132).  Taken together, these data show that for genes specific to 
brain developmental processes, there was a significant decrease in the percent of in vitro to brain 
tissue differences over our timecourse and that this observation was primarily due to the 
activation of genes that were originally downregulated in vitro (Fig. 14A).   
 Trends in differential lincRNA expression also showed a decrease in the percentage of in 
vitro to brain tissue differences.  These trends showed more variation (or less linearity) than that 
of protein-coding genes, and the decrease only showed a significant decreasing monotonic 
correlation for the total number of differences of all putative lincRNAs (8,262) (p < 0.05)          
(Fig. 14B).  Conversely, these trends were not significant for “Brain Tissue-specific” (183) or for 
“Non-Brain Tissue-specific” (avg. 130) lincRNAs, nor were they significant for trends specific to 
lincRNAs downregulated or upregulated in vitro (Fig. 14B).  These data show that for all putative 
lincRNAs, we observed a significant decrease in the number of in vitro to brain tissue differences, 
but this trend was due to the combined effects of both activation of lincRNAs downregulated in 
vitro, and inactivation of lincRNAs upregulated in vitro (Fig. 14B).  Also, there was less recovery 
(or progressive activation) of brain-specific lincRNAs than there was for protein-coding genes.  
Venn diagrams (for both CCDS genes and all putative lincRNAs) displaying the number and 
relative proportion of conserved in vitro to brain tissue differences between each adjacent step in 
the timecourse, as well as the differences conserved across all in vitro to tissue comparisons are 
also shown (Fig. 15).   
 Finally, differences in DNA methylation between two of the in vitro neural samples (NPC 
and D140) and the endogenous brain tissue (BRAIN) were also evaluated.  Differential 
methylation was defined as a site that had a beta value difference of at least 20% (i.e., ≥ 0.2) 
between the brain tissue and respective in vitro sample.  Trends in differential methylation were 
plotted for all methylation sites (485,261) on the array, as well as those specific to CpG islands 
(150,176), shores (North=62,827; South=49,166), and shelves (North=24,824; South=22,283).  
Shores are methylation regions 0-2 kilobases (kb) from CpG islands (CGI), and shelves are 
regions 2-4kb from CGI (Bibikova et al.; Doi et al.; Irizarry et al.).  Overall, there was a decrease 
in the total number of differentially methylated sites from the beginning (NPC) to end (D140) of 
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our timecourse compared to the brain (BRAIN).  This trend was apparent for both CGI shores and 
shelves; however, for CGI themselves, there was a slight increase in the percent of in vitro to 
brain tissue differences (Fig. 14C). The percentage of methylation sites that were hypomethylated 
in vitro compared to the brain tissue decreased after differentiation (D140) for all methylation 
regions (islands, shores and shelves), which correlates with our previous observation of a global 
increase in DNA methylation.   Conversely, the percentage of methylation sites that were 
hypermethylated in vitro compared to brain increased after differentiation (D140) for most of the 
methylation regions examined.  The only exception to this trend was the percent of north-shore 
(N-Shore) methylation sites hypermethylated in vitro, which decreased after differentiation (D140) 
(Fig. 14C).   
This observation was further examined by looking at CGI associated with a subset of 
genes that were originally downregulated in vitro and were transcriptionally activated during 
differentiation, or were originally upregulated in vitro and were transcriptionally inactivated during 
differentiation.  Although we observed a global increase in CpG methylation, the percent of 
hypermethylated sites (for both NPC and D140 compared to BRAIN) was lower for genes 
activated during differentiation, than it was for genes inactivated during differentiation. These 
trends were most pronounced in the N-shore regions of associated CGI (Fig. 16).  These 
observations are consistent with previous studies that have shown dynamic changes in CpG 
methylation in the developing and adult human brain (Siegmund et al.) and during in vitro 
differentiation, as well as previous reports that have identified the shore regions (0-2kb from CGI) 
as having the most tissue-specific methylation patterns (Irizarry et al.; Doi et al.).  
Data sets comparing in vitro cell culture models versus tissue-derived counterparts are 
beneficial for evaluating the physiological and pathological relevance of iPSC-derived cell lines 
and disease models.  Patterson et al. previously reported a comparison of several tissue types 
(i.e. hepatocytes, fibroblasts, and fetal neural progenitor cells) to their iPSC-derived counterparts 
(Patterson et al.).  Using microarrays, they identified subsets of genes that were upregulated or 
downregulated in all in vitro samples compared to the endogenous tissues.  We identified a 
significant number of genes in their data set that demonstrated the same pattern in our in vitro to  
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Figure 14.  
 
Tissue-Specific Expression, Trends in Gene and lincRNA Expression, and CpG Methylation.  
Percentage of (A) genes and (B) lincRNAs that were differentially expressed between each in 
vitro sample and the endogenous brain tissue.  Significant differential expression was defined as 
a comparison that had a log2 fold change > 2, as well as a p-value < 0.01.  Trends are show for 
all genes/lincRNAs, as well as tissue specific lists (GeneGO and Cabili et al.). P-values shown 
are from a one-tailed, non-parametric Kendall’s tau correlation test.  (C) Percentage of CpG 
methylation sites differentially methylated between the two in vitro samples analyzed (NPC and 
D140) and the brain tissue.  Differential methylation was defined as a site that had a beta value 
difference of at least 20% (i.e., ≥ 0.2).  Trends are show for all methylation sites, as well as CpG 
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Figure 15.  
 
Conserved In Vitro to Brain Tissue Differences. The number of significant differences between 
each in vitro sample and the in vivo brain tissue is shown below each Venn diagram. Circle sizes 
(area) for Venn diagram within each group are scaled in size relative to one another. Venn 
diagrams show the number of conserved differences between adjacent timepoints, and those 
conserved across all samples for (A) genes downregulated in vitro, (B) genes upregulated in vitro, 
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Figure 16.                                                                                                                                               
Evaluation of Hypermethylated CpG Shores in Relation to Transcriptional Activation. Genes that 
followed a pattern of transcriptional inactivation (I), or transcriptional activation (A), were 
evaluated for differences in hypermethylated CpG sites.  The percent of sites hypermethylated in 
both in vitro neural samples (NPC, D140) vs. the endogeous brain tissue (BRAIN) are shown, 
along with sites hypermethylated at the end of the timecourse (D14)) vs. the beginning (NPC).  
The North Shore (N-Shore) regions (0-2kb upstream of CpG Island) demonstrate a distinct 
association with transcriptional activation/inactivation (i.e., genes activated always had a lower % 
of hypermethylated sites compared to genes that were inactivated).  These trends were not 
apparent in other flanking regions, like the South Shore (S-Shore), which is shown alongside for 
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Table 5. 
 
Genes Significantly Different that Overlap with Previously Published Results. Genes that had in 
vitro to in vivo differences consistent with the results from Patterson et al. are shown. * = List of 
genes had significant overlap (p < 0.05) with Patterson et al., as determined by binomial 
distribution tests.  Genes that were downregulated or upregulated at all timepoints are shown in 
dashed line (Hjelm, Salhia, et al.; Patterson et al.). 
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upregulated in iPSC-derived cell types, 7 to 9 of these genes were also upregulated in our 
samples compared to the endogenous brain tissue, from NPC to D140, respectively.  All of the 
timepoints were significant when tested by binomial distribution tests (Table 5).  Also, out of 19 
genes that were consistently downregulated in iPSC-derived cell types in their study, 10 to 2 of 
these genes were also downregulated in our in vitro samples, from NPC to D140, respectively. 
Interestingly, this was only statistically significant at the NPC, D35 and D105 timepoints (Table 5).   
These data support the results of Patterson et al. and, in addition, suggest that in vitro activation 
of downregulated genes is more easily accomplished over time in culture than is the deactivation 
of upregulated genes.   These deductions are consistent with our previously mentioned results of 
progressive and global transcriptional activation.  Additional studies will need to be performed in 
order to determine if these results are specific to neural differentiation, or are likewise supported 
in prolonged culture of other iPSC-derived cell types. 
In Vitro and Brain Tissue Transcript Abundance of Selected Neurologically Relevant Genes  
 We further investigated the physiological and pathological relevance of our in vitro iPSC-
derived neural cell cultures by focusing on neurologically relevant genes.  This includes genes 
important to neurogenesis and gliogenesis (Figs. 17, 18), and genes associated with certain 
neurological disorders and related pathways (Fig. 18). Genes were selected based on their 
redundancy in neurological GO processes, Pubmed, OMIM, and/or commercially available arrays 
containing neural-specific expression markers. 
 Neuronal expression markers included the following: MAPT, which was significantly 
downregulated in vitro; MAP2, which was significantly downregulated in vitro until the last 
differentiation timepoint (D140) when it was expressed at similar levels to the brain; TUBB3, 
which was expressed at similar levels to the brain until the last differentiation timepoint (D140) 
when it was significantly upregulated in vitro; the synaptic vesicle gene SYN1, which was also 
significantly downregulated in vitro (although an increase in expression was observed over time); 
and DLG4, the gene that encodes for the postsynaptic density protein, PSD-95, which was 
significantly downregulated in vitro until the last differentiation timepoint (D140) when it was 
expressed at similar levels to the brain (Fig. 17A). There was a progressive increase in 
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expression for the three astrocyte genes, SLC1A3(GLAST), GFAP and S100B; however, all in 
vitro timepoints remained significantly downregulated compared to the brain tissue, as was 
expected for the smaller proportion of astrocytic glia in our in vitro neural cell cultures (Fig. 17B). 
Oligodendroglial markers MBP and OLIG2 were both significantly downregulated in vitro, and did 
not increase during our timecourse suggesting these neural cell cultures did not contain terminally 
differentiated oligodendrocytes (Fig. 17B).  Additional genes evaluated for differential expression 
included two neurotrophic growth factors (BDNF and NGF), as well as genes involved in neuronal 
cell adhesion (CNTNAP2), transcriptional repression (MECP2), and calcium channel signaling 
(CACNA1C) (Fig. 17C).  Neuronal subtype-specific markers included genes for glutamatergic 
(SLC17A7), GABAergic (GAD1), and serotonergic (SLC6A4) neurons, as well as the forebrain 
developmental markers PAX6 and FOXG1, all of which had some degree of transcriptional 
activation both in vitro and in the endogenous brain tissue (Fig. 17D).  Lastly, evaluation of genes 
associated with excitatory (OTX1 and OTX2) or inhibitory (NKX2-1 and GSX2) neuronal activity 
demonstrated transcriptional activation occurred predominantly for the excitatory (not inhibitory) 
markers (Fig. 17E).  Relative expression of some of these neurologically relevant genes, as well 
as a selected list of those associated with Alzheimer’s disease and temporal lobe epilepsy are 
also displayed (Fig. 18).  
Characterization of Genes and lincRNAs Ascribed to Early-to-Late Models of Differentiation 
 The differential expression results between our in vitro neural samples and the 
endogenous brain tissue were used to create five separate models of neural differentiation, based 
on the fact that we had five points in our timecourse.  Genes and lincRNAs that were originally 
significantly different between the in vitro NPC sample and the BRAIN sample were divided into 
groups, based on if they changed to similar expression levels as the endogenous brain tissue 
(i.e., not significant vs. BRAIN) at early (D35; Model I), early-mid (D70; Model II), mid-late (D105; 
Model III), or late (D140; Model IV) timepoints, or if all in vitro samples remained significantly 
different compared to the brain (in vitro ≠ brain; Model V) (Fig. 19A).  For genes that were 
originally upregulated in NPC compared to the brain tissue (1,123), 66% (740) fit into one of these 
five models, and for genes that were originally downregulated in NPC compared to the brain 
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tissue (2,862), 77% (2,216) fit into one of these five models.  Likewise, for lincRNAs upregulated 
in NPC compared to brain tissue (70), 86% (60) fit into one of these five models, and for lincRNAs 
downregulated in NPC (148), 64% (95) fit into one of these five models.  The number of genes 
and lincRNAs in each model (for those both upregulated and downregulated in vitro) are shown, 
along with heatmaps of the relative expression (FPKM log2 vs. BRAIN) within each model       
(Fig. 19).  For clarification of Models I-IV, those listed as upregulated were originally expressed in 
vitro at higher levels than the brain, then were inactivated to similar levels as the brain at a given 
step in our timecourse.  Likewise, those listed as downregulated were originally expressed in vitro 
at lower levels than the brain, then were activated to similar levels as the brain during the 
differentiation timecourse.  Heatmaps of differential expression for all genes in each of these 
models are shown, along with heatmaps of 20 selected neurologically relevant genes per model 
that were originally downregulated in vitro and demonstrated various rates of progressive 
activation (Fig. 19B).  Likewise, heatmaps of differential expression for all lincRNAs in each of 
these models is shown (Fig. 19C). 
 Analysis of GO processes revealed the following sets of enriched processes for our 
neural differentiation models: genes inactivated during our neural differentiation timecourse 
(Model I-IV up) included those involved in mitosis, cell cycle control, biogenesis, chromatin 
assembly, and mitotic cell cycle checkpoints; genes activated during our neural differentiation 
timecourse (Models I-IV down) included those involved in nervous system development, 
neurogenesis, cell communication and signaling, and synaptic transmission.  A description of 
each model can be found in Appendix A. The FPKM values for each gene and lincRNA 
corresponding to each of these models can be found in Appendix B.  In addition, the significant 
GO processes associated with each of these models can be found in Appendix C.  Future studies 
may use these lists as an initial association screen of which lincRNAs may be involved in mitosis, 
cell cycle control, neurogenesis and synaptic transmission.  Likewise, genes and lincRNAs that 
remained significantly different between all our in vitro samples and the endogenous brain tissue  
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Figure 17. 
 
Gene Expression of 24 Neurologically Relevant Genes.  Bar graphs displaying the FPKM value 
(log10 scale) of various neurological genes for each in vitro sample along with the endogenous 
brain tissue.  Significance (*) was defined as a comparison that had a log2 fold change > 2, as 
well as a p-value < 0.01. 24 genes associated with (A) neurons and synapses, (B) astrocytic and 
oligodendrocytic glia, (C) neurotrophic factors, adhesion, transcriptional repression, and calcium 
signaling, (D) neuronal subtypes (glutamatergic, GABAergic, serotonergic) and forebrain 
development, and (E) excitatory or inhibitory regional specificity are displayed.  Gene lists were 
selected based on their redundancy in GeneGO, Pubmed, OMIM, and/or commercially available 
arrays containing neural-specific expression markers (Hjelm, Salhia, et al.).   
!"#$%&#'&($)&*+,-.#&/&
 4 – 
 3 – 
 2 – 
 1 – 













* * * 
* * * * * 
* 
* * * 
* 
* 











* * * * 
* 
* * * * 
* 
SLC1A3                        GFAP                        S100B                        MBP                          OLIG2 
 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 












* * * 














 4 – 
 3 – 
 2 – 
 1 – 











TUBB3                       MAP2                        MAPT                          SYN1                        DLG4 
 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











CNTNAP2                     MECP2                      BDNF                          NGF                      CACNA1C 
 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











 4 – 
 3 – 
 2 – 
 1 – 











* * * * 









   OTX1                         OTX2                        NKX2-1                       GSX2               






   60 
Figure 18. 
 
Gene Expression of 50 Neurological and Disease-Associated Genes.  Bar graphs displaying the 
log2 fold difference of each in vitro sample compared to the in vivo brain tissue.  Significance (*) 
was defined as a comparison that had a log2 fold change > 2, as well as a p-value < 0.01.  Above 
each graph has the list of 17 genes known to be (A) neurologically relevant, or have been 
associated with pathways involved in the pathogenesis of (B) Alzheimer’s disease or (C) 
Temporal Lobe Epilepsy.  Below each graph, the FPKM value for the BRAIN sample is given as a 
reference.  Gene lists were selected based on their redundancy in neurological GO processes, 
Pubmed, OMIM, and/or commercially available arrays containing neural-specific expression 
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Figure 19. 
 
Models of Neural Differentiation.  Genes that were significantly different (log2 fold change > 2 and 
p-value < 0.01) between the neural precursor (NPC) and brain tissue (BRAIN) samples were 
divided into five models of differentiation, based on if or when in the timecourse the gene became 
not significant (compared to the endogenous brain tissue).  (A) Table of the five models (I-V), 
corresponding samples in each model, and the number of genes significantly upregulated or 
downregulated in vitro compared to the brain tissue in each model. (B) Heatmaps of all genes in 
each model, and heatmaps of 20 selected neurologically relevant genes per model that were 
downregulated in the NPC sample compared to the BRAIN and showed progressive activation at 
a given timepoint.  Increasing models (I-IV) demonstrate the order in which these selected genes 
were transcriptionally activated/inactivated in vitro (i.e., early-to-late).  Model V demonstrates 
selected genes that remained significantly different between all the in vitro neural samples 
compared to the endogenous brain tissue (i.e., in vitro ≠ brain).  Genes were selected based on 
their redundancy in GO processes related to neural development, synaptogenesis, etc. (C) 
Heatmaps of all lincRNAs in each model (Hjelm, Salhia, et al.).    
!"#$%&#'&($)&*+,-.#&/&
         Differentiation          Significant vs. BRAIN        Not Significant vs. BRAIN   # Genes up / down / total   # lincRNAs up / down / total 
      Model              Type                  (log2 fold >2 & p<0.01)         (log2 fold <2 or p>0.01)                   vs. BRAIN                               vs. BRAIN 
 
            I                   early    NPC      D35, D70, D105, D140        305   /   601   /   906               48   /   20   /   68 
           II               early-mid                       NPC, D35                D70, D105, D140          23   /   194   /   217                 1   /   12   /   13 
          III                 mid-late                      NPC, D35, D70              D105, D140          70   /   120   /   190                 1   /     2   /     3 
          IV                     late    NPC, D35, D70, D105      D140           51   /   358   /   409                 0   /   12   /   12 



















































































































































Up & Down  
N = 906 
Model II 
early-mid 
Up & Down 




Up & Down  




Up & Down 
N = 409 
 
Model V 
in vitro ! 
brain  
Up & Down  







































































































































































-10         -8          -6          -4          -2    0    +2      +4          +6         +8       +10    
log2 scale 
Models of Differentiation 
      Heatmaps of Differential Genes per Model 










































FPKM(log2) vs. BRAIN 
Heatmaps of Differential             
lincRNAs per Model 
Model I 
early 
Up & Down  
N = 68 
Model II 
early-mid 
Up & Down 




Up & Down  




Up & Down 
N = 12 
 
Model V 
in vitro ! 
brain  
Up & Down  
N = 59 
 
   62 
(Model V) may serve as a potential list of markers associated with highly specific features or 
terminal stages of neural differentiation. 
Discussion 
In this study, we focused on the in vitro to brain tissue differential expression of protein-
coding genes and lincRNAs using RNA-Seq. We also evaluated some global differences in DNA 
CpG methylation using a genome-wide array. Future studies could also look at other functional 
features that may be predicted to have physiologically relevant differences.  This includes, but is 
not limited to, microRNAs, histone methylation, protein translation and post-translational 
modifications, etc.  In addition, RNA-Seq data could be further investigated beyond gene and 
lincRNA expression, for differences in alternative splicing, alternative promoter usage, intron 
retention, etc. 
The variable we tested in this study was time, or time in neural differentiation conditions.  
Temporal effects are an intriguing variable to study, because they may be relevant to many cell 
culture systems regardless of the specific protocol. There are many additional variables, however, 
that are likely to influence the physiological or pathological relevance of in vitro neurological 
disease models. These variables include what the neural cells were differentiated or grown on 
(e.g., synthetic or biological scaffolds, adherent matrices, 3-dimensional vs. 2-dimensional cell 
culture conditions, polymer coated surfaces, feeder layers), what cell culture media and 
conditions were used (e.g., differentiation protocol, growth factors and their concentrations, 
ambient oxygen levels, feeder layers), and what additional steps were performed that may affect 
the cell population complexity (e.g., purification or cell sorting steps, genetic modification, cell 
seeding density, passage of NPC used, etc.).  Future studies may include RNA-Seq analyses on 
some of these in vitro variables in order to determine their effects on physiological transcription.  
Here, we focused on in vitro comparisons to temporal lobe brain tissue from an elderly, 
male autopsy donor identified as a neurological control.  In addition to this specific comparison, it 
will be interesting to examine the in vitro to brain tissue differences using other brain regions, as 
well as comparisons with donors of different ages, sexes, and those with different stages of 
neurological disease progression.  Likewise, larger data sets that include multiple donors and/or 
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multiple iPSC clones (potentially generated by various methods or independent research groups) 
will be valuable in order to examine the variation that may exist and which aspects of the in vitro 
neural transcriptome are more fixed or plastic.   
Also, additional studies should not only look at comparisons of complex cell populations 
and tissues, but also investigate more simplified or specific cell types obtained after 
purification/isolation by flow cytometry or laser capture microdissection (LCM).  One particularly 
intriguing question that has important technical implications is- if our neural cell cultures described 
herein contain both immature and mature neurons, how much of the observed transcriptional 
activation (and hence brain-specific progression) is due to neuronal maturation?  If this accounts 
for even a portion of the observed transcriptional progression, one would predict that cell sorting 
techniques specific to mature neuronal markers could demonstrate temporal progression and an 
increase in physiological transcription.  Future studies may include RNA-Seq evaluations of in 
vitro neural cell populations and in vivo brain tissue, where both samples are analyzed prior to 
and following single-cell isolation or cell sorting. 
While homogenous neuronal cell cultures offer many technical advantages, evaluation of 
more complex cell culture models, that may include the additional co-culture of astrocytes, 
oligodendrocytes, microglia, capillary endothelial cells, etc., may also be beneficial RNA-Seq 
studies as they allow us to evaluate the transcriptome while different cell types are in 
communication or contact with one another.  Some transcriptional, and possibly even 
pathological, effects may not be present in monotypic cell culture models.  
Overall, our analysis demonstrates the power of RNA-Seq and CpG methylation array 
data sets in evaluating the temporal effects of in vitro development and maturation of an iPSC-
derived neural cell culture model.  In vitro and tissue comparisons like these are not only useful 
resources, but also provide unique opportunities for collaboration amongst experts in genomics, 
stem cell biology, neuroscience, neuropathology, and bioengineering. We hope that this study 
provides a valuable resource for those interested in the physiological or pathological relevance of 
iPSC-derived neural cell culture models, and encourages others to collaborate and consider 
performing in vitro to tissue comparisons when evaluating their model system(s).
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Model Significant vs. BRAIN Not Significant vs. BRAIN Description Pattern 
I up NPC D35, D70, D105, D140 early 
Originally upregulated in 
NPC, then inactivated to 
similar levels as BRAIN by 
D35 
I down NPC D35, D70, D105, D140 early 
 
Originally downregulated in 
NPC, then activated to 
similar levels as BRAIN by 
D35 
II up NPC, D35 D70, D105, D140 early-mid 
 
Originally upregulated in 
NPC&D35, then 
inactivated to similar levels 
as BRAIN by D70 
II down NPC, D35 D70, D105, D140 early-mid 
 
Originally downregulated in 
NPC&D35, then activated 
to similar levels as BRAIN 
by D70 
III up NPC, D35, D70 D105, D140 mid-late 
 
Originally upregulated in 
NPC&D35&D70, then 
inactivated to similar levels 
as BRAIN by D105 
III down NPC, D35, D70 D105, D140 mid-late 
 
Originally downregulated in 
NPC&D35&D70, then 
activated to similar levels 
as BRAIN by D105 
IV up NPC, D35, D70, D105 D140 late 
 
Originally upregulated in 
NPC&D35&D70&D105, 
then inactivated to similar 
levels as BRAIN by D140 
IV down NPC, D35, D70, D105 D140 late 
 
Originally downregulated in 
NPC&D35&D70&D105, 
then activated to similar 
levels as BRAIN by D140 




Upregulated in all in vitro 
samples, NPC&D35&D70&   
D105&D140 
 
V down NPC, D35, D70, D105, D140  
in vivo 
specific 
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(in 
vitro) 











Gene FABP4 UP I early 17.363 0.01 0.01 0.01 0.01 0.01 
Gene KRT18 UP I early 9.24333 0.502807 0.726268 0.01 0.77445 0.01 
Gene GAL UP I early 8.0785 0.68174 1.6583 1.6127 0.837218 0.01 
Gene ODAM UP I early 5.17817 1.15765 0.689352 1.12956 0.01 0.01 
Gene KRT25 UP I early 5.14986 0.643092 0.759947 0.192975 0.01 0.01 
Gene HIST1H3B UP I early 5.10666 2.66459 1.15297 7.1207 3.26108 0.01 
Gene HIST1H2BL UP I early 5.08622 3.34654 1.18232 7.62017 4.05453 0.01 
Gene CSN3 UP I early 4.9494 0.01 0.01 0.371625 0.273954 0.01 
Gene SFRP5 UP I early 4.93195 0.01 0.01 0.01 0.01 0.01 
Gene KRT8 UP I early 4.84173 0.299933 0.01 0.01 0.58329 0.01 
Gene ETV4 UP I early 4.55848 0.29035 0.181384 0.416495 3.32672 0.01 
Gene CD70 UP I early 4.5219 0.01 0.01 0.01 0.569416 0.01 
Gene ZCCHC3 UP I early 4.05778 0.60023 0.659799 0.574652 0.0702157 0.01 
Gene NMB UP I early 3.73694 1.12387 0.66883 0.542431 0.378133 0.01 
Gene EIF4EBP1 UP I early 3.48664 1.07343 1.56644 3.73857 1.68741 0.01 
Gene SLC23A3 UP I early 3.38989 0.479758 0.925294 1.03181 0.117412 0.01 
Gene TRAPPC5 UP I early 3.27103 2.08734 1.13913 3.1525 2.4694 0.01 
Gene HIST1H3J UP I early 2.96005 0.851213 0.930967 2.00409 1.06509 0.01 
Gene RD3 UP I early 2.88711 0.690372 0.121812 0.743054 1.5023 0.01 
Gene UNC93A UP I early 2.39486 0.51156 0.01 0.01 0.0914826 0.01 
Gene RHOH UP I early 2.32954 0.0900847 0.221742 0.0801966 1.3224 0.01 
Gene SLC25A10 UP I early 2.26947 0.883098 1.55997 3.36239 0.507862 0.01 
Gene TK1 UP I early 2.15481 0.402932 0.571112 0.81985 0.512841 0.01 
Gene ENDOG UP I early 2.00382 0.308474 0.137878 0.748734 0.317341 0.01 
Gene TNFSF12-TNFSF13 UP I early 1.97653 0.320182 0.01 0.0581281 0.000454864 0.01 
Gene C11orf52 UP I early 1.96314 0.601428 0.78412 4.1278 1.05836 0.01 
Gene MTFP1 UP I early 1.82177 0.899341 0.68344 2.2938 0.498489 0.01 
Gene NDST4 UP I early 12.1545 0.760958 0.358852 0.15015 0.315871 0.0710939 
Gene KIF18B UP I early 1.67856 0.91657 0.652462 1.39642 1.34834 0.01 
Gene MACROD1 UP I early 1.659 1.22374 0.373829 1.06353 0.830244 0.01 
Gene YDJC UP I early 1.62309 0.426243 0.302805 0.967591 0.781194 0.01 
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Gene GSDMD UP I early 1.52431 0.443662 0.253274 0.884339 0.339038 0.01 
Gene TRPC7 UP I early 1.36528 0.01 0.01 0.0461169 0.01 0.01 
Gene PRSS21 UP I early 1.35896 0.388035 1.39368 0.01 0.611426 0.01 
Gene SDR42E1 UP I early 1.34832 0.817806 0.701413 0.79777 1.51665 0.01 
Gene TNNI3 UP I early 1.27376 0.989124 0.01 0.01 1.69811 0.01 
Gene CMA1 UP I early 1.26925 0.525128 0.190766 0.236944 0.235253 0.01 
Gene CPNE7 UP I early 1.26082 0.757155 0.2204 0.781889 0.431732 0.01 
Gene RAC2 UP I early 1.23033 1.32397 1.96688 3.35621 0.788159 0.01 
Gene SMR3B UP I early 1.17468 0.293121 0.614136 1.51721 0.01 0.01 
Gene PRPS1L1 UP I early 1.16407 0.152021 0.01 0.213815 0.268969 0.01 
Gene CLPP UP I early 1.13776 0.410592 0.616268 1.11283 1.54856 0.01 
Gene SKA1 UP I early 8.96681 4.98974 4.64132 6.85726 7.52027 0.0808942 
Gene RGS21 UP I early 1.09224 0.100916 0.0310284 0.113012 0.184683 0.01 
Gene CREB3L4 UP I early 1.06485 0.669788 0.802366 0.707653 0.687378 0.01 
Gene LRP5 UP I early 1.04628 0.93252 2.30436 4.63983 2.66165 0.01 
Gene FAM150A UP I early 0.992967 0.01 0.298069 0.722028 0.01 0.01 
Gene RHOD UP I early 0.979354 0.365503 1.85895 1.82797 1.14051 0.01 
Gene ESPL1 UP I early 0.958751 0.346136 0.46142 0.878525 1.08349 0.01 
Gene WDR34 UP I early 0.848006 0.27367 0.444162 0.535801 0.309043 0.01 
Gene RIPK4 UP I early 0.827516 0.0695989 0.0100313 0.01 3.40319 0.01 
Gene GABRR1 UP I early 0.79932 0.487604 0.0590941 0.370295 0.01 0.01 
Gene CABS1 UP I early 0.79354 0.616522 0.23545 0.139742 0.01 0.01 
Gene B3GNT3 UP I early 0.782199 0.01 0.01 0.01 0.0598412 0.01 
Gene MAGEA11 UP I early 0.780747 0.365086 0.030124 0.283898 0.01 0.01 
Gene E2F2 UP I early 0.777111 0.65203 0.60701 0.728427 0.530479 0.01 
Gene PLA2G3 UP I early 0.774941 0.272015 0.111991 0.150826 0.42929 0.01 
Gene MAGEA2 UP I early 0.769283 0.877683 0.189781 0.881698 7.04254 0.01 
Gene FAM109B UP I early 0.751758 1.13869 0.953024 2.27231 0.755482 0.01 
Gene RAB43 UP I early 0.737179 0.01 0.137449 0.01 0.01 0.01 
Gene STEAP3 UP I early 6.67092 2.54845 3.97658 2.82647 4.43115 0.0973044 
Gene KBTBD8 UP I early 93.3065 3.62706 5.9442 2.06167 4.25339 1.68683 
Gene FAM159B UP I early 32.8433 9.35302 0.01 0.01 0.783868 0.639555 
Gene CDCA2 UP I early 16.5713 10.1735 10.0162 9.30018 7.53336 0.375326 
Gene SGCG UP I early 16.0163 0.683357 0.415935 0.184016 1.65358 0.380417 
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Gene SKA3 UP I early 21.711 16.4203 16.7805 5.20831 8.82811 0.581476 
Gene AQP3 UP I early 13.9164 5.64171 9.83499 7.09067 0.94173 0.448419 
Gene ORC1 UP I early 3.53642 2.1927 1.558 1.21496 3.8307 0.117173 
Gene TRIB3 UP I early 2.64401 0.32975 0.2615 0.732872 0.544787 0.0923836 
Gene LRR1 UP I early 8.14887 3.89022 4.45317 2.28392 1.78244 0.30204 
Gene KIF2C UP I early 3.76136 1.51977 1.89207 1.47876 1.55525 0.152165 
Gene IL18RAP UP I early 1.91553 1.0517 0.713547 0.536253 0.01 0.0780139 
Gene ZPLD1 UP I early 6.41015 0.324497 0.0709367 0.0484571 0.411803 0.297855 
Gene CDC45 UP I early 11.0457 5.62721 3.88862 5.9083 6.25091 0.552801 
Gene AIM1 UP I early 30.6586 0.836323 0.413944 0.44897 2.08538 1.61845 
Gene MOCOS UP I early 0.965234 0.0324019 0.185566 0.0828186 0.3804 0.0577295 
Gene GPX1 UP I early 9.97624 2.13866 1.3877 5.33787 2.16799 0.625335 
Gene DCPS UP I early 8.58055 3.26766 3.29781 6.82721 4.70777 0.539624 
Gene AGPAT9 UP I early 10.1884 0.480237 1.71243 0.0705546 1.42391 0.656486 
Gene CARD11 UP I early 2.62748 0.01 0.157522 0.01 0.155867 0.171688 
Gene MICB UP I early 4.93579 0.494185 1.07972 0.297874 1.38159 0.346642 
Gene TMEM171 UP I early 12.171 1.59844 0.580206 2.06744 2.81229 0.861596 
Gene CA12 UP I early 8.48939 1.79996 1.6124 0.668916 1.05058 0.625056 
Gene CORO2A UP I early 4.51333 0.01 0.10801 0.0804905 0.934732 0.342724 
Gene SLC16A6 UP I early 9.76386 0.69897 2.81584 0.30042 2.87709 0.827135 
Gene PLS1 UP I early 12.7942 2.92658 1.11723 0.719727 1.87964 1.09908 
Gene FDXR UP I early 8.16152 1.81042 1.11748 2.68388 1.74903 0.705343 
Gene TSEN34 UP I early 8.16742 2.92181 4.15849 3.82891 3.21147 0.706395 
Gene TNFAIP8L3 UP I early 10.986 0.0620785 0.01 0.0231674 0.374758 0.971213 
Gene SDF2L1 UP I early 13.0445 5.76902 4.42604 1.61183 1.18802 1.15389 
Gene BOLA3 UP I early 115.185 35.2484 36.2673 36.1166 24.4537 10.2241 
Gene MRTO4 UP I early 7.27327 2.59963 3.09877 4.21636 3.83971 0.647289 
Gene CSK UP I early 4.6651 1.02279 0.955785 2.14969 1.24066 0.415756 
Gene MSTN UP I early 10.5998 0.826943 0.797646 0.711102 0.163275 0.955773 
Gene RPL26L1 UP I early 13.0099 6.13166 9.64066 6.57211 9.02287 1.20729 
Gene TFAP2C UP I early 24.0674 5.48997 6.89545 2.15729 8.23349 2.23503 
Gene ACLY UP I early 108.024 50.4904 56.9639 61.5798 88.06 10.045 
Gene KAZALD1 UP I early 4.12056 0.960704 1.1245 2.28373 0.667947 0.397918 
Gene FAM72D UP I early 3.4723 2.43515 2.45993 0.721833 3.21391 0.342262 
Gene MIF UP I early 8.95255 0.868587 4.53451 8.64134 7.16053 0.891423 
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Gene HIST1H4B UP I early 20.1725 8.85679 9.45147 12.6068 16.3739 2.01338 
Gene ACAT2 UP I early 125.895 45.4523 28.8549 20.5283 29.4642 12.6568 
Gene MRPL11 UP I early 16.7748 4.15344 6.46336 6.68825 5.60183 1.78395 
Gene NPY2R UP I early 5.99046 1.01407 1.53949 0.39496 0.242545 0.638706 
Gene DOT1L UP I early 9.4912 3.57175 2.67171 3.42612 4.09509 1.03849 
Gene CYP1A1 UP I early 2.42895 0.137648 0.165165 0.01 0.322363 0.278263 
Gene C4orf49 UP I early 10.94 1.05509 0.406439 0.300253 0.96844 1.26341 
Gene TECTA UP I early 8.58465 0.649879 0.521956 0.7996 0.676503 1.00133 
Gene C9orf140 UP I early 4.26779 1.3494 0.446596 1.37222 1.28409 0.50853 
Gene EYA4 UP I early 35.1287 7.52429 8.52749 1.15679 10.7675 4.20615 
Gene C3orf37 UP I early 42.0578 8.74896 10.4637 11.8908 13.8603 5.04402 
Gene AEN UP I early 3.0492 1.56095 1.19062 0.948393 2.11899 0.367111 
Gene C16orf91 UP I early 8.43463 3.72843 4.04251 6.38789 4.93123 1.01906 
Gene BDKRB2 UP I early 1.48796 0.138515 0.109145 0.244586 0.241124 0.181485 
Gene IL18R1 UP I early 9.09447 4.88848 5.0108 1.44326 0.905654 1.1237 
Gene COQ3 UP I early 17.3358 6.73551 6.78735 4.37874 4.17512 2.17404 
Gene POP1 UP I early 39.0835 15.9743 14.089 17.5705 13.4242 4.95608 
Gene MRPS15 UP I early 152.703 67.4899 52.2058 68.3921 57.5045 19.954 
Gene ZNRD1 UP I early 7.17983 2.99623 5.58797 5.70909 6.13972 0.949699 
Gene TRIM7 UP I early 10.1404 1.1923 1.10714 0.263306 0.01 1.34425 
Gene C16orf80 UP I early 84.3654 23.5338 24.3668 35.1645 33.2514 11.2007 
Gene JAG2 UP I early 2.35052 0.562362 0.837062 1.05521 0.971241 0.312964 
Gene CHRNA5 UP I early 38.964 15.8656 15.6549 4.18857 10.8624 5.20235 
Gene CTSC UP I early 37.7168 20.433 17.0332 9.69969 56.1816 5.18358 
Gene PKP2 UP I early 9.52634 0.797126 0.0480199 0.464881 2.98309 1.33977 
Gene PSMA7 UP I early 249.853 106.501 138.61 119.714 91.172 35.2443 
Gene EBPL UP I early 8.70363 5.75118 4.94338 4.32309 4.67401 1.23721 
Gene SCIN UP I early 58.8241 5.13018 21.6615 20.9911 16.2542 8.41589 
Gene CCDC86 UP I early 8.4909 2.55934 2.1813 5.81399 3.72635 1.22557 
Gene PNP UP I early 17.734 5.40885 5.42125 6.26005 5.68526 2.56187 
Gene PGK1 UP I early 189.53 85.2674 104.469 64.3325 102.71 27.7774 
Gene PPP1CA UP I early 20.199 10.1785 5.87987 8.06815 9.07464 2.99816 
Gene CHAF1B UP I early 10.475 5.78056 5.15426 4.35136 8.41082 1.56989 
Gene TUBG1 UP I early 10.8319 3.64283 2.71501 6.27834 3.30252 1.63052 
Gene TACO1 UP I early 21.2974 8.20055 5.97266 7.65376 10.8142 3.22067 
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Gene NUP88 UP I early 53.4596 29.1598 23.6539 17.9241 22.8173 8.11055 
Gene PGAM4 UP I early 7.13793 2.81397 3.17721 2.22288 1.80608 1.08338 
Gene LYN UP I early 20.9637 3.40578 5.48496 2.89339 7.51406 3.18298 
Gene NDUFAB1 UP I early 77.8404 38.874 42.24 22.9881 22.2754 11.9379 
Gene CCNF UP I early 2.88134 1.14791 0.823606 1.40477 1.51532 0.443525 
Gene PERP UP I early 29.6484 2.67159 6.24286 2.35175 5.76522 4.61558 
Gene MRPS9 UP I early 40.4805 12.352 13.1573 11.4628 13.656 6.30932 
Gene CENPP UP I early 8.84489 2.2625 1.30227 2.55893 3.507 1.37962 
Gene UCK2 UP I early 19.8056 6.34881 5.99917 8.96618 8.64349 3.10057 
Gene UMPS UP I early 25.0718 10.5096 14.3649 12.4791 12.7089 3.95484 
Gene TIMM50 UP I early 6.93826 2.37312 2.83589 5.19078 4.07289 1.0962 
Gene LRRC59 UP I early 21.5112 9.0226 11.6145 11.5027 9.91865 3.45961 
Gene MCTP2 UP I early 6.31177 1.33361 1.12451 0.364897 0.858101 1.01697 
Gene PFKP UP I early 82.385 22.8242 21.036 38.6428 33.7435 13.3929 
Gene MTHFD1L UP I early 27.1911 6.62281 17.2616 10.4757 13.8784 4.45981 
Gene MRPL4 UP I early 2.98568 1.42207 1.17585 2.45517 1.47898 0.491033 
Gene CXorf57 UP I early 69.0246 24.5033 9.63276 4.60874 9.66475 11.375 
Gene SMYD2 UP I early 60.3609 19.0465 16.5154 12.144 14.2722 10.0116 
Gene UTP14A UP I early 31.0984 16.745 16.7728 20.2923 19.1837 5.19408 
Gene TRIM14 UP I early 56.9319 18.2948 12.5228 26.8784 17.0719 9.52083 
Gene FAM96A UP I early 56.5915 17.3056 23.2074 9.14836 15.2265 9.50434 
Gene SPRY4 UP I early 86.6761 13.5904 25.0044 11.4962 41.5787 14.5724 
Gene DTYMK UP I early 7.59237 6.11415 5.62683 6.58336 3.54855 1.28344 
Gene DIAPH1 UP I early 26.2606 8.21396 13.7348 13.9869 14.4146 4.45923 
Gene THAP4 UP I early 10.5028 3.36268 3.68634 5.96789 3.82452 1.79354 
Gene MRPL47 UP I early 22.3144 12.959 13.5026 8.73533 14.7256 3.85641 
Gene EXPH5 UP I early 32.881 9.12941 13.4745 2.86666 7.84896 5.69103 
Gene FAM162B UP I early 8.54232 3.95305 3.02861 0.855543 0.01 1.48507 
Gene SNRPD3 UP I early 76.4982 48.0977 51.5169 36.2261 41.4755 13.3047 
Gene CYC1 UP I early 14.1226 5.23164 3.92799 9.43869 6.00529 2.46273 
Gene APOL2 UP I early 132.36 25.4994 29.8729 64.5087 44.7066 23.0817 
Gene WDR77 UP I early 25.0925 11.4512 12.6187 8.15141 13.4245 4.39209 
Gene PTDSS1 UP I early 27.6892 10.5579 14.3534 17.4678 16.1511 4.86101 
Gene CD3EAP UP I early 4.78313 2.28204 3.63511 3.51195 3.87789 0.844777 
Gene HNRNPD UP I early 1317.19 762.874 740.522 490.718 808.967 233.219 
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Gene HNRNPM UP I early 291.3 170.287 157.002 126.523 151.998 51.7598 
Gene SLC16A7 UP I early 42.0933 15.4477 19.574 9.27915 9.51387 7.57506 
Gene TUBA1B UP I early 956.561 121.345 168.231 382.95 105.248 172.258 
Gene LTV1 UP I early 154.43 83.636 84.7822 39.3686 51.69 27.8886 
Gene EXOSC8 UP I early 57.859 27.687 32.106 20.7596 36.3661 10.5026 
Gene SAMM50 UP I early 28.8484 12.4608 12.7162 14.374 15.3481 5.24922 
Gene MTHFD1 UP I early 14.8737 8.96049 8.54657 10.4516 7.17086 2.70737 
Gene VDAC1 UP I early 533.509 274.978 274.496 180.138 290.134 97.2701 
Gene LBR UP I early 78.8657 29.8054 24.8188 20.5891 39.7449 14.4425 
Gene ANXA11 UP I early 37.8726 12.6828 11.6517 23.6286 20.084 6.9684 
Gene KDELC2 UP I early 29.6686 17.3119 19.4312 8.99899 16.7706 5.46075 
Gene BLMH UP I early 36.9517 17.9621 22.5318 23.0132 20.6582 6.80317 
Gene CCT4 UP I early 87.7126 52.0459 60.5549 35.4495 51.43 16.1881 
Gene CASP7 UP I early 19.3629 7.72853 8.81205 7.92308 5.78654 3.57959 
Gene AFG3L2 UP I early 13.4574 7.60398 8.68303 7.26866 7.92797 2.50041 
Gene EIF3C UP I early 142.365 48.8377 60.5127 84.9763 83.3774 26.513 
Gene COASY UP I early 4.87893 1.13343 1.12947 2.2476 2.14414 0.923601 
Gene PDSS1 UP I early 16.4421 11.7303 10.123 6.12543 6.32154 3.12081 
Gene CCDC110 UP I early 14.3914 6.26856 5.0386 1.73503 2.38592 2.73212 
Gene MAPKAPK3 UP I early 6.19958 1.34123 1.64821 2.96001 5.08072 1.18793 
Gene ATP5F1 UP I early 210.455 113.492 117.375 65.7849 97.2 40.6174 
Gene RRP15 UP I early 68.4379 40.6512 44.9581 29.5676 35.3346 13.2112 
Gene SLC25A39 UP I early 5.11365 1.42573 2.52248 3.664 4.06997 0.98742 
Gene PDIA6 UP I early 155.916 58.917 93.4711 62.3557 78.6988 30.2101 
Gene NDNL2 UP I early 59.5741 31.9018 38.3191 7.2548 3.43786 11.5694 
Gene SRSF7 UP I early 169.089 110.476 100.037 59.4528 113.362 32.8952 
Gene RPS12 UP I early 41.0767 30.2709 24.2896 20.735 24.0518 8.00708 
Gene MRPS23 UP I early 58.5843 20.792 20.461 19.4841 25.667 11.4469 
Gene ARPC1B UP I early 95.8531 27.262 44.1138 39.6107 33.4967 18.7293 
Gene MRPL34 UP I early 47.9576 18.2174 16.4722 27.1843 17.8408 9.44037 
Gene TOMM5 UP I early 94.1796 64.8084 66.4671 44.9822 73.3126 18.618 
Gene EIF3CL UP I early 124.018 43.5802 54.5965 75.7585 75.14 24.533 
Gene HSPA4 UP I early 387.184 140.665 174.717 87.1679 118.649 76.5989 
Gene RAD23A UP I early 56.9862 24.3152 22.5824 43.7437 25.8439 11.2867 
Gene HNRNPF UP I early 64.2781 29.3648 42.6576 25.8119 27.4134 12.7614 
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Gene WDR76 UP I early 21.4591 14.6396 13.3193 10.6479 13.2655 4.26099 
Gene RPA3 UP I early 15.6452 5.10262 10.1973 3.64687 2.61419 3.11721 
Gene EIF3D UP I early 53.5424 30.1053 38.0167 33.4458 33.3365 10.6911 
Gene FKBP4 UP I early 149.776 51.0103 47.6911 65.4372 54.5481 29.9213 
Gene GOT2 UP I early 87.4922 28.3725 25.1607 32.6497 40.707 17.4854 
Gene CHAC2 UP I early 6.4934 4.27642 4.42785 0.717074 1.06867 1.3003 
Gene VPS25 UP I early 5.18051 3.0264 2.65099 5.85141 4.03623 1.03999 
Gene CACYBP UP I early 241.628 89.814 60.7292 53.6246 48.6755 48.7911 
Gene MRPL40 UP I early 33.7746 11.8894 17.4545 26.9513 15.7002 6.82253 
Gene C15orf23 UP I early 12.2186 6.26043 6.59771 5.9032 7.91216 2.47531 
Gene FERMT1 UP I early 25.974 8.01788 7.32059 3.96923 8.01015 5.27869 
Gene PSMB5 UP I early 169.63 114.956 136.346 128.151 83.5972 34.7221 
Gene ATP5A1 UP I early 277.135 168.774 148.223 166.835 195.865 56.8296 
Gene GTF2A2 UP I early 126.176 66.071 92.9504 40.2199 59.6313 26.0279 
Gene C20orf20 UP I early 28.0288 10.4878 11.0219 7.89608 7.85479 5.81403 
Gene IFI16 UP I early 117.971 66.3008 86.7031 23.0155 35.2751 24.541 
Gene MASTL UP I early 22.6228 16.9113 22.128 7.30685 14.9782 4.74357 
Gene EFTUD2 UP I early 14.5398 7.42544 7.07682 8.95092 8.84535 3.07369 
Gene SERPINB6 UP I early 71.0601 9.27315 9.0356 10.3924 12.439 15.0359 
Gene ERCC6L UP I early 7.04419 4.19278 4.68492 1.87041 4.32819 1.49428 
Gene VRK1 UP I early 62.2602 36.8919 31.028 11 26.2552 13.2197 
Gene MRPS7 UP I early 21.1649 10.6518 10.3553 10.0994 10.5306 4.4941 
Gene MRPL14 UP I early 11.2639 6.50191 7.58496 9.62244 8.08197 2.3952 
Gene SAC3D1 UP I early 6.71924 2.96149 2.37808 5.55435 3.80855 1.43514 
Gene PSMD14 UP I early 116.305 56.7364 63.6665 35.183 78.9939 24.8699 
Gene POU3F1 UP I early 3.15245 2.16979 1.7028 0.924761 1.07218 0.679579 
Gene ISOC1 UP I early 41.5737 16.4634 11.3131 7.79029 8.56767 8.97319 
Gene CCDC109B UP I early 8.05682 2.49341 4.4501 3.78706 5.58407 1.73931 
Gene PSME1 UP I early 126.05 69.3963 89.5734 96.8557 76.7207 27.298 
Gene EIF3B UP I early 27.7895 14.1816 14.9478 15.0514 14.1534 6.0289 
Gene CMBL UP I early 24.8901 2.89502 4.86221 5.11885 8.77966 5.4033 
Gene EBNA1BP2 UP I early 210.495 107.032 116.713 159.038 151.253 46.0138 
Gene PGAM1 UP I early 73.2606 26.7353 28.9724 32.9523 47.8003 16.0153 
Gene TTLL12 UP I early 3.07617 1.46381 1.81567 2.11377 2.36894 0.673712 
Gene NSUN2 UP I early 29.9744 18.3261 21.5585 15.8521 23.4519 6.56594 
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Gene EXOSC2 UP I early 14.7806 9.20035 6.85684 8.90115 11.0277 3.24864 
Gene CHCHD3 UP I early 58.9155 35.3762 37.4425 28.3242 43.0198 12.9864 
Gene RPS27L UP I early 97.4469 62.064 83.3655 57.793 55.8631 21.5217 
Gene PRPS2 UP I early 13.4762 6.3708 5.31096 1.84726 2.48558 2.97662 
Gene WBSCR22 UP I early 40.8143 16.9105 26.0674 30.6478 32.4642 9.0454 
Gene ST3GAL2 UP I early 5.52544 2.24515 3.62426 4.7928 3.90934 1.22497 
Gene NIP7 UP I early 22.4004 13.4916 18.5559 7.03949 17.2687 4.96698 
Gene ATP5C1 UP I early 114.996 85.263 83.2259 78.6852 88.9715 25.5674 
Gene PGR UP I early 2.70306 0.0512697 0.0698244 0.0545845 0.387762 0.602037 
Gene ARPC2 UP I early 297.902 219.692 227.826 151.778 252.087 66.8954 
Gene POLR3K UP I early 44.6058 37.0914 27.701 19.1516 27.9804 10.0232 
Gene SUV39H1 UP I early 7.41213 4.0877 1.44428 3.45213 4.03881 1.66556 
Gene HIGD2A UP I early 41.2685 35.1676 27.7458 34.3836 27.9387 9.28211 
Gene C6orf211 UP I early 21.8402 15.8054 13.0848 3.10225 13.7633 4.91707 
Gene ALDOA UP I early 28.6994 11.6645 10.0287 21.2164 20.9366 6.47316 
Gene SEPHS1 UP I early 28.5653 19.7347 21.2879 12.1818 16.3406 6.4449 
Gene DAPK1 UP I early 145.789 84.2455 70.1687 78.432 97.1709 33.0405 
Gene JAGN1 UP I early 5.73809 4.70837 3.60852 4.06046 5.33581 1.3015 
Gene CYP4X1 UP I early 6.92905 3.32485 1.53768 0.664399 0.848962 1.57407 
Gene ILF3 UP I early 31.9258 23.1889 20.3157 27.3488 35.5107 7.26392 
Gene SURF2 UP I early 64.4163 12.2905 22.3428 29.0294 26.7814 14.7159 
Gene DTD1 UP I early 73.3643 26.6731 23.5815 32.6355 61.3347 16.7812 
Gene SORD UP I early 10.6484 6.63654 5.61322 4.63694 5.22829 2.43671 
Gene PSPH UP I early 16.749 5.63642 7.35082 10.8542 10.2599 3.83741 
Gene SLC7A5 UP I early 8.29696 1.92975 1.06968 1.5005 0.805086 1.90646 
Gene XRCC5 UP I early 221.509 158.242 160.867 116.152 185.274 51.0885 
Gene CCT3 UP I early 146.17 77.5024 100.853 133.769 119.258 33.8032 
Gene FRMPD2 UP I early 3.89074 0.286572 0.459051 0.716458 1.04418 0.902431 
Gene DSN1 UP I early 8.35332 6.10852 10.9981 7.57772 11.7147 1.94087 
Gene RNF128 UP I early 2.64186 1.72022 1.10609 0.320526 0.643895 0.614113 
Gene CPNE3 UP I early 92.8527 24.8331 29.6264 15.0427 22.9787 21.5968 
Gene SDHB UP I early 44.5667 23.7163 20.823 17.0807 12.765 10.3769 
Gene PRMT6 UP I early 11.4831 8.20763 9.79601 5.77219 1.54275 2.6805 
Gene NDUFA12 UP I early 310.414 168.135 160.649 141.934 221.262 72.5377 
Gene CIRH1A UP I early 35.5361 19.3066 15.6819 27.7286 30.0827 8.33932 
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Gene STIP1 UP I early 244.101 105.554 100.617 171.688 168.753 57.3223 
Gene FARSB UP I early 50.7799 27.8575 28.2004 28.4723 42.038 11.9309 
Gene NUP37 UP I early 17.3255 9.44046 12.6042 7.52616 11.9677 4.07441 
Gene RPIA UP I early 15.9552 12.9551 11.601 6.26167 11.6862 3.76895 
Gene RPUSD4 UP I early 39.4404 27.845 29.6717 22.295 25.7123 9.32189 
Gene EIF4B UP I early 122.602 69.3199 67.2076 56.1625 98.8626 29.1086 
Gene TIPIN UP I early 28.535 12.2709 12.4982 6.00745 8.10597 6.78459 
Gene MRPL51 UP I early 881.573 485.617 478.701 805.844 893.959 210.631 
Gene TRMT112 UP I early 189.082 121.099 109.952 158.771 130.242 45.3559 
Gene LETM1 UP I early 9.44342 2.65958 2.93929 7.13374 4.63223 2.26823 
Gene NHEJ1 UP I early 12.984 10.0008 9.30053 11.7457 11.1407 3.12584 
Gene LARS2 UP I early 49.3624 46.5631 43.1722 42.4082 42.7976 11.9052 
Gene SDCCAG3 UP I early 12.0004 5.95488 4.41279 7.08396 8.41972 2.89444 
Gene TSR1 UP I early 31.6617 15.1941 14.5396 13.488 24.875 7.65453 
Gene NDUFS5 UP I early 205.829 96.6506 127.409 155.875 130.817 49.8 
Gene KLHL29 UP I early 4.25917 0.876756 1.44105 2.46809 1.56165 1.031 
Gene ITPR3 UP I early 1.20071 0.291836 0.135134 0.205104 0.242128 0.291282 
Gene HSPA9 UP I early 289.696 105.234 113.102 111.064 122.096 70.9026 
Gene EXOSC9 UP I early 35.9766 28.6068 24.1006 11.5688 17.4762 8.81349 
Gene BUD31 UP I early 41.2809 24.5659 30.2018 25.2011 34.5265 10.1332 
Gene U2AF1 UP I early 109.804 94.298 105.223 89.4442 37.1685 26.9648 
Gene PSMB6 UP I early 30.2376 10.8177 14.217 26.5202 20.7162 7.4455 
Gene HMGN2 UP I early 51.9573 36.5453 41.9571 27.0406 29.5073 12.794 
Gene GMNN UP I early 23.5389 12.6689 9.77149 4.2821 5.84962 5.80697 
Gene RRS1 UP I early 21.9736 12.4244 12.968 9.71964 8.33081 5.44302 
Gene VMA21 UP I early 36.565 15.6549 15.6326 3.91821 8.29484 9.0589 
Gene RBM34 UP I early 240.275 218.741 205.091 110.502 179.579 59.601 
Gene YEATS4 UP I early 57.9352 33.9181 37.371 10.9607 7.92205 14.3903 
Gene DRG1 UP I early 54.4401 32.1873 39.5269 41.8972 48.9959 13.5517 
Gene TFB1M UP I early 24.6992 11.6083 17.7051 17.2961 22.6029 6.15529 
Gene HIST1H2BI UP II early-mid 12.6957 4.01273 4.28649 12.9633 4.91834 0.01 
Gene HIST1H3I UP II early-mid 11.8664 13.9892 5.72165 28.5781 22.4838 0.01 
Gene HIST1H2BO UP II early-mid 11.8369 6.43726 4.0738 10.1967 3.08411 0.01 
Gene CENPA UP II early-mid 8.14601 3.55395 7.24246 0.974116 1.79542 0.01 
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Gene HIST1H2BM UP II early-mid 7.09741 5.57296 2.84608 8.72795 13.9404 0.01 
Gene FAM64A UP II early-mid 1.8706 1.90818 1.08935 2.67938 2.57179 0.01 
Gene GPRC5A UP II early-mid 23.9528 16.3403 8.01347 8.76918 4.80459 0.237759 
Gene ERP27 UP II early-mid 8.89644 5.85818 2.52176 0.119394 0.747521 0.727111 
Gene RACGAP1 UP II early-mid 54.3518 26.0167 19.9518 20.5253 19.9926 5.74452 
Gene MIXL1 UP II early-mid 3.6412 6.04185 2.33826 2.27378 0.530999 0.39 
Gene HIST1H1A UP II early-mid 11.2864 15.3797 4.66522 6.47065 4.85665 1.42535 
Gene FAM65B UP II early-mid 22.8557 11.9477 8.95499 6.04951 5.65423 2.98652 
Gene C1orf135 UP II early-mid 6.4062 3.86638 3.33706 3.21736 3.08547 0.907369 
Gene TCERG1L UP II early-mid 2.51895 2.1562 1.88124 2.1018 0.948937 0.366191 
Gene POLE2 UP II early-mid 2.81763 2.74439 2.17489 0.684857 2.28492 0.454514 
Gene CYCS UP II early-mid 822.928 561.651 438.857 314.169 417.484 138.975 
Gene SERBP1 UP II early-mid 280.348 202.785 164.851 81.7401 145.306 49.0875 
Gene LANCL3 UP II early-mid 6.17257 5.1526 3.22167 1.56941 2.83515 1.08858 
Gene HDAC1 UP II early-mid 104.058 77.3349 51.1561 59.2535 70.8653 19.3113 
Gene IDH2 UP II early-mid 20.1978 16.8289 11.1061 14.4354 5.71413 3.88688 
Gene CCDC58 UP II early-mid 48.3454 43.227 34.2777 24.1551 25.6554 10.0911 
Gene HSPE1 UP II early-mid 377.166 384.639 265.084 208.463 222.15 83.2387 
Gene ZNF732 UP II early-mid 4.35318 5.65254 3.43861 1.85597 1.77503 1.02763 
Gene HOXD8 UP III mid-late 31.1366 16.2076 25.4225 3.96661 3.84163 0.0484361 
Gene MYBL2 UP III mid-late 3.66404 1.72302 1.59744 2.75706 1.67271 0.01 
Gene HOXA5 UP III mid-late 3.51213 2.99899 3.33875 3.62481 2.24097 0.01 
Gene HOXA13 UP III mid-late 2.53594 2.91398 2.34338 1.16806 0.419265 0.01 
Gene CDK1 UP III mid-late 22.6619 19.31 22.1391 2.52898 1.05787 0.0896141 
Gene NPSR1 UP III mid-late 2.52812 2.24852 1.15825 0.136066 1.11836 0.01 
Gene HOXB7 UP III mid-late 2.48001 1.8343 3.0015 0.540706 1.10039 0.01 
Gene KIAA0101 UP III mid-late 15.4799 10.3397 14.7537 4.87024 1.7302 0.122694 
Gene C3orf55 UP III mid-late 0.784391 1.8069 2.69596 0.494032 1.54022 0.01 
Gene AGMO UP III mid-late 12.3456 2.66374 6.57738 1.50537 1.42278 0.181025 
Gene CASC5 UP III mid-late 43.5881 29.7604 28.4445 6.2619 8.53113 0.692275 
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Gene CKS2 UP III mid-late 44.7741 26.4989 32.4683 6.36566 9.05517 0.837844 
Gene SIX1 UP III mid-late 7.66985 3.0083 2.96544 0.936823 1.99258 0.159537 
Gene CERKL UP III mid-late 8.3371 2.62656 2.44565 1.11827 1.19431 0.196413 
Gene FAM83D UP III mid-late 7.76887 3.91065 3.95618 1.84739 1.81628 0.221432 
Gene TTK UP III mid-late 23.5188 23.8834 14.4983 6.37897 7.2526 0.708033 
Gene NEIL3 UP III mid-late 7.4825 12.2142 6.94568 3.65599 1.89119 0.243555 
Gene DLX2 UP III mid-late 4.17327 5.814 7.05168 0.870944 2.21377 0.148256 
Gene ITGA4 UP III mid-late 45.4241 11.6658 14.0405 5.32919 5.22583 1.6937 
Gene FAM72A UP III mid-late 6.10154 3.4601 4.9234 1.15715 2.64739 0.228904 
Gene CEP55 UP III mid-late 28.6594 15.5373 14.2276 6.91272 8.23881 1.19451 
Gene MAD2L1 UP III mid-late 18.1164 11.6071 13.3473 3.4461 2.45909 0.789811 
Gene DBF4 UP III mid-late 27.1441 20.329 18.6896 4.08339 1.52648 1.22136 
Gene AKAP2 UP III mid-late 46.9486 18.8501 20.7009 6.89385 3.79677 2.44648 
Gene COCH UP III mid-late 21.7077 9.59599 5.20214 2.11187 3.71059 1.21839 
Gene GGH UP III mid-late 176.718 66.279 66.749 39.7979 26.5655 10.1104 
Gene IKZF3 UP III mid-late 4.08312 8.28584 5.74821 1.95154 1.14268 0.237734 
Gene LMNB1 UP III mid-late 138.566 48.9783 35.9507 29.3737 32.312 8.60001 
Gene FAM72B UP III mid-late 6.45911 3.31106 4.08469 0.952471 2.22147 0.418112 
Gene OSTM1 UP III mid-late 171.532 63.567 57.8155 20.9209 31.2724 11.3222 
Gene ULBP3 UP III mid-late 9.38538 10.1646 14.5821 4.58005 7.00096 0.729776 
Gene CCNA2 UP III mid-late 37.0575 17.1974 15.6737 4.41578 7.38705 2.97073 
Gene DDX21 UP III mid-late 124.214 67.389 73.7654 38.1992 46.0081 11.6053 
Gene SLC25A5 UP III mid-late 269.273 126.1 118.275 106.366 89.5077 27.1923 
Gene SPC25 UP III mid-late 14.3235 12.5958 11.0166 2.35998 2.72142 1.47637 
Gene RANBP1 UP III mid-late 74.9429 40.4723 35.2797 16.6865 11.8048 7.92407 
Gene MCM4 UP III mid-late 78.0733 55.7944 43.7416 25.2823 32.4588 8.51756 
Gene CKAP2 UP III mid-late 74.8817 76.9483 75.9329 21.7773 25.0653 8.45208 
Gene SMC4 UP III mid-late 469.645 457.651 476.598 88.6062 64.7157 54.7126 
Gene HMGB2 UP III mid-late 387.477 315.022 402.138 129.584 136.109 45.4058 
Gene MIS18A UP III mid-late 24.5086 12.4174 13.4275 3.87505 12.2554 2.96165 
Gene TLL2 UP III mid-late 3.92559 2.15422 4.10378 1.69713 1.20992 0.477759 
Gene DARS2 UP III mid-late 15.5499 10.4759 8.19855 4.75594 5.95291 1.94326 
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Gene PCNA UP III mid-late 53.9617 29.122 28.5632 10.9338 13.9228 7.014 
Gene DOCK11 UP III mid-late 16.3303 17.8238 9.34571 4.2822 6.05996 2.21247 
Gene HNRNPA3 UP III mid-late 949.686 663.767 553.587 235.505 391.065 130.603 
Gene RPS13 UP III mid-late 416.454 271.545 309.112 107.794 183.834 57.3296 
Gene RFWD3 UP III mid-late 23.9882 15.7896 18.3356 10.0032 13.0808 3.34003 
Gene TMPO UP III mid-late 81.9778 46.4175 52.2688 20.676 33.6044 11.4381 
Gene SNRPG UP III mid-late 181.948 152.969 124.046 44.6397 23.4877 25.6097 
Gene HAUS1 UP III mid-late 8.16978 6.42732 6.35887 3.80729 6.31123 1.16468 
Gene PUS7 UP III mid-late 30.3094 18.7511 23.0665 12.5768 15.4448 4.33527 
Gene PPPDE1 UP III mid-late 64.6379 37.7841 45.0864 23.9402 25.1495 9.29778 
Gene MYH15 UP III mid-late 9.43161 7.95394 8.49358 4.85353 3.47179 1.36468 
Gene SGOL2 UP III mid-late 11.1196 9.91216 12.2107 2.69593 1.58819 1.67532 
Gene ZNF367 UP III mid-late 5.16965 3.80469 4.25994 0.622499 0.305971 0.790714 
Gene SNRPE UP III mid-late 52.5585 72.5035 57.5831 21.6511 9.27867 8.06769 
Gene PIM2 UP III mid-late 5.68875 3.86378 3.54591 2.59318 4.80622 0.87878 
Gene MINA UP III mid-late 95.3087 76.9886 74.1973 39.8629 27.9797 15.1043 
Gene KIF20B UP III mid-late 50.154 33.2906 52.0939 16.4821 20.6698 8.06513 
Gene SMC2 UP III mid-late 110.325 86.4279 83.2255 41.2975 69.9389 18.7396 
Gene PLK4 UP III mid-late 29.6087 40.1316 26.8322 12.0422 20.1807 5.0516 
Gene IKBIP UP III mid-late 10.4747 7.73514 16.1573 3.0376 4.98381 1.79725 
Gene C4orf43 UP III mid-late 41.9927 32.6552 33.7471 18.1081 24.8679 7.55584 
Gene HAT1 UP III mid-late 203.824 176.666 182.405 53.9454 135.834 38.3856 
Gene VDAC2 UP III mid-late 170.192 157.077 149.188 117.634 109.54 35.0379 
Gene OSTC UP III mid-late 29.4727 29.2419 49.8923 9.88988 20.7782 6.07898 
Gene NMI UP III mid-late 7.84286 7.35719 10.4016 3.23077 4.95162 1.74403 
Gene LSM6 UP III mid-late 37.6649 37.2585 41.9155 18.9177 16.2461 8.40477 
Gene RPL22L1 UP III mid-late 9.78986 9.51333 13.636 6.0899 8.10571 2.37362 
Gene RRM2 UP IV late 67.9237 34.7113 33.6775 13.3768 17.6154 0.01 
Gene HIST1H2AJ UP IV late 13.951 10.1294 8.65238 20.5634 11.8205 0.01 
Gene NEK2 UP IV late 13.1824 7.76696 5.90729 2.04673 5.03702 0.01 
Gene HIST1H1B UP IV late 10.7462 3.77638 4.33803 7.65638 6.4831 0.01 
Gene GSG2 UP IV late 3.72115 2.24653 2.21415 1.66106 2.51941 0.01 
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Gene ISL1 UP IV late 2.99051 9.57871 5.51527 3.35796 0.809667 0.01 
Gene IGF2BP1 UP IV late 2.38499 3.573 3.68521 3.27452 9.29564 0.01 
Gene RGS13 UP IV late 1.75441 13.8155 2.21251 4.01955 0.376299 0.01 
Gene POU2F3 UP IV late 1.71591 4.43205 2.66264 2.88034 1.65273 0.01 
Gene HOXD4 UP IV late 1.62814 2.46504 2.19357 1.43997 0.798633 0.01 
Gene OR51F1 UP IV late 1.30658 16.1633 23.1214 15.5836 4.56099 0.01 
Gene PBK UP IV late 45.7326 33.8475 28.9719 9.3 2.79627 0.356567 
Gene EN2 UP IV late 1.14653 3.98318 8.5693 2.75683 5.04104 0.01 
Gene IRX3 UP IV late 1.05763 7.5178 13.6298 8.5065 6.26942 0.01 
Gene HOXA3 UP IV late 0.853364 2.8792 4.51269 5.03597 2.01025 0.01 
Gene HOXA10 UP IV late 14.2986 13.262 13.1655 9.21647 6.32746 0.195221 
Gene FOXM1 UP IV late 15.9636 7.02385 5.88438 5.44371 3.06383 0.274095 
Gene NPM3 UP IV late 24.768 16.7231 12.3669 34.4324 3.97995 0.527561 
Gene NUSAP1 UP IV late 68.4066 69.6114 61.3141 25.7069 31.6285 1.52357 
Gene ZWINT UP IV late 40.2918 39.6023 44.9569 10.5538 3.23772 1.12487 
Gene SHCBP1 UP IV late 9.82754 3.03586 4.28384 1.84924 1.86887 0.337096 
Gene BZW2 UP IV late 93.7738 79.4908 78.0135 45.7159 64.31 4.71446 
Gene C1QBP UP IV late 183.024 53.7375 57.5758 53.7616 46.4965 9.74272 
Gene CENPK UP IV late 15.864 18.5789 15.9905 5.69753 5.20605 1.06669 
Gene NCAPD2 UP IV late 46.1647 31.255 23.1355 50.5939 26.312 3.65021 
Gene PPP1R14C UP IV late 39.8659 30.8334 42.4505 35.3236 12.2945 3.46417 
Gene DIRAS3 UP IV late 17.4958 14.4257 27.4329 13.0912 7.01398 1.65038 
Gene SNRPC UP IV late 23.2632 17.5368 19.2835 19.124 9.38091 2.38153 
Gene RUNX3 UP IV late 1.68475 1.8904 1.93784 2.95664 1.1962 0.174666 
Gene AHCY UP IV late 112.978 109.856 88.7567 127.349 45.3887 11.8844 
Gene RPL10A UP IV late 121.865 82.1178 94.6418 122.828 66.0033 13.1143 
Gene DDT UP IV late 133.629 79.125 78.1742 86.1256 35.7829 14.5749 
Gene ATP5G3 UP IV late 353.524 180.254 200.865 175.81 119.22 41.451 
Gene TUBA1C UP IV late 249.878 129.11 169.731 130.388 55.653 30.219 
Gene RRP36 UP IV late 9.77024 5.93544 5.93831 8.44073 7.15731 1.26624 
Gene FRAT2 UP IV late 3.63699 3.66873 3.36793 3.5385 3.10085 0.509789 
Gene TCF19 UP IV late 3.6908 2.58839 2.32772 2.85142 1.37196 0.528475 
Gene BTF3 UP IV late 201.885 239.669 248.124 123.032 78.9294 29.1051 
Gene TFAM UP IV late 84.3307 58.4173 55.5112 55.9865 60.0625 12.442 
Gene SH2D4A UP IV late 41.8356 35.3761 39.8931 61.8866 19.2159 6.39088 
Gene TIMM22 UP IV late 6.27573 4.5858 4.00044 13.4085 4.13777 0.970344 
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Gene RPL19 UP IV late 551.298 352.021 422.845 580.13 283.824 86.197 
Gene HNRNPL UP IV late 26.1655 18.5873 16.8161 17.3628 15.8564 4.11959 
Gene YRDC UP IV late 5.63714 5.35632 4.83621 4.37111 3.16713 0.929475 
Gene ECT2 UP IV late 59.8977 72.3106 49.2683 50.2722 26.0801 10.212 
Gene NKIRAS2 UP IV late 4.0854 4.71841 4.16802 7.84725 8.07757 0.740802 
Gene RPS3A UP IV late 216.163 229.095 255.192 184.507 161.671 42.8927 
Gene GEN1 UP IV late 8.63311 12.5139 17.6842 8.07734 7.11824 1.75005 
Gene RPL39 UP IV late 41.9559 40.831 63.9783 37.483 33.6771 9.31378 
Gene HSBP1L1 UP IV late 10.436 9.88612 10.7106 18.372 11.0324 2.32491 
Gene MRPL36 UP IV late 38.1956 38.4832 43.9271 44.201 24.4987 8.95216 




168.001 91.8413 54.0289 37.994 29.8306 0.01 




26.2926 20.5681 14.5762 20.7589 26.0457 0.01 




20.3097 19.6911 19.6874 13.434 12.2143 0.01 




16.5205 11.7094 12.9234 39.2614 6.81938 0.01 




13.6887 14.3383 18.6789 10.2782 33.6167 0.01 




60.8936 27.3915 22.6939 45.8975 38.1117 0.0573954 




10.4127 14.9936 33.9138 24.1339 14.6997 0.01 




9.35744 8.77125 13.0938 2.24705 32.4585 0.01 




8.78579 13.7402 12.6671 7.07075 7.45502 0.01 




8.39442 8.9806 12.5985 24.6084 7.29107 0.01 




28.9868 17.0238 13.034 13.9234 24.5239 0.0395957 




6.48753 8.55418 4.68786 3.0746 2.14529 0.01 




6.4697 7.44579 3.19496 6.343 2.79748 0.01 




6.2704 7.0054 10.312 9.42735 38.3165 0.01 




6.24624 4.02577 2.88724 3.07322 7.24882 0.01 
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5.64082 3.25976 1.42542 2.97378 3.78641 0.01 




95.5566 69.5566 78.0382 22.7828 53.397 0.207085 




48.0114 28.4895 23.3649 8.22209 20.4484 0.132452 




35.5457 55.0052 18.2285 27.7961 26.2435 0.103083 




66.3375 25.9775 15.9779 14.4216 18.3878 0.218202 




2.74653 5.16968 6.23125 4.7196 5.6929 0.01 




121.246 139.365 246.349 557.574 114.646 0.506434 




2.31289 11.3586 3.59632 12.3378 6.02621 0.01 




12.3204 6.25378 11.5264 12.5664 5.38087 0.0615409 




17.4081 13.3025 13.2573 7.17383 15.5294 0.0891807 




16.9606 29.0682 20.9978 75.1248 17.295 0.0903434 




67.3222 36.0784 29.7849 12.063 4.81572 0.362828 




12.5225 5.43845 5.0905 9.29233 4.73798 0.0782112 




13.3495 11.0374 8.74866 16.9463 23.9217 0.0850768 




339.921 14.9986 31.2863 15.8322 398.443 2.25077 




79.1246 283.53 311.694 101.971 71.1639 0.584066 




67.9556 35.1121 31.5179 24.3309 40.3852 0.503749 




38.2688 28.247 23.125 16.5024 28.0427 0.285509 




11.6936 7.42429 8.63179 4.22983 4.1977 0.0878136 




27.3951 48.5064 59.8329 69.2617 45.4796 0.210554 




10.084 3.40274 6.37575 5.7776 2.3003 0.0810349 




12.6171 8.52833 8.74457 1.43197 1.99782 0.107542 
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27.4213 21.2582 27.0459 8.31128 41.7383 0.252416 




17.3392 14.2293 24.4925 14.2042 25.3172 0.162101 




51.7192 81.4688 47.6433 11.6365 10.9782 0.484144 




24.41 14.6754 11.0676 8.69315 11.8165 0.238907 




21.2168 9.97079 10.98 11.4688 13.8864 0.207751 




5.2324 3.59423 2.76734 3.91111 3.4773 0.0524508 




75.4276 69.9555 62.3877 39.3591 48.6539 0.767844 




0.972323 20.3084 54.3725 31.3034 132.319 0.01 




136.389 107.355 85.9259 23.2909 21.0234 1.42644 




148.678 54.9577 61.2686 19.0555 16.9555 1.76799 




172.839 69.342 46.9111 143.37 31.519 2.17237 




85.9961 18.0007 6.68984 9.3738 56.4347 1.09612 




8.01767 73.0748 131.792 250.499 105.609 0.102849 




17.4668 9.25578 7.66365 9.0613 11.0465 0.227263 




110.423 132.287 265.774 196.459 386.21 1.52859 




14.6629 11.7041 14.0704 2.84042 3.95993 0.207019 




24.3884 18.3995 12.2557 14.4235 9.6588 0.356697 




15.3859 31.024 39.1249 26.2453 15.7193 0.233309 




20.851 17.8839 17.2613 4.2674 6.00179 0.33844 




43.2057 29.2596 16.329 49.0229 16.8506 0.727696 




52.9944 33.3572 34.4975 21.0128 23.5558 0.912453 




113.041 43.4324 21.0667 45.4547 18.9813 2.02256 
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135.269 102.086 71.6593 79.3456 60.0975 2.45679 




40.0178 39.974 37.1241 12.2641 17.4821 0.740276 




25.8608 12.5982 10.356 3.37678 5.74706 0.504315 




5.55176 7.36072 13.0251 2.93999 7.63766 0.114873 




13.8937 7.8656 7.02546 7.40889 6.44015 0.289289 




69.5974 42.9978 33.0865 16.8462 36.8434 1.46833 




108.536 48.3975 40.1314 36.013 40.4488 2.30836 




19.9034 33.3602 33.5287 11.1867 16.8195 0.516104 




276.41 211.457 152.061 247.161 126.379 7.23857 




16.7361 21.2497 22.6451 8.54738 3.70812 0.468342 




145.342 45.1711 47.3476 40.6997 37.6931 4.12765 




126.479 128.432 130.772 227.277 141.903 3.62126 




24.7178 22.6634 38.267 56.0998 59.746 0.721037 




16.6782 7.60041 6.79504 7.87064 7.96187 0.490735 




34.9332 25.9304 33.1824 39.4648 36.1505 1.08193 




117.525 83.2449 79.0318 44.1198 100.862 3.68769 




26.1768 25.8271 15.5381 26.1853 32.7601 0.834968 




136.072 22.0429 96.8045 19.1594 20.36 4.44407 




108.544 107.312 141.602 245.742 171.926 3.57445 




19.2118 176.143 283.656 69.3842 81.5957 0.640122 




44.3158 49.0586 33.1418 12.7133 11.2617 1.48938 




39.4187 32.1325 33.9016 7.66443 9.42191 1.41854 
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119.705 31.1811 38.5966 49.249 34.3536 4.33946 




17.0541 8.87666 9.12414 4.94165 8.52625 0.636943 




8.59933 5.03112 5.10595 2.13583 7.31989 0.332983 




28.5332 15.6545 12.1625 13.0113 8.84481 1.11197 




162.239 50.0483 109.088 166.838 366.817 6.45959 




15.7454 22.4064 32.4193 92.6977 59.0983 0.628481 




98.3281 51.1603 41.292 54.5789 58.9616 4.0352 




4.63833 5.75862 6.79825 2.44407 7.06084 0.192206 




40.7409 45.7842 44.1144 11.373 9.03349 1.69933 




129.197 74.7445 62.3931 33.0165 35.2918 5.39401 




38.8736 38.7448 28.6864 29.3394 26.3291 1.62365 




56.728 23.1655 18.6399 53.6826 32.3335 2.3703 




14.2556 22.6343 30.8561 8.3921 12.0385 0.598459 




3.35747 3.38601 15.7358 20.9758 21.4344 0.146794 




30.2539 6.94506 17.7092 25.3268 24.0858 1.34233 




2.93289 2.0159 1.80749 1.73145 2.56282 0.130503 




11.1081 23.0464 26.6229 16.2065 17.2827 0.507584 




84.0382 45.7975 35.3903 27.2384 16.4179 3.92523 




71.4533 37.9062 38.1949 16.3601 83.7985 3.47362 




19.4481 9.3909 6.10526 7.00416 6.90291 0.972091 




23.2125 14.6058 12.0052 41.1865 37.1576 1.16908 




22.8644 10.0369 8.52256 15.6227 13.3952 1.15572 
   91 




59.3318 48.7959 31.6351 40.7251 58.6795 3.00162 




62.4727 26.2119 26.5763 34.4336 39.832 3.19047 




48.3448 17.7444 28.3849 19.2701 13.2977 2.51189 




77.2282 28.4696 20.1734 23.5345 21.1846 4.04648 




78.3917 30.9333 24.5329 29.1072 25.0341 4.28572 




27.6454 18.3921 18.1419 8.11421 14.5429 1.53727 




301.76 488.026 624.437 173.809 208.997 17.0282 




19.708 16.0972 12.8533 13.59 12.0443 1.11462 




17.7743 13.8893 9.55464 5.07263 14.5578 1.02999 




11.6966 4.89232 4.48906 5.02856 7.3067 0.681715 




134.673 88.5483 110.391 49.2104 68.0643 7.96876 




5.06315 10.3177 8.11932 2.91102 21.2519 0.299926 




13.477 10.36 10.9603 9.66591 15.7039 0.800354 




15.3941 40.5723 101.332 50.4338 55.2236 0.915839 




4.20666 6.95376 7.44467 4.55259 6.09505 0.250612 




716.116 393.943 234.995 230.262 374.543 43.5219 




120.714 57.6159 44.0988 98.2822 97.316 7.3842 




3093.44 1992.98 2198.19 1572.86 2273.42 189.242 




46.6465 42.5374 47.6329 27.3472 24.1751 2.86584 




11.4231 6.90645 5.22578 8.52079 7.22666 0.705294 




1626.67 1090.56 617.825 773.749 901.783 100.772 




46.2336 41.9629 38.4333 20.5844 59.3064 2.89059 
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47.1777 27.8853 28.3708 42.9177 81.1134 2.98511 




868.096 347.054 378.198 254.226 483.576 54.9532 




22.2957 17.9833 15.4766 26.4468 20.334 1.41254 




9.56802 6.34124 7.10422 10.2702 7.18523 0.60674 




60.5607 54.7975 54.3908 77.7245 47.022 3.87686 




27.5539 9.91141 13.2553 12.7137 11.5315 1.81057 




937.684 696.123 514.973 420.815 426.751 61.8178 




391.448 226.766 247.023 336.177 348.643 25.8333 




62.5994 43.2982 60.5992 38.847 70.5696 4.17524 




116.071 45.5971 54.6065 89.5029 92.2993 7.76821 




4.52882 2.80186 4.26334 3.22828 2.46591 0.308718 




519.595 327.146 412.173 908.186 208.074 35.8127 




56.2737 91.2919 86.6327 55.3147 136.28 3.89242 




5.12941 2.87479 2.52328 2.56177 3.72519 0.361763 




3.36209 2.93086 4.47341 4.78372 2.49475 0.238474 




9.78543 8.84473 7.68104 9.35224 8.70445 0.696149 




65.2172 25.7764 19.7131 34.1901 29.6808 4.6613 




4.02564 5.44364 4.9398 3.7331 5.87957 0.287863 




5.62332 33.9016 56.744 24.1287 17.0525 0.403383 




155.264 139.014 233.867 151.291 141.636 11.2161 




36.9112 51.4366 86.0908 39.9561 79.1955 2.67765 




30.5688 17.7822 14.8124 16.0687 20.7556 2.23304 
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195.953 65.6484 113.892 110.401 144.157 14.3455 




7.00761 2.70695 3.3359 5.11084 3.77004 0.515057 




50.7504 18.8287 61.2314 34.2535 59.8021 3.74314 




14.0441 5.33823 4.90042 11.4345 17.1666 1.04358 




31.0077 100.962 67.222 170.206 225.538 2.30471 




522.246 227.072 292.326 335.529 423.836 38.9852 




58.4896 41.8061 39.8256 49.7463 39.0415 4.54035 




10.3253 12.8196 11.678 20.4622 13.4511 0.804504 




121.497 65.8934 46.0013 94.4892 89.3587 9.53391 




33.5965 23.9184 36.1255 15.7343 47.8187 2.66953 




3.43911 3.5294 3.91702 2.07888 2.51231 0.273954 




7.41101 4.61437 9.08977 11.5163 14.6577 0.600657 




5.23025 3.64273 2.86941 3.32943 2.64446 0.427514 




14.6646 8.00571 13.8314 21.9806 20.625 1.2056 




36.2003 61.138 56.6053 16.2652 54.8577 3.03351 




17.895 11.1998 12.3634 13.5204 10.9483 1.51515 




186.841 122.811 107.356 136.503 120.798 15.9423 




48.7218 65.4269 77.972 77.8037 49.6198 4.16963 




164.619 75.7462 82.8243 95.4913 101.864 14.1186 




24.3398 12.9584 28.037 50.5036 46.0772 2.09856 




25.7068 26.0752 32.0365 23.1147 58.7162 2.24008 




42.3018 20.182 23.0738 31.0613 28.561 3.70062 
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19.5075 13.4213 28.066 13.6798 20.3026 1.71164 




74.233 61.1228 46.9124 104.73 55.7122 6.53523 




121.711 651.884 1132.11 654.261 745.021 10.9424 




3.56514 2.88438 2.12294 1.43442 2.42323 0.323425 




51.9207 37.2674 32.8566 26.7717 45.5672 4.72252 




177.73 134.703 181.906 315.109 146.427 16.3648 




54.0505 94.754 113.816 64.0705 93.4712 5.06895 




147.795 73.2063 367.135 486.376 667.273 13.9876 




95.0636 69.5518 86.7933 67.8293 86.1157 9.00628 




166.026 126.455 121.264 94.7892 150.716 16.0915 




112.283 58.5662 59.4798 77.8434 109.005 10.992 




33.1667 26.8233 21.0342 23.8481 32.7516 3.31458 




20.2119 12.6159 24.007 15.4313 25.9976 2.02987 




18.0872 8.62853 7.99908 24.581 17.7942 1.82048 




7.1973 26.2917 46.3648 17.1222 15.8604 0.73739 




57.4525 46.314 56.2914 86.7215 72.5527 5.94743 




159.995 105.977 193.928 253.376 239.706 16.7199 




225.957 146.164 114.295 303.404 159.208 23.9012 




6.83206 8.45091 9.99877 5.96709 6.83297 0.733385 




3.79085 2.47661 3.11519 3.62593 3.52672 0.413389 




8.70305 13.5841 9.39988 20.1536 14.7881 0.95006 




25.9119 39.9 29.4587 24.7026 51.0705 2.83271 
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80.5376 62.7941 97.5129 72.4734 93.2944 8.82424 




13.2509 11.3824 21.3607 14.9266 16.0672 1.4523 




90.8975 65.2202 53.4513 61.5296 76.2732 9.97223 




571.353 276.598 310.445 416.315 344.005 63.3424 




208.778 173.683 399.163 502.304 598.166 23.5012 




97.6514 46.0423 71.0674 52.5192 116.991 11.1543 




15.3736 17.8918 33.6473 33.5737 53.477 1.7794 




3.13062 3.91967 8.03848 4.37237 27.6577 0.363735 




19.1711 10.4527 13.0952 8.94506 11.962 2.23028 




39.7111 25.011 23.5069 20.3162 25.7675 4.62271 




8.30471 13.1508 17.6789 40.8813 29.7716 0.977179 




33.0074 53.4172 64.3758 28.9659 76.2702 3.88447 




51.2382 52.3561 188.553 183.311 263.618 6.11298 




60.5047 35.6162 41.6901 76.9687 51.4812 7.25312 




50.3094 33.0688 31.9348 36.1932 40.1244 6.03396 




16.3371 13.0197 15.2441 11.3007 22.2701 1.9607 




17.3931 10.0526 9.48661 8.88681 13.2252 2.09426 




166.069 125.309 118.871 113.024 135.983 20.0042 




170.727 90.8074 94.5626 243.481 425.117 20.6538 




1.73904 2.69441 3.49785 3.08187 4.40262 0.21131 




35.0134 49.7742 47.1056 69.5221 82.2238 4.29679 




12.3809 10.5687 12.8802 11.6869 16.158 1.52528 
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53.9396 30.1692 31.7266 40.2571 32.527 6.72937 




11.6835 9.25143 7.96688 7.18881 10.0786 1.46369 




61.4076 63.5669 62.1744 31.4064 52.7171 7.70129 




35.8401 37.7341 37.9483 36.1575 44.0162 4.54427 




16.4925 19.2741 22.5711 11.7646 10.3533 2.09439 




24.5294 32.2246 31.2532 40.9888 35.4439 3.12817 




114.62 65.2636 71.1863 115.723 72.5243 14.6885 




59.1986 44.8965 48.1175 71.9145 57.6926 7.59197 




32.9855 19.8976 23.9299 20.5928 21.0941 4.23728 




90.6459 48.936 53.7038 102.221 75.0177 11.7281 




33.8398 25.1147 32.8895 22.5205 25.9336 4.43054 




33.0819 17.9502 28.8129 18.4461 18.1551 4.35668 




27.1541 19.6063 20.1518 30.5466 19.2778 3.58688 




4.14175 9.44159 14.9425 9.65581 3.08982 0.548857 




137.221 108.639 113.22 73.9211 135.735 18.1979 




444.979 281.943 330.992 311.318 444.304 59.2155 




15.9077 11.199 12.1715 13.5302 11.3425 2.11972 




11.6016 6.52222 12.3973 9.05673 10.4837 1.55167 




192.927 122.258 144.074 221.826 178.215 25.947 




21.9507 15.6481 28.1239 34.9331 37.5108 2.95461 




8.54514 11.1471 9.17069 6.91384 10.7312 1.1713 




7.72133 6.32984 7.20134 9.24973 7.40224 1.06272 
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19.8951 42.869 63.8449 125.355 60.2873 2.76043 




2.35573 1.97663 7.52905 11.401 9.38816 0.328435 




152.724 165.921 136.249 192.072 196.643 21.5629 




14.7691 9.70834 11.5011 13.178 13.0281 2.08935 




20.881 17.3275 23.1926 15.3763 14.2257 2.95717 




41.6541 129.09 215.885 160.216 470.223 5.89908 




4.81228 3.23987 3.34743 7.93859 5.25346 0.68435 




2936.24 1912.71 2043.57 2776.3 2793.36 420.61 




784.471 453.194 497.704 476.704 821.255 112.493 




20.4905 17.9145 28.5681 55.5302 42.9111 2.93909 




9.4041 18.6866 20.3367 14.1879 26.4526 1.35063 




27.7005 22.34 20.5083 33.4227 22.9623 3.99333 




7.34133 9.88903 8.77927 11.048 15.7386 1.05851 




7.74832 9.86048 11.5634 15.3695 14.5197 1.12474 




55.8695 54.5592 82.5033 60.4164 42.8789 8.12915 




15.2369 17.777 18.2736 16.0897 28.333 2.234 




6.87606 11.1647 13.8127 13.9633 8.34867 1.02337 




355.088 273.222 276.426 273.015 218.419 53.7516 




92.3827 151.259 364.528 627.875 553.877 14.0011 




2.75669 4.80398 5.72808 3.58185 6.21164 0.421499 




199.167 155.471 181.982 148.204 141.46 30.7753 




142.521 104.126 110.662 116.53 99.5442 22.1168 
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40.6774 34.3879 30.6363 58.2473 57.8522 6.37415 




5.83953 6.23843 11.34 4.21893 17.9349 0.937587 




1154.28 784.277 1009.2 1352.32 1503.51 186.064 




5.00387 17.645 20.2569 14.778 9.49157 0.820346 




12.3986 17.888 23.334 22.509 24.6251 2.0544 




12.8049 16.6399 10.0913 10.3453 11.1405 2.14253 




190 135.047 142.954 377.283 329.362 32.461 




92.9342 179.455 224.381 264.622 355.309 15.9847 




319.364 364.457 384.219 283.011 250.808 55.4076 




64.7785 90.8351 136.95 91.3686 121.913 11.2961 




25.076 22.8372 37.4107 53.8689 30.2376 4.38147 




40.4146 31.1773 43.1795 32.9286 39.1226 7.11632 




118.166 111.588 112.296 119.427 222.273 20.8786 




18.1471 28.3937 36.0837 24.268 35.9624 3.25084 




9.57382 11.003 12.1385 8.84536 9.77173 1.72285 




32.8106 27.5029 35.5219 49.2308 42.8019 6.20993 




3.1191 3.40219 4.77728 2.70523 5.82398 0.596732 




161.65 162.382 220.63 141.096 250.19 31.633 




66.6052 61.8547 66.2063 96.3314 97.9629 13.1384 




53.3592 68.3146 79.4788 64.3086 69.2407 10.8647 




21.3516 25.1165 21.0908 18.5673 45.252 4.38966 




441.093 598.321 559.056 536.697 874.731 91.9126 
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30.6016 26.5352 27.3062 28.2217 26.0221 6.4212 




33.5911 29.8372 34.5392 31.9306 37.7054 7.13458 




392.522 585.89 464.895 963.63 787.283 83.4359 




10.9471 23.7497 29.6741 15.7601 14.6037 2.36697 




113.757 135.884 138.776 645.763 129.832 25.4563 




523.751 539.258 663.687 734.042 793.143 119.19 




4.84307 5.67687 6.54606 12.5195 8.24031 1.10517 




444.884 411.164 481.227 426.005 602.559 102.031 




1.97486 5.99592 5.36575 3.71023 3.2228 0.45509 




16.5976 29.558 45.5053 24.7671 62.6739 4.02022 




13.9068 86.243 134.98 34.9683 151.685 3.37694 




106.103 113.646 119.647 129.087 163.337 26.2992 
Gene GRIA2 DOWN I early 0.01 354.062 374.944 357.818 407.833 521.085 
Gene CFH DOWN I early 0.0058227 23.1134 45.2783 20.9704 12.8457 17.76 
Gene PCDH15 DOWN I early 0.01 24.684 24.5944 6.65492 13.6352 20.5292 
Gene ZNF711 DOWN I early 0.0201074 19.8557 28.6272 9.22222 35.5077 26.1322 
Gene SOX6 DOWN I early 0.0186252 6.50441 15.3244 13.1577 6.38765 18.863 
Gene BEND5 DOWN I early 0.01 3.31567 5.91994 3.47907 7.37857 10.029 
Gene CCND2 DOWN I early 0.0630804 47.7283 114.698 57.9708 154.356 60.3871 
Gene CNTN4 DOWN I early 0.01 17.2732 3.31116 14.6524 13.9653 9.56171 
Gene SLC24A5 DOWN I early 0.0176812 5.03554 11.4212 4.16837 6.01453 15.9749 
Gene PALMD DOWN I early 0.01 6.33658 7.85717 5.9967 2.31607 7.67324 
Gene GYPB DOWN I early 0.01 0.132516 0.0929535 0.149752 0.120879 7.35409 
Gene FBXL7 DOWN I early 0.01 5.98913 7.82124 6.93121 5.96442 7.22009 
Gene MYRIP DOWN I early 0.01 3.55395 15.1314 13.7215 7.37838 6.10141 
Gene EPHA5 DOWN I early 0.01 6.71715 11.7345 3.61644 2.37013 5.7194 
Gene MAMLD1 DOWN I early 0.01 2.9897 13.2141 6.74256 4.40601 5.6522 
Gene DTX4 DOWN I early 0.01 0.62849 1.57131 3.7131 2.5181 4.74818 
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Gene GLDC DOWN I early 0.01 1.9029 1.25035 3.57038 12.46 4.6788 
Gene ITGB8 DOWN I early 0.0851869 11.9084 43.5265 13.9098 10.1668 37.9503 
Gene CBLN2 DOWN I early 0.01 11.2268 12.4819 6.03247 1.26015 4.24101 
Gene SEMA4A DOWN I early 0.01 0.757138 1.67794 1.22754 3.73746 4.10999 
Gene CFHR1 DOWN I early 0.01 4.63711 9.20523 4.94535 2.48372 3.9308 
Gene ARSE DOWN I early 0.01 0.0975371 0.0149941 1.21649 0.251915 3.82609 
Gene BCHE DOWN I early 0.0182178 6.79723 10.5589 4.82174 5.252 6.47425 
Gene MARCKS DOWN I early 0.2105 106.278 190.258 38.4064 64.737 74.7031 
Gene RALYL DOWN I early 0.0445581 35.1605 45.1874 16.4473 4.4325 15.7254 
Gene RNF150 DOWN I early 0.01 1.23574 2.03356 2.82371 3.11706 3.42567 
Gene CD274 DOWN I early 0.0128343 0.475651 5.116 1.50784 8.91543 3.9491 
Gene SPI1 DOWN I early 0.01 0.674549 1.08744 3.41111 0.467221 2.92034 
Gene GRID2 DOWN I early 0.0212415 10.7892 8.6364 7.63187 2.46232 5.7816 
Gene PLD5 DOWN I early 0.0551761 10.4315 15.4278 28.6142 20.5484 13.3698 
Gene PCDHB11 DOWN I early 0.0216993 0.549718 0.338518 0.676285 1.72155 4.77847 
Gene MBNL3 DOWN I early 0.0221563 2.74971 2.79094 1.68093 4.67832 3.90678 
Gene ODZ1 DOWN I early 0.0206027 2.98481 3.032 2.19493 5.47596 3.53059 
Gene SYNPR DOWN I early 0.257258 10.3422 59.2308 35.1746 89.9933 40.6105 
Gene PARD3B DOWN I early 0.0702041 6.35282 16.5522 9.66499 15.5275 10.6257 
Gene ADCY1 DOWN I early 0.108854 19.0039 8.99356 6.09363 5.9588 15.9204 
Gene KLF9 DOWN I early 0.0454573 1.72545 4.1089 2.54177 2.37186 6.13218 
Gene HLA-DQB1 DOWN I early 0.0325952 1.66846 1.60899 0.498474 2.31496 4.28405 
Gene MYEF2 DOWN I early 0.176918 12.172 24.8062 6.64252 34.4451 22.3879 
Gene NLGN4X DOWN I early 0.0474034 3.70646 3.68716 2.1679 4.58623 5.75744 
Gene CACHD1 DOWN I early 0.0980909 3.05904 13.5962 11.125 39.1217 11.6939 
Gene BICC1 DOWN I early 0.0233148 1.76364 4.42979 1.62462 5.35341 2.74891 
Gene FREM1 DOWN I early 0.0263838 0.919993 3.05122 6.58566 6.16956 3.01624 
Gene NLGN4Y DOWN I early 0.131228 4.49989 10.0324 12.6143 17.6126 12.2263 
Gene LIX1 DOWN I early 0.100117 2.75974 3.13412 2.46412 6.46147 9.21703 
Gene VCAN DOWN I early 0.901847 45.4561 51.4656 57.9182 110.931 79.6997 
Gene ST6GALNAC5 DOWN I early 0.0917698 11.008 29.8271 23.6837 20.9511 7.87468 
Gene YAP1 DOWN I early 0.146063 3.86298 15.7354 10.5821 17.2487 12.1054 
Gene SHC3 DOWN I early 0.130222 4.04654 2.99671 6.7362 4.85482 10.6849 
Gene KCNH1 DOWN I early 0.0880702 2.78622 3.06495 4.01666 3.22433 6.82289 
Gene HSPA12A DOWN I early 0.279483 6.38005 12.2798 13.5844 10.5477 19.2368 
   101 
Gene PLAC8L1 DOWN I early 0.103829 2.36199 1.92055 3.92262 10.4614 6.80793 
Gene DDX26B DOWN I early 0.0478164 3.72463 3.24919 1.38817 2.06964 3.12564 
Gene ABCA1 DOWN I early 0.160608 4.92941 8.03599 3.59957 13.4696 10.2526 
Gene RERG DOWN I early 0.245957 22.2937 28.1489 14.0851 24.5883 14.4432 
Gene SAMD9L DOWN I early 0.281895 11.1722 11.9333 11.5289 24.3103 15.9527 
Gene SYNPO DOWN I early 0.302843 6.06296 10.9354 27.0055 12.9499 16.7791 
Gene TRPS1 DOWN I early 0.627294 23.9342 43.6454 45.5093 27.4369 33.7636 
Gene PARP8 DOWN I early 0.533842 36.9645 21.7019 100.99 22.6347 27.9403 
Gene C3orf70 DOWN I early 0.27453 5.89281 16.39 14.0149 13.0577 13.4573 
Gene DAPK2 DOWN I early 0.101248 1.64892 1.25316 1.2952 1.01806 4.91761 
Gene TUB DOWN I early 0.19871 2.55402 3.57 3.33324 6.59563 8.91369 
Gene FLRT3 DOWN I early 0.218783 6.90769 17.7899 3.55049 27.088 9.56801 
Gene C9orf131 DOWN I early 0.0880231 0.394346 1.37204 0.606061 0.723304 3.72817 
Gene ASAP2 DOWN I early 0.353653 3.98873 11.0869 6.75763 8.69739 14.5356 
Gene MT1F DOWN I early 0.194977 6.14536 3.88046 4.22425 2.06223 7.96158 
Gene ABAT DOWN I early 0.949596 13.1601 18.1887 15.7203 18.3732 37.202 
Gene OLFM2 DOWN I early 0.825789 8.24931 17.747 9.00081 10.3407 32.1772 
Gene MAST4 DOWN I early 0.557037 7.23179 19.5849 16.6732 33.4948 21.3564 
Gene AIG1 DOWN I early 0.775464 24.325 30.6765 23.7309 40.6278 27.9024 
Gene S100A8 DOWN I early 0.124429 0.423793 0.344591 1.26119 15.1243 4.46536 
Gene GEM DOWN I early 0.138764 2.66912 13.9923 4.10798 2.55192 4.92059 
Gene SESN3 DOWN I early 2.05919 28.4167 73.0975 34.183 68.4601 72.6783 
Gene LEF1 DOWN I early 0.606956 11.7937 10.6175 6.46113 47.2402 21.12 
Gene DCLK2 DOWN I early 0.466139 4.87593 10.4667 11.6749 12.3147 16.158 
Gene ADCY2 DOWN I early 1.12893 16.9709 28.0896 35.7318 42.1515 37.5328 
Gene ARRDC4 DOWN I early 0.510382 5.33855 13.9765 7.33427 22.0637 15.5004 
Gene ZNF660 DOWN I early 0.228419 6.95816 7.88158 2.98757 8.18816 6.92972 
Gene USP49 DOWN I early 1.04278 10.403 23.4252 24.8176 37.7521 31.1789 
Gene KLHL5 DOWN I early 1.55144 18.9102 17.3559 12.7262 34.1069 45.6112 
Gene PAM DOWN I early 0.532455 39.1083 45.2865 26.2608 42.637 15.1287 
Gene CTSO DOWN I early 0.374098 6.18183 9.29652 3.08132 6.03929 10.5006 
Gene CXCR4 DOWN I early 0.165358 5.40197 5.68223 4.89712 6.45591 4.63953 
Gene NIPAL2 DOWN I early 0.916386 8.54783 10.5555 25.2427 15.7448 25.418 
Gene DHRS3 DOWN I early 0.139816 1.51881 2.42845 10.6312 7.2728 3.79369 
Gene AXIN2 DOWN I early 0.114282 0.903662 2.70851 2.67089 3.88172 2.99251 
Gene IGDCC4 DOWN I early 0.168508 1.50274 2.55413 1.23189 4.94648 4.38318 
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Gene RNF144B DOWN I early 0.120729 2.25172 9.06818 3.51942 7.2924 3.13822 
Gene MAN1C1 DOWN I early 0.207973 1.55593 3.66244 6.97311 4.90294 5.28055 
Gene AKD1 DOWN I early 1.54463 20.9715 27.2305 24.2818 53.6112 39.1943 
Gene MSRB3 DOWN I early 0.245762 1.79062 9.71892 6.18096 7.73083 6.21261 
Gene PMP22 DOWN I early 9.23659 175.021 581.101 417.741 383.903 231.114 
Gene PID1 DOWN I early 0.735779 14.7943 15.88 6.54436 11.7185 18.2304 
Gene PRDM5 DOWN I early 0.340449 2.80746 8.22451 5.29888 9.55892 8.40773 
Gene ID2 DOWN I early 0.851012 6.29706 14.0372 10.4446 11.54 20.545 
Gene LPAR6 DOWN I early 0.366074 0.755423 2.80649 2.14683 2.88849 8.70645 
Gene ZFP36L1 DOWN I early 1.19659 10.6624 36.8972 33.9433 44.5982 28.3374 
Gene PEG10 DOWN I early 2.40814 40.9447 31.9803 29.0504 61.3888 55.6565 
Gene GALNT13 DOWN I early 0.507777 26.0117 32.572 19.0947 15.6521 11.2408 
Gene FNDC5 DOWN I early 0.169924 1.12345 0.622407 1.8845 1.74548 3.69866 
Gene RAB33A DOWN I early 0.125475 0.545356 0.402497 0.699507 0.355368 2.72679 
Gene TAS2R19 DOWN I early 0.258596 1.89204 3.68728 3.23229 2.56356 5.35201 
Gene RASAL2 DOWN I early 1.15627 6.75957 7.98008 7.77181 12.4628 23.8788 
Gene NAIP DOWN I early 0.855538 6.10015 11.028 8.48318 11.4837 17.6102 
Gene CHD7 DOWN I early 1.88214 23.6268 45.1743 41.3077 82.7954 37.5927 
Gene ALS2CR8 DOWN I early 2.06517 11.4519 13.1991 16.4346 17.5676 40.4935 
Gene TIMP2 DOWN I early 2.70471 34.2566 90.8985 127.477 149.66 53.0133 
Gene IGFBP5 DOWN I early 0.316785 3.68405 1.5981 5.44162 8.06256 6.17439 
Gene ARMCX2 DOWN I early 0.417503 3.34819 4.04297 12.0834 10.6734 8.1087 
Gene ADAM15 DOWN I early 0.272133 0.607742 1.05582 1.27326 1.07132 5.23493 
Gene MGAT5 DOWN I early 0.678123 4.60916 11.7373 8.70038 14.839 12.8308 
Gene GPR162 DOWN I early 0.22218 1.03169 2.26934 1.131 1.91253 4.10817 
Gene ERV3-1 DOWN I early 0.54822 4.94325 8.13937 7.4579 19.3373 10.1013 
Gene LRRC27 DOWN I early 0.339583 2.70443 3.16238 3.37551 4.61563 6.25071 
Gene ST3GAL1 DOWN I early 0.263245 2.47438 7.39966 3.43597 2.53345 4.74713 
Gene PLA2G6 DOWN I early 0.155422 1.1183 1.2681 1.21557 3.61557 2.76014 
Gene TRIB1 DOWN I early 0.503026 11.375 31.4144 6.47742 24.3244 8.91945 
Gene DCBLD1 DOWN I early 0.183578 0.352213 1.38029 2.14477 3.15165 3.16141 
Gene NDN DOWN I early 1.65692 8.31417 14.6557 16.9277 30.5013 27.6623 
Gene FRMD3 DOWN I early 0.307189 6.59772 18.9369 12.9678 13.2633 5.08855 
Gene MAML2 DOWN I early 0.381816 3.48778 9.96584 6.85401 8.93906 6.29603 
Gene GLIPR2 DOWN I early 0.445466 4.13961 2.89231 1.95113 4.28364 7.29226 
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Gene C3orf58 DOWN I early 1.918 15.4239 18.4031 9.52848 10.1152 31.2801 
Gene PDK2 DOWN I early 0.791928 3.2605 4.08505 6.32123 4.07713 12.5651 
Gene C1orf54 DOWN I early 0.274219 2.28983 1.95283 0.82389 7.24829 4.32469 
Gene PALM3 DOWN I early 0.474319 3.05756 3.37879 1.9741 7.63866 7.45217 
Gene SYNGAP1 DOWN I early 0.905164 3.43584 4.14235 13.2115 19.5522 14.1323 
Gene TUBA1A DOWN I early 29.125 309.548 575.536 254.379 371.809 450.999 
Gene ZNRF1 DOWN I early 0.177873 1.25161 1.48592 1.0251 1.46727 2.7401 
Gene ZNF610 DOWN I early 0.385121 1.93196 3.53154 2.41567 9.47761 5.92301 
Gene MGLL DOWN I early 0.653268 2.66563 2.85943 6.27794 3.40366 9.8645 
Gene MYO5C DOWN I early 0.183537 0.976961 2.81749 2.37258 3.01449 2.72108 
Gene SEMA3E DOWN I early 0.241963 11.9788 8.30795 1.00945 2.47693 3.52434 
Gene NKAIN1 DOWN I early 0.496706 2.68723 2.29461 2.96399 12.0325 7.23305 
Gene NAV1 DOWN I early 1.95099 8.54047 14.2142 15.2545 13.7943 28.2042 
Gene KATNAL1 DOWN I early 3.25018 19.0616 18.7157 22.4318 35.8134 46.462 
Gene IQCA1 DOWN I early 2.96471 15.2573 32.8011 34.8334 53.8751 42.3241 
Gene JUN DOWN I early 0.598339 9.52782 19.1506 7.14957 21.6001 8.52802 
Gene TAS2R20 DOWN I early 0.290701 1.41495 3.52861 5.29011 5.84039 4.08944 
Gene GOLGA8A DOWN I early 0.737616 3.83871 4.06887 5.77566 8.95641 10.3641 
Gene PRKD1 DOWN I early 0.650105 7.65227 10.6885 11.7087 5.65879 9.08455 
Gene HDAC9 DOWN I early 1.51922 37.8215 25.0161 37.3361 27.9874 21.1489 
Gene ZNF713 DOWN I early 1.39609 5.17876 6.17043 11.3268 7.69882 19.3971 
Gene THBS4 DOWN I early 0.255858 0.69421 1.00615 4.51247 11.7335 3.53264 
Gene GAB1 DOWN I early 14.9643 66.585 109.058 91.6937 120.87 206.007 
Gene NR4A2 DOWN I early 0.530011 4.0192 13.3862 1.99516 6.49285 7.29034 
Gene ADRA1A DOWN I early 0.240052 1.74116 1.40984 1.07295 1.29832 3.27822 
Gene LRP1 DOWN I early 0.224801 1.02692 2.4361 5.33401 3.65296 3.06104 
Gene SYTL4 DOWN I early 0.359334 5.98792 10.0884 3.67323 6.55195 4.81379 
Gene EML1 DOWN I early 0.278865 4.10717 5.45622 3.98805 7.38355 3.73434 
Gene SDC3 DOWN I early 1.35714 16.6655 23.0498 45.037 15.5419 18.0718 
Gene TRO DOWN I early 1.25556 12.0659 13.6556 23.107 30.5146 16.6876 
Gene ARRDC3 DOWN I early 2.31894 10.5156 28.6492 16.1312 36.0645 30.7395 
Gene KLF12 DOWN I early 1.9891 10.4908 17.652 14.5924 35.9216 26.1829 
Gene RDH5 DOWN I early 0.329469 6.38904 3.25127 0.312951 4.75617 4.32659 
Gene ZSCAN30 DOWN I early 0.981179 3.57292 5.27125 3.23438 9.24514 12.75 
Gene GLCCI1 DOWN I early 2.65972 18.441 32.254 16.7039 34.7952 34.5254 
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Gene PCDHGB7 DOWN I early 0.463259 1.99608 2.99129 3.92656 4.35946 6.00938 
Gene SLC30A4 DOWN I early 0.415763 1.36369 4.18381 1.85422 3.51003 5.32434 
Gene SLC44A3 DOWN I early 0.247373 1.40977 1.19871 0.789217 0.442707 3.16514 
Gene PLN DOWN I early 0.490871 7.82314 8.9928 4.77234 9.17709 6.24438 
Gene TAS2R14 DOWN I early 0.609757 3.53473 6.89766 3.38633 7.00802 7.6819 
Gene RCBTB2 DOWN I early 0.466526 3.42109 3.42306 2.57527 6.69873 5.83513 
Gene COL4A5 DOWN I early 1.24347 16.5992 23.1958 15.7434 11.1976 15.3486 
Gene CROT DOWN I early 0.506213 1.73879 5.73743 2.34596 4.54753 6.24363 
Gene ZMAT4 DOWN I early 0.988377 9.73473 15.7067 28.3239 26.7744 12.053 
Gene PKIG DOWN I early 0.418835 1.88136 3.953 6.35845 3.47437 5.06797 
Gene CRMP1 DOWN I early 1.00845 8.05425 22.0832 21.3293 30.7652 12.1411 
Gene ZNF345 DOWN I early 0.275492 1.45791 3.44589 1.65644 1.79552 3.30831 
Gene FBXL17 DOWN I early 1.06019 4.08829 7.35359 3.25971 6.80333 12.6523 
Gene IFI6 DOWN I early 1.72739 33.0724 46.8065 20.0654 7.97444 20.5814 
Gene AHDC1 DOWN I early 0.601312 4.73181 6.59934 6.36665 10.2962 7.048 
Gene TMEM178 DOWN I early 1.81831 14.6016 17.9066 7.1015 10.5919 21.308 
Gene LIMCH1 DOWN I early 11.5101 110.536 173.611 164.958 134.556 131.018 
Gene FAM125B DOWN I early 2.11461 6.37583 8.34282 6.68734 6.52317 24.0156 
Gene C1S DOWN I early 0.314728 1.233 2.02215 1.46316 4.67592 3.55006 
Gene ITGA6 DOWN I early 2.9185 17.5304 29.336 14.027 88.3522 32.9008 
Gene CHD6 DOWN I early 25.1443 82.4391 88.6986 150.798 150.026 281.928 
Gene PER3 DOWN I early 1.41125 4.76025 9.42199 8.57856 17.2878 15.5316 
Gene TSPYL2 DOWN I early 46.3429 171.682 256.136 131.922 270.535 506.071 
Gene LIMS2 DOWN I early 0.416577 0.380037 1.83693 7.37659 3.64498 4.49371 
Gene ZNF596 DOWN I early 1.35884 7.21314 9.03506 7.24552 13.0906 14.6436 
Gene CALCOCO1 DOWN I early 2.87957 12.3573 15.2451 28.6497 17.4602 30.9945 
Gene FANK1 DOWN I early 1.0499 3.00718 8.44986 12.0119 35.0376 11.2465 
Gene FAM117B DOWN I early 0.686725 3.8219 6.5493 3.6347 10.2463 7.25716 
Gene SSBP2 DOWN I early 3.49605 26.1987 39.6988 34.3762 72.5032 36.9371 
Gene LPP DOWN I early 2.07491 12.1271 48.8362 68.3685 85.4848 21.8918 
Gene PDE5A DOWN I early 1.52597 6.38448 6.50183 4.09939 6.79613 16.0214 
Gene GNAI1 DOWN I early 28.4968 210.145 240.727 105.078 262.959 298.975 
Gene AMT DOWN I early 0.407402 1.6675 1.16859 3.33254 3.14983 4.2736 
Gene ACRC DOWN I early 0.426267 1.39566 2.21699 1.1347 1.45435 4.44949 
Gene DUSP1 DOWN I early 0.441873 2.6834 2.99041 1.94263 6.68998 4.60963 
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Gene AUTS2 DOWN I early 2.25912 6.56604 18.1633 17.9197 39.5627 23.5193 
Gene LRRC4C DOWN I early 5.02036 32.9653 39.7426 33.4749 35.6184 52.1148 
Gene RNPC3 DOWN I early 28.0179 82.9751 103.821 118.785 186.699 283.125 
Gene NGFRAP1 DOWN I early 17.6781 185.656 276.64 158.775 212.661 177.52 
Gene ZNF285 DOWN I early 0.96596 3.12792 4.06831 2.50605 4.05302 9.64818 
Gene FAM135B DOWN I early 1.44363 11.9603 20.3325 46.6234 30.6347 14.3724 
Gene ADARB1 DOWN I early 0.407831 1.53468 3.17842 2.19304 3.18016 4.0532 
Gene WDR66 DOWN I early 0.2861 1.26367 1.19675 2.06809 1.68125 2.82523 
Gene GPR18 DOWN I early 0.536879 1.82659 5.74353 8.84433 6.87987 5.27731 
Gene CHRM3 DOWN I early 0.814719 12.5628 18.7434 10.2249 7.09147 8.0005 
Gene DPY19L2 DOWN I early 1.18977 4.09827 7.50493 3.69664 6.35032 11.4667 
Gene ATP6AP1L DOWN I early 1.59656 4.48159 5.96788 5.85395 6.14707 15.2592 
Gene PAK3 DOWN I early 10.3719 25.3105 33.9689 33.8807 50.8847 97.8872 
Gene PHF21A DOWN I early 49.1833 121.543 268.047 171.22 521.129 452.653 
Gene RTDR1 DOWN I early 0.721587 0.370639 0.512641 2.96764 2.24619 6.63082 
Gene SLC12A6 DOWN I early 2.56197 9.29742 12.5168 9.7619 22.6076 23.3899 
Gene ATP2B4 DOWN I early 4.19408 21.3797 19.5139 13.5208 19.478 38.2899 
Gene AKAP3 DOWN I early 0.306288 0.424925 0.939501 0.471162 1.34673 2.76281 
Gene LTBP3 DOWN I early 1.35417 4.35348 4.05597 10.4332 5.88499 12.1006 
Gene PEX11A DOWN I early 0.717022 2.02817 3.17291 2.01985 1.71087 6.39653 
Gene CREB3L1 DOWN I early 0.319955 1.8794 4.24334 3.27762 2.17065 2.82902 
Gene ZNF577 DOWN I early 3.17386 7.91941 11.3883 12.8944 31.8396 27.991 
Gene C15orf38 DOWN I early 0.660735 1.7168 2.48002 1.73243 2.50498 5.82142 
Gene CELF2 DOWN I early 6.00885 49.7458 82.7845 31.2759 46.7218 51.6307 
Gene SOCS2 DOWN I early 0.857129 9.24386 22.6751 5.76686 14.2318 7.34498 
Gene C5orf54 DOWN I early 0.321376 0.893471 1.17814 0.743753 1.59238 2.7439 
Gene FOXO1 DOWN I early 1.5495 5.56651 14.8671 4.68274 9.00103 13.2167 
Gene MKL1 DOWN I early 3.41734 7.32681 23 14.4074 20.8123 28.9028 
Gene WDR52 DOWN I early 1.44035 6.53477 10.954 7.64276 11.3184 12.141 
Gene CSRNP3 DOWN I early 2.38681 19.4672 18.787 11.7325 11.5048 20.0574 
Gene LMOD1 DOWN I early 6.46148 25.891 109.569 21.1543 43.2364 54.2628 
Gene B3GNT4 DOWN I early 0.542622 2.39872 0.757352 1.09413 5.44138 4.55609 
Gene ALPK1 DOWN I early 0.395198 1.12942 2.76151 2.53937 4.52346 3.30703 
Gene SLC44A2 DOWN I early 1.11762 3.16522 7.03186 11.1586 15.9004 9.29104 
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Gene CXCL12 DOWN I early 2.03127 4.87253 9.13947 13.081 34.6879 16.8583 
Gene NUMBL DOWN I early 0.677693 1.99894 1.42885 6.3873 2.70717 5.61657 
Gene AHI1 DOWN I early 29.7142 85.2477 177.129 71.0888 140.46 244.239 
Gene RARRES3 DOWN I early 1.70985 4.47943 5.38811 15.3704 11.3314 14.0374 
Gene STX3 DOWN I early 0.540274 1.15173 1.91346 2.05363 8.67844 4.43457 
Gene C2orf63 DOWN I early 2.20905 8.39856 15.2128 7.96217 6.80721 18.1225 
Gene CAP2 DOWN I early 7.64096 60.8767 154.775 245.007 91.5723 62.5868 
Gene NAGK DOWN I early 1.63208 5.88826 8.98033 14.652 12.4563 13.3478 
Gene CCDC13 DOWN I early 0.361815 0.01 0.861303 0.474059 1.39643 2.95451 
Gene CLIP2 DOWN I early 0.32908 1.8274 0.976245 1.36259 0.711883 2.67308 
Gene FNBP1L DOWN I early 6.28957 43.4477 74.8863 41.0484 126.821 50.9014 
Gene FBXW4 DOWN I early 0.692917 1.48526 2.17341 3.17571 2.43703 5.56238 
Gene CYP2R1 DOWN I early 0.549472 2.3125 4.11534 1.92517 4.73611 4.40697 
Gene EPB41L5 DOWN I early 3.8204 17.7272 18.5295 7.90337 32.144 30.4867 
Gene SH3PXD2A DOWN I early 1.29646 3.02132 4.16873 5.79525 3.00872 10.339 
Gene BTBD9 DOWN I early 1.68434 4.83573 5.55223 8.87315 5.54221 13.4196 
Gene RALGDS DOWN I early 0.571383 0.997429 1.87562 4.07058 1.16158 4.52364 
Gene KCNJ13 DOWN I early 0.980399 2.96808 4.62942 15.2289 4.67823 7.73594 
Gene STK32A DOWN I early 1.23199 3.4076 5.99075 2.93128 16.0122 9.6935 
Gene FGF9 DOWN I early 1.78246 38.6453 16.2227 33.7632 14.1835 13.9644 
Gene RUNX1T1 DOWN I early 6.49672 43.959 69.2777 55.5966 41.7929 50.8912 
Gene NOTCH2 DOWN I early 7.58098 23.7631 48.254 16.8695 29.6055 59.3148 
Gene POU3F2 DOWN I early 1.36219 21.5355 19.4741 4.49074 4.835 10.623 
Gene ZNF780B DOWN I early 1.93408 5.52541 8.89768 8.20503 6.59756 15.0317 
Gene FAM168A DOWN I early 3.00578 6.6664 8.34576 35.0929 17.2794 23.2725 
Gene ATG16L2 DOWN I early 0.913517 2.67208 2.74527 3.42877 3.99532 7.06875 
Gene DEAF1 DOWN I early 1.24074 5.58444 4.24113 17.6718 6.28747 9.55898 
Gene RANBP17 DOWN I early 1.54452 12.7495 19.3489 3.77439 15.3342 11.8924 
Gene KCNIP1 DOWN I early 0.885313 3.77731 10.4591 12.4523 10.4941 6.79832 
Gene FREM2 DOWN I early 0.428627 3.38157 3.15407 1.7422 8.76852 3.26969 
Gene TAS2R30 DOWN I early 0.720092 3.26798 5.24854 3.85313 9.04383 5.49303 
Gene FXYD5 DOWN I early 0.44901 0.268846 0.879051 0.263668 6.45008 3.42196 
Gene ZNF763 DOWN I early 0.485061 1.03257 2.08994 0.95075 3.14174 3.67158 
Gene FBXL2 DOWN I early 2.71652 7.56888 13.4869 19.6826 25.1684 20.4499 
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Gene MAB21L2 DOWN I early 0.794644 4.55292 6.897 3.19914 2.91247 5.96046 
Gene NELF DOWN I early 0.497156 1.32936 0.496233 1.65782 1.77073 3.72572 
Gene ELK1 DOWN I early 0.69809 1.58679 3.3569 2.49082 2.56051 5.18797 
Gene MICAL3 DOWN I early 0.603126 1.56296 3.567 2.33578 4.15951 4.4806 
Gene RND2 DOWN I early 0.460215 1.19236 0.88478 1.63366 8.65658 3.41632 
Gene NKTR DOWN I early 26.7523 75.1171 108.352 55.9873 106.254 198.57 
Gene AS3MT DOWN I early 0.925058 4.15958 2.56178 4.2866 10.0015 6.86344 
Gene KIAA1109 DOWN I early 19.581 43.7023 56.442 46.2699 61.8752 144.546 
Gene MYO9A DOWN I early 2.19935 4.091 9.3525 5.5264 11.1039 15.9626 
Gene PBXIP1 DOWN I early 1.06497 3.08132 4.6096 10.2047 7.54974 7.71961 
Gene SLC5A3 DOWN I early 2.00466 5.60001 9.90979 4.33245 17.7244 14.5249 
Gene PPFIA2 DOWN I early 31.7498 121.326 185.412 96.3868 87.0909 229.783 
Gene SLC40A1 DOWN I early 1.30938 5.94686 8.92801 2.61962 8.78562 9.47018 
Gene IKBKB DOWN I early 1.97058 5.84366 5.618 12.6035 10.2596 14.1453 
Gene IFT172 DOWN I early 2.51591 5.52006 5.31738 12.2552 10.2396 18.0569 
Gene ZNF71 DOWN I early 1.16546 2.46398 3.16704 3.92614 5.58935 8.33389 
Gene KIFAP3 DOWN I early 8.29005 20.8681 30.0399 18.9113 39.6382 59.2391 
Gene FOSL2 DOWN I early 1.40561 21.0138 35.7925 8.47742 18.019 9.99961 
Gene RHOB DOWN I early 5.6811 27.5063 36.7272 12.3278 45.5967 40.3614 
Gene LRRC48 DOWN I early 0.391046 0.417072 1.69448 1.21086 2.92924 2.77222 
Gene FGFR1 DOWN I early 0.723699 4.9099 12.2987 12.1624 19.0039 5.12571 
Gene PSEN2 DOWN I early 0.396324 1.33846 1.92699 5.82558 3.2037 2.8028 
Gene PTPRS DOWN I early 0.697796 2.55553 3.01128 6.34707 8.59387 4.91303 
Gene DOCK2 DOWN I early 0.392599 0.913359 1.09759 1.66093 3.79645 2.75263 
Gene TCEA2 DOWN I early 1.41273 5.48232 6.43401 5.42413 5.36968 9.90112 
Gene EPM2AIP1 DOWN I early 4.44432 17.8521 19.2462 9.93973 18.4394 31.0998 
Gene JHDM1D DOWN I early 1.02818 2.9894 8.6814 3.32132 8.99446 7.19435 
Gene THNSL2 DOWN I early 0.487027 2.76562 2.89507 3.49558 2.94006 3.40035 
Gene ZSCAN16 DOWN I early 1.10706 7.72484 9.40459 6.24287 4.02475 7.71049 
Gene ZDHHC21 DOWN I early 2.75769 11.2184 17.4343 6.06618 12.6209 19.1478 
Gene CTSF DOWN I early 1.68541 3.66719 8.23768 12.5753 13.2431 11.6973 
Gene EPHA7 DOWN I early 0.734707 8.96605 7.77764 4.16774 18.1293 5.08447 
Gene TRAM1L1 DOWN I early 0.761404 2.15934 3.69958 1.48133 1.18096 5.24625 
Gene TMEM14A DOWN I early 5.74836 18.9846 26.0821 15.0198 23.2204 39.4493 
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Gene SMAD9 DOWN I early 0.932835 6.23001 5.47339 1.90475 3.58722 6.39673 
Gene NTN4 DOWN I early 1.30208 15.5797 34.632 10.1125 31.786 8.88782 
Gene SELENBP1 DOWN I early 0.590416 4.01029 3.55657 6.57737 3.03617 4.01846 
Gene FAM115A DOWN I early 4.79884 23.4175 40.3425 9.48938 15.8069 32.4761 
Gene AMOTL2 DOWN I early 0.720271 4.12825 10.5733 8.66318 8.59594 4.86278 
Gene KIDINS220 DOWN I early 9.33037 17.8871 20.8656 23.5306 37.7561 62.9003 
Gene SRR DOWN I early 0.839729 4.65413 3.46867 2.81678 8.15423 5.61318 
Gene TSPAN12 DOWN I early 1.35087 5.645 15.468 9.40846 25.4653 9.0257 
Gene ZNF793 DOWN I early 1.20114 3.19377 7.06745 2.92542 5.29922 8.02143 
Gene COBLL1 DOWN I early 4.3529 22.8471 31.7626 20.3055 12.4115 28.9809 
Gene C7orf46 DOWN I early 0.525295 1.94187 2.39482 1.3103 2.50133 3.49437 
Gene FAM3A DOWN I early 0.520052 1.3477 1.58789 1.15232 1.81346 3.45598 
Gene ZFP90 DOWN I early 0.872766 2.51643 4.90661 2.90429 5.82472 5.78974 
Gene TMEM234 DOWN I early 0.855465 4.7836 3.11341 8.34317 4.32414 5.6738 
Gene IFI27 DOWN I early 1.90761 35.8316 26.0755 5.9662 3.86662 12.6249 
Gene KLHL22 DOWN I early 0.645918 1.10419 1.78839 3.1105 4.76611 4.26852 
Gene PRR4 DOWN I early 5.92275 25.9179 30.4736 38.7695 37.2952 39.0683 
Gene TJAP1 DOWN I early 1.21182 2.30209 3.12893 3.0955 4.27004 7.98844 
Gene DYNC2H1 DOWN I early 1.64932 2.91505 11.0145 5.21235 14.3348 10.8718 
Gene ADCY6 DOWN I early 0.622909 2.76187 3.63565 6.71669 4.7323 4.08685 
Gene GTDC1 DOWN I early 15.2994 30.7266 46.9134 44.0953 81.5996 100.165 
Gene MLL3 DOWN I early 8.98061 21.5618 34.2523 22.7808 32.3304 58.7627 
Gene NLGN2 DOWN I early 1.99474 6.13945 8.44432 24.9826 25.5465 12.8902 
Gene ZNF425 DOWN I early 3.81204 18.4443 25.4043 12.324 27.0406 24.5881 
Gene ZNF292 DOWN I early 19.9162 52.7057 89.5397 68.2141 128.789 128.054 
Gene ARMCX1 DOWN I early 1.21887 4.46911 8.98293 3.96834 6.37046 7.83204 
Gene CCDC65 DOWN I early 0.70581 1.42121 2.12087 3.06068 2.20555 4.53293 
Gene PDE8A DOWN I early 4.67317 14.2572 19.4257 13.6819 11.3735 29.8285 
Gene STIM1 DOWN I early 0.98731 2.60764 2.91527 6.20211 4.34464 6.29185 
Gene MICAL1 DOWN I early 0.467605 1.34955 1.28229 2.83896 3.3882 2.97145 
Gene SSBP3 DOWN I early 1.57698 3.79503 3.15482 4.75299 7.50337 10.0207 
Gene NT5DC3 DOWN I early 1.02741 2.00676 2.76483 2.90862 3.95456 6.52516 
Gene INPP5F DOWN I early 9.30293 28.2149 23.2709 21.3085 26.1631 58.9384 
Gene TRIO DOWN I early 5.51333 11.8722 20.9587 27.3489 38.7256 34.8505 
Gene CNKSR2 DOWN I early 7.73693 21.6326 32.8881 16.6936 24.337 48.5357 
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Gene PDE7A DOWN I early 4.55547 12.8635 18.5222 10.3628 42.1387 28.5414 
Gene ZNF555 DOWN I early 0.898396 1.83757 2.04887 1.84656 3.43324 5.62101 
Gene AKAP13 DOWN I early 2.32108 11.1682 24.8552 19.0655 39.8257 14.5145 
Gene PPM1L DOWN I early 1.66524 6.62051 20.3482 10.6133 17.4223 10.3884 
Gene NELL1 DOWN I early 1.81296 28.2477 34.1191 13.4478 8.63171 11.2881 
Gene ZMYND11 DOWN I early 22.3852 37.1614 42.6197 60.7986 67.2624 139.319 
Gene RRAGB DOWN I early 3.51924 15.1843 17.411 29.4127 34.0381 21.8793 
Gene RNFT2 DOWN I early 1.46214 2.29581 4.53773 7.15858 17.6526 9.07732 
Gene FKBP1B DOWN I early 1.49737 3.78649 7.31395 2.66611 7.58772 9.27676 
Gene CYLD DOWN I early 1.43024 2.67236 4.87521 2.22882 6.21322 8.85726 
Gene GRK4 DOWN I early 2.04299 6.78218 8.89192 3.58364 5.18327 12.6187 
Gene SERTAD2 DOWN I early 1.49056 5.03959 16.0551 14.5015 35.5869 9.18741 
Gene TLE4 DOWN I early 18.5224 62.729 86.6721 88.8661 129.486 114.134 
Gene ZNF280D DOWN I early 12.5841 31.0309 44.4775 29.7316 38.5275 77.1541 
Gene HPCAL1 DOWN I early 11.7098 42.1712 107.712 181.308 130.397 71.5001 
Gene WWOX DOWN I early 0.652866 1.82301 1.0351 1.96398 2.42957 3.98361 
Gene MED12 DOWN I early 2.85556 5.28858 7.62471 16.2904 11.3423 17.4179 
Gene PDE4D DOWN I early 7.23215 20.9728 32.8456 32.5474 39.3389 43.9781 
Gene ARL17A DOWN I early 4.28304 10.2779 16.8632 20.536 30.2766 26.0235 
Gene PGBD1 DOWN I early 0.975013 4.05642 3.58476 1.6436 2.97283 5.91681 
Gene TCTN1 DOWN I early 1.52448 2.76029 6.53641 7.85683 11.1387 9.24391 
Gene KIAA1267 DOWN I early 2.35581 4.48016 4.74005 6.18654 10.778 14.2665 
Gene CDR2L DOWN I early 0.610623 1.12807 1.74808 1.36572 1.21416 3.69441 
Gene TRAPPC6A DOWN I early 0.535561 1.78674 4.53606 5.81316 5.62501 3.22769 
Gene PSTK DOWN I early 2.34936 4.44546 5.24447 5.3361 7.72763 14.139 
Gene GOLGA8B DOWN I early 1.93461 5.63164 8.59111 7.06421 14.6934 11.5819 
Gene ZNF253 DOWN I early 2.86883 10.417 14.3508 5.96154 15.1938 17.0579 
Gene PLCG1 DOWN I early 3.47782 8.41055 9.5824 18.9764 12.1149 20.6197 
Gene CCDC91 DOWN I early 38.5014 80.2691 110.072 152.439 163.992 226.745 
Gene PINK1 DOWN I early 7.25525 13.8895 22.8713 34.8544 34.839 42.666 
Gene ZNF585A DOWN I early 2.96572 5.42204 6.57807 6.53029 16.5079 17.4286 
Gene AKTIP DOWN I early 2.11971 6.01812 9.15989 3.16479 5.204 12.3268 
Gene PPP2R3A DOWN I early 1.46762 7.3394 14.9433 8.33035 11.4424 8.48933 
Gene C1orf198 DOWN I early 4.78126 11.9192 19.8958 13.0892 24.7219 27.599 
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Gene ARMCX3 DOWN I early 8.9676 32.834 43.0225 13.1999 31.2408 51.5309 
Gene DDX60L DOWN I early 1.33805 5.34869 6.47861 6.43671 5.05114 7.68655 
Gene PHC2 DOWN I early 1.02574 1.73418 4.59218 5.79758 1.65244 5.88121 
Gene MUTYH DOWN I early 0.512557 0.447839 0.781878 1.37166 1.05109 2.932 
Gene TMEM42 DOWN I early 0.690983 1.53404 1.2827 3.11122 2.17427 3.94147 
Gene SHPRH DOWN I early 8.62424 12.9966 22.9338 14.0175 28.4724 49.0485 
Gene ZNF638 DOWN I early 53.7398 111.198 183.665 89.5903 184.807 303.785 
Gene PJA1 DOWN I early 1.04182 1.7839 3.73733 4.07848 3.60125 5.88493 
Gene GNL1 DOWN I early 5.06636 7.71468 10.0777 10.3851 11.5631 28.3046 
Gene PRCP DOWN I early 7.22077 15.6182 22.9286 21.1884 38.672 40.0405 
Gene TPP1 DOWN I early 19.224 51.3 92.7208 114.402 118.258 106.289 
Gene ZNF70 DOWN I early 0.488041 1.37974 2.16004 1.83091 2.3865 2.69625 
Gene ZBTB38 DOWN I early 7.81336 18.7069 28.1489 10.8304 28.6321 43.1373 
Gene NRBP2 DOWN I early 6.10683 10.2143 17.3034 29.9136 16.9994 33.7115 
Gene IFT27 DOWN I early 1.62827 3.23308 4.35877 9.34435 7.60364 8.97769 
Gene AKAP9 DOWN I early 64.7174 183.769 381.615 122.5 336.125 354.279 
Gene WNK3 DOWN I early 4.22673 9.44867 9.8259 5.78849 31.6267 23.1311 
Gene JAK2 DOWN I early 1.48013 2.67546 5.94074 2.51138 4.71473 8.09996 
Gene FUT8 DOWN I early 6.08651 17.951 22.0879 19.5599 32.7584 32.994 
Gene FAM160A2 DOWN I early 1.24471 3.92103 4.5162 8.93111 6.66283 6.73053 
Gene PHC3 DOWN I early 41.6655 69.4066 150.808 122.422 130.882 225.099 
Gene ZFP3 DOWN I early 1.84534 5.91478 7.28855 8.53529 5.27806 9.96131 
Gene MLLT11 DOWN I early 4.20406 34.419 26.3229 18.4253 25.7684 22.6924 
Gene DPF3 DOWN I early 0.87039 3.4023 1.22207 4.21313 1.9418 4.69106 
Gene PAG1 DOWN I early 1.28335 3.10189 5.38073 2.23033 2.76014 6.88453 
Gene BCL7A DOWN I early 2.24071 13.9878 8.44875 20.9631 8.34136 11.9883 
Gene MKRN3 DOWN I early 0.772737 1.8226 1.74561 1.26137 3.13415 4.13081 
Gene ZNF81 DOWN I early 1.58984 3.21977 5.12324 4.86352 5.12099 8.48734 
Gene MOAP1 DOWN I early 2.78686 5.13124 9.85348 5.44243 6.93053 14.7734 
Gene URGCP DOWN I early 2.38882 5.5338 6.7248 7.65635 4.13094 12.6552 
Gene PCM1 DOWN I early 126.919 333.212 411.307 226.85 501.616 668.114 
Gene ING4 DOWN I early 6.58856 28.0554 27.8761 37.4417 35.7894 34.6054 
Gene C11orf54 DOWN I early 3.63959 10.8576 17.3381 11.7279 22.0892 19.1135 
Gene MASP2 DOWN I early 0.861841 4.50421 4.04565 7.57886 11.4915 4.50766 
Gene FBXL20 DOWN I early 3.3747 8.97672 16.1103 15.1715 21.6159 17.5928 
Gene NAB1 DOWN I early 1.86118 8.41378 15.3662 7.26035 5.40043 9.67439 
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Gene ZNF655 DOWN I early 19.4693 58.6339 100.784 37.6521 45.4027 101.173 
Gene TAGLN3 DOWN I early 3.255 15.5451 7.90008 9.82285 10.9302 16.8607 
Gene BRAF DOWN I early 7.52769 11.3369 17.5461 15.1968 31.4644 38.8179 
Gene ACAD11 DOWN I early 2.7709 8.45074 9.25748 20.08 14.2565 14.2829 
Gene P4HA2 DOWN I early 0.703005 1.84461 5.45004 5.07995 6.80494 3.62106 
Gene KIF27 DOWN I early 2.77821 4.97348 7.00085 4.9195 15.4559 14.206 
Gene SPIN3 DOWN I early 0.554156 1.31885 1.68268 2.61396 3.62106 2.82993 
Gene KLC1 DOWN I early 8.42395 15.0816 18.9722 22.4093 32.6538 42.7272 
Gene TFDP2 DOWN I early 3.50358 31.5373 27.3753 23.9757 34.8858 17.7267 
Gene KIAA0355 DOWN I early 1.13834 2.15282 4.14087 2.96171 4.54702 5.75954 
Gene CDH11 DOWN I early 2.16808 11.2034 29.5006 30.6281 33.8688 10.9674 
Gene SAT1 DOWN I early 31.175 94.865 162.295 47.9327 170.802 157.479 
Gene HGSNAT DOWN I early 1.8929 7.17058 13.3215 17.0279 13.3894 9.55576 
Gene SPDYA DOWN I early 0.577239 1.41641 3.66543 1.53308 5.08581 2.90857 
Gene ACO1 DOWN I early 3.64333 6.2881 10.5728 15.4325 29.1963 18.3547 
Gene ZNF673 DOWN I early 2.44841 3.28836 12.3241 4.32995 8.27701 12.3053 
Gene FAM184B DOWN I early 2.24903 4.44792 6.97077 2.89754 5.34055 11.2845 
Gene TTC3 DOWN I early 18.0961 49.4306 86.907 42.6284 135.617 90.6231 
Gene HMGCL DOWN I early 0.736362 1.83005 1.25236 4.07001 1.79258 3.68602 
Gene C9orf3 DOWN I early 15.5201 23.0485 79.2169 134.309 136.91 77.571 
Gene LRCH4 DOWN I early 0.750724 1.43298 2.94517 3.29684 1.88615 3.74738 
Gene KIAA0528 DOWN I early 24.9815 41.3427 65.7106 58.0651 65.8801 124.671 
Gene GAS1 DOWN I early 0.961821 11.9012 18.3409 6.10575 9.48001 4.79094 
Gene DOCK10 DOWN I early 37.5057 195.847 217.275 139.689 67.8095 186.515 
Gene ZMIZ2 DOWN I early 0.906837 1.84929 1.36886 5.3235 3.87641 4.50703 
Gene SBF1 DOWN I early 0.592211 1.16312 1.04014 1.04496 0.734115 2.94157 
Gene ZHX2 DOWN I early 8.24211 19.8619 27.0716 30.8799 22.0682 40.8782 
Gene MLH3 DOWN I early 4.49065 7.43557 10.0266 5.88028 9.94581 22.1948 
Gene HIST2H2BE DOWN I early 2.00421 9.08308 6.90055 6.72273 39.0716 9.90432 
Gene ANO10 DOWN I early 1.96715 2.43824 4.97423 3.34161 6.83126 9.69819 
Gene SLC38A9 DOWN I early 2.57086 5.40967 4.28633 3.84787 7.40644 12.6526 
Gene MED13L DOWN I early 4.23987 11.4368 20.8632 21.1505 28.176 20.8502 
Gene BMPR2 DOWN I early 8.9204 23.1869 46.4441 13.5328 46.0722 43.848 
Gene EFR3B DOWN I early 1.71269 4.63524 8.13138 17.5668 10.9223 8.405 
Gene POU2F1 DOWN I early 2.59108 8.89064 17.87 11.7801 25.0079 12.6845 
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Gene FAM110B DOWN I early 2.5023 16.0868 25.2944 24.444 21.8777 12.2457 
Gene ZBTB25 DOWN I early 0.777509 1.79272 2.55609 2.52222 2.84623 3.79801 
Gene SCARB2 DOWN I early 13.4199 24.0327 43.0081 18.5508 38.0725 65.5253 
Gene ZNF606 DOWN I early 3.43916 6.65423 8.04781 5.70315 13.705 16.7683 
Gene TCF7 DOWN I early 0.983714 4.34521 2.93771 4.43295 4.13914 4.76432 
Gene PHF1 DOWN I early 1.22177 2.32401 2.38543 6.30114 6.1888 5.91054 
Gene APPL2 DOWN I early 7.98294 18.9039 23.3974 21.6907 29.2985 38.6047 
Gene ZNF175 DOWN I early 2.14621 4.15627 6.69174 4.7824 5.45332 10.3405 
Gene ARL17B DOWN I early 1.14848 2.83499 3.07984 1.93842 3.41668 5.5244 
Gene FNIP2 DOWN I early 3.4813 6.08594 9.08247 6.14481 11.8229 16.743 
Gene TCEAL4 DOWN I early 114.125 253.246 518.737 750.622 770.515 548.754 
Gene FAM92A1 DOWN I early 4.70457 10.9899 17.7539 8.26704 10.6142 22.5727 
Gene ZNF221 DOWN I early 1.32245 1.87446 2.57471 2.852 4.32009 6.34511 
Gene C1orf56 DOWN I early 0.914923 2.21137 3.29747 1.54619 1.36586 4.38931 
Gene SDC4 DOWN I early 13.8551 40.5613 105.224 75.5113 79.9832 66.3048 
Gene SNX18 DOWN I early 2.43172 6.51326 13.5902 4.17528 7.03609 11.6282 
Gene RASGEF1B DOWN I early 2.56772 3.36706 6.66813 6.85958 14.5891 12.2651 
Gene AHNAK DOWN I early 10.3116 28.2494 65.3181 97.9169 98.3114 49.2256 
Gene CLSTN1 DOWN I early 11.0962 13.2781 18.0195 22.8081 39.0573 52.9506 
Gene TK2 DOWN I early 1.25027 2.44093 3.59253 7.09928 6.49585 5.95002 
Gene NBPF10 DOWN I early 3.86027 9.46901 19.9813 7.8328 13.5327 18.3085 
Gene BCAS3 DOWN I early 2.82814 5.5564 5.34426 11.6375 11.4571 13.3942 
Gene ANKHD1-EIF4EBP3 DOWN I early 0.795967 1.18116 2.59354 3.42115 3.96336 3.76684 
Gene ZNF652 DOWN I early 18.2083 21.8553 41.106 23.3589 32.3414 86.0402 
Gene SOX13 DOWN I early 0.652235 1.05113 1.76685 4.75269 8.98122 3.0794 
Gene EPHA4 DOWN I early 4.25113 9.87382 16.2541 19.337 29.9885 20.0486 
Gene CRELD1 DOWN I early 0.653452 1.41695 2.10101 5.46367 3.01568 3.07063 
Gene SEMA3A DOWN I early 0.714969 11.46 8.49618 5.57937 8.00082 3.35093 
Gene NEDD9 DOWN I early 1.15562 11.1878 18.9051 15.8654 15.9181 5.40997 
Gene SNURF DOWN I early 23.0668 39.769 34.9466 63.0573 103.484 107.775 
Gene DENND4B DOWN I early 1.57155 1.92718 1.87233 7.90317 3.10052 7.33827 
Gene SLC11A2 DOWN I early 12.0188 16.8266 25.9957 29.6403 44.4676 56.0386 
Gene RALGAPA2 DOWN I early 3.57095 10.3419 13.4939 7.7553 12.4956 16.6016 
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Gene DYNLL2 DOWN I early 24.6083 64.5835 62.942 141.653 181.34 114.282 
Gene LHFP DOWN I early 10.2722 29.5347 52.7289 18.593 83.8412 47.6982 
Gene C6orf191 DOWN I early 0.903862 5.64693 2.71977 1.95101 2.775 4.19401 
Gene BAZ2B DOWN I early 95.7255 170.321 276.814 232.048 320.277 443.538 
Gene ETS1 DOWN I early 1.65847 9.88095 25.3604 8.33019 14.4035 7.67831 
Gene WSB1 DOWN I early 22.9981 77.6621 113.338 84.5901 189.967 106.451 
Gene SDC2 DOWN I early 12.8015 24.9045 74.0355 98.115 114.556 59.2162 
Gene VPS13B DOWN I early 10.4969 26.6119 37.7536 52.4205 78.9666 48.5255 
Gene RABL2B DOWN I early 2.24861 3.12675 4.09955 11.2876 13.3995 10.374 
Gene LRRC37B DOWN I early 1.89288 2.30357 3.75914 2.20591 3.05161 8.72935 
Gene TMEM220 DOWN I early 0.772275 2.02037 4.4703 1.07877 1.75966 3.56133 
Gene DTX3 DOWN I early 0.896052 4.52276 3.24998 4.62567 3.17054 4.12974 
Gene ATRN DOWN I early 5.14725 19.6126 29.5865 15.1798 15.8204 23.7225 
Gene SATB1 DOWN I early 9.19224 30.6938 18.4496 24.1848 33.5935 42.2641 
Gene ZNF470 DOWN I early 1.60278 2.07756 4.38693 2.49603 5.48446 7.35914 
Gene PTK2 DOWN I early 61.4305 86.1235 111.453 99.9093 102.593 281.805 
Gene C10orf58 DOWN I early 9.71479 14.2786 25.0745 18.4857 28.5198 44.5598 
Gene C22orf25 DOWN I early 1.02687 0.631602 1.2194 3.27225 2.47465 4.70952 
Gene MGMT DOWN I early 0.674889 0.410261 2.09643 2.35298 1.30653 3.09135 
Gene TCEAL3 DOWN I early 23.1898 41.7239 59.5866 104.247 55.3508 106.108 
Gene TIAM2 DOWN I early 3.36818 13.1557 20.606 22.9868 30.8713 15.411 
Gene ZNF34 DOWN I early 0.59678 0.776417 1.85981 1.05004 1.89697 2.72625 
Gene SALL2 DOWN I early 1.69027 3.65045 3.45505 3.20691 18.6799 7.68952 
Gene MAN2A2 DOWN I early 4.90125 7.40383 10.9772 7.30886 13.9689 22.2436 
Gene FER DOWN I early 31.168 114.981 147.358 42.6111 63.3172 140.856 
Gene ZNF605 DOWN I early 4.66543 9.87841 14.1803 6.83876 13.4282 21.0469 
Gene LRRC37A2 DOWN I early 1.88567 2.57809 5.08664 4.82721 6.35778 8.50451 
Gene ZNF224 DOWN I early 1.7944 2.79543 2.7454 4.42455 8.73607 8.087 
Gene PRDM2 DOWN I early 17.6923 37.8238 54.3266 39.57 72.0423 79.52 
Gene IL6ST DOWN I early 58.1309 107.672 163.787 76.634 168.849 260.872 
Gene NUMA1 DOWN I early 4.96355 7.14945 10.5516 16.3079 15.0618 22.2397 
Gene ZKSCAN1 DOWN I early 9.64292 16.8717 25.6086 25.3846 36.0699 43.181 
Gene TAPT1 DOWN I early 3.67112 6.90508 8.47656 10.9814 12.8811 16.3712 
Gene ZNF84 DOWN I early 4.29831 15.0944 15.6868 7.30866 19.328 19.1497 
Gene BSDC1 DOWN I early 2.94406 5.27585 6.02869 4.43408 4.46056 13.0474 
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Gene DNAJC27 DOWN I early 1.1524 1.69298 2.98833 1.72334 1.60321 5.10091 
Gene ATG2B DOWN I early 3.03701 4.22959 5.88299 3.68227 6.61117 13.4273 
Gene PHKA2 DOWN I early 12.6391 25.5654 41.3484 77.913 44.9664 55.8645 
Gene JMY DOWN I early 3.55906 10.0749 16.4692 6.36238 13.7268 15.6907 
Gene CSAD DOWN I early 1.8661 3.33281 3.52386 6.47262 6.1866 8.21774 
Gene GABARAPL1 DOWN I early 20.675 39.4288 62.2723 51.2891 107.942 90.9097 
Gene CDK9 DOWN I early 1.83409 4.90723 2.99647 5.10112 10.5269 8.05484 
Gene ANKZF1 DOWN I early 3.71846 8.00353 9.43743 17.9219 24.7371 16.3269 
Gene CLK4 DOWN I early 18.4279 34.654 54.0639 25.2279 63.9896 80.8622 
Gene FRS2 DOWN I early 104.2 248.786 309.521 242.3 414.885 456.453 
Gene UTY DOWN I early 5.42104 10.5827 15.8716 8.52147 13.729 23.6945 
Gene GPHN DOWN I early 3.12353 5.09961 8.59783 8.80382 12.9538 13.6412 
Gene ZNF658 DOWN I early 0.620385 0.972511 2.1527 0.804305 1.04718 2.70597 
Gene N6AMT1 DOWN I early 0.992797 1.76395 1.79728 1.93227 3.61586 4.32688 
Gene KLHL24 DOWN I early 21.1141 69.0096 86.0859 57.9193 115.811 91.9406 
Gene ZNF184 DOWN I early 13.1455 48.388 26.8423 66.1039 21.6821 57.1852 
Gene OSCP1 DOWN I early 2.40751 4.62317 2.94777 5.57868 3.45021 10.4667 
Gene ASAH1 DOWN I early 9.32445 13.9765 31.0839 22.6905 46.0625 40.5077 
Gene NICN1 DOWN I early 0.807931 2.13419 1.59383 3.06329 3.19283 3.50914 
Gene ARMC9 DOWN I early 8.32736 10.7585 29.5694 22.7922 30.5907 36.0645 
Gene DBNL DOWN I early 3.75893 5.75452 10.4446 8.61946 6.32142 16.2554 
Gene SEC62 DOWN I early 89.7485 116.095 165.249 114.64 203.024 388.112 
Gene CLN8 DOWN I early 0.757329 1.34356 1.79428 1.99794 1.26608 3.27406 
Gene DBC1 DOWN I early 1.17792 6.86048 8.21921 15.4665 4.75295 5.09129 
Gene NUDT16 DOWN I early 8.85396 10.5004 14.4722 13.9997 25.4358 38.2114 
Gene ACVR2A DOWN I early 4.02774 10.8964 19.6809 6.74386 20.6485 17.3678 
Gene C6orf170 DOWN I early 3.82781 8.64746 11.3708 6.70121 4.78067 16.4949 
Gene POLI DOWN I early 2.68757 7.77587 9.54459 3.88982 10.7172 11.5813 
Gene SPTBN1 DOWN I early 47.6917 110.499 213.393 398.251 224.866 205.454 
Gene PDP1 DOWN I early 9.48865 32.069 53.0929 20.2324 27.4543 40.814 
Gene NISCH DOWN I early 2.52641 5.96684 4.73244 14.658 9.30714 10.8532 
Gene TMEM106A DOWN I early 0.813489 1.529 3.05596 5.39184 2.35112 3.49305 
Gene ZFYVE9 DOWN I early 4.50156 7.3141 9.21852 5.05419 8.00206 19.3003 
Gene MAP3K3 DOWN I early 0.838405 0.915162 2.74449 4.7514 3.57442 3.59113 
Gene NEXN DOWN I early 2.04038 17.858 33.711 5.43319 20.2024 8.69744 
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Gene RAPGEF2 DOWN I early 22.788 75.6534 98.6856 91.0321 86.0544 97.0204 
Gene C8orf37 DOWN I early 1.00452 1.54402 2.07294 1.16741 1.67526 4.27165 
Gene ZNF397 DOWN I early 1.98076 3.70748 4.33642 2.78388 7.6199 8.41367 
Gene SOCS7 DOWN I early 6.00078 7.11689 11.5901 10.9154 11.1472 25.4635 
Gene IL1RAP DOWN I early 2.15258 13.5062 5.84801 13.079 5.02519 9.11814 
Gene ARHGAP6 DOWN I early 1.01736 1.42068 3.15426 1.9384 2.96288 4.30221 
Gene MEF2C DOWN I early 48.8358 64.8001 67.3241 61.9437 62.443 206.494 
Gene ZMYND8 DOWN I early 7.46023 21.4394 12.1415 20.8001 75.3998 31.5152 
Gene USP47 DOWN I early 25.4415 53.1709 75.471 36.9775 64.1162 107.429 
Gene TXNIP DOWN I early 19.1947 51.48 97.6549 111.79 161.833 81.032 
Gene ZNF417 DOWN I early 3.00609 3.94289 5.25611 4.28534 10.7822 12.6877 
Gene ZNF461 DOWN I early 1.83131 3.16143 6.33774 3.28144 9.24568 7.71886 
Gene RBM41 DOWN I early 12.6196 22.1069 38.2498 14.1718 31.7752 53.1835 
Gene LRCH3 DOWN I early 30.8179 41.5614 103.295 66.4463 79.7601 129.813 
Gene AGER DOWN I early 2.58522 5.90463 19.0507 14.6018 22.6685 10.8515 
Gene FXC1 DOWN I early 18.5 23.9181 36.199 32.0589 87.0805 77.5139 
Gene WHSC1L1 DOWN I early 45.8695 66.3497 87.0144 58.6664 101.761 192.12 
Gene KCND2 DOWN I early 1.84602 6.24323 7.25829 2.70641 3.26374 7.73125 
Gene ARNTL DOWN I early 2.60381 6.9919 11.8337 11.4655 11.1765 10.8963 
Gene INPP5A DOWN I early 1.11586 1.56179 2.59741 6.71946 2.9534 4.66507 
Gene MAML3 DOWN I early 1.29948 2.73621 5.56224 4.50622 10.3863 5.43218 
Gene ZNF548 DOWN I early 2.54728 8.1292 10.8528 3.43323 6.60586 10.6433 
Gene EFNB3 DOWN I early 1.30409 4.35955 3.44643 6.19328 10.1346 5.43944 
Gene ASH1L DOWN I early 18.917 30.9374 49.2683 36.6664 64.1426 78.8402 
Gene SEC14L1 DOWN I early 17.0147 46.4967 44.5102 44.6954 77.9927 70.8561 
Gene CXorf23 DOWN I early 13.5778 18.165 26.2577 29.6802 76.769 56.4772 
Gene ZNF83 DOWN I early 2.28133 5.02375 6.18391 3.53646 11.6251 9.48883 
Gene ZNF283 DOWN I early 2.07395 4.19591 3.80348 6.48557 11.1402 8.62552 
Gene STARD9 DOWN I early 1.0586 1.82058 2.59088 2.34676 2.10591 4.3949 
Gene ZNF211 DOWN I early 2.19054 2.49978 5.75618 5.04035 6.02771 9.09148 
Gene ZNF585B DOWN I early 1.63884 2.54915 3.78916 2.9077 4.3278 6.78918 
Gene FAM122A DOWN I early 1.91269 4.65346 7.06514 3.20937 6.69868 7.92044 
Gene FBXL4 DOWN I early 2.55066 3.87204 6.58824 4.9181 10.8998 10.5514 
Gene SASH1 DOWN I early 10.7908 18.6637 22.9476 11.7038 23.0528 44.5173 
Gene ITGA1 DOWN I early 1.74533 8.62499 15.2545 5.08589 13.8169 7.20029 
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Gene NPHP3 DOWN I early 6.8715 15.1313 26.7995 19.1459 20.1552 28.3172 
Gene ZNF334 DOWN I early 1.40538 3.54859 2.80375 2.10337 2.41494 5.7829 
Gene USP11 DOWN I early 4.07709 9.20326 11.1416 19.8073 18.5316 16.7709 
Gene MSI2 DOWN I early 6.68426 12.1595 21.8488 25.0595 23.0646 27.4951 
Gene TCTN2 DOWN I early 0.934992 1.67708 2.6596 4.75866 2.97094 3.83949 
Gene ASTN2 DOWN I early 1.15592 1.20039 2.53218 4.80849 4.49347 4.73534 
Gene CCDC84 DOWN I early 5.01174 5.26662 9.10508 11.8785 14.849 20.5172 
Gene GYPC DOWN I early 1.12525 5.59174 7.20431 13.9742 3.38556 4.60631 
Gene AGAP4 DOWN I early 0.86493 1.48955 2.08863 2.84152 3.68184 3.53975 
Gene FAM63A DOWN I early 1.03821 1.73863 1.81473 2.40437 2.71791 4.24566 
Gene AGAP3 DOWN I early 2.53217 3.5409 2.80602 4.85425 3.13828 10.3512 
Gene CRTC3 DOWN I early 2.06487 4.48777 9.99657 17.3298 11.3787 8.42012 
Gene FAM193A DOWN I early 4.70589 7.47017 11.137 14.179 18.943 19.1554 
Gene ZMYM5 DOWN I early 10.2884 17.1029 29.8714 11.5787 19.2097 41.7878 
Gene AHSA2 DOWN I early 8.15342 19.6149 22.4747 11.393 19.6138 33.1038 
Gene FAM164A DOWN I early 8.70666 12.3724 22.3858 13.5224 31.4179 35.2777 
Gene GBP3 DOWN I early 3.11701 3.23152 9.06137 12.6739 33.7147 12.628 
Gene UBE2D4 DOWN I early 0.838471 2.14823 1.91647 3.37028 3.37963 3.39646 
Gene SMPD1 DOWN I early 1.06248 1.86379 3.45387 9.87847 7.6026 4.29752 
Gene HOMEZ DOWN I early 1.88686 4.15353 5.20689 8.90002 15.4187 7.62994 
Gene TSGA10 DOWN I early 9.0206 10.9582 12.0679 11.6355 15.622 36.4474 
Gene BID DOWN I early 1.30941 2.97454 2.99574 2.16925 2.61881 5.27646 
Gene KIAA0240 DOWN I early 3.31017 6.60564 7.89954 6.99918 9.89834 13.3046 
Gene STK17A DOWN I early 2.53278 4.4469 12.0587 3.2163 7.97998 10.1767 
Gene C11orf71 DOWN I early 7.89459 17.6225 12.2653 9.68775 38.9882 31.69 
Gene SEC14L2 DOWN I early 0.868915 1.13039 2.11602 2.33599 2.79413 3.48253 
Gene ZNF154 DOWN I early 1.26631 2.18962 3.93271 2.30274 3.88353 5.06897 
Gene C11orf80 DOWN I early 0.980514 1.72105 1.84883 0.984358 1.94856 3.92368 
Gene DMTF1 DOWN I early 44.5772 118.84 148.72 102.508 242.309 178.344 
Gene LRRC7 DOWN II early-mid 0.0166697 5.43688 18.9051 11.4396 19.7951 43.267 
Gene SLC4A4 DOWN II early-mid 0.0247963 5.58985 29.855 36.7092 43.7684 57.8893 
Gene PCSK2 DOWN II early-mid 0.01 1.46601 15.4233 18.7116 28.129 10.077 
Gene PDGFA DOWN II early-mid 0.0655948 11.2327 38.7967 29.44 58.6463 46.7031 
Gene KCND3 DOWN II early-mid 0.0184061 1.57787 5.28594 5.90857 8.75133 12.8361 
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Gene LRRN1 DOWN II early-mid 0.0365075 1.08551 8.01371 9.04604 94.7039 24.7237 
Gene NT5E DOWN II early-mid 0.01 0.272259 10.059 3.78542 21.896 6.54429 
Gene FHOD3 DOWN II early-mid 0.01 0.57585 5.01348 13.2979 20.3648 5.9564 
Gene MPDZ DOWN II early-mid 0.318977 39.0037 87.1101 74.2105 133.95 165.024 
Gene GREB1 DOWN II early-mid 0.0119639 1.34064 3.80635 2.22262 5.94535 5.73616 
Gene THBS2 DOWN II early-mid 0.01 0.202653 2.12561 2.89265 4.93372 4.64352 
Gene ERG DOWN II early-mid 0.0228353 1.10886 12.0647 22.3601 32.725 10.0593 
Gene LARGE DOWN II early-mid 0.01 0.258495 1.59239 1.40091 1.29287 4.38752 
Gene CHST3 DOWN II early-mid 0.01 0.482523 1.51457 2.50275 1.64476 4.08001 
Gene GSG1L DOWN II early-mid 0.01 0.328862 0.982077 1.8508 3.22741 3.65356 
Gene TCP10L DOWN II early-mid 0.01 0.01 0.05754 0.0670704 1.4983 3.56947 
Gene C2orf84 DOWN II early-mid 0.01 0.01 0.187008 1.56004 0.661829 3.44285 
Gene GRIK4 DOWN II early-mid 0.01 0.216938 1.64187 1.25837 2.32807 3.43052 
Gene ARHGEF10L DOWN II early-mid 0.01 0.112128 0.934219 1.14786 0.90523 3.38133 
Gene DUSP8 DOWN II early-mid 0.01 0.0951071 0.11831 0.475796 1.29339 3.10365 
Gene SOX5 DOWN II early-mid 0.132776 8.03319 19.8727 13.8433 16.8779 40.7592 
Gene SSTR1 DOWN II early-mid 0.01 0.641013 1.01628 2.08856 2.09016 2.89548 
Gene MAPK4 DOWN II early-mid 0.0603255 2.40085 10.3357 11.3864 15.3376 14.7579 
Gene NAV2 DOWN II early-mid 0.099957 1.97275 13.0443 13.138 20.8319 19.8637 
Gene SPEF2 DOWN II early-mid 0.0627556 1.01956 3.19873 4.89513 5.70854 11.897 
Gene PMEPA1 DOWN II early-mid 0.0535875 0.845194 9.49858 9.39049 9.77829 9.12984 
Gene FBXO32 DOWN II early-mid 0.136486 1.91417 8.264 6.31918 21.7687 22.5163 
Gene PPAP2A DOWN II early-mid 0.118333 3.25396 9.47184 8.812 16.0368 17.8146 
Gene PLXDC2 DOWN II early-mid 0.136932 4.31221 10.2732 8.8447 10.0538 19.1634 
Gene TNS3 DOWN II early-mid 0.107385 1.68144 3.49898 12.8209 10.4472 13.1975 
Gene GFRA1 DOWN II early-mid 0.0735189 1.03547 3.78279 8.40508 18.4533 7.34401 
Gene MYOM1 DOWN II early-mid 0.0386638 0.803997 1.7894 1.92945 2.30284 3.4999 
Gene DIP2C DOWN II early-mid 0.129439 0.962078 4.03547 4.0258 4.14059 11.5669 
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Gene SERPING1 DOWN II early-mid 0.145507 1.69395 5.54278 5.79137 33.1493 12.231 
Gene LRRC70 DOWN II early-mid 0.0371246 0.589423 0.927306 1.02757 4.28907 2.86628 
Gene TTN DOWN II early-mid 0.232792 3.0435 19.3719 7.51255 15.818 17.9505 
Gene DKK3 DOWN II early-mid 2.91751 18.1739 54.6339 126.784 154.728 210.819 
Gene PDZD2 DOWN II early-mid 0.762727 7.14716 22.444 21.6146 30.2238 51.2368 
Gene AGPAT4 DOWN II early-mid 0.330153 2.62152 6.82831 6.87303 13.8959 21.6254 
Gene GRB10 DOWN II early-mid 0.159173 1.30384 4.60192 4.59875 13.1103 10.395 
Gene C18orf1 DOWN II early-mid 0.201495 0.510849 7.547 6.31484 14.0579 12.3616 
Gene BGN DOWN II early-mid 0.381616 2.72862 11.3852 20.5097 6.91237 15.9964 
Gene PPAPDC1A DOWN II early-mid 0.104899 0.552785 1.47986 1.70063 2.21906 4.09902 
Gene SLC41A2 DOWN II early-mid 1.05845 3.35136 17.3956 14.7216 15.8489 38.7456 
Gene GRAMD3 DOWN II early-mid 2.8478 15.8942 33.6661 50.8809 55.8133 104.242 
Gene GPR183 DOWN II early-mid 0.157337 0.3975 1.45884 2.36939 2.43219 5.66313 
Gene CTSS DOWN II early-mid 0.193659 0.442142 2.14177 2.79882 4.0753 6.86886 
Gene SLC2A11 DOWN II early-mid 9.24191 75.5515 190.914 122.557 144.91 318.002 
Gene PDE4DIP DOWN II early-mid 11.9185 57.4881 120.008 127.246 113.559 408.105 
Gene CXXC5 DOWN II early-mid 0.246065 1.85866 4.66918 2.38592 3.06168 7.74522 
Gene C17orf57 DOWN II early-mid 0.192336 1.41451 5.82453 1.96454 6.18542 6.00473 
Gene YPEL2 DOWN II early-mid 0.40247 1.79814 3.66511 3.22746 4.64055 12.2782 
Gene ERRFI1 DOWN II early-mid 0.534212 3.24293 11.6315 4.95617 20.0073 15.8862 
Gene ITGA9 DOWN II early-mid 0.265897 1.12071 6.27296 17.4709 8.0348 7.70001 
Gene MITF DOWN II early-mid 0.416261 0.920256 3.0248 5.66234 7.42687 11.2191 
Gene DFNA5 DOWN II early-mid 0.331906 1.88441 5.25708 4.3941 9.22669 8.93577 
Gene WWC1 DOWN II early-mid 2.71172 12.9419 23.4635 42.1015 43.3518 68.7123 
Gene MUC6 DOWN II early-mid 0.179829 0.575959 5.46005 2.84024 2.32512 4.53659 
Gene INA DOWN II early-mid 1.06888 6.15397 14.9442 7.0136 17.3661 26.9478 
Gene RNF130 DOWN II early-mid 1.42581 6.65599 12.2143 11.7978 27.0149 34.7612 
Gene ARHGEF17 DOWN II early-mid 0.216589 1.15818 2.04916 4.12986 2.61547 5.25712 
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Gene GFPT2 DOWN II early-mid 0.17755 0.293074 0.807477 1.81855 6.7217 4.08283 
Gene SORBS1 DOWN II early-mid 2.99635 12.5663 22.1171 22.135 34.925 68.2219 
Gene PLEKHH2 DOWN II early-mid 0.386578 1.06904 3.76193 2.15741 7.42782 8.43389 
Gene NCF2 DOWN II early-mid 0.138198 0.249701 1.01039 1.04456 1.31129 2.90988 
Gene CCDC92 DOWN II early-mid 1.67266 6.47128 15.4961 23.5823 21.1797 35.1289 
Gene NR1D1 DOWN II early-mid 0.400914 0.706182 2.91851 6.35625 4.5094 8.39511 
Gene CRTC1 DOWN II early-mid 0.14755 0.371326 0.859146 1.49369 2.4937 3.08435 
Gene THRA DOWN II early-mid 0.854673 4.16644 4.87839 15.8307 5.57789 17.0998 
Gene SLC15A2 DOWN II early-mid 0.64899 2.16021 7.5113 3.95846 9.165 12.9786 
Gene FAM114A1 DOWN II early-mid 0.531179 1.57971 4.89274 4.26154 9.16236 9.96331 
Gene AXL DOWN II early-mid 0.337147 1.06749 3.0854 4.30124 2.96944 6.23774 
Gene GSDMB DOWN II early-mid 0.423706 1.54482 2.0413 3.06912 7.10247 7.32886 
Gene C20orf112 DOWN II early-mid 0.924939 3.50459 6.57971 5.46857 8.62434 15.3879 
Gene PPP1R12B DOWN II early-mid 3.77254 14.6752 29.9523 26.9265 27.0379 62.5697 
Gene C1orf51 DOWN II early-mid 0.691617 1.8935 6.2769 8.43669 25.088 11.2422 
Gene IGF1R DOWN II early-mid 0.587887 1.1348 2.49216 4.0602 12.272 9.09449 
Gene EVL DOWN II early-mid 0.434359 1.46736 2.46841 3.84576 3.77262 6.70341 
Gene CCDC113 DOWN II early-mid 0.201317 0.379851 1.11575 1.57754 2.87327 3.09594 
Gene C11orf49 DOWN II early-mid 0.890474 2.38119 5.74634 5.75056 6.74085 13.6076 
Gene DCLK1 DOWN II early-mid 3.11716 11.717 22.7721 19.288 25.482 47.0243 
Gene PPAP2B DOWN II early-mid 1.66996 6.12871 11.9806 11.1996 11.879 25.0406 
Gene ZER1 DOWN II early-mid 0.423653 1.17623 1.85126 4.86701 3.28998 6.238 
Gene ARHGAP31 DOWN II early-mid 0.290456 0.525877 2.07072 1.7473 1.53417 4.19518 
Gene CCDC149 DOWN II early-mid 0.879072 2.15467 4.22894 3.48803 4.12062 12.6734 
Gene MATN2 DOWN II early-mid 1.37227 2.29743 5.76721 9.83419 13.3397 19.1361 
Gene TMEM14E DOWN II early-mid 0.822302 2.80484 6.14189 3.762 12.5364 11.3314 
Gene RAB15 DOWN II early-mid 0.323941 1.02294 1.16177 1.29161 2.58093 4.28316 
Gene NPIP DOWN II early-mid 2.33607 3.97104 8.21193 10.3042 17.0198 30.2917 
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Gene FRMD4A DOWN II early-mid 1.75234 3.59638 7.67583 14.7938 18.6814 22.3511 
Gene KIAA1328 DOWN II early-mid 1.66614 4.2258 8.31064 7.68821 6.26213 20.9599 
Gene TANC2 DOWN II early-mid 1.05132 2.89259 4.49874 9.07023 11.4854 13.0507 
Gene LPHN1 DOWN II early-mid 0.457814 1.08005 1.38509 3.31548 4.51406 5.34274 
Gene TMEM175 DOWN II early-mid 0.47715 0.414121 0.844813 5.85428 1.69695 5.44924 
Gene HEG1 DOWN II early-mid 1.22522 3.14029 17.3865 13.4478 25.7545 13.8311 
Gene SEC61A2 DOWN II early-mid 18.962 51.3365 73.8119 117.062 263.184 211.722 
Gene CSRP1 DOWN II early-mid 2.68189 5.65762 8.76861 14.6975 14.6928 29.5032 
Gene KCNMA1 DOWN II early-mid 2.05601 1.85733 7.43167 7.92321 15.7759 22.0628 
Gene TOM1L2 DOWN II early-mid 1.06775 1.78628 2.9761 6.28701 10.3602 11.2186 
Gene TMEM140 DOWN II early-mid 0.506293 0.33507 1.37192 1.4757 1.4728 5.29641 
Gene LMLN DOWN II early-mid 1.28973 2.83129 12.8135 14.3331 15.504 13.4518 
Gene TECPR2 DOWN II early-mid 0.782202 1.20725 2.66949 6.05038 4.52107 8.01794 
Gene COTL1 DOWN II early-mid 0.465766 1.02011 5.5214 6.40686 8.78339 4.77107 
Gene SPG20 DOWN II early-mid 9.01044 21.0629 38.6032 26.8861 51.7539 91.8692 
Gene MAK DOWN II early-mid 0.32988 0.695888 1.86964 4.82018 1.25647 3.34478 
Gene ZNF594 DOWN II early-mid 0.791639 1.74201 2.06838 2.45931 3.24136 8.01672 
Gene SIRT2 DOWN II early-mid 2.03544 4.3044 6.54022 8.70805 7.81288 20.4088 
Gene SDCCAG8 DOWN II early-mid 8.03821 11.7251 24.7203 31.7492 23.6059 80.2678 
Gene KANK1 DOWN II early-mid 1.28996 2.42306 6.21304 10.7317 17.9009 12.8503 
Gene ALOX12 DOWN II early-mid 0.930308 1.81371 4.93668 2.6007 3.64899 9.16518 
Gene EFHD1 DOWN II early-mid 6.53997 9.74275 19.8472 76.9836 35.9229 63.9561 
Gene ZNF841 DOWN II early-mid 0.991188 2.17389 5.3017 4.42363 6.80201 9.47595 
Gene NRIP3 DOWN II early-mid 0.947307 2.0952 3.59586 2.90129 2.98963 8.99832 
Gene LHFPL2 DOWN II early-mid 1.41225 1.73904 4.95403 4.60526 16.2785 13.2976 
Gene ZBTB4 DOWN II early-mid 3.80857 6.99138 12.3913 25.9446 24.9013 35.3132 
Gene ZDHHC14 DOWN II early-mid 3.61049 3.11413 17.4271 8.72253 14.6153 33.1047 
Gene FAM131A DOWN II early-mid 0.452322 0.608306 1.13664 1.18327 1.11754 4.11187 
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Gene PODN DOWN II early-mid 0.539627 0.922954 4.75411 9.84426 4.91924 4.81984 
Gene ZNF528 DOWN II early-mid 1.70495 3.68601 5.85256 7.78987 13.5066 15.0953 
Gene ZNF782 DOWN II early-mid 1.95071 4.00402 7.53549 4.68784 9.20532 17.1695 
Gene TMEM116 DOWN II early-mid 0.714329 1.01193 1.64835 2.20161 2.16553 6.23786 
Gene SPATA7 DOWN II early-mid 0.661595 1.08461 1.85337 2.07905 6.629 5.77571 
Gene WDR91 DOWN II early-mid 0.373305 0.486308 1.2479 1.80917 2.19833 3.21982 
Gene FAM171A1 DOWN II early-mid 4.11368 4.95249 11.3289 13.35 18.7132 35.0114 
Gene CLSTN3 DOWN II early-mid 0.824886 0.713414 2.90379 5.05779 6.06417 6.97647 
Gene RGS12 DOWN II early-mid 1.52058 2.66508 6.25208 4.59342 3.99926 12.7775 
Gene HDAC4 DOWN II early-mid 0.959829 2.00422 3.8729 2.61878 3.4116 8.05457 
Gene MKL2 DOWN II early-mid 5.2627 9.50955 14.6863 12.197 18.3955 43.5232 
Gene FHIT DOWN II early-mid 1.50812 2.69711 6.5341 7.57867 9.92576 12.4266 
Gene ALMS1 DOWN II early-mid 4.3885 7.25565 9.22255 14.3077 19.635 35.8165 
Gene SFI1 DOWN II early-mid 0.749345 1.11092 2.62961 2.45487 5.49889 6.08065 
Gene MORN4 DOWN II early-mid 0.740544 0.849223 1.55612 2.23246 2.02548 5.93771 
Gene PKD2 DOWN II early-mid 2.57348 4.43368 12.8265 5.73349 13.497 20.1581 
Gene FAM22D DOWN II early-mid 0.523123 0.817623 1.12122 0.89411 1.41782 4.01733 
Gene ZNF790 DOWN II early-mid 2.41425 4.53742 10.0272 7.26493 11.1013 18.4632 
Gene HYI DOWN II early-mid 2.13984 3.66875 8.76668 7.17992 4.86242 16.3586 
Gene SRPK2 DOWN II early-mid 16.0759 26.1622 58.8082 52.3323 83.0957 121.973 
Gene MACF1 DOWN II early-mid 91.4055 131.807 271.999 268.163 406.275 688.397 
Gene ZNF25 DOWN II early-mid 1.99203 3.72216 5.52215 4.20207 4.22418 14.9412 
Gene FCHSD2 DOWN II early-mid 12.4282 17.672 38.1282 32.2649 75.7098 92.9736 
Gene RSPH3 DOWN II early-mid 1.94838 2.54088 5.16174 5.69678 7.62024 14.4107 
Gene CD99L2 DOWN II early-mid 1.39974 2.10413 4.43521 3.4421 6.12232 10.1575 
Gene PPFIBP2 DOWN II early-mid 2.63168 2.19914 7.13472 17.3945 17.6069 18.8517 
Gene GPX3 DOWN II early-mid 1.82134 1.84576 11.3479 13.4665 26.5576 12.9638 
Gene LRRC37A DOWN II early-mid 1.39281 1.96438 4.02536 3.28287 4.24898 9.87216 
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Gene ZHX3 DOWN II early-mid 2.37637 2.4657 4.60412 8.43387 7.03381 16.6328 
Gene UBE2L6 DOWN II early-mid 1.44689 1.00502 3.25975 7.0815 17.162 9.96605 
Gene DOCK5 DOWN II early-mid 7.06485 6.13953 20.8072 24.0229 39.8165 48.1068 
Gene RABL2A DOWN II early-mid 1.3162 1.80374 3.67137 7.89324 5.54327 8.76047 
Gene CHKA DOWN II early-mid 2.54649 3.08286 4.9598 4.54397 6.55398 16.5942 
Gene SNX24 DOWN II early-mid 2.15163 3.45163 7.17909 4.22999 3.90375 13.9473 
Gene NUPR1 DOWN II early-mid 3.35356 4.9388 30.9172 66.3343 67.4496 21.7246 
Gene PACS2 DOWN II early-mid 0.945437 0.876013 1.55369 4.8557 5.57866 6.07423 
Gene USP31 DOWN II early-mid 2.16859 3.21482 4.7673 4.11821 5.56776 13.9149 
Gene HERC1 DOWN II early-mid 4.90759 6.63005 9.62038 10.3539 13.6759 31.17 
Gene DNHD1 DOWN II early-mid 1.95499 2.23691 4.37323 5.13077 5.04083 12.2675 
Gene NFIA DOWN II early-mid 8.05755 11.2589 18.6913 22.0639 24.2549 49.8813 
Gene SIRT3 DOWN II early-mid 2.47977 3.185 4.79491 7.8502 8.933 15.3472 
Gene PTPRA DOWN II early-mid 16.464 21.3291 32.4051 33.6281 46.3156 101.893 
Gene GSN DOWN II early-mid 1.72372 2.36352 5.49445 9.9277 7.39274 10.5326 
Gene TOLLIP DOWN II early-mid 0.79693 0.728338 3.32567 1.40455 1.95382 4.86955 
Gene KIF16B DOWN II early-mid 8.55828 8.63831 20.0534 29.0855 23.4471 51.9681 
Gene MAGI1 DOWN II early-mid 4.75063 4.23091 24.9196 31.2788 57.5415 28.7697 
Gene ARHGAP21 DOWN II early-mid 56.4859 71.3063 111.167 117.7 104.646 336.834 
Gene PTPN21 DOWN II early-mid 1.28861 1.80253 6.24579 3.72705 10.4211 7.68224 
Gene RAB4B DOWN II early-mid 1.1384 0.952481 5.30906 9.70651 2.78433 6.72142 
Gene PLD3 DOWN II early-mid 2.05753 2.60571 4.77086 9.63393 7.4197 12.0479 
Gene ARHGEF1 DOWN II early-mid 0.828 0.860696 2.50591 4.37809 2.94413 4.81907 
Gene ATP9A DOWN II early-mid 11.869 16.0982 31.3745 25.6307 31.9429 66.6287 
Gene ZDHHC9 DOWN II early-mid 8.40727 9.40823 12.5204 28.0304 32.1126 45.3039 
Gene RFTN1 DOWN II early-mid 0.704149 0.645425 1.01738 1.34729 2.05757 3.70571 
Gene UBR3 DOWN II early-mid 14.2442 17.828 36.9218 19.3355 37.6049 74.9058 
Gene NBPF3 DOWN II early-mid 0.613797 0.721236 2.64737 3.57986 1.69272 3.22129 
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Gene ST6GALNAC6 DOWN II early-mid 3.64163 2.95052 5.0866 10.345 5.76684 19.0232 
Gene RBMS3 DOWN II early-mid 4.65356 3.04483 12.3155 13.497 37.6336 24.1597 
Gene SGMS1 DOWN II early-mid 3.15946 3.34224 4.64322 6.48397 9.46484 16.2406 
Gene FNDC3B DOWN II early-mid 33.2309 40.2286 137.042 168.061 197.766 169.007 
Gene CBFA2T2 DOWN II early-mid 1.99413 1.5471 3.15218 3.83171 5.46857 9.84635 
Gene ZNF438 DOWN II early-mid 0.851194 0.931342 1.35881 1.44134 2.42373 4.18671 
Gene VPS13D DOWN II early-mid 3.87488 4.13834 6.27473 8.32337 8.57514 18.6871 
Gene CAMKK2 DOWN II early-mid 1.89792 1.88508 2.3672 4.55406 2.51149 8.80454 
Gene BICD1 DOWN II early-mid 9.77116 10.4812 15.3231 20.1789 62.4573 45.0914 
Gene ABR DOWN II early-mid 7.87195 6.17226 12.1431 28.8423 37.7798 36.1517 
Gene MINK1 DOWN II early-mid 1.70088 1.71812 4.85687 8.65999 5.22119 7.73772 
Gene PIK3C2B DOWN II early-mid 1.22394 1.1534 2.04474 2.52768 5.07452 5.46361 
Gene ZSCAN18 DOWN II early-mid 1.83581 1.69391 2.80896 3.23084 6.55092 7.9723 
Gene AP1G2 DOWN II early-mid 2.21342 1.23829 2.21697 3.48261 3.72056 9.61074 
Gene CDC14A DOWN II early-mid 5.25893 5.26134 6.34243 7.9737 24.3898 22.5327 
Gene PPP1R13B DOWN II early-mid 1.66915 0.899056 3.88923 3.53811 2.25223 7.059 
Gene AAK1 DOWN II early-mid 12.6119 10.737 19.2008 23.4758 28.5371 52.5722 
Gene ZNF674 DOWN II early-mid 1.22767 0.862744 4.45416 1.33048 2.2989 5.08944 
Gene CSRP2 DOWN II early-mid 1.60696 1.20229 3.53673 4.00008 19.1719 6.57438 
Gene PHLDA1 DOWN II early-mid 0.877649 0.79113 4.98908 2.03034 3.78985 3.57574 
Gene TMTC2 DOWN II early-mid 12.7997 8.11151 24.5386 18.6875 33.4901 51.371 
Gene PDE1C DOWN III mid-late 0.00446751 9.18624 12.5943 46.6136 52.8288 95.6967 
Gene CADM3 DOWN III mid-late 0.01 1.36694 1.13004 29.4744 35.3384 48.4246 
Gene CTNNA2 DOWN III mid-late 0.01 1.25031 3.80085 13.7877 16.6682 39.9649 
Gene CHI3L1 DOWN III mid-late 0.01 0.892828 1.20059 8.96919 15.3893 31.3867 
Gene CNTN3 DOWN III mid-late 0.01 3.88169 3.65512 8.98761 8.9162 17.1416 
Gene PCDHB5 DOWN III mid-late 0.01 0.268537 2.63433 8.44462 10.5777 16.0138 
Gene FAM177B DOWN III mid-late 0.01 1.52271 1.27056 11.2865 11.5847 15.621 
Gene KCNN3 DOWN III mid-late 0.01 0.432775 1.99368 6.43746 5.47912 9.38239 
   124 
Gene SETBP1 DOWN III mid-late 0.01 0.236965 0.991785 2.69466 3.50843 8.85131 
Gene TSTD1 DOWN III mid-late 0.01 0.01 0.01 0.12326 0.187953 7.01829 
Gene PCDHB7 DOWN III mid-late 0.01 0.367527 0.109045 1.98926 1.54941 6.60179 
Gene ADAMTS9 DOWN III mid-late 0.01 0.0582848 0.366369 4.15084 6.59678 6.17265 
Gene C5 DOWN III mid-late 0.0136069 0.702079 0.640651 1.66119 0.641353 6.83895 
Gene NOS1AP DOWN III mid-late 0.01 0.275412 0.954785 1.53156 1.56178 4.78905 
Gene IFFO2 DOWN III mid-late 0.00923388 0.312703 0.6029 1.50838 1.13397 3.81958 
Gene FNDC9 DOWN III mid-late 0.01 0.01 0.0929292 2.62937 0.916736 4.03956 
Gene C20orf26 DOWN III mid-late 0.01 0.01 0.01 0.18005 0.799601 4.03561 
Gene TMEM196 DOWN III mid-late 0.01 0.01 0.0415291 0.10066 0.26328 3.98528 
Gene KLF8 DOWN III mid-late 0.01 0.0967823 0.323602 2.28708 2.20325 3.67299 
Gene CUX2 DOWN III mid-late 0.0104544 0.665131 0.713116 1.70969 4.69633 3.77406 
Gene EPHX2 DOWN III mid-late 0.01 0.519967 0.20947 1.09876 1.62734 3.60317 
Gene SLC24A3 DOWN III mid-late 0.01 0.0452318 0.443455 2.04688 1.26934 3.50976 
Gene ARHGAP25 DOWN III mid-late 0.01 0.0900672 0.179722 0.787741 1.16363 3.14829 
Gene LRRTM1 DOWN III mid-late 0.01 0.142695 0.182869 1.03877 0.760625 3.11192 
Gene FAM19A5 DOWN III mid-late 0.01 0.01 0.01 0.226761 0.674851 2.98411 
Gene CLDN1 DOWN III mid-late 0.01 0.01 0.01 0.705481 4.69477 2.87871 
Gene PDZRN4 DOWN III mid-late 0.0190071 0.368182 0.508297 0.963374 0.884996 3.98415 
Gene HSPB8 DOWN III mid-late 0.170297 2.47573 2.21077 17.8081 15.2996 35.4909 
Gene SYT2 DOWN III mid-late 0.0277645 0.500898 0.458662 2.79597 2.65348 5.68726 
Gene FAM129A DOWN III mid-late 0.0158095 0.125773 0.291266 0.840843 1.9862 3.23404 
Gene SRGAP3 DOWN III mid-late 0.529238 5.62085 14.3723 28.4507 50.4046 92.2894 
Gene ZIM2 DOWN III mid-late 0.431263 12.6723 10.1748 22.6292 54.5947 69.5051 
Gene LRRC4 DOWN III mid-late 0.0836376 2.23328 2.76135 6.08326 6.25039 12.8557 
Gene CDH8 DOWN III mid-late 0.0284355 0.918685 0.775575 1.09473 1.78674 3.81703 
Gene CRYAB DOWN III mid-late 8.63532 38.0428 210.018 391.986 320.286 1091.49 
Gene C2CD2 DOWN III mid-late 0.237935 3.06359 6.47651 10.9457 20.6729 27.0202 
Gene THY1 DOWN III mid-late 0.206658 3.35371 5.17978 11.0377 13.234 22.7125 
Gene EPHB1 DOWN III mid-late 0.0353721 0.01 0.0949765 0.604089 2.18243 3.41761 
Gene ZBTB20 DOWN III mid-late 2.45906 25.085 55.2674 64.4909 126.908 235.585 
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Gene NOTCH4 DOWN III mid-late 0.0411875 0.0332294 0.139027 0.932529 0.624416 2.79204 
Gene TSPAN5 DOWN III mid-late 0.276106 0.632694 3.88329 5.35586 8.45527 17.3911 
Gene BHMT2 DOWN III mid-late 0.380535 2.79241 2.69436 14.4809 42.6195 23.3741 
Gene GRM1 DOWN III mid-late 0.136766 0.540603 1.59284 4.0434 6.37634 8.33096 
Gene GAB2 DOWN III mid-late 0.881091 2.10903 5.67827 12.89 13.8513 47.704 
Gene INSR DOWN III mid-late 0.182385 0.684903 1.45402 2.51082 5.20145 9.41679 
Gene PTGDS DOWN III mid-late 2.21209 8.19892 8.94478 47.279 32.0293 95.5388 
Gene PADI2 DOWN III mid-late 0.83222 2.00452 8.22945 12.0282 10.3319 33.5303 
Gene IGFBP3 DOWN III mid-late 0.116029 0.01 0.01 0.472074 1.76687 4.39233 
Gene VAMP2 DOWN III mid-late 33.4482 229.548 270.772 424.973 333.892 1138.59 
Gene TAS2R4 DOWN III mid-late 0.116304 0.179845 0.595353 1.26577 2.11058 3.72059 
Gene WBSCR17 DOWN III mid-late 0.167116 0.384141 1.14954 3.03369 7.16773 4.97513 
Gene C5orf4 DOWN III mid-late 2.24948 8.00869 14.605 17.5459 22.3206 63.915 
Gene KIAA1671 DOWN III mid-late 0.354996 0.806556 1.84177 2.64228 10.0944 9.59431 
Gene FMNL3 DOWN III mid-late 0.363118 1.73314 2.10727 3.32572 6.73434 9.74345 
Gene PCDHGB6 DOWN III mid-late 0.142809 0.298489 0.77088 1.76428 5.65159 3.71856 
Gene TTC21A DOWN III mid-late 0.178406 0.510978 0.288872 1.51994 1.19696 4.28745 
Gene KIAA0513 DOWN III mid-late 0.234121 0.721763 0.931607 1.97954 1.43124 5.37089 
Gene ZNF135 DOWN III mid-late 0.851408 2.33694 4.24288 14.5572 10.7467 19.1033 
Gene KIFC2 DOWN III mid-late 0.142499 0.343492 0.476182 0.449548 0.619275 2.9482 
Gene LDOC1 DOWN III mid-late 0.600529 2.07637 2.49027 7.65711 8.04744 11.126 
Gene C6orf105 DOWN III mid-late 0.200306 0.01 0.439828 0.120355 0.553724 3.51091 
Gene PCDHGC3 DOWN III mid-late 0.492015 1.05123 1.24099 2.21663 3.53148 8.50114 
Gene ADHFE1 DOWN III mid-late 0.836761 2.12109 1.37536 6.10496 5.23945 14.3172 
Gene ZFHX2 DOWN III mid-late 0.323154 0.944776 1.25763 2.54846 3.33018 5.45355 
Gene DNAJB2 DOWN III mid-late 1.33243 1.03952 4.04316 6.84328 8.65737 22.4487 
Gene SNX32 DOWN III mid-late 0.180614 0.195349 0.269358 0.903644 1.38884 2.85539 
Gene SLC48A1 DOWN III mid-late 2.15478 5.13264 5.85081 12.4044 10.823 33.7899 
Gene DUSP18 DOWN III mid-late 0.625057 0.524662 0.952156 2.76319 3.15597 9.36431 
Gene AMIGO1 DOWN III mid-late 0.391868 0.680401 1.22444 2.36036 2.50601 5.73342 
Gene APOL3 DOWN III mid-late 0.581346 0.904414 1.07195 3.17309 3.8105 8.2159 
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Gene MRAS DOWN III mid-late 15.6208 21.6623 31.9781 56.0949 91.4615 210.621 
Gene SHISA4 DOWN III mid-late 0.345273 0.593317 0.221482 3.3408 2.43455 4.64863 
Gene ZCCHC24 DOWN III mid-late 0.902865 1.26199 1.76167 2.98996 3.145 11.8555 
Gene PHC1 DOWN III mid-late 1.91753 2.53975 2.76724 13.8747 38.2383 24.8447 
Gene ANKRD6 DOWN III mid-late 0.413163 0.82252 1.12349 2.91493 4.82019 5.12067 
Gene MAPRE3 DOWN III mid-late 0.59547 0.236593 1.26107 1.79072 2.81953 7.11185 
Gene LAT2 DOWN III mid-late 0.364655 0.545559 0.612591 0.933915 0.735225 4.18508 
Gene SPRYD3 DOWN III mid-late 0.515752 0.604298 0.477995 2.3857 1.72967 5.84388 
Gene BIN1 DOWN III mid-late 0.982687 1.02766 1.90298 10.2965 8.2301 10.872 
Gene CLSTN2 DOWN III mid-late 0.670613 0.290485 0.885106 2.08408 2.61379 7.00031 
Gene MXI1 DOWN III mid-late 15.5394 28.2665 28.0402 46.364 77.2198 161.845 
Gene ROGDI DOWN III mid-late 0.413398 0.519153 0.625062 3.42083 1.74483 4.17307 
Gene DUSP22 DOWN III mid-late 1.07095 1.43105 1.51866 2.76901 8.65581 10.1477 
Gene BBS1 DOWN III mid-late 1.14285 2.05362 1.43637 7.00078 5.18248 10.7609 
Gene SH3GLB2 DOWN III mid-late 0.557312 0.558476 0.521364 1.59089 1.98799 5.23903 
Gene PCDHA3 DOWN III mid-late 0.285005 0.182669 0.291746 0.825501 0.459683 2.6738 
Gene KIF3C DOWN III mid-late 1.88234 2.75064 2.67879 6.31732 5.6842 16.8544 
Gene AKR1E2 DOWN III mid-late 0.759466 0.977093 0.935051 3.51585 5.5111 6.73079 
Gene YPEL3 DOWN III mid-late 0.90373 0.92219 1.20464 5.48787 3.25586 7.92864 
Gene RNF24 DOWN III mid-late 0.586794 0.902093 1.23064 1.83019 4.08296 4.97744 
Gene GM2A DOWN III mid-late 2.49662 3.26473 3.93761 6.15579 6.94992 21.1757 
Gene VAMP1 DOWN III mid-late 3.04967 4.43286 3.21001 25.1197 9.48561 24.7402 
Gene RERE DOWN III mid-late 23.7109 29.2464 47.2909 61.1704 71.9 189.211 
Gene TEF DOWN III mid-late 0.455962 0.23838 0.744982 0.973469 1.04081 3.5819 
Gene CRY2 DOWN III mid-late 1.13604 1.79567 2.17375 3.4392 3.05754 8.9031 
Gene TRIM3 DOWN III mid-late 0.738384 0.83406 1.26277 2.177 2.17048 5.67314 
Gene NCS1 DOWN III mid-late 1.16939 1.44016 1.25351 2.76071 2.42996 8.86207 
Gene RAD52 DOWN III mid-late 4.71064 5.64937 4.66798 28.3067 19.0876 35.3485 
Gene EZH1 DOWN III mid-late 2.67136 4.10572 3.71204 6.84524 10.9992 18.2905 
Gene SFXN3 DOWN III mid-late 1.88958 0.940387 1.88559 8.956 5.01915 12.2904 
Gene PRPF40B DOWN III mid-late 2.11734 1.61906 2.482 10.9405 4.10313 13.5807 
Gene ZNRF3 DOWN III mid-late 0.796661 0.913154 0.815922 1.2961 1.41576 5.08253 
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Gene WDR60 DOWN III mid-late 22.6058 31.0957 34.9373 40.0964 49.7371 141.564 
Gene C9orf25 DOWN III mid-late 1.88749 2.23815 2.25339 3.41335 4.05209 11.6908 
Gene CNIH3 DOWN III mid-late 1.23905 0.99797 1.78843 2.03816 3.14705 7.59142 
Gene DENND3 DOWN III mid-late 1.78578 1.18754 1.73988 2.72768 2.7147 10.8235 
Gene RAB3A DOWN III mid-late 1.84676 1.57898 0.929774 7.63533 5.26326 9.91159 
Gene MPP1 DOWN III mid-late 1.94718 1.8513 2.3791 3.75963 5.8036 10.1242 
Gene SYNJ1 DOWN III mid-late 7.9068 9.30234 6.06825 16.8934 15.2933 40.977 
Gene CD160 DOWN III mid-late 0.587141 0.523579 0.706953 1.29921 1.31788 2.90427 
Gene ECE2 DOWN III mid-late 0.622062 0.229684 0.467479 0.746791 0.438954 2.87198 
Gene IQCE DOWN III mid-late 0.722779 0.484603 0.78811 2.28429 2.73798 3.31748 
Gene CPNE2 DOWN III mid-late 0.767781 0.656357 0.815407 2.02081 1.33156 3.47582 
Gene GCNT1 DOWN III mid-late 1.29677 0.345224 0.864336 0.794258 5.14541 5.68135 
Gene RAB3B DOWN III mid-late 1.60474 0.338327 0.403377 1.88105 12.7145 6.93825 
Gene DDRGK1 DOWN III mid-late 5.34055 5.05852 5.06621 8.09989 8.34966 22.8607 
Gene CAMK2B DOWN III mid-late 3.53198 3.03184 3.30208 7.88123 4.84124 15.0421 
Gene HSPA1L DOWN III mid-late 0.846076 0.749744 0.772684 1.30885 1.77508 3.52619 
Gene CACNA1C DOWN III mid-late 2.09597 0.745916 1.98091 2.45031 7.53611 8.71739 
Gene VASH1 DOWN III mid-late 0.704599 0.455243 0.645822 1.46519 1.9906 2.90574 
Gene SH3D19 DOWN IV late 0.00925732 0.345858 5.27738 25.2381 112.142 162.14 
Gene GAP43 DOWN IV late 0.01 0.365633 0.284645 2.27546 71.3796 153.875 
Gene MAPK10 DOWN IV late 0.01 0.138849 0.550277 0.01 25.8985 99.8518 
Gene PTPRD DOWN IV late 0.0112903 14.0147 7.93112 7.36984 35.2754 100.757 
Gene CPNE8 DOWN IV late 0.01 0.7626 0.01 0.358679 23.9828 76.9657 
Gene NMNAT2 DOWN IV late 0.00916796 0.633892 0.863147 2.79502 18.9918 68.7209 
Gene NEGR1 DOWN IV late 0.01 2.88244 10.0378 2.24212 24.2646 72.9833 
Gene LRRTM4 DOWN IV late 0.01 2.34728 4.49842 5.62541 50.1696 50.2879 
Gene NELL2 DOWN IV late 0.0563069 26.3118 38.7786 6.16877 111.591 262.376 
Gene STMN2 DOWN IV late 0.01 0.209051 0.255367 0.831551 34.5501 41.192 
Gene C9orf4 DOWN IV late 0.01 0.0692595 0.382995 0.01 8.91721 32.8248 
Gene PTPN13 DOWN IV late 0.01 0.0885463 0.0288563 0.0368781 34.1888 30.5599 
Gene LGI1 DOWN IV late 0.01 0.942492 2.11842 0.481633 14.5116 28.1772 
Gene TTLL7 DOWN IV late 0.294215 5.64971 2.04449 6.83917 47.8979 798.464 
Gene HDX DOWN IV late 0.01 2.06885 0.728915 0.256784 12.1111 23.1477 
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Gene SH3BGRL DOWN IV late 0.0472391 9.41492 18.6064 15.6247 38.0396 107.036 
Gene ADD2 DOWN IV late 0.01 0.01 0.0803461 0.01 42.2011 21.5166 
Gene CDH9 DOWN IV late 0.01 0.0984899 0.01 0.87094 39.2692 19.2831 
Gene CD200 DOWN IV late 0.01 0.460136 0.143034 0.960682 10.584 18.1667 
Gene FAM131B DOWN IV late 0.01 0.0613441 0.153929 0.102343 7.74492 17.9322 
Gene CDH2 DOWN IV late 0.01 0.259487 0.532287 2.62069 24.7019 17.7893 
Gene ST6GALNAC3 DOWN IV late 0.00585721 0.0545745 0.16486 0.189045 6.52373 10.1607 
Gene NCALD DOWN IV late 0.01 3.48723 3.31424 3.00726 5.20181 17.1063 
Gene NAP1L3 DOWN IV late 0.0166782 4.53379 0.84787 1.64248 9.34718 28.1134 
Gene PTPRZ1 DOWN IV late 0.0856027 0.279653 0.0065426 0.0629194 63.5671 136.723 
Gene PHKA1 DOWN IV late 0.00814829 0.25944 0.649278 2.1796 6.38728 12.7231 
Gene CA8 DOWN IV late 0.01 1.04156 0.53321 0.182687 7.44443 13.9786 
Gene NEK10 DOWN IV late 0.01 0.682492 1.96508 2.9694 4.43629 13.3367 
Gene KLHL4 DOWN IV late 0.01 0.01 0.01 0.01 7.36445 13.2375 
Gene ST6GAL1 DOWN IV late 0.0126504 1.4941 0.0781711 0.042184 23.9503 14.6864 
Gene BEX1 DOWN IV late 0.0674912 1.33124 0.0682625 0.0866021 19.7413 77.8326 
Gene RAMP2 DOWN IV late 0.01 1.84366 0.0731007 0.73148 5.57418 11.4403 
Gene DPYSL5 DOWN IV late 0.01 0.494936 0.557593 0.113016 10.2156 11.2193 
Gene PCDH11X DOWN IV late 0.01 0.0340529 0.00452103 0.01 4.56508 10.9065 
Gene SRRM4 DOWN IV late 0.01 0.01 0.00630704 0.01 4.33591 10.0937 
Gene SYT4 DOWN IV late 0.01 0.296762 0.0453333 0.250839 4.53741 9.95681 
Gene C8orf34 DOWN IV late 0.01 0.351685 1.05117 0.653102 3.03337 9.62189 
Gene ZC4H2 DOWN IV late 0.01 0.01 0.746509 0.01 11.5656 9.59559 
Gene PARM1 DOWN IV late 0.01 0.187829 0.101992 0.0574943 6.4912 9.45864 
Gene TRPM3 DOWN IV late 0.01 0.135877 0.16635 1.0422 4.84499 9.15793 
Gene MRAP2 DOWN IV late 0.01 0.14821 2.08621 1.48372 5.8442 8.96142 
Gene MIPOL1 DOWN IV late 0.01 0.772193 1.14282 0.988992 2.16252 8.83737 
Gene LPL DOWN IV late 0.01 0.618024 0.0838625 0.41537 4.20692 8.39142 
Gene MAP6 DOWN IV late 0.0147671 0.993719 0.01 0.170569 5.95057 12.3892 
Gene MBOAT2 DOWN IV late 0.0361627 1.77747 4.11118 6.35873 8.84765 29.6176 
Gene SCG2 DOWN IV late 0.0179878 0.01 0.239735 0.142888 3.16448 14.5845 
Gene CSF1R DOWN IV late 0.01 0.01 0.01 0.0538512 0.0401761 8.01687 
Gene GRM3 DOWN IV late 0.029708 0.227633 0.109362 0.137528 5.93295 23.0911 
Gene RASA3 DOWN IV late 0.01 0.105877 1.2961 0.29387 2.53029 7.75604 
Gene LST1 DOWN IV late 0.01 0.506461 0.199756 0.273475 1.65582 7.68187 
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Gene PLA2G7 DOWN IV late 0.01 0.107361 0.01 0.0562912 3.89224 7.40549 
Gene C1orf21 DOWN IV late 0.279531 0.924778 2.63946 11.4494 122.415 206.553 
Gene PCDHB14 DOWN IV late 0.01 0.515208 0.775093 0.901289 3.14986 7.36779 
Gene TMEM150C DOWN IV late 0.01 0.01 0.690464 0.267364 3.94748 7.14044 
Gene DLEU7 DOWN IV late 0.01 0.381051 0.233675 0.87638 1.36162 7.10144 
Gene RHOJ DOWN IV late 0.01 0.211923 0.713923 0.805233 1.95847 6.91452 
Gene C7orf62 DOWN IV late 0.01 0.01 0.01 0.01 1.83892 6.86594 
Gene C12orf53 DOWN IV late 0.01 0.337835 0.369282 0.549844 1.7564 6.81225 
Gene ELAVL3 DOWN IV late 0.01 0.01 0.0299732 0.01 1.78913 6.6285 
Gene GIMAP5 DOWN IV late 0.01 0.01 0.01 0.01 2.79443 6.62007 
Gene CDH13 DOWN IV late 0.01 0.658615 0.470379 0.870604 1.70498 6.30237 
Gene KCNMB2 DOWN IV late 0.01 0.01 0.0479974 0.01 0.281919 6.23644 
Gene C3orf15 DOWN IV late 0.01 0.01 0.01 0.271895 6.36578 5.9829 
Gene UNC5D DOWN IV late 0.01 0.112001 0.137971 0.01 3.48067 5.73907 
Gene SOX21 DOWN IV late 0.01 0.01 0.01 0.01 2.8846 5.7187 
Gene PRKAA2 DOWN IV late 0.0110757 0.193946 0.125467 0.134777 3.02017 6.00335 
Gene FLI1 DOWN IV late 0.01 0.01 0.01 0.0612866 1.82783 5.37745 
Gene SYT16 DOWN IV late 0.01 0.01 0.190141 0.331771 1.02014 5.30799 
Gene RSPO3 DOWN IV late 0.01 0.0217163 0.01 0.128452 1.29891 5.27573 
Gene XKR4 DOWN IV late 0.01 0.0450636 0.0795328 0.01 3.63548 5.19504 
Gene BMP7 DOWN IV late 0.01 0.01 0.01 0.01 2.08459 5.19482 
Gene SPINK7 DOWN IV late 0.01 0.151463 0.660697 0.251025 0.926336 5.10616 
Gene MAP2 DOWN IV late 0.445874 7.75035 8.03997 7.8645 75.8441 226.647 
Gene SULT1C4 DOWN IV late 0.01 1.08403 1.1738 0.497918 3.41469 5.02005 
Gene RIC3 DOWN IV late 0.0659801 1.37011 1.66024 1.14969 17.8246 32.7278 
Gene CAMK1G DOWN IV late 0.01 0.01 0.01 0.125285 6.29721 4.70622 
Gene SLITRK5 DOWN IV late 0.01 0.186644 0.658906 0.305287 1.14276 4.66759 
Gene CALN1 DOWN IV late 0.01 0.391519 0.256153 1.02702 1.30634 4.59614 
Gene C6orf138 DOWN IV late 0.01 0.166809 0.246863 0.0748185 1.08108 4.52589 
Gene RPS6KA6 DOWN IV late 0.01 0.01 0.01 0.01 1.48896 4.47725 
Gene HEPH DOWN IV late 0.0120109 0.0477284 0.172522 0.368172 1.92158 5.34427 
Gene ZNF462 DOWN IV late 0.053184 0.856764 1.84655 4.91365 47.5149 23.5596 
Gene FABP7 DOWN IV late 0.0578476 0.228998 0.181451 0.01 16.0914 24.8315 
Gene HIF3A DOWN IV late 0.04254 0.937567 0.314334 0.0869139 10.7981 18.2161 
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Gene CEND1 DOWN IV late 0.01 0.01 0.137937 0.108072 1.23632 4.28171 
Gene HPSE2 DOWN IV late 0.01 0.01 0.134092 0.181344 2.11417 4.1594 
Gene PCP4L1 DOWN IV late 0.01 0.139609 0.162726 0.2526 3.12179 4.03481 
Gene ZIC5 DOWN IV late 0.01 0.208098 0.01 0.0856756 2.35105 4.02817 
Gene KCNH5 DOWN IV late 0.01 0.01 0.01 0.020636 1.13411 3.92785 
Gene SNCB DOWN IV late 0.01 0.01 0.01 0.01 0.340048 3.88215 
Gene ZNF521 DOWN IV late 0.01 0.233959 0.0261061 0.191956 8.56884 3.87568 
Gene EHD3 DOWN IV late 0.0267477 0.40841 0.924669 1.00076 2.8541 10.2334 
Gene ANGPTL2 DOWN IV late 0.01 0.0888583 0.193499 0.912344 1.87856 3.7836 
Gene KBTBD12 DOWN IV late 0.01 0.368517 0.466978 0.065267 0.164704 3.71152 
Gene PKNOX2 DOWN IV late 0.0123444 0.213826 0.149412 0.41622 1.79605 4.55379 
Gene INSM1 DOWN IV late 0.01 0.158698 0.17362 0.13303 10.3435 3.62908 
Gene KLHL34 DOWN IV late 0.01 0.357743 0.869537 0.863485 0.842483 3.62528 
Gene GABRB3 DOWN IV late 0.0562726 0.122463 0.01 0.471614 41.9501 20.2607 
Gene PATE3 DOWN IV late 0.01 0.01 0.01 0.01 0.897825 3.52928 
Gene ST6GAL2 DOWN IV late 0.01 0.0756277 0.422074 0.0279047 1.09682 3.46837 
Gene FXYD6 DOWN IV late 0.199915 0.401572 0.0663032 0.01 33.9098 69.1084 
Gene ZDHHC15 DOWN IV late 0.01 0.0449183 0.0710175 0.0600654 1.34475 3.44619 
Gene GABRG3 DOWN IV late 0.01 0.01 0.01 0.01 1.16928 3.41324 
Gene LINGO1 DOWN IV late 0.01 0.153138 0.42259 0.664187 1.46471 3.41112 
Gene PTPRN DOWN IV late 0.01 0.01 0.01 0.01 0.478871 3.34488 
Gene KIF21B DOWN IV late 0.01 0.01 0.0315972 0.254134 1.18009 3.28437 
Gene CADPS DOWN IV late 0.173818 1.32305 4.68074 3.29281 16.5603 56.2849 
Gene PCDHB13 DOWN IV late 0.01 0.412542 0.765433 0.617662 0.950777 3.2015 
Gene CELF5 DOWN IV late 0.0116075 0.030407 0.0695789 0.0148721 2.38127 3.70184 
Gene GDPD2 DOWN IV late 0.01 0.01 0.01 0.01 6.38023 3.1424 
Gene ERVW-1 DOWN IV late 0.01 0.0545925 0.036207 0.0466982 0.572047 3.07909 
Gene PRMT8 DOWN IV late 0.01 0.01 0.01 0.0740259 5.24975 3.03022 
Gene SLC19A3 DOWN IV late 0.01 0.01 0.01 0.0523696 0.65651 3.02805 
Gene C11orf63 DOWN IV late 0.01 0.01 0.169452 0.11989 0.709922 3.00085 
Gene TMEM132B DOWN IV late 0.14224 3.11051 1.96131 4.64299 16.3416 42.6773 
Gene PPP1R1C DOWN IV late 0.01 0.01 0.01 0.01 2.7165 2.86813 
Gene PZP DOWN IV late 0.01 0.01 0.215298 0.0155177 0.399599 2.84923 
Gene CELF3 DOWN IV late 0.01 0.01 0.01 0.01 2.81784 2.84292 
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Gene TMEM133 DOWN IV late 0.01 0.120279 0.275448 0.121374 3.76581 2.81846 
Gene DMRTC1 DOWN IV late 0.01 0.01 0.01 0.01 0.43406 2.72349 
Gene DMRTC1B DOWN IV late 0.01 0.01 0.01 0.01 0.434116 2.72349 
Gene PABPC5 DOWN IV late 0.01 0.28738 0.288065 0.0984371 0.651943 2.7188 
Gene HSD3B1 DOWN IV late 0.01 0.01 0.01 0.01 0.116866 2.66984 
Gene CACNG7 DOWN IV late 0.0184822 0.0662031 0.01 0.01 3.399 4.73105 
Gene RFX4 DOWN IV late 0.0844138 0.655707 0.222477 0.0348014 12.2764 21.0216 
Gene BAALC DOWN IV late 0.118801 0.334326 1.69486 1.03052 1.96635 29.1901 
Gene JAM2 DOWN IV late 0.263768 1.38828 2.75104 5.0912 23.9054 63.7923 
Gene TMEM35 DOWN IV late 0.0207181 0.107945 0.0251204 0.0680135 2.21593 4.96183 
Gene FILIP1 DOWN IV late 0.0480318 0.351933 0.518369 0.168553 34.1492 11.4989 
Gene CDK14 DOWN IV late 0.0908935 0.608602 2.701 2.57073 10.5433 21.7542 
Gene AMY1C DOWN IV late 0.0570266 0.317871 1.80556 0.878193 5.16303 13.3158 
Gene CNTNAP4 DOWN IV late 0.0800496 0.767997 0.285609 1.17925 4.86525 18.5595 
Gene TOX DOWN IV late 0.0418742 0.795577 0.77652 0.476026 3.85338 9.51013 
Gene FYN DOWN IV late 0.357841 6.21776 10.7841 11.3515 32.3131 79.184 
Gene ARHGEF6 DOWN IV late 0.123642 0.815958 1.71618 4.06876 14.3266 27.0965 
Gene GNG2 DOWN IV late 0.0434282 0.356896 0.228431 0.0991951 3.2076 9.14808 
Gene GABRA5 DOWN IV late 0.0278852 0.01 0.01 0.01 3.14934 5.80847 
Gene IGF2 DOWN IV late 0.0516671 0.207361 0.51665 0.212963 10.7905 10.5934 
Gene RNF152 DOWN IV late 0.0437547 1.17261 0.887211 1.6167 4.95651 8.10319 
Gene PCDHB10 DOWN IV late 0.0166205 0.174024 0.110352 0.328964 0.421154 2.91217 
Gene RCAN2 DOWN IV late 0.220291 0.0305187 0.0533787 0.240414 8.73426 38.5548 
Gene TRIM36 DOWN IV late 0.0491443 0.94958 0.29516 0.268143 5.36908 8.02817 
Gene C1orf114 DOWN IV late 0.118238 0.756168 1.36468 0.694705 5.02203 19.1393 
Gene ZNF280B DOWN IV late 0.0529789 0.116204 0.0383928 0.0673123 5.54707 8.57004 
Gene GKAP1 DOWN IV late 0.21408 1.66767 3.42871 2.28386 11.9076 33.5636 
Gene MARK1 DOWN IV late 0.141817 1.10456 0.100338 0.0167072 5.05919 21.044 
Gene GPR85 DOWN IV late 0.0623674 1.5359 1.65889 0.881306 4.94171 9.00181 
Gene SMOC1 DOWN IV late 0.0817114 1.26041 0.893083 2.25666 3.01174 11.5582 
Gene LHFPL1 DOWN IV late 0.0288943 0.01 0.01 0.01 1.60817 3.9653 
Gene UTRN DOWN IV late 0.361474 10.6937 6.53313 7.22714 53.987 47.6525 
Gene WIPF3 DOWN IV late 0.112265 0.039593 0.1504 0.0430686 4.60801 14.7754 
Gene CNTNAP2 DOWN IV late 0.313954 0.30733 1.44957 0.0282076 52.0791 39.3576 
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Gene FAM171A2 DOWN IV late 0.0223328 0.373132 0.654905 0.493345 1.44388 2.70401 
Gene PCDHGB1 DOWN IV late 0.0644568 0.0249066 0.427785 0.133159 2.91265 7.72801 
Gene DDX25 DOWN IV late 0.12036 0.662631 0.547855 0.261644 3.85746 14.2566 
Gene LRRTM2 DOWN IV late 0.249677 0.754214 3.66439 3.03474 8.3016 27.8413 
Gene FZD3 DOWN IV late 0.105479 0.793403 0.710636 0.599862 22.2298 10.5375 
Gene CCDC102B DOWN IV late 0.0857873 0.381209 0.947008 0.592302 4.08645 8.21364 
Gene ZNF423 DOWN IV late 0.02975 0.112337 0.118299 0.607752 2.78799 2.84487 
Gene NBEA DOWN IV late 0.232693 1.26702 2.90473 1.29859 12.2074 22.2306 
Gene PDE1B DOWN IV late 0.0513237 0.993828 0.513303 0.352976 4.29432 4.87083 
Gene KLHDC1 DOWN IV late 0.183355 1.46086 1.97212 0.438128 4.18902 16.8207 
Gene KCNIP2 DOWN IV late 0.160819 0.242376 0.592157 1.09189 4.32108 14.3053 
Gene APLF DOWN IV late 0.0922344 0.339951 0.797439 0.488592 3.13578 8.08951 
Gene ARL4C DOWN IV late 0.130468 0.44532 0.725674 0.144769 10.1123 11.3845 
Gene CPEB4 DOWN IV late 0.875228 4.10781 7.27864 6.48035 22.8725 75.639 
Gene TUBB2B DOWN IV late 1.56317 19.725 16.1086 9.03876 193.767 134.936 
Gene ESYT3 DOWN IV late 0.0688385 0.129489 1.1436 0.584494 2.08525 5.44348 
Gene TM4SF1 DOWN IV late 0.0982392 0.01 0.01 0.127047 2.42287 7.5436 
Gene PLA2G4C DOWN IV late 0.0415231 0.148997 0.114886 0.300497 1.38509 3.18185 
Gene ELAVL2 DOWN IV late 0.163924 0.367227 0.0989722 1.56126 4.81669 12.4602 
Gene RAB39B DOWN IV late 0.10044 0.193295 0.122332 0.0817835 1.56239 7.47075 
Gene KIAA1257 DOWN IV late 0.0468941 0.01 0.01 0.01 1.72031 3.42163 
Gene SGCE DOWN IV late 0.725162 9.89206 11.5409 4.89098 45.7768 51.6253 
Gene C14orf38 DOWN IV late 0.0390499 0.0662236 0.0183872 0.01 0.0263406 2.77544 
Gene FGF1 DOWN IV late 3.19305 17.8177 31.8767 47.2866 80.1613 218.853 
Gene SORCS1 DOWN IV late 0.20023 0.959377 0.909686 0.334783 4.44066 13.5776 
Gene NUDT10 DOWN IV late 0.137015 0.0694671 0.763605 0.0634931 3.77755 9.10784 
Gene CCDC136 DOWN IV late 0.147603 0.676677 1.19915 0.244713 14.0091 9.79044 
Gene ENO2 DOWN IV late 1.9482 5.4185 2.50994 14.7744 86.4161 127.725 
Gene PCNXL2 DOWN IV late 2.23332 2.18444 7.63487 12.073 35.8902 140.077 
Gene OPHN1 DOWN IV late 0.432135 1.72411 4.34436 2.88981 9.00183 26.7992 
Gene TBC1D4 DOWN IV late 0.167561 0.599819 0.210988 0.359528 5.76888 10.1809 
Gene FAM190A DOWN IV late 0.117185 0.980941 0.87386 0.366971 1.99287 6.95998 
Gene MANBA DOWN IV late 0.262216 1.01523 1.7585 1.80383 11.4112 14.73 
Gene TMEM232 DOWN IV late 0.237617 1.39149 1.64463 0.884714 6.16241 13.3289 
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Gene KIAA1324L DOWN IV late 0.609032 5.35573 6.30577 3.94022 19.5977 31.374 
Gene OCLN DOWN IV late 0.29839 1.98381 3.17762 1.58387 5.85468 15.2479 
Gene EPB41L4A DOWN IV late 0.446928 0.92797 1.06617 0.342396 6.28593 22.7307 
Gene PNMA2 DOWN IV late 0.669762 2.48919 3.61325 1.14484 15.9443 33.8495 
Gene FAM78B DOWN IV late 0.0816521 0.338997 0.275902 0.420192 1.35398 4.08036 
Gene BHLHB9 DOWN IV late 0.251085 1.34569 2.47546 0.684216 3.1837 12.5029 
Gene LPCAT2 DOWN IV late 0.165411 0.629041 0.258647 0.302611 2.6656 8.02035 
Gene ZNF454 DOWN IV late 0.0881047 0.520832 0.769186 0.820005 2.51721 4.20206 
Gene CCDC144A DOWN IV late 3.4279 16.0853 27.8123 12.7904 49.2194 161.887 
Gene ARHGEF9 DOWN IV late 3.44396 5.70368 18.2166 28.0388 47.4435 162.6 
Gene ZSWIM5 DOWN IV late 0.080921 0.331317 0.192037 0.519805 3.34624 3.80291 
Gene GPR98 DOWN IV late 1.21966 2.63123 5.34955 0.604557 22.9085 56.9209 
Gene SCN4B DOWN IV late 0.128558 0.209911 0.282802 0.285996 2.08153 5.97423 
Gene DCX DOWN IV late 0.103766 0.168064 0.0880604 0.0750542 15.9933 4.73536 
Gene ATP8A2 DOWN IV late 0.201501 0.745973 0.612899 0.127045 2.08524 9.15003 
Gene DEPTOR DOWN IV late 0.248664 0.354998 0.854359 2.21718 3.58369 11.2159 
Gene ICA1 DOWN IV late 0.636203 1.86731 4.87451 3.26359 14.3243 28.4616 
Gene PPIL6 DOWN IV late 0.0943958 0.620909 0.621761 0.96461 1.21699 4.1618 
Gene ARNTL2 DOWN IV late 0.252369 1.53432 0.80876 0.699954 3.7906 11.078 
Gene UNC5B DOWN IV late 0.0613038 0.311146 0.118249 0.421776 1.08709 2.69059 
Gene AIF1L DOWN IV late 1.43536 0.351105 0.71589 0.591306 31.2967 62.6762 
Gene CLIP3 DOWN IV late 10.074 71.4939 101.548 67.4948 226.392 438.964 
Gene TNFSF4 DOWN IV late 0.0851085 0.0852443 0.32413 0.499479 1.64428 3.67344 
Gene HCLS1 DOWN IV late 0.170472 0.824225 0.327865 0.146218 1.88889 7.19832 
Gene TMEM98 DOWN IV late 0.173692 0.01 0.539075 0.43672 2.69718 7.21942 
Gene PRELID2 DOWN IV late 0.171988 0.482691 0.575356 0.149501 1.41895 7.14162 
Gene RAP1GAP2 DOWN IV late 0.0704788 0.01 0.0278108 0.01 0.76236 2.92091 
Gene PCDHGB2 DOWN IV late 0.195719 0.39186 1.89309 2.00714 2.88096 8.07599 
Gene GCNT4 DOWN IV late 0.121466 0.179905 0.882829 0.0197377 1.11079 4.993 
Gene ZFP2 DOWN IV late 0.157539 0.645889 0.807309 0.303406 2.80766 6.4744 
Gene CCDC160 DOWN IV late 0.0878405 0.01 0.01 0.01 1.05443 3.58416 
Gene KRT222 DOWN IV late 0.198895 1.17859 0.720376 0.120278 0.0248212 8.06346 
Gene TMEM169 DOWN IV late 0.106967 0.220954 0.239194 0.139291 2.52714 4.27494 
Gene MYO10 DOWN IV late 1.30276 3.12423 1.10709 2.05021 68.6846 51.4125 
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Gene SLC4A8 DOWN IV late 0.975788 2.19715 4.26777 4.52351 12.7831 37.5772 
Gene ANO4 DOWN IV late 0.510184 2.36521 1.34798 0.661375 4.93567 19.3561 
Gene ZNF483 DOWN IV late 2.3458 4.46869 4.02767 3.6316 23.9139 88.1629 
Gene CP DOWN IV late 0.343102 1.8902 1.5113 0.365606 8.82543 12.6412 
Gene STXBP1 DOWN IV late 6.85209 11.5763 26.5746 29.6044 79.2726 249.443 
Gene ST18 DOWN IV late 7.79585 3.1416 1.74222 1.52414 8.72382 282.985 
Gene PPP1R3F DOWN IV late 0.412191 1.77342 1.76353 1.75233 4.01731 13.8974 
Gene C12orf68 DOWN IV late 0.235436 0.292814 0.322071 0.01 15.9911 7.91992 
Gene FAM18A DOWN IV late 0.111515 0.156259 0.114462 0.123551 1.33228 3.6774 
Gene CDKN1C DOWN IV late 0.174372 1.15468 0.969581 1.24353 5.36829 5.60903 
Gene NTM DOWN IV late 3.8511 20.6797 19.6662 24.0146 34.8931 119.72 
Gene STAG3 DOWN IV late 0.585942 2.38286 3.03073 3.03404 7.19266 18.0801 
Gene C16orf45 DOWN IV late 0.47928 0.744533 2.57358 3.36489 8.55855 14.7244 
Gene FAM188B DOWN IV late 0.12778 0.414786 0.900865 0.86287 1.4456 3.8158 
Gene ZNF471 DOWN IV late 0.323268 1.03292 1.82202 0.99606 2.48388 9.1709 
Gene FAM102B DOWN IV late 0.21166 0.28134 0.232774 0.0668433 3.07656 5.84922 
Gene BEX2 DOWN IV late 3.17375 13.9409 21.2958 6.28698 50.2903 86.4236 
Gene TESK2 DOWN IV late 0.620333 0.719283 0.527332 1.43728 4.73637 16.8263 
Gene HS3ST4 DOWN IV late 0.223813 0.62025 0.0165038 0.01 0.939765 5.91028 
Gene TTC18 DOWN IV late 0.216547 0.258905 0.444066 0.957064 2.94947 5.70206 
Gene RALGPS2 DOWN IV late 0.309785 0.633597 0.219884 0.0470877 8.83569 8.15674 
Gene GOLM1 DOWN IV late 2.76452 9.94107 16.0009 12.782 51.7764 70.8761 
Gene FAM70A DOWN IV late 0.187892 0.213429 0.570428 0.05491 1.0763 4.63049 
Gene SERP2 DOWN IV late 0.411177 1.00835 0.636334 1.61927 4.07193 10.0641 
Gene MMD DOWN IV late 0.850764 2.45727 4.48317 0.974311 7.90229 20.7991 
Gene YPEL4 DOWN IV late 0.264356 0.275052 0.19905 0.328443 1.59388 6.45111 
Gene DGKG DOWN IV late 1.5738 0.0784835 1.29862 0.01 1.38156 38.0513 
Gene HSD17B6 DOWN IV late 0.313261 0.301952 0.669358 0.419833 2.33093 7.49981 
Gene SEMA5B DOWN IV late 0.326451 0.01 0.01 0.01 23.4194 7.6776 
Gene TMOD1 DOWN IV late 0.964713 3.19664 3.12378 2.49969 8.46139 22.1351 
Gene ABCA10 DOWN IV late 0.292953 0.791329 0.922329 1.61782 2.62244 6.70873 
Gene RNF175 DOWN IV late 0.121575 0.01 0.0999975 0.01 1.50107 2.78212 
Gene COL16A1 DOWN IV late 0.157135 0.143151 0.0191333 0.01 0.660367 3.46774 
Gene LRRN3 DOWN IV late 0.361748 0.680586 1.45208 1.19103 4.05579 7.97422 
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Gene C7orf63 DOWN IV late 0.332424 1.10002 0.81069 0.463483 1.84246 7.26316 
Gene HS3ST2 DOWN IV late 0.138561 0.01 0.083399 0.0473649 1.28656 3.02145 
Gene FAM169A DOWN IV late 1.01839 2.23566 4.79277 3.56108 6.95483 22.1479 
Gene FEZ1 DOWN IV late 4.85692 15.9027 8.96576 9.83336 33.3355 102.262 
Gene ABHD6 DOWN IV late 0.265469 0.293108 0.651791 0.468901 1.28012 5.57554 
Gene SESTD1 DOWN IV late 2.31779 5.67715 8.40306 8.00451 27.934 48.248 
Gene APC DOWN IV late 10.9914 22.2943 35.038 22.3102 47.1369 224.345 
Gene F8 DOWN IV late 0.177823 0.341748 0.592482 0.286262 0.99176 3.57728 
Gene CYP4V2 DOWN IV late 3.10731 3.16799 3.4856 7.41871 20.6174 61.5608 
Gene SLCO3A1 DOWN IV late 0.463147 0.270649 0.929583 0.429525 2.61249 8.97478 
Gene PDE4B DOWN IV late 8.30903 22.0894 32.9136 12.7269 47.0872 159.255 
Gene SNN DOWN IV late 0.714527 1.22123 1.88331 2.09793 4.7864 13.5928 
Gene CDKL5 DOWN IV late 1.46007 1.68289 3.73925 4.27281 11.0035 27.0416 
Gene RUFY3 DOWN IV late 4.16336 6.43848 12.4438 10.5781 28.4853 76.6655 
Gene ZNF323 DOWN IV late 0.589349 1.67209 1.87581 2.38943 3.41905 10.8405 
Gene BCL6 DOWN IV late 0.87956 1.65677 3.4224 1.42049 8.41473 16.1148 
Gene DYX1C1 DOWN IV late 6.75868 9.10477 24.1896 10.8553 49.1022 122.996 
Gene PDGFRA DOWN IV late 1.44698 1.05957 1.65005 1.71283 18.4757 25.9386 
Gene DNM1 DOWN IV late 0.820525 0.593631 0.454472 0.609278 3.88401 14.5788 
Gene SLC26A4 DOWN IV late 0.315565 0.01 0.0558972 0.174452 2.8426 5.56543 
Gene DLG4 DOWN IV late 1.24763 2.34925 2.59639 5.19626 8.80814 21.1528 
Gene CELSR2 DOWN IV late 1.14125 3.20727 2.20932 4.36906 11.3285 18.6923 
Gene PHACTR2 DOWN IV late 2.22534 0.739637 0.598034 0.804627 32.5319 36.1239 
Gene ZNF177 DOWN IV late 0.337531 0.916551 0.875411 1.35825 3.65703 5.44952 
Gene ADAM22 DOWN IV late 1.40401 4.53349 2.37586 0.614486 6.4348 22.3348 
Gene ANKDD1A DOWN IV late 1.308 2.26778 3.90378 3.18448 5.88567 20.7188 
Gene PDE10A DOWN IV late 0.20954 0.607483 0.0572934 0.0374885 3.43169 3.24603 
Gene ZNF613 DOWN IV late 0.37546 0.773516 1.27822 1.05709 1.7926 5.81347 
Gene EPB41L1 DOWN IV late 4.02186 3.07059 4.88653 9.37025 24.528 60.3557 
Gene GDPD1 DOWN IV late 0.335707 0.655949 0.421637 0.153205 1.70771 4.89627 
Gene HLA-DMA DOWN IV late 0.277675 0.231336 0.361973 0.51987 1.0785 4.00159 
Gene SCAMP5 DOWN IV late 0.349834 0.290053 0.292824 0.89304 1.20501 5.03957 
Gene AGAP1 DOWN IV late 3.27902 2.47923 4.94982 5.23656 12.8738 46.0238 
Gene FAM167A DOWN IV late 0.33132 0.492027 0.396309 0.131233 1.8489 4.61191 
   136 
Gene LRRC6 DOWN IV late 5.85917 4.57952 4.90265 7.15982 20.4634 81.5485 
Gene CALB1 DOWN IV late 0.294839 0.354143 0.543815 0.032163 0.63669 4.10097 
Gene ZNF565 DOWN IV late 0.629533 1.01865 1.7587 1.12823 2.64814 8.64275 
Gene FN3K DOWN IV late 0.660721 0.897354 1.68109 1.81326 2.36715 8.95561 
Gene BLNK DOWN IV late 0.679877 0.551311 0.961668 1.39519 7.03136 8.98582 
Gene MCART6 DOWN IV late 0.676754 0.990398 2.11637 1.05496 5.52279 8.88977 
Gene AGTPBP1 DOWN IV late 4.94126 7.67097 9.14724 4.62555 20.44 60.7697 
Gene RABGAP1L DOWN IV late 8.99237 16.4283 23.8474 15.0995 43.8821 108.064 
Gene C20orf118 DOWN IV late 0.325059 0.431135 0.172476 0.182303 1.11106 3.83328 
Gene CDH26 DOWN IV late 0.248175 0.508059 0.238561 0.0674881 0.583236 2.89767 
Gene KIAA1407 DOWN IV late 0.929739 1.39196 2.12644 1.68138 3.32095 10.7693 
Gene RNF157 DOWN IV late 1.6637 0.675787 1.89415 1.14792 7.07873 18.9798 
Gene LEPR DOWN IV late 0.719816 0.666139 1.18687 1.14716 4.64073 8.20743 
Gene NEFM DOWN IV late 50.2096 99.9103 108.694 65.0197 452.288 568.566 
Gene SH3BGR DOWN IV late 1.97512 2.50621 1.38262 2.83957 17.118 22.1993 
Gene LRRC49 DOWN IV late 0.79353 0.705059 1.14764 0.469786 2.45095 8.58349 
Gene C12orf76 DOWN IV late 4.9322 4.61789 7.93205 4.99774 14.8701 51.287 
Gene RNASET2 DOWN IV late 1.21949 1.69415 1.89927 2.83814 3.41415 12.486 
Gene CDO1 DOWN IV late 1.42412 1.74283 2.22516 2.90969 5.77377 14.5295 
Gene STK33 DOWN IV late 1.33732 1.67813 0.731799 0.0285424 8.64241 13.5051 
Gene TRANK1 DOWN IV late 1.26366 1.88191 1.13043 2.67076 4.6247 12.258 
Gene ZNF418 DOWN IV late 0.989175 1.18781 1.2114 1.97526 4.83193 9.43477 
Gene EPHX1 DOWN IV late 2.00283 1.32085 0.757704 2.61134 6.1701 18.7648 
Gene TNFRSF21 DOWN IV late 6.60338 11.2985 8.74971 3.67528 21.2051 60.8798 
Gene NIPAL3 DOWN IV late 2.90928 3.23742 5.19685 5.08999 15.1447 26.0857 
Gene BBS2 DOWN IV late 4.19895 5.61507 6.71589 5.82809 15.5481 36.7501 
Gene ADORA1 DOWN IV late 1.25759 1.24945 1.07793 1.64208 7.56269 10.8102 
Gene NRIP1 DOWN IV late 3.46291 2.87976 6.65152 1.94025 13.1705 29.5806 
Gene SLC22A23 DOWN IV late 2.01552 2.41619 4.22731 3.45456 5.60389 17.0084 
Gene MCTP1 DOWN IV late 7.3328 3.39095 7.90863 11.4715 30.9979 61.0644 
Gene WDR7 DOWN IV late 2.97007 3.95262 6.07077 4.49406 8.42373 24.4139 
Gene SLC1A1 DOWN IV late 0.623155 0.304813 0.408726 0.512802 1.88496 4.94199 
Gene ZEB1 DOWN IV late 37.2996 21.1679 54.6123 45.6845 201.275 290.756 
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Gene SLC35F1 DOWN IV late 2.12098 3.17184 1.55248 0.973248 9.05078 16.2436 
Gene BCL2L2 DOWN IV late 2.08468 3.15053 3.35321 2.53288 5.43098 15.852 
Gene SCN8A DOWN IV late 2.35517 0.507631 1.19951 0.875548 6.40072 17.8904 
Gene PTPRJ DOWN IV late 1.55169 0.912045 1.34982 1.89982 4.35938 11.7125 
Gene MECOM DOWN IV late 0.65246 0.0694173 0.04237 0.0125989 2.61942 4.91673 
Gene DST DOWN IV late 135.666 133.466 192.391 128.628 378.25 991.423 
Gene SPRY1 DOWN IV late 1.76613 0.428865 0.15202 0.0149633 6.28559 12.9054 
Gene CAMKV DOWN IV late 0.873733 0.0525307 0.01 0.938212 5.24705 6.35685 
Gene PRKCH DOWN IV late 2.32342 1.13998 0.288112 0.358585 7.33233 16.8471 
Gene ALAD DOWN IV late 12.2402 15.52 12.8514 12.5031 27.6661 88.1478 
Gene STON2 DOWN IV late 0.849766 0.787482 0.885331 1.23268 2.71932 6.09326 
Gene ZDHHC23 DOWN IV late 1.13467 1.49428 0.760698 0.29537 2.01091 8.11393 
Gene C16orf46 DOWN IV late 1.49359 1.04506 1.74162 1.74708 16.1683 10.0653 
Gene ITM2C DOWN IV late 7.44268 5.08134 7.77934 9.10283 17.1542 49.6784 
Gene PRNP DOWN IV late 20.7731 5.08676 22.6329 15.9619 44.3919 136.861 
Gene MYOM2 DOWN IV late 1.07169 0.640675 0.698325 0.817568 2.37932 6.99938 
Gene SNTG1 DOWN IV late 5.42362 0.106606 0.167345 0.13358 20.6385 34.2881 
Gene GLIS3 DOWN IV late 1.38982 0.199645 1.70868 1.04151 3.49403 8.47841 
Gene FLRT2 DOWN IV late 2.67812 0.914107 0.725625 1.56943 8.57996 16.2079 
Gene DFNB31 DOWN IV late 1.40176 1.0128 0.347925 0.676451 3.93076 8.41409 
Gene HIP1 DOWN IV late 1.65469 0.561558 0.945606 1.28656 5.13486 9.88095 
Gene PCYT1B DOWN IV late 1.83127 1.87836 1.06341 0.0959551 8.86741 10.06 
Gene IL18 DOWN IV late 0.701071 0.339995 0.814664 0.617186 1.10421 3.66331 
Gene FAM19A1 DOWN IV late 0.865892 0.370669 0.52018 0.348015 1.42748 4.52443 
Gene CCDC85A DOWN IV late 2.24476 0.632188 1.91097 0.5282 1.73773 11.5676 
Gene AMN1 DOWN IV late 9.57888 8.58133 7.04927 5.96293 14.0962 48.3834 
Gene PVRL1 DOWN IV late 1.04713 0.42033 1.27078 1.13973 5.62639 5.27329 
Gene SMAP2 DOWN IV late 8.16935 6.59075 8.06103 9.40994 12.5519 40.461 
Gene PTP4A2 DOWN IV late 107.489 83.2055 126.821 49.7358 150.807 530.27 
Gene LRRC8D DOWN IV late 2.86222 1.59421 3.28989 2.43444 8.66254 14.0589 
Gene STAT4 DOWN IV late 2.24503 1.07906 1.5458 0.930363 4.43725 10.5605 
Gene APBB1 DOWN IV late 2.03257 1.25361 0.462028 0.641965 2.42126 9.46411 
Gene PRKAG2 DOWN IV late 3.68739 1.39148 3.51664 2.44601 5.23827 17.0467 
Gene C6orf168 DOWN IV late 1.40962 0.958622 0.957294 0.330007 1.47463 6.43633 
Gene KIF13B DOWN IV late 5.54225 1.7952 2.47851 4.15066 9.14529 25.0665 
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Gene BMPER DOWN IV late 2.55041 0.240648 0.238974 0.0119807 1.62063 11.292 
Gene LXN DOWN IV late 1.29337 0.38507 0.619633 0.516714 5.68076 5.6188 




0.01 38.5898 117.343 43.9403 113.736 1927.78 




0.01 0.01 0.01 0.01 8.62912 1533.3 




0.01 0.0375852 0.0688913 0.108075 1.10085 657.196 




0.01 0.308152 0.0185167 0.477843 0.813259 586.482 




0.01 1.63646 5.14523 4.40897 21.4104 563.952 




0.01 0.01 0.01 0.0115297 0.01 532.188 




0.0131527 1.46734 0.429569 1.2681 12.5344 594.278 




0.01 0.100082 0.0950262 0.0430224 0.104339 428.854 




0.00777692 0.381639 0.500099 8.82279 1.9105 310.686 




0.01 1.44388 0.193721 0.0764418 1.20873 319.028 




0.01 0.475294 2.64597 2.4459 18.6181 213.845 




0.033777 0.01 0.120985 0.227604 0.162754 662.573 




0.01 0.532115 0.01 0.0843213 5.40512 190.31 




0.01 0.01 0.01 0.01 0.01 176.356 




0.0238689 4.01882 9.60783 0.775376 4.81647 387.542 




0.01 0.01 0.24552 2.02554 9.20485 157.283 




0.01 0.01 0.01 0.01 1.18978 146.777 




0.00386953 0.132014 0.0858445 0.0260942 0.692891 52.8251 




0.01 3.3108 1.9337 1.80732 3.26101 126.432 




0.01 0.90485 2.97239 10.6838 9.28291 126.146 




0.01 0.01 0.01 0.01 0.024921 123.001 
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0.0109429 0.777815 0.411724 1.09297 3.65071 126.428 




0.0183694 0.0524882 0.112449 0.0973284 0.117232 195.707 




0.0103415 0.0241588 0.0849567 0.01 1.71344 93.9894 




0.0677795 1.23661 0.149171 0.01 20.1539 582.124 




0.01 6.57419 8.77292 3.2684 12.8797 84.9445 




0.01 0.273266 0.01 0.745888 0.01 83.1509 




0.01 0.0501297 0.203238 0.01 0.01 82.2278 




0.0116114 0.01 0.742484 0.01 10.0308 93.0329 




0.00354255 0.324176 0.373902 0.0215296 0.410533 27.8857 




0.01 7.20357 1.58189 1.01548 1.80746 76.6057 




0.0705504 13.0395 26.9833 9.09664 30.5949 536.162 




0.01 0.01 0.01 0.01 0.251706 72.6138 




0.01 3.70916 2.2413 1.83351 0.885011 72.1605 




0.01 0.01 0.01 0.01 0.743023 71.9684 




0.01 0.0568437 0.0466367 0.15848 0.01 70.804 




0.01 0.01 0.01 0.01 0.01 69.6652 




0.01 1.65825 0.0378221 12.4329 1.67092 64.6785 




0.01 2.97821 8.87341 8.37249 14.3371 64.3961 




0.01 0.01 0.01 0.00288733 0.01 60.6412 




0.01 0.01 0.0150593 0.01 0.044817 59.3524 




0.01 0.0607316 0.564053 0.87065 1.81371 59.0211 




0.01 0.01 0.01 0.0208963 0.332845 58.2031 
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0.01 0.134452 0.073977 0.273818 2.42787 58.171 




0.01 2.20576 1.63329 4.28179 0.464372 57.8551 




0.01 8.13765 0.01 0.01 0.01 51.3175 




0.01 0.01 0.01 0.01 4.63012 50.42 




0.01 0.01 0.01 0.317147 0.01 48.8878 




0.0161475 4.2824 11.3385 3.11016 9.09523 78.7583 




0.01 1.5442 0.0180863 0.253022 0.01 48.4821 




0.01 4.33085 11.6459 4.26638 9.18985 46.9607 




0.01 0.291918 0.197547 0.01 0.59294 42.7886 




0.0204373 0.275238 0.910635 1.59334 4.94698 86.0868 




0.0119885 0.106064 0.315196 0.230698 1.04531 49.9103 




0.0466162 0.200283 0.178064 0.242128 0.189979 190.52 




0.00784926 0.0575477 0.138868 0.101504 0.295434 31.7284 




0.01 2.89404 3.51328 4.70513 8.75665 40.3881 




0.01 0.0454548 0.12378 0.01 0.01 40.2939 




0.01 0.74011 1.4584 0.427986 5.8516 39.2313 




0.0100017 0.01 0.01 0.01 1.91181 37.7869 




0.01 0.11122 0.0189122 0.0431538 5.75253 37.3727 




0.116383 5.47192 2.91379 4.33789 13.6965 432.354 




0.01 0.282532 0.247243 0.01 7.94903 36.9584 




0.0280869 0.0417413 0.0573275 0.162712 3.2516 103.468 




0.01 0.124985 0.153789 0.01 1.97265 35.8254 
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0.01 0.01 0.01 0.01 7.13855 35.2253 




0.01 0.01 0.01 0.01 4.63353 35.0865 




0.01 0.01 0.21949 0.0326399 0.01 34.7227 




0.01 0.01 0.01 0.01 0.572674 34.6095 




0.01 0.375843 1.24907 0.445266 3.65231 34.5914 




0.0199975 0.993695 1.83943 10.2127 1.60329 69.1344 




0.0188008 0.369525 3.32474 0.760734 3.49758 64.2812 




0.01 0.01 0.01 0.01 0.01 34.0843 




0.01 0.195989 1.65988 2.7161 4.05283 33.9041 




0.0889421 0.180716 0.227036 0.114534 1.12264 301.4 




0.01 0.177202 0.226635 0.119257 4.15338 33.7549 




0.01 0.251974 0.869529 3.64204 3.54297 33.3581 




0.0196954 5.49991 7.16232 0.405553 1.16723 65.1268 




0.151866 1.05688 12.34 13.3782 20.28 500.862 




0.01 0.739525 2.45232 3.25874 0.0492196 32.6736 




0.01 0.364907 4.00771 0.268477 4.40312 31.3717 




0.01 0.01 0.01 0.01 1.06565 31.339 




0.01 0.409671 0.0553026 0.40211 2.86871 30.9369 




0.01 0.01 0.01 0.01 1.84068 30.7848 




0.01 0.208388 0.318103 0.0901686 4.27383 28.7913 




0.01 0.01 0.131778 0.141908 1.09291 28.4879 




0.01 0.0847273 0.0441219 0.429988 0.398644 28.2083 
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0.01 0.01 0.781941 0.58118 1.54247 28.0727 




0.036582 0.694297 0.143018 1.46364 5.96073 102.099 




0.01 1.02892 0.753701 0.291347 0.812183 27.0906 




0.140644 7.0932 6.46892 6.56813 18.281 379.7 




0.01 0.599058 0.01 0.01 0.01 26.9587 




0.01 0.0531094 0.0844514 0.340942 1.29423 26.8505 




0.01 0.01 0.01 0.01 0.655514 26.3667 




0.01 0.01 0.01 0.01 1.45463 26.2198 




0.01 0.01 0.01 0.01 0.412692 25.9855 




0.01 0.0213768 0.160434 0.0833161 0.431861 25.7994 




0.01 0.086605 0.261266 0.132596 0.100567 25.3148 




0.01 0.01 0.01 0.01 0.01 25.1571 




0.01 0.01 0.271587 0.01 0.0510784 25.1093 




0.01 0.270726 0.165903 0.952513 0.486344 24.9901 




0.0092199 0.333251 0.488961 0.100811 1.25754 22.9125 




0.01 0.0301858 0.161662 0.0552835 0.156662 24.7407 




0.01 0.01 0.01 0.01 0.0808795 24.6191 




0.01 0.0632948 0.01 0.01 0.940155 24.3791 




0.350707 1.6265 3.20416 0.632656 10.8656 845.93 




0.102744 0.990565 6.38288 4.51975 10.1453 238.224 




0.311834 6.61811 2.74522 10.4873 30.1386 714.851 




0.0146631 0.596408 1.512 3.10599 3.63144 33.4506 
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0.01 0.01 0.0487813 0.01 0.01 22.567 




0.01 0.0543849 1.00153 0.0521498 0.630016 22.4478 




0.01 0.111281 0.01 0.0767276 1.63102 22.1739 




0.01 0.01 0.0219425 0.01 0.326508 22.1084 




0.01 0.381512 0.024916 0.01 0.253601 21.9429 




0.01 0.263461 0.0135096 0.72156 3.0561 21.891 




0.01 1.04377 0.23732 0.374671 2.62756 21.6552 




0.01 0.206687 0.293778 0.0228758 2.19679 20.9605 




0.00944342 0.01 0.01 0.01 0.705604 19.6749 




0.0106334 0.0445585 0.391154 0.0851135 0.520216 22.1221 




0.01 0.207246 0.361509 0.344625 3.94862 20.541 




1.39823 18.3223 114.714 617.431 610.859 2871.16 




0.01 0.01 0.01 0.01 0.01 20.4808 




0.01 0.0406147 0.0689455 0.342935 0.01 20.4679 




0.208092 6.88325 5.22263 3.7787 23.9088 423.806 




0.01 0.01 0.677084 0.253144 0.28443 20.3499 




0.01 0.356667 1.23774 0.0896006 0.162797 20.3478 




0.01 0.202632 0.419052 0.924722 1.93838 20.1585 




0.01 1.37987 0.01 0.0366952 0.01 20.0571 




0.01 0.308455 0.217157 0.01 0.251306 19.8027 




0.01 0.380159 0.150464 0.517617 0.322297 19.7857 




3.62687 0.59959 2.01738 0.714722 1.25033 7121.93 
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0.01 0.01 0.364482 0.01 2.72106 18.6127 




0.01 0.01 0.201522 0.145583 0.762292 18.5433 




0.01 0.01 0.01 0.01 3.53554 18.5033 




0.01 0.01 0.0700623 0.066738 0.320216 18.2475 




0.01 0.01 0.0879027 0.0202647 0.523902 17.8509 




0.01 0.405061 0.523765 0.382995 0.01 17.7937 




0.01 0.01 0.108409 0.392964 1.02143 17.6792 




0.0213412 0.0830212 0.01 0.877658 1.79218 37.7089 




0.01 0.01 0.01 0.01 0.260612 17.5687 




0.01 0.471633 0.328833 0.399252 4.19172 17.3723 




0.00664343 0.792886 1.66918 0.298651 0.16382 11.5244 




0.01 0.01 0.114624 0.01 2.36394 17.0224 




0.01 0.01 0.01 0.01 0.063255 17.0202 




0.01 0.01 0.01 0.01 3.02324 16.956 




0.0189484 0.116558 0.05915 0.451247 2.14414 31.8079 




0.01 0.01 0.01 0.01 0.01 16.6598 




0.01 0.01 0.210642 0.01 0.01 16.6199 




0.01 0.218524 0.384081 0.0367919 2.7168 16.553 




0.01 0.01 0.0679714 0.01 0.01 16.4754 




0.01 0.01 0.01 0.01 0.246677 16.4389 




0.01 1.38718 0.01 0.0228087 0.332746 16.3723 




0.32252 10.423 4.36989 2.60082 4.69851 523.435 
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0.01 0.0971552 0.0209097 0.01 0.01 15.7608 




0.01 0.01 0.01 0.01 1.25713 15.7256 




0.0446412 2.68999 2.17939 0.531884 13.9274 69.6259 




0.01 0.139596 0.437136 0.121185 0.01 15.3746 




0.01 0.01 0.01 0.01 0.01 15.2824 




0.01 0.01 0.0468746 0.01 0.0508206 15.1561 




0.01 1.50017 2.42356 0.0231259 1.30268 15.0832 




0.01 0.309571 0.0574508 0.01 1.9676 14.947 




0.01 0.0360401 0.01 0.0827164 0.0796774 14.9 




0.01 0.01 0.01 0.01 0.653221 14.8917 




0.01 0.01 0.0841762 0.01 0.01 14.8331 




0.01 0.01 0.01 0.01 2.30932 14.7266 




0.01 0.01 0.01 0.01 0.01 14.5359 




0.546904 2.73669 3.42978 5.79427 6.10873 784.314 




0.256052 0.589364 0.951678 0.749749 8.66314 367.136 




0.01 0.01 0.01 0.01 0.01 14.0758 




0.01 0.01 0.347233 0.0225907 1.63178 14.005 




0.01 0.01 0.01 0.01 0.01 13.8888 




0.187695 0.879575 0.0877752 0.401501 0.363374 255.843 




0.01 0.369803 1.80453 0.528514 2.9907 13.5096 




0.01 0.01 0.600996 0.01 0.01 13.4375 




0.00544938 1.682 1.43887 0.998643 1.68758 7.3073 
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0.01 0.699466 0.39081 0.209354 0.333564 13.3227 




0.01 0.0509803 0.01 0.01 0.0719826 13.3192 




0.01 0.01 0.0179264 0.01 0.01 13.2924 




0.01 0.74546 0.392834 1.35874 0.815519 13.2179 




0.0227668 0.216165 0.740042 0.0338979 0.83927 29.8677 




0.01 0.483486 0.530282 0.831882 2.35723 13.0539 




0.01 0.01 0.01 0.01 0.01 12.7887 




0.447051 0.502844 1.21679 0.68299 7.68419 564.917 




0.01 0.595193 0.021332 0.0176947 0.64701 12.0224 




0.01 0.975574 1.08404 0.468623 0.728898 11.9419 




0.01 0.01 0.01 0.0161161 0.01 11.9157 




0.01 0.01 0.01 0.01 0.513571 11.7958 




0.01 0.185235 0.0191674 0.0736422 0.405647 11.7731 




0.01 0.0499027 0.445533 0.0247172 1.67136 11.6722 




0.01 0.01 0.0789604 0.0363535 0.01 11.6602 




0.01 0.01 0.01 0.01 0.199613 11.6414 




0.01 0.13215 0.0406316 1.85605 0.241845 11.5635 




0.01 0.01 0.01 0.01 0.01 11.2935 




0.01 0.01 0.01 0.01 1.07733 11.1249 




0.446011 2.00125 1.38235 9.49676 11.9086 484.099 




0.01 0.01 1.65435 0.0601944 0.337376 10.8212 




0.01 0.01 0.01 0.01 0.01 10.7672 
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0.01 0.116161 0.01 0.01 0.0462472 10.7665 




0.01 0.01 0.01 0.01 1.28891 10.6704 




0.01 0.01 0.01 0.0522423 0.01 10.6466 




0.01 0.193036 0.17961 0.165254 0.285639 10.5429 




0.050396 0.350767 0.01 0.01 1.39142 52.3545 




0.01 0.01 0.01 0.22124 0.01 10.3878 




0.0112699 0.19997 0.283141 0.167174 0.272109 11.687 




0.01 0.01 0.155448 0.01 0.01 10.1812 




0.263223 1.25494 1.2934 0.613997 4.57509 266.632 




0.01 0.476669 0.43589 0.0368582 2.203 10.1191 




0.0786976 3.06149 0.807931 0.606408 4.59355 78.7017 




0.0182832 0.0489355 0.0507886 0.177319 4.48054 18.2336 




0.01 0.01 0.191988 0.01 1.5855 9.81683 




0.01 0.01 0.01 0.01 0.194854 9.72745 




0.0761536 0.0675746 0.0195259 0.431609 1.0358 74.0229 




0.01 0.01 0.0341224 0.01 0.113578 9.66097 




0.01 0.01 0.01 0.01 0.01 9.6046 




0.01 0.315684 0.331651 0.0843047 0.616694 9.52041 




0.0143445 0.0296728 0.0597927 0.0314968 0.534448 13.5056 




0.01 0.442854 0.0681432 1.0059 0.0297819 9.39697 




0.01 0.01 0.01 0.01 0.01 9.33821 




0.01 0.01 0.0860278 0.0511986 0.687581 9.27704 
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0.01 0.01 0.01 0.01 0.40543 9.22666 




0.01 0.01 0.01 0.01 1.14818 9.2159 




0.01 0.01 0.01 0.121736 0.150466 9.20992 




0.01 0.01 0.0347592 0.01 0.940402 9.20109 




0.01 0.10355 0.01 0.01 0.421908 9.1813 




0.01 0.626816 0.596707 0.477466 0.119995 9.17852 




0.01 0.01 0.01 0.01 0.0592333 9.15618 




0.01 0.01 0.28018 1.80839 0.412979 9.10128 




0.01 0.01 0.01 0.01 0.413653 9.09627 




0.01 0.194097 0.589378 1.01365 0.57185 9.09319 




0.01 0.0777407 0.260808 0.196807 0.528953 9.08266 




0.01 0.01 0.301702 0.00970048 0.01 8.93248 




0.01 0.440189 1.28593 0.211672 0.811855 8.80475 




0.01 0.01 0.01 0.01 2.13437 8.7754 




0.0411897 0.348186 0.999536 0.208885 2.36829 35.9906 




0.0227766 0.0290237 0.0105167 0.0073147 0.125038 19.7154 




0.01 0.137633 0.01 0.01 0.01 8.65006 




0.0349852 0.850839 2.74525 1.87562 5.94509 30.2081 




0.01 0.01 0.01 0.01 0.01 8.58568 




0.01 0.01 0.01 0.01 0.797836 8.58199 




0.0484153 0.0908762 0.162209 0.0355424 0.18438 41.4739 




0.026535 2.36399 2.83112 1.48982 3.14932 22.3376 
   149 




0.01 0.01 0.01 0.01 0.01 8.1785 




0.0553226 0.148041 0.50145 0.484522 1.70678 44.7884 




0.0435185 0.515256 2.35965 2.12404 5.59639 35.1888 




0.0124648 0.0646716 0.250079 0.764107 0.597008 10.0218 




0.01 0.0434377 0.0325316 0.01 0.399188 8.03291 




0.01 0.0390279 0.01 0.01 0.01 7.99589 




0.01 0.01 0.133382 0.01 0.774153 7.95051 




0.00946454 0.380167 1.40706 0.950798 1.56343 7.47509 




0.0301611 0.721373 0.243605 0.382005 0.318709 23.773 




0.01 0.213832 0.01 0.025143 0.130499 7.86062 




0.01 0.0679817 0.01 0.01 1.13074 7.83955 




0.0157974 0.01 0.479023 0.01 0.448702 12.3581 




0.0179002 0.523353 0.648548 0.0704055 0.235224 13.9818 




0.01 0.01 0.0605611 0.01 1.08165 7.81028 




0.0380265 0.761065 0.855481 0.456399 1.07927 29.6357 




0.01 0.0563414 0.0195127 0.0334028 0.178047 7.77145 




0.041471 0.188284 0.160885 2.57718 1.16511 32.02 




0.01 0.837504 0.0807039 1.08326 0.738707 7.70438 




0.01 0.01 0.01 0.01 0.059592 7.64531 




1.11836 13.6844 17.1692 10.4757 16.1781 853.915 




0.01 0.01 0.01 0.01 0.792964 7.62972 




0.01 0.18103 0.263957 0.0775404 1.1777 7.58526 
   150 




0.01 0.01 0.01 0.0571319 0.01 7.56926 




0.0115145 0.01 0.01 0.01 0.403915 8.67022 




0.01 0.0318122 0.01 0.0121261 0.01 7.50229 




0.0806048 2.48719 1.31349 1.33173 3.46652 60.3335 




0.0111563 0.500057 0.24516 0.0981203 0.570013 8.066 




0.01 0.01 0.01 0.01 0.01 7.21035 




0.01 0.0557734 0.0350996 0.0986597 0.52386 7.19452 




0.0494332 0.024009 0.127053 0.115144 0.703182 35.1896 




0.01 0.01 0.210534 0.01 0.01 7.11816 




0.01 0.01 0.01 0.01 0.01 7.07767 




0.01 0.01 0.01 0.00941251 0.01 7.07141 




0.0824899 0.249263 0.199324 0.29522 6.82489 58.2594 




0.01 0.0253212 0.193975 0.0896746 0.218583 6.99599 




0.01 0.01 0.01 0.01 1.05323 6.90523 




0.01 0.01 0.0602039 0.177128 0.84347 6.87916 




0.01 0.01 0.675488 0.470626 0.01 6.86547 




0.01 0.01 0.01 0.01 0.01 6.76581 




0.0116592 0.01 0.0283383 0.01 0.251324 7.87009 




0.0595737 0.516121 2.35726 0.780896 7.1109 39.5714 




0.01 0.01 0.01 0.01 1.27909 6.61165 




0.01 0.01 0.01 0.242884 0.160122 6.59891 




0.01 0.01 0.0694615 0.0122417 0.01 6.59212 
   151 




0.01 0.01 0.01 0.0168019 0.146585 6.57123 




0.01 0.01 0.0224527 0.105737 1.21228 6.51505 




0.0196603 0.01 0.01 0.01 1.52717 12.7118 




0.01 0.0487151 0.158209 0.0625108 0.244915 6.4363 




0.01 0.01 0.0756264 0.0332451 0.01 6.43215 




0.01 0.01 0.01 0.01 0.0277428 6.43089 




0.0358801 0.634718 3.11839 0.256737 0.964568 22.8852 




0.01 0.01 0.01 0.01 0.304889 6.34772 




0.01 0.01 0.0231982 0.245685 0.837612 6.30107 




0.01 0.608563 0.272169 0.369692 0.542648 6.26157 




0.01 0.0328691 0.0490856 0.0348727 0.160697 6.21935 




0.01 0.01 0.01 0.01 0.01 6.19652 




0.01 0.01 0.01 0.0267812 0.37332 6.16519 




0.00785386 0.01 0.01 0.01 0.113732 4.7968 




0.01 0.01 0.0489368 0.01 0.750142 6.08671 




0.01 0.01 0.01 0.01 0.01 6.02784 




0.01 0.01 0.01 0.01 1.01404 6.00002 




0.01 0.0597289 0.0164386 0.01 0.0915922 5.99823 




0.01 0.01 0.01 0.01 0.190414 5.93804 




0.01 0.01 0.01 0.01 0.165006 5.92583 




0.01 0.01 0.01 0.01 0.01 5.91708 




0.01 0.01 0.01 0.01 0.551027 5.90632 
   152 




0.01 0.310764 0.140869 0.714734 0.459709 5.8955 




0.057792 1.1605 0.432445 0.362332 7.48143 33.906 




0.01 0.01 0.164653 0.0434671 0.01 5.79475 




0.01 0.01 0.0265832 0.01 1.10054 5.78149 




0.0366091 0.0376406 0.0767774 0.113989 0.790166 21.0543 




0.01 0.01 0.325035 0.01 0.0909019 5.70545 




0.01 0.01 0.0519472 0.01 0.371745 5.70267 




0.0401613 0.01 0.0277258 0.00414771 0.91026 22.8219 




0.01 0.01 0.01 0.0122755 0.179691 5.65614 




0.0105829 0.419186 0.345153 0.302395 0.444511 5.98129 




0.01 0.01 0.01 0.01 0.0308711 5.62301 




0.01 0.270416 0.124115 0.01 0.356871 5.61353 




0.0877782 0.225438 0.257998 0.410188 6.8076 49.2106 




0.01 0.01 0.01 0.0576565 0.790511 5.59612 




1.46894 2.39932 7.92998 1.52036 21.3263 820.118 




0.01 0.01 0.01 0.01 0.133879 5.50128 




0.915624 0.982124 0.595273 0.392487 3.04283 500.899 




0.01 0.01 0.01 0.01 0.01 5.45406 




0.0237755 0.01 0.01 0.206475 0.382198 12.9256 




1.36456 57.4104 96.4527 131.837 107.425 735.013 




0.00944056 0.242886 0.295283 0.01 0.302259 5.03127 




0.01 1.21138 1.13626 0.380008 0.624844 5.18876 
   153 




0.01 0.01 0.110236 0.01 0.241698 5.18616 




0.01 0.118666 0.700193 0.402842 0.433875 5.146 




0.01 0.01 0.01 0.01 1.07665 5.13859 




0.01 0.01 0.01 0.01 0.01 5.12586 




0.01 0.740717 0.896035 0.903741 0.122785 5.08002 




0.01 0.01 0.0211783 0.01 0.01 5.07596 




0.01 0.01 0.01 0.01 0.01 5.04816 




0.01 0.01 0.245705 0.01 0.01 5.03951 




0.01 0.01 0.01 0.01 0.01 5.02453 




0.01 0.01 0.01 0.01 0.01 4.97803 




0.0402226 0.0213688 0.186586 0.0686912 0.531973 19.999 




0.01 0.01 0.01 0.01 0.01 4.94833 




0.01 0.01 0.0237342 0.01 0.141267 4.92261 




0.01 0.0952256 0.611244 0.0681692 0.648126 4.87265 




0.872413 23.6482 12.5574 13.2213 50.354 422.754 




0.01 0.343367 0.26686 0.124254 0.75221 4.78447 




0.01 0.01 0.034328 0.0152094 0.0657928 4.75918 




0.01 0.0290789 0.0812769 0.136583 0.0730623 4.72282 




0.01 0.01 0.220248 0.01 0.0652293 4.64785 




0.01 0.01 0.01 0.14548 0.01 4.64493 




0.01 0.01 0.0323281 0.01 0.368898 4.64046 




0.01 0.01 0.01 0.01 0.01 4.63171 
   154 




0.01 0.01 0.0204337 0.01 0.01 4.63019 




0.01 0.01 0.01 0.117003 0.334722 4.58742 




0.01 0.182265 0.11021 0.0294499 0.348533 4.55534 




0.0323576 0.155385 0.487058 0.01 0.01 14.7395 




0.01 0.01 0.01 0.363504 0.01 4.53402 




0.01 0.01 0.01 0.09232 0.68059 4.50522 




0.104942 0.01 0.277653 0.01 0.01 47.0509 




0.035091 0.01 0.163724 0.01 1.87427 15.5013 




0.01 0.0329542 0.109353 0.00937108 0.01 4.3398 




0.01 0.01 0.01 0.054175 0.104787 4.27594 




0.01 0.01 0.0590265 1.00696 0.0889161 4.16435 




0.0440889 0.208122 0.121445 0.169336 4.24552 18.3196 




0.0910557 3.34058 4.02445 3.24927 1.23556 37.3978 




0.01 0.106151 0.0778368 0.01 0.282408 4.08389 




0.0157598 0.0271545 0.118937 0.192064 0.394788 6.41409 




0.158197 2.24574 2.13004 5.67419 15.0781 64.0115 




0.01 0.126796 0.116331 0.0439436 0.448174 4.04377 




0.01 0.01 0.386888 0.0943398 0.156971 4.01648 




0.0146095 0.173111 0.486732 0.107254 0.108593 5.82487 




0.022237 0.01 0.01 0.01 0.808803 8.82032 




0.01 0.0134043 0.02902 0.0103286 0.311411 3.96486 




0.551648 16.0039 25.9825 16.7681 4.80806 218.589 
   155 




0.0264673 0.0270661 0.0761567 0.0244682 0.13797 10.4847 




0.0381807 0.406159 1.15395 0.320889 1.63929 15.0528 




0.00726071 0.01 0.01 0.0567055 0.413522 2.85696 




0.01 0.01 0.01 0.01 0.01 3.9264 




0.01 0.01 0.0313675 0.01 0.183039 3.88522 




0.01 0.01 0.01 0.01 0.01 3.8732 




0.208121 1.89726 0.649926 1.7602 14.6136 80.344 




0.01 0.120524 0.113291 0.01 0.01 3.85982 




0.01 0.01 0.117734 0.01 0.01 3.83011 




0.01 0.01 0.01 0.01 0.01 3.82974 




0.01 0.01 0.01 0.01 0.01 3.79509 




0.3351 0.01 0.0220149 0.165152 1.74289 126.979 




0.0219707 0.01 0.01 0.01 0.171282 8.28519 




0.01 0.01 0.01 0.01 0.01 3.7483 




0.01 0.0601025 0.234618 0.01 0.01 3.74311 




0.01 0.01 0.01 0.01 0.115257 3.73196 




1.19137 5.88702 17.3367 33.743 35.3318 444.491 




0.01 0.01 0.139796 0.202797 0.200819 3.706 




0.0539543 1.62776 2.56282 2.1598 2.39832 19.9833 




0.0121752 0.0304104 0.214328 0.0297833 0.159245 4.49035 




0.01 0.01 0.01 0.01 0.01 3.66382 




0.01 0.01 0.0563402 0.01 0.325473 3.62145 
   156 




0.0863776 0.467627 0.538906 0.295752 1.63425 30.8696 




0.0401681 0.01 0.0126349 0.01 0.652243 14.3361 




0.0771258 0.636684 1.344 0.85595 1.71936 27.4938 




0.0226022 0.0900832 0.695674 0.331394 0.955042 8.05282 




0.01 0.01 0.01 0.01 0.0553399 3.54214 




0.0503496 0.01 0.01 0.01 0.677026 17.7409 




0.0163554 0.01 0.136977 0.0192034 0.621201 5.72447 




0.01 0.01 0.01 0.01 0.0396074 3.32756 




0.038128 0.145242 0.44512 0.0918992 0.42347 12.6524 




0.01 0.01 0.0700708 0.01 0.453079 3.30938 




0.0305585 0.0968968 0.192362 0.492381 0.803506 10.11 




0.0684813 0.0362108 0.0652011 0.0180636 0.242138 22.4499 




0.01 0.261917 0.0867483 0.026594 0.249808 3.26259 




0.01 0.01 0.0138455 0.309046 0.122177 3.25505 




0.0344614 0.467631 0.223963 0.162047 2.15404 11.2062 




0.01 0.132072 0.213537 0.0498924 0.529606 3.24348 




0.01 0.01 0.01 0.01 0.01 3.24037 




0.01 0.01 0.01 0.01 0.01 3.20708 




0.101073 0.535429 1.92822 4.97356 3.80975 32.2922 




0.01 0.0482197 0.123107 0.0140628 0.237435 3.16448 




0.01 0.01 0.01 0.01 0.01 3.15016 




0.0255038 0.0965773 0.163666 0.00798854 0.0186771 8.03313 
   157 




0.01 0.01 0.157693 0.36221 0.151617 3.14689 




0.203088 0.847371 0.761118 1.86633 9.20359 63.5532 




0.01 0.01 0.0188337 0.01 0.01 3.11426 




0.01 0.0731555 0.022493 0.0674286 0.133879 3.11293 




0.01 0.01 0.01 0.01 0.01 3.11114 




0.0198507 0.01 0.0886737 0.0717375 1.15189 6.16778 




0.01 0.01 0.01 0.01 0.01 3.10635 




0.01 0.01 0.01 0.01 0.01 3.08173 




0.0189057 0.0971114 0.01 0.01 0.794823 5.80805 




0.01 0.01 0.01 0.01 0.284298 3.05271 




0.0176212 0.01 0.01 0.0826927 1.23598 5.37641 




0.0638864 0.316005 0.462921 0.17757 1.06046 19.4391 




0.599676 18.0435 14.875 8.14858 8.70149 181.968 




0.0605645 0.141785 0.0978116 0.190057 1.22921 18.3648 




0.01 0.0131203 0.0135732 0.260396 0.237029 2.99157 




0.01 0.01 0.111378 0.01 0.01 2.98669 




0.0111865 0.0289336 0.585111 0.163261 0.160656 3.29269 




0.01 0.01 0.01 0.01 0.01 2.93553 




0.00924814 0.104158 0.119075 0.01 0.0326102 2.6944 




0.01 0.01 0.12185 0.004182 0.01 2.90624 




0.130946 0.683286 0.327667 0.154559 3.99512 37.8567 




0.01 0.01 0.01 0.01 0.01 2.89097 
   158 




0.01 0.01 0.01 0.01 0.01 2.88836 




0.01 0.01 0.01 0.01 0.01 2.88694 




0.01 0.01 0.01 0.01 0.01 2.86523 




0.01 0.01 0.01 0.01 0.01 2.86075 




0.01 0.0553088 0.103045 0.381122 0.1857 2.82003 




0.0359463 0.100577 0.160775 0.0827114 0.514776 10.1188 




0.236805 1.52832 6.41918 7.82336 11.0712 66.5478 




0.0369803 0.265167 0.649348 0.105981 1.12359 10.3703 




0.0457113 0.144398 0.154452 0.489605 0.549145 12.7619 




0.01 0.01 0.01 0.01 0.01 2.74791 




0.01 0.0223245 0.0377307 0.124248 0.0786573 2.73349 




0.01 0.01 0.01 0.01 0.171575 2.73261 




0.0533829 0.563381 0.355999 1.65548 2.63276 14.4294 




0.0552357 0.348413 0.52704 0.388321 0.976063 14.9261 




0.01 0.01 0.01 0.01 0.225132 2.69355 




0.0488844 0.0188683 0.0161054 0.234968 2.67271 12.9333 




0.0767534 0.807158 2.15973 1.16114 3.02543 20.2959 




0.603275 22.3934 25.1537 4.72532 3.94108 159.102 




0.266994 0.566732 2.01127 3.97511 8.29002 70.1839 




0.01 0.0901647 0.0739306 0.2425 0.184839 2.61534 




0.0625357 0.0493532 0.0438259 0.00773735 0.01 16.3193 




0.0426521 0.01 0.0605164 0.01 1.54533 10.7522 
   159 




0.0461769 0.271123 0.152902 0.214324 1.80122 11.6088 




0.0769442 0.135713 0.179619 0.105264 0.168714 18.7355 




0.0519914 0.509475 0.0475527 0.0284489 0.0431388 12.6368 




1.74327 15.8035 8.71454 5.13383 25.6122 416.096 




0.118564 0.119141 0.445621 0.0956563 5.63235 28.0386 




0.0914935 0.0424903 0.240224 0.268008 0.310414 21.4445 




0.198864 0.331711 3.14197 1.91286 4.52261 46.1949 




0.0998798 0.191095 1.57943 0.668772 2.57097 23.0414 




0.129661 0.01 0.01 0.01 0.01 29.6472 




0.0748345 0.403168 0.176895 0.579406 0.132031 17.0522 




0.0214447 0.104516 0.129063 0.482139 0.164665 4.87779 




0.236108 0.433559 4.86233 1.29929 10.2852 53.5576 




0.138708 0.289152 0.335812 0.160979 0.407543 31.2444 




0.138954 0.01 0.033764 0.01 0.589122 30.9937 




0.0235823 0.221205 0.13376 0.01 0.53184 5.21074 




0.750315 1.08727 1.59222 0.358536 2.21635 163.534 




0.0177967 0.043767 0.270115 0.0767016 0.133936 3.86177 




0.0682674 0.72768 0.812066 1.95587 1.06207 14.7503 




0.0410008 1.01774 0.411696 0.516132 0.813543 8.8458 




0.0381376 0.129796 0.272929 0.106746 0.164203 8.19149 




0.0562247 0.115731 0.768194 0.141699 0.501875 11.887 




0.16166 0.332671 0.874366 1.19141 4.68166 33.8973 
   160 




0.287085 3.98769 4.76843 3.29885 0.771365 58.924 




0.0713674 0.781633 1.6348 0.185744 2.03862 14.5885 




0.0541245 0.193966 0.201712 0.0843304 0.910827 11.0478 




0.0437557 0.465977 0.42079 0.827469 0.893219 8.91376 




0.109204 0.422439 0.558874 1.76518 0.38375 21.9397 




0.0238629 0.651249 0.0797507 0.165227 0.595652 4.71124 




0.0240069 0.0292935 0.00792324 0.0952427 0.167678 4.73579 




0.060389 0.571503 1.14375 0.223553 0.557111 11.8582 




0.390804 0.731606 1.13568 1.0544 2.86544 76.6535 




0.340672 1.91419 4.24313 0.996163 7.25847 65.8498 




0.0226811 0.249003 0.192592 0.576751 0.688466 4.33916 




0.0343005 0.00777069 0.0889726 0.01 0.468088 6.5442 




0.133043 0.710087 1.72821 1.61084 3.77609 25.1448 




0.0543148 0.01 0.0888274 0.55934 1.89301 10.241 




0.0476835 0.369186 0.0430125 0.141468 1.42778 8.98107 




0.040544 0.23075 0.134063 0.141489 0.401807 7.60338 




0.192712 0.350548 0.442089 0.171191 3.33376 35.9402 




0.109564 0.137112 0.0421144 0.01 0.0821708 20.2811 




0.0798108 0.693758 0.242064 0.188922 0.538271 14.6978 




0.124907 0.591773 1.39266 0.514022 4.895 22.7068 




1.37397 15.1755 21.1213 12.6791 22.7366 248.173 




0.413002 3.53246 3.48427 3.92339 13.3861 74.286 
   161 




0.0183924 0.138405 0.01 0.0267456 0.0750173 3.29367 




0.0488674 0.240948 0.474846 0.40721 1.19192 8.69165 




0.0690516 1.37202 1.28486 0.932895 0.632227 11.8253 




0.0198949 0.01 0.01 0.01 0.01 3.40428 




0.0685739 0.51088 0.545288 0.548911 0.139042 11.6641 




0.13676 0.446875 0.493006 0.01 0.416214 22.9963 




0.0631428 0.01 0.01 0.01 1.29797 10.5043 




0.0703929 0.663327 1.4707 0.384535 2.09282 11.6528 




0.058597 0.242861 0.187864 0.400709 1.2903 9.58574 




0.0623263 0.162578 0.124018 0.0142002 0.903707 10.104 




0.0246466 0.0996398 0.0909412 0.105337 0.483941 3.9742 




0.364267 0.417895 0.0827995 0.277171 11.3891 58.3613 




0.489643 0.399757 0.207378 0.95148 3.32306 78.3142 




0.0297403 0.01 0.01 0.01 0.478319 4.70511 




0.380868 2.24704 6.26103 3.82262 6.18676 59.7422 




4.06354 47.7655 84.9509 77.4635 100.947 634.15 




0.0406009 0.0305698 0.215434 0.0621195 0.0494249 6.3016 




0.351519 2.42952 10.5647 5.8408 4.46454 54.2797 




0.20792 1.44609 0.13249 0.654351 5.95956 31.6799 




0.206795 0.10492 0.511129 0.548688 0.770785 31.0461 




1.73844 58.4442 61.9791 43.269 39.5704 260.866 




0.0644318 0.121665 0.485547 1.11781 0.420869 9.48427 
   162 




0.182601 0.01 0.01 0.01 0.0395382 25.7223 




0.151685 1.38577 0.01 1.46542 1.56166 21.3227 




0.173749 0.0451797 0.0912877 0.0707248 2.33965 24.3503 




0.0238634 0.01 0.01 0.0819678 0.0292729 3.28852 




0.142461 0.589441 1.3818 0.817523 4.03082 19.368 




0.19513 0.01 0.01 0.01 0.01 26.3299 




0.151432 0.50466 0.128085 0.0554075 0.18931 20.1963 




0.13788 0.01 0.01 0.0866243 0.01 18.3351 




0.0292408 0.63368 0.094415 0.214272 0.167158 3.87321 




0.0401365 0.124701 0.343076 0.203281 0.491563 5.3085 




6.98894 24.273 60.9898 20.9283 33.3896 917.755 




0.148476 0.733841 1.64764 0.896457 3.55417 19.2493 




1.31244 7.7556 6.92798 2.52449 5.81889 167.011 




1.45245 8.04552 13.0062 15.2914 17.5947 184.445 




0.266183 0.01 0.566676 0.057891 0.614975 33.7045 




0.114264 0.0274419 0.0376707 0.01 0.630674 14.4245 




0.157064 0.545902 0.469172 1.15532 3.70854 19.6473 




0.28333 1.66422 2.99204 2.30945 8.7062 35.3495 




0.0362826 0.01 0.0726994 0.01 0.126943 4.47791 




0.230793 1.19904 1.13489 0.852498 3.19071 28.3284 




0.0945526 0.0209855 0.0293721 0.175317 1.15905 11.5791 




0.129696 0.696933 0.360558 1.45566 2.79942 15.8788 
   163 




0.157242 0.388542 0.269976 0.468942 1.2537 19.1428 




0.239534 0.01 0.557343 0.0538197 0.588361 28.6024 




0.0291014 0.01 0.0209332 0.01 0.01 3.43206 




0.0306271 0.01 0.229285 0.01 0.415601 3.6081 




1.60929 15.2464 8.65848 12.4228 19.2518 184.411 




0.154704 0.163353 0.112408 0.170268 0.758719 17.7018 




0.159159 0.497737 2.13468 1.17217 2.424 17.7406 




0.0967804 0.585066 0.844915 0.32128 0.170614 10.59 




1.55466 9.6993 15.3702 5.58213 13.0988 169.233 




0.687367 0.385397 0.185067 0.0717918 2.70446 74.2134 




0.181566 0.922178 0.481856 0.718222 0.0645878 19.5848 




0.169768 0.0966616 0.171976 0.733388 1.61053 18.2985 




0.718273 1.00409 0.482672 0.143513 6.58458 77.3963 




0.458726 1.56464 1.94902 4.99119 5.20957 49.3695 




0.0704253 0.47356 0.205053 0.199346 0.495976 7.5726 




0.119732 0.0268346 0.167492 0.627036 0.433542 12.7906 




0.895563 3.35902 6.53785 14.0201 9.78754 95.5509 




0.369612 0.503883 1.10529 1.017 2.27124 39.2162 




0.176613 0.125511 1.30831 0.346958 0.287444 18.6974 




0.0914293 0.01 0.01 0.01 0.01 9.65121 




0.135623 0.27663 0.110493 0.0646024 0.503108 14.3093 




0.129994 0.0791094 0.274655 0.38444 0.880614 13.5767 
   164 




0.0418774 0.01 0.0156565 0.01 0.0465943 4.343 




0.0782837 0.066988 0.0955009 0.743433 1.00395 8.11724 




0.0854133 0.01 0.143971 0.0501856 1.05551 8.85062 




0.257401 0.813874 1.10048 0.61234 1.63641 26.2865 




0.0454668 0.176722 0.01 0.01 0.583086 4.64251 




0.482364 0.473689 2.19631 6.94706 4.94396 48.6363 




1.2596 7.06855 12.5161 14.1922 26.2207 125.943 




0.0319289 0.01 0.270069 0.0483294 0.379925 3.17865 




0.0951732 0.8871 1.03333 0.981701 0.317241 9.45471 




0.138447 0.631278 0.278626 0.415451 1.13855 13.7041 




0.565071 0.249298 0.779131 0.175202 1.69321 55.9014 




0.474006 0.34185 0.707437 5.37191 2.15659 46.2263 




0.206289 0.378449 0.187038 0.246425 0.50619 19.5238 




4.81027 14.7734 16.0502 12.0078 20.5876 454.914 




0.658459 0.335625 2.48802 0.40081 9.49716 61.6758 




0.204253 0.480169 0.413319 0.308034 0.730152 19.0034 




0.07972 0.600778 0.0849665 0.543233 0.299035 7.41607 




0.0442381 0.118458 0.161556 0.0261625 0.13097 4.08787 




0.124782 0.390245 0.510131 0.689026 2.42082 11.5235 




0.269539 1.23631 5.23371 1.86877 4.74375 24.6872 




0.541194 0.403987 0.01 0.0409629 1.16327 49.4719 




0.076409 0.252494 0.364059 0.232674 0.346357 6.87171 
   165 




0.199689 0.8925 3.25379 1.81062 2.65438 17.8675 




0.121701 0.340996 0.01 0.201532 0.202129 10.764 




0.884025 1.49213 6.47674 2.57951 7.98601 77.4131 




0.109051 0.235474 0.800532 0.898044 0.621905 9.52618 




0.034489 0.0981654 0.192822 0.01 0.214493 2.99057 




0.0598262 0.294866 0.68606 0.152751 0.462685 5.17695 




0.0551009 0.589125 0.460319 0.382576 0.271128 4.6964 




0.302628 2.66999 3.26457 0.57223 3.22629 25.5841 




0.55509 0.989692 0.337537 0.622893 6.24298 45.8797 




0.113297 0.101794 0.156313 0.110711 0.622243 9.28719 




0.135559 0.142655 0.269701 0.193173 0.640773 11.0666 




0.496673 1.69846 3.30761 3.56136 3.28162 40.499 




0.262169 1.41917 0.761656 0.927014 0.249339 21.2576 




0.108055 0.234473 0.929547 1.22399 1.65107 8.75388 




0.0576183 0.417029 0.841811 0.286296 0.896866 4.66027 




0.146985 0.347287 0.713137 0.522036 1.98584 11.647 




0.248162 0.882765 1.98357 1.61035 1.09585 19.632 




0.0671834 0.139602 0.562722 0.0742935 0.542755 5.26807 




1.78051 2.21879 4.41841 3.26121 4.66117 139.208 




0.0486843 0.0265443 0.0540751 0.01 0.270646 3.80313 




0.214577 0.844306 1.54502 0.84778 1.90594 16.5711 




0.110319 0.0279923 0.112096 0.0574526 1.19913 8.46104 
   166 




0.106271 0.032598 0.091906 0.0642083 0.0287704 8.13404 




0.315545 0.560934 0.822549 0.701084 0.379377 24.0001 




0.0951293 0.01 0.01 0.01 0.0640613 7.20908 




0.911455 3.16767 13.4322 5.98265 17.1906 68.9431 




0.0570563 0.259264 0.0763567 0.227416 0.339066 4.25046 




0.0859828 1.18951 1.50852 0.564664 1.13566 6.38722 




0.40537 0.01 0.01 2.18406 0.512365 30.0724 




0.209199 0.01 0.01 0.01 0.10084 15.4749 




0.093005 0.0526291 0.312841 0.01 0.905634 6.74664 




0.566395 1.65968 5.80078 5.62827 9.5451 40.6766 




0.135345 0.424548 0.660729 0.218586 0.112251 9.69825 




4.14491 11.4421 29.2708 9.9517 17.7109 293.504 




0.386518 0.828966 0.966533 0.761117 0.854542 27.311 




0.279769 0.272497 0.430358 0.0864709 3.75234 19.6161 




0.615413 1.03725 3.08027 0.332334 1.53919 43.0239 




0.1345 0.238729 0.0720756 0.0167669 0.315451 8.82432 




6.33193 4.47492 13.4472 28.9564 70.9735 407.279 




0.359133 0.284018 0.479706 0.214467 2.87869 22.7397 




0.174728 1.18446 2.53303 1.04087 2.33125 10.9941 




0.355035 0.28221 0.362505 0.358038 0.584624 22.2654 




0.19745 0.210118 1.10945 2.59044 2.8175 12.1213 




0.304161 0.751699 1.78614 1.39516 2.95266 18.5556 
   167 




1.19537 6.64119 12.7234 8.75398 5.2022 72.8005 




0.107008 0.515208 0.316734 0.604945 1.09628 6.50421 




0.0880563 0.208427 0.253312 0.142538 0.237818 5.25455 




0.442667 1.26824 3.75774 2.47784 2.5413 26.2504 




2.38947 6.84554 4.5951 17.5738 27.3791 140.801 




0.390253 1.53944 3.17905 2.41414 3.69483 22.4632 




0.216237 0.366111 1.14439 0.838796 2.98304 12.2489 




0.631426 2.50576 3.18054 2.91785 0.252161 35.7311 




0.101875 0.01 0.01 0.01 0.32929 5.70629 




0.553288 0.153598 0.424557 0.496592 1.1666 30.9574 




0.109329 0.703354 0.688464 1.21801 1.27536 6.03103 




0.153692 0.413421 0.121002 0.254887 0.646578 8.45608 




0.497449 1.59463 3.45016 3.1882 5.53053 27.3316 




0.288376 0.460957 1.29805 0.54666 0.995557 15.7875 




0.615756 0.909903 0.353995 1.44351 3.10026 33.5546 




0.193286 1.88128 1.63759 2.44547 1.07202 10.4022 




1.30207 0.417214 1.66236 0.324865 1.87078 69.5865 




1.69962 2.2373 2.24936 3.46069 4.61502 90.2456 




0.229634 0.786522 0.840249 0.658789 1.89371 12.1608 




0.381781 4.80076 1.55196 1.46912 1.31302 20.1361 




0.188273 0.01 0.379854 0.214595 0.496562 9.91167 




0.174677 0.260683 0.414013 0.42642 0.614858 8.98791 
   168 




0.673115 1.58465 0.357656 0.13986 0.234057 34.3207 




0.0933595 0.163576 0.429997 0.01 0.384774 4.73127 




4.10142 4.13923 2.71312 2.27586 12.9715 207.412 




1.51828 5.17325 5.74116 3.08182 2.55793 76.6821 




0.123624 0.245477 0.0968268 0.796101 0.290735 6.15207 




1.60332 0.074673 0.0957373 0.0742738 4.48299 79.6491 




0.108206 0.346498 0.941131 0.2175 0.870158 5.16471 




0.721933 1.52763 1.5547 1.89937 0.636621 34.4275 




4.36615 3.96562 2.74684 6.36164 7.6656 207.858 




5.83652 9.93173 28.0443 27.5787 49.7144 277.673 




0.617765 0.791178 0.787238 0.333102 6.45657 29.3446 




0.0676304 0.639715 0.563447 0.465318 0.0908824 3.15035 




0.434977 0.217811 1.23868 0.858433 3.52594 20.125 




0.586528 0.569456 0.724989 0.541761 4.22604 27.1007 




0.138345 0.114895 0.440484 0.059516 0.032 6.38279 




0.57574 1.64854 3.27136 1.7603 2.5722 26.5518 




0.494086 0.837372 1.01003 0.321387 0.333204 22.6606 




0.281043 0.835906 1.15134 0.596895 1.08769 12.8503 




0.130456 0.252885 0.162282 0.149193 0.375003 5.95363 




0.0973115 0.0746565 0.20534 0.234814 0.294784 4.40506 




0.225348 0.531812 1.22922 1.26446 2.22837 10.1336 




0.623848 0.395986 1.04716 2.30908 1.97007 28.0488 
   169 




0.105899 0.488156 0.450283 0.0575122 0.280623 4.72629 




0.264206 0.203069 0.6411 1.08285 2.55851 11.5669 




0.453166 2.81364 1.78342 3.85438 2.53768 19.8372 




1.97404 4.34034 7.28399 2.89096 7.11894 86.3932 




0.0775689 0.430043 0.201284 0.0623028 0.151672 3.39167 




0.113589 0.01 0.0846455 0.209375 0.06023 4.94742 




0.0954682 0.01 0.301062 0.338662 0.0622224 4.12975 




0.250498 2.5775 2.42245 1.7909 2.40354 10.8356 




0.304819 1.40652 1.07178 0.186522 0.530228 13.1113 




0.067594 0.0979198 0.242005 0.0907349 0.215938 2.79648 




0.0848767 0.0944862 0.103672 0.138682 0.436523 3.49742 




1.20674 1.02258 0.759223 0.75346 0.705396 48.9668 




0.121782 0.243136 0.312003 0.167127 0.497767 4.88728 




0.831401 1.95651 3.91548 3.75603 5.70792 33.3204 




0.0910943 0.0831576 0.705637 0.228605 0.652121 3.65028 




0.547463 2.1591 2.67585 3.16207 3.06909 21.9352 




0.102862 0.192553 0.662154 0.593163 0.145164 4.11161 




0.867909 0.632535 0.069338 0.0917709 2.33899 34.6778 




0.218727 0.436814 1.07587 1.81818 0.611104 8.70364 




0.58516 0.120761 0.0691496 0.560689 3.58022 23.0204 




0.585453 0.290457 0.514348 0.383553 0.654133 23.0118 




0.152961 0.01 0.319487 0.01 0.01 6.0094 
   170 




0.367519 0.217348 0.427382 0.49312 1.13883 14.1036 




0.102996 0.01 0.0725699 0.01 0.01 3.89418 




0.194522 0.01 0.161984 0.01 0.381265 7.31161 




1.31263 2.31276 2.52989 1.90761 1.24035 48.8718 




0.187654 0.232355 0.154353 0.139522 0.224129 6.97393 




0.103714 0.392586 0.0578161 0.158196 0.0478686 3.83661 




0.276857 0.81593 1.11654 0.889347 1.03019 10.2405 




0.0969528 0.190141 0.693494 0.413905 0.257288 3.57609 




0.172795 1.405 0.81631 0.542587 0.242642 6.3667 




3.45732 5.22109 6.10716 4.97877 12.6544 126.354 




4.42794 6.92524 5.14284 8.03667 5.74171 161.537 




0.473698 1.05185 1.15733 0.91828 3.55853 17.2348 




0.43293 0.94157 1.58078 0.651254 1.52251 15.5872 




0.248739 0.228849 0.221369 0.243058 0.608308 8.84117 




0.474663 0.884837 0.950605 0.667807 0.152504 16.8556 




0.295555 0.569562 0.194401 0.155071 0.41604 10.4827 




0.106551 0.222824 0.289505 0.176083 0.722748 3.76818 




1.90166 4.93903 3.63902 3.60054 3.04414 67.2136 




0.202029 0.264179 0.127653 0.370731 0.993765 7.13259 




0.14087 0.307589 1.03873 0.432348 0.894699 4.95836 




0.189388 0.375598 0.61841 0.337904 1.17845 6.60229 




0.206291 0.306652 0.232915 0.188684 0.957863 7.12828 
   171 




0.896233 0.0256198 0.0833672 0.0187017 0.552409 30.8628 




6.68949 22.739 50.5006 10.6229 30.9177 228.339 




0.252313 0.242087 0.30355 0.01 1.61272 8.5364 




3.53955 5.33943 13.2431 18.4872 29.7262 119.015 




0.551418 0.796113 1.4321 1.90168 2.44145 18.4171 




0.203389 0.589418 0.310954 0.0492675 0.383167 6.75037 




1.49822 2.01834 3.46767 6.265 4.22279 49.6212 




0.218484 0.078068 0.01 0.0802688 0.701365 7.05234 




0.104652 0.170909 0.01 0.01 0.288573 3.36806 




0.31246 1.3321 0.705749 1.0513 0.967544 10.0118 




0.163782 0.0305465 0.0436193 0.205659 0.0935126 5.2455 




3.56045 0.510429 0.0890317 0.116317 0.278599 112.38 




1.61333 3.79292 3.19386 0.929309 3.35126 50.4509 




0.388098 0.920753 0.902248 0.563189 1.53099 12.1014 




0.667828 0.01 0.350715 0.505377 1.15766 20.5628 




0.11341 0.0974158 0.182983 0.0304218 0.15984 3.46287 




0.112856 0.209176 0.461248 0.151466 0.597583 3.38383 




5.26575 6.39084 15.6871 12.5138 14.7192 156.058 




0.133368 0.361184 0.493933 0.616899 0.471913 3.90837 




0.12682 0.195066 0.310995 0.138691 0.239954 3.64295 




3.47487 12.3768 10.6256 4.59775 2.69766 99.6423 




0.335834 0.837766 0.393963 1.02989 0.798104 9.60685 
   172 




0.466349 0.730313 1.03177 0.158463 1.52035 13.2893 




22.9836 46.753 44.2077 35.0794 104.423 652.332 




0.388934 0.460552 1.7398 0.864759 0.916755 11.0335 




0.708005 1.54475 2.27209 0.211323 4.61186 19.8998 




0.212157 0.349481 0.396816 0.118192 0.453488 5.94579 




2.80295 4.6803 8.6705 3.66819 10.1112 78.1986 




1.20241 3.92274 5.42867 4.97577 5.60696 33.5309 




3.7593 12.8166 17.8042 14.3083 24.4073 104.144 




1.00322 2.83183 0.798156 0.34187 1.14687 27.6761 




0.843938 0.750204 0.0411464 0.01 0.01 23.1534 




2.16272 2.07885 1.57038 1.65466 4.0014 59.1111 




0.923614 1.97228 3.05859 3.18886 5.2224 25.1606 




0.510327 1.60256 0.64187 2.61063 0.490285 13.5775 




0.132181 0.0912502 0.124996 0.297407 0.485524 3.50176 




0.325347 1.48451 1.40466 0.266147 0.320126 8.58073 




2.00285 3.76622 12.5973 4.05549 7.4875 52.1724 




0.561002 1.70551 0.533474 0.743093 1.18847 14.3526 




0.208503 0.164634 0.455918 0.726541 0.771999 5.33327 




0.423449 0.31841 0.155623 0.459091 0.583348 10.8007 




1.24734 7.35595 6.0394 2.10054 4.91084 31.4737 




8.80296 18.6253 37.0723 29.6463 22.5345 220.142 




0.321108 0.171343 1.32805 0.466109 0.463372 8.01038 
   173 




11.3922 9.5871 12.9993 9.9238 13.1582 283.942 




0.492449 1.42055 2.15595 1.81898 0.505613 12.2653 




17.8702 39.2639 59.5702 48.7298 70.1072 442.448 




0.233276 0.0734679 0.01 0.01 0.0672255 5.66005 




0.929268 0.903935 4.63168 3.61879 4.87853 22.4725 




2.26604 2.6795 6.71058 8.74689 11.7562 54.5338 




0.179074 0.01 0.01 0.01 0.521638 4.2968 




0.676912 0.13588 0.0746915 0.26836 0.464768 16.016 




6.83392 0.799906 0.192582 1.76528 18.209 159.66 




0.436383 2.45619 0.788233 0.0728892 1.70272 10.1079 




2.58293 3.32135 10.2379 0.813313 5.55023 59.1665 




0.857188 1.85966 1.44252 0.781458 3.87775 19.6027 




0.162802 0.311974 0.636592 0.388592 0.649166 3.71822 




0.119656 0.329726 0.123807 0.0689679 0.35781 2.71766 




1.37586 2.77601 1.46519 0.526663 6.77924 31.2061 




0.210336 0.516436 0.727503 0.904508 0.523777 4.75989 




1.60168 4.71741 5.31172 3.62581 4.7456 35.8855 




0.307132 0.297556 0.451364 0.269035 0.401608 6.81521 




0.694734 0.779131 0.905974 0.642219 2.10851 15.299 




1.0734 0.0114431 0.0368251 0.117575 0.177719 23.5145 




0.193524 0.114099 0.01 0.0595707 0.271921 4.2305 




1.32285 0.415081 0.456923 3.54759 2.28971 28.5902 
   174 




0.386615 0.75788 0.423892 0.203917 1.25471 8.32896 




0.498313 0.281076 0.573083 0.44476 0.815326 10.7271 




0.676853 2.06484 1.78255 1.16553 2.02191 14.4377 




0.393772 0.208198 0.555914 0.78287 0.6499 8.1661 




0.173769 0.0947951 0.214508 0.14851 0.376289 3.53148 




1.5049 2.39649 3.39956 1.96725 2.37911 29.9727 




0.763204 1.14646 2.15826 2.84927 0.908529 15.0609 




0.458126 0.769918 0.768628 1.75389 0.930195 8.96799 




0.443093 0.453268 0.01 0.01 0.01 8.67274 




0.575862 0.01 0.0173338 0.01 0.627647 11.2048 




3.81737 2.12153 2.61984 1.55292 17.4128 74.1968 




0.964524 0.214216 0.248953 0.473501 0.962022 18.5573 




0.434493 1.92187 1.04424 0.521739 0.451806 8.34494 




1.18379 5.06616 0.532251 1.29652 4.55251 22.6685 




1.48401 0.189706 0.286287 0.328451 2.09106 28.3439 




4.96676 5.54088 13.4736 14.5532 14.9025 93.6386 




0.307439 0.111686 0.910908 0.27128 0.668432 5.70927 




1.97281 1.67539 2.18233 7.60265 4.7915 36.4013 




0.486173 0.246627 0.116491 0.282123 0.405059 8.95197 




0.920172 0.39457 1.05795 1.3872 1.18292 16.7527 




0.791635 1.35516 1.60972 0.70486 1.47356 14.366 




0.309544 0.301146 0.532435 1.05055 0.894254 5.58821 
   175 




5.90821 1.09597 13.9295 15.1123 23.012 105.84 




0.42833 0.366394 0.750316 1.42709 1.23295 7.60174 




10.0394 4.84335 7.67175 5.96888 11.87 178.14 




9.11383 3.25024 9.59258 25.0471 26.3568 161.379 




0.568556 0.715679 1.13262 0.721303 1.16774 9.88836 




0.175821 0.2278 0.337652 0.427005 0.200499 3.04833 




0.176013 0.0579483 0.138284 0.0253231 0.441119 2.97954 




0.761535 1.16719 2.12379 0.988028 1.4249 12.7359 




0.432955 0.406907 0.0792454 0.01 0.01 7.18314 




1.57166 1.31766 2.33932 0.928073 0.749228 26.0737 




0.870354 3.03378 2.3655 0.382646 0.663625 14.4314 




42.2712 78.627 167.373 29.9984 73.2667 679.283 




0.443678 0.886709 0.0268234 0.914108 0.251881 7.05829 




5.00161 9.63694 9.84314 6.4201 14.2773 79.3545 




0.288219 0.287684 0.01 0.01 0.454166 4.51683 




0.605628 1.12631 1.52461 0.529031 0.280349 9.46226 




0.934839 2.33561 0.969803 0.450103 0.338868 14.4112 




0.873945 0.0353421 0.392413 0.465716 0.566784 13.4674 




0.610468 0.251043 0.272868 0.379356 1.07652 9.38355 




0.316772 0.0517635 0.01 0.210805 0.430593 4.85628 




4.44038 2.96673 5.31541 4.20937 2.55911 67.2891 




0.242354 0.384292 0.128564 0.259371 0.73461 3.63163 
   176 




0.91885 1.10046 1.50843 1.38128 1.33394 13.6888 




123.583 195.491 246.452 400.744 374.977 1833.06 




2.56505 1.89061 3.16787 5.48345 4.35351 36.8935 




3.35075 2.05916 4.71931 2.29628 2.36502 47.3652 




0.350957 0.111008 0.307864 0.217539 0.101576 4.80671 




13.8108 26.3285 37.7241 17.9539 32.5777 187.449 




3.21193 0.715019 2.63707 2.22876 5.7482 43.4351 




1.07437 1.59661 0.861352 0.747012 2.87277 14.4701 




1.76091 2.89239 4.48023 1.35783 2.78976 23.6309 




21.0079 10.1715 6.76175 2.17196 26.9748 270.992 




29.1218 28.3203 46.8712 38.1925 83.236 371.073 




0.492781 1.5466 1.3694 0.407278 0.849833 6.27122 




0.411287 0.446 0.212455 0.501177 1.11004 5.20439 




1.75574 5.02538 4.12835 1.69584 2.07642 21.9631 




0.65101 0.354729 0.598904 1.7491 1.2371 7.89749 




0.384822 0.504822 0.723789 0.679975 0.847701 4.64659 




1.84598 1.03755 1.05245 0.0995936 0.540245 21.2922 




0.901436 0.791156 0.904226 0.442344 0.92271 10.3242 




0.390011 0.177746 0.53973 0.313746 0.81916 4.4442 




1.40121 1.14572 1.34961 0.314051 0.931511 15.8698 




2.74092 3.11675 4.14124 7.24201 7.28529 30.9084 




1.13696 0.998038 3.13223 2.11331 2.73962 12.7803 
   177 




0.845656 0.5669 0.457618 0.0502532 0.1438 9.46434 




1.25373 0.752048 0.716712 1.9355 2.93822 14.03 




6.11856 1.07998 2.37882 2.81156 2.87502 68.3264 




0.413526 0.71102 0.972201 0.121668 0.151093 4.59304 




8.17233 1.40425 1.72451 1.16434 11.2288 90.3203 




0.575729 0.575633 0.80537 0.500996 0.557867 6.36222 




1.98955 4.93297 5.38988 1.43024 3.83053 21.9613 




17.1584 18.6254 28.9388 7.09081 14.8834 183.745 




4.18556 3.13243 3.45661 3.22602 7.93984 44.6253 




7.65652 5.5722 3.65139 0.632405 3.57013 81.2765 




0.566766 0.522019 0.260511 0.0875753 0.194869 6.00379 




7.49953 0.284961 1.55017 5.60085 9.60834 78.5745 




0.973352 1.28188 1.5975 1.32993 1.19598 10.0324 




2.21312 2.48449 5.52747 3.11008 4.96203 22.5085 




1.02064 0.866552 0.652547 0.184165 0.214893 10.2607 




25.9963 14.8683 18.3554 23.2883 42.9453 260.24 




4.12524 6.04864 10.2086 4.82701 5.51557 41.0242 




5.78628 0.706679 1.3898 1.06167 2.90299 57.475 




1.25061 1.13425 1.87417 0.436636 0.270741 12.2258 




1.06578 0.18956 0.21576 0.542503 0.130983 10.2257 




0.739393 0.460474 0.52967 0.108891 0.622073 6.96892 




2.25764 1.7722 3.49687 1.80464 2.57104 20.9253 
   178 




1.01509 0.832644 1.2266 0.557228 0.59583 8.97273 




43.8313 27.9848 34.5945 27.9947 71.1716 382.942 




0.35897 0.0400824 0.162775 0.01 0.516605 3.13368 




0.82896 0.613126 0.954472 0.785177 0.96134 7.21144 




1.4672 1.426 1.40517 1.37897 2.40158 12.6915 




0.890321 1.31193 0.875087 0.667142 1.24873 7.69378 




1.44635 2.87172 2.24686 1.3002 3.04197 12.3879 




2.1203 3.43313 3.35002 1.54475 3.88143 18.1039 




2.11168 0.679892 0.694691 0.826316 0.01 17.9556 




4.29576 6.10909 8.05766 1.23386 2.0274 36.0406 




3.5317 0.479971 0.726054 0.0744408 1.32141 29.5936 




28.0495 33.5614 43.9049 33.0084 53.999 234.685 




0.763879 1.24265 1.23917 1.35955 1.29543 6.36471 




17.0139 6.32358 8.15513 16.6226 27.6453 138.605 




2.87451 0.174112 0.677295 0.0065934 5.57014 23.2176 




6.09504 0.573842 2.2629 4.16379 10.0646 49.0876 




5.32913 5.00682 6.59828 0.819082 1.76278 42.5632 




2.51798 2.80459 3.86523 1.08024 3.12102 19.869 




8.29459 2.785 4.03322 1.93175 3.91603 63.0166 




5.12798 3.31641 3.51928 5.08108 7.44949 38.7907 




2.70656 1.30117 1.92619 0.680347 3.88711 20.1001 




0.865437 0.213267 1.12554 1.24606 1.26314 6.35034 
   179 




6.73434 7.44956 11.6536 5.10451 10.9759 49.1216 




14.2342 1.00337 1.09629 1.73119 5.30122 101.87 




1.14995 0.913814 0.328461 0.776411 1.51568 8.15532 




57.9905 9.53056 1.96392 5.63815 92.5357 400.052 




6.14295 3.699 4.89459 2.08297 4.61563 41.2213 




0.618509 0.4181 0.529646 0.730619 0.435606 4.14977 




1.00475 0.570243 0.67369 0.572813 1.04938 6.57891 




0.435763 0.325249 0.468046 0.100034 0.145585 2.8119 




2.28502 2.44135 2.76849 2.53253 3.06211 14.7401 




3.32026 0.116863 0.0509453 0.449577 4.0884 21.3227 




112.746 29.3944 10.9123 8.48956 117.75 698.412 




2.18841 0.577244 1.51035 0.779131 2.09829 13.522 




26.9179 11.3747 6.72606 2.51485 33.4327 164.106 




0.886841 0.424614 0.815746 0.956298 0.781303 5.40245 




2.20518 1.97936 2.0145 1.00121 2.35739 13.1098 




3.50586 3.14256 3.72255 4.13524 2.1593 20.7884 




1.33432 0.875003 0.85867 1.70122 1.41379 7.68302 




8.40873 5.01077 7.25711 3.87328 9.18481 48.3155 




2.11237 0.448392 0.595553 0.837921 0.983011 11.965 




11.1348 12.074 11.7313 5.34986 12.5814 62.1186 




10.5006 4.07725 3.11287 7.98092 6.94481 57.5117 




14.4899 12.9059 4.22506 6.33803 11.1595 77.2972 
   180 




1.53854 1.28016 1.55752 1.47681 1.49118 8.11035 




3.89084 0.219557 0.212401 0.227436 0.162311 20.2013 




6.04397 5.12489 5.58898 6.41523 3.10729 31.3736 




5.30705 1.54782 4.19783 2.29607 2.01637 27.4761 




3.76837 3.17396 3.58494 2.90155 1.99035 18.7109 




0.923623 0.818551 0.699438 0.323952 0.37111 4.55333 




1.36544 0.01 0.0335276 1.04901 0.723979 6.67797 




3.09363 0.626246 1.35409 0.880371 1.35636 15.0897 




8.34409 5.36301 6.52574 7.93464 6.78642 40.3365 




12.0273 2.47423 1.59389 0.213751 0.475916 58.0943 




6.17121 1.04522 2.13221 0.768032 4.02281 29.6912 




1.10214 0.812067 0.90765 0.353574 0.482453 5.14807 




7.48761 1.70512 2.62684 2.3489 3.91776 33.5598 




1.07231 1.07108 0.438315 0.527279 0.590802 4.73271 




10.2064 3.88777 3.95786 1.01256 3.23638 44.5697 




34.0418 22.2685 19.2068 8.05563 4.98932 147.99 




56.9662 28.4849 43.5707 45.6103 33.0897 246.349 




118.804 63.0727 69.1508 24.3213 27.8973 498.737 




2.23525 0.70563 0.954011 0.594992 1.26995 9.362 




1.89763 0.111327 0.198839 0.0752341 0.282515 7.62881 
lincRNA linc-OPCML UP I early 116.145 0.01 0.01 0.01 9.89971 0.01 
lincRNA linc-KLHL29-9 UP I early 82.4978 0.01 0.01 0.01 0.01 0.01 
   181 
lincRNA linc-C10orf119-1 UP I early 75.0602 4.18187 1.39603 0.01 11.4666 0.01 
lincRNA linc-CHMP7 UP I early 70.8149 4.76307 21.0118 17.1471 9.04622 0.01 
lincRNA linc-DGCR6-1 UP I early 68.8051 33.0682 7.62485 8.32175 7.15619 0.01 
lincRNA linc-HNRNPA3-4 UP I early 44.2978 15.565 13.1263 13.9824 2.03585 0.01 
lincRNA linc-LRRC32-2 UP I early 42.4707 7.91042 6.85625 11.94 15.0071 0.01 
lincRNA linc-CCND1-4 UP I early 39.7513 0.01 0.01 0.01 4.10552 0.01 
lincRNA linc-ZNF236-4 UP I early 39.4523 6.07915 16.7932 0.01 1.59173 0.01 
lincRNA linc-PIK3C3-2 UP I early 30.5923 15.3722 30.0155 27.2763 5.57638 0.01 
lincRNA linc-GGTLC1-2 UP I early 86.127 0.01 0.01 1.80775 6.21863 0.448121 
lincRNA linc-TMEM90B-2 UP I early 2945.04 6.68591 3.4051 8.72741 42.8962 15.4258 
lincRNA linc-EVX2-8 UP I early 545.353 51.2354 105.596 38.6965 46.731 4.44876 
lincRNA linc-OR52K2-1 UP I early 412.342 22.7722 1.56491 2.62622 3.21341 3.70815 
lincRNA linc-GPNMB UP I early 163.954 22.1803 4.4463 5.47478 8.77121 2.93188 
lincRNA linc-ITPRIP-1 UP I early 257.758 26.8832 14.835 19.8478 47.8261 7.66117 
lincRNA linc-RASD2 UP I early 32.806 16.6334 8.83569 0.556303 22.5219 1.68836 
lincRNA linc-TMEM90B-1 UP I early 323.372 0.01 1.49914 3.7814 7.32405 17.12 
lincRNA linc-CSMD1-1 UP I early 58.9229 18.2754 17.2208 16.2696 8.17262 3.61411 
lincRNA linc-ZIC5 UP I early 151.187 15.5709 29.1747 38.0007 62.0329 9.42939 
lincRNA linc-BTF3-2 UP I early 324.63 83.0632 114.916 73.0675 14.359 20.7033 
lincRNA linc-IGFBP2-3 UP I early 597.293 22.9162 41.5887 33.7007 154.383 46.8526 
lincRNA linc-C1orf227-1 UP I early 121.811 11.9966 13.1397 25.0393 29.3329 10.9906 
lincRNA linc-CHST7 UP I early 112.049 39.7752 66.7911 46.2963 58.6916 10.5494 
   182 
lincRNA linc-AGAP5-1 UP I early 111.13 24.7731 65.9444 41.905 40.1363 12.1858 
lincRNA linc-GALNTL5-1 UP I early 209.962 59.8341 54.7369 62.8236 39.3234 24.0793 
lincRNA linc-PEX14 UP I early 2144.32 522.497 706.792 668.1 422.277 255.026 
lincRNA linc-CREBBP UP I early 44.2818 7.33568 5.78383 7.67122 6.13731 5.45104 
lincRNA linc-HIATL1-1 UP I early 6144.43 2635.96 2988.6 2227.44 2055.78 769.231 
lincRNA linc-PCF11-2 UP I early 3149.5 1323.51 1473.76 1003.8 660.76 409.194 
lincRNA linc-DHX37-22 UP I early 176.292 28.8005 27.2292 29.042 13.5595 24.7751 
lincRNA linc-AP3B1 UP I early 92.6525 33.0785 45.6332 52.8486 50.0022 13.1452 
lincRNA linc-NDRG1 UP I early 2295.1 666.178 1017.96 675.421 1196.51 328.539 
lincRNA linc-TLN2-1 UP I early 211.38 112.349 183.305 102.159 88.5 33.0647 
lincRNA linc-MRPL22 UP I early 63.8797 14.1577 34.5652 16.2695 19.5514 10.0689 
lincRNA linc-STXBP5-2 UP I early 261.558 7.5542 0.01 0.01 0.01 42.6329 
lincRNA linc-BCL2A1-1 UP I early 372.454 110.43 14.4872 24.1485 51.8089 62.6713 
lincRNA linc-BRAP-2 UP I early 812.763 296.604 341.678 244.176 353.434 142.644 
lincRNA linc-MTHFD2 UP I early 917.321 320.104 503.791 380.973 370.211 165.291 
lincRNA linc-CCT5-8 UP I early 313.132 109.098 183.549 175.501 124.357 56.6703 
lincRNA linc-NUSAP1 UP I early 6661.63 1600.2 2242.89 2504.92 2397.39 1249.59 
lincRNA linc-ITGB2-1 UP I early 318.012 35.9815 59.0392 128.906 107.379 61.2884 
lincRNA linc-STIM2-1 UP I early 649.741 280.519 408.769 222.319 215.188 126.564 
lincRNA linc-RPS7-1 UP I early 464.073 174.636 229.869 130.255 109.352 93.9005 
lincRNA linc-RGS18-3 UP I early 759.355 324.853 198.644 141.715 40.3595 156.752 
lincRNA linc-NADSYN1-1 UP I early 213.412 36.7299 75.9076 63.7466 84.3037 47.9917 
lincRNA linc-XRCC6 UP I early 338.889 116.244 128.241 220.06 146.979 79.7876 
lincRNA linc-CTDSP2-1 UP I early 928.833 282.866 225.765 382.591 406.586 231.472 
   183 
lincRNA linc-EXD1 UP II early-mid 485.013 201.562 92.2694 15.4474 11.405 46.1597 
lincRNA linc-JPH1-6 UP III early-late 111.167 97.3599 103.135 51.1833 41.1561 3.69133 
lincRNA linc-CDH6-5 UP V InVivo-sp. 1483.21 405.002 587.423 845.931 2524.98 1.96336 
lincRNA linc-CXXC4-1 UP V InVivo-sp. 5922.94 2029.97 1639.19 500.709 1276.2 68.3217 
lincRNA linc-PXN UP V InVivo-sp. 1315.89 240.431 482.779 613.214 385.961 28.4573 
lincRNA linc-ITGB8-4 UP V InVivo-sp. 243.365 335.292 221.559 99.1429 157.387 5.35704 
lincRNA linc-IRX3-5 UP V InVivo-sp. 649.863 936.28 1539.42 919.042 306.923 19.1878 
lincRNA linc-DLGAP5-1 UP V 
InVivo-
sp. 2259.58 547.438 736.532 635.719 778.314 133.823 
lincRNA linc-TMEM132C-2 UP V 
InVivo-
sp. 584.773 327.795 385.987 349.045 248.826 47.6478 
lincRNA linc-ARHGAP28-2 UP V 
InVivo-
sp. 498.807 270.892 406.353 351.207 419.68 54.062 
lincRNA linc-OPRK1-4 UP V InVivo-sp. 80.6886 48.8705 121.704 119.945 140.971 9.98352 
lincRNA linc-C1orf201-2 UP V 
InVivo-
sp. 419.69 846.102 1430.84 494.366 750.287 69.5695 
lincRNA linc-DDX51 DOWN I early 0.01 19.8808 347.883 108.893 173.8 277.937 
lincRNA linc-NCKAP1-1 DOWN I early 0.01 66.8243 255.054 238.307 408.948 214.518 
lincRNA linc-LSAMP-2 DOWN I early 0.01 15.4043 20.5022 17.3327 10.2675 94.8731 
lincRNA linc-TET2-4 DOWN I early 0.01 13.8285 37.3407 11.0536 8.06111 73.9332 
lincRNA linc-TRIM29-3 DOWN I early 0.01 23.2257 14.2843 11.5659 14.469 57.6074 
lincRNA linc-CRYL1 DOWN I early 0.01 20.746 4.37584 22.6837 6.86677 42.6146 
lincRNA linc-TEKT1-3 DOWN I early 0.01 3.44952 10.0474 20.1519 13.8111 31.667 
lincRNA linc-SPNS3 DOWN I early 4.0811 77.9455 34.8028 118.869 27.6573 185.51 
lincRNA linc-HIST1H2AG-4 DOWN I early 8.59544 67.4487 318.566 121.587 88.769 244.681 
lincRNA linc-COL28A1 DOWN I early 17.3267 145.699 467.236 192.353 896.638 417.24 
lincRNA linc-CBLB-6 DOWN I early 6.61285 63.9232 22.6903 24.8402 26.2061 127.526 
   184 
lincRNA linc-FAM103A1 DOWN I early 5.15828 20.3876 56.0902 57.2142 30.3673 51.4267 
lincRNA linc-FAM116B-1 DOWN I early 67.765 175.793 316.953 590.492 382.934 561.526 
lincRNA linc-CXADR-2 DOWN I early 78.7996 875.985 1343.47 673.02 314.59 610.616 
lincRNA linc-ZNF227 DOWN I early 17.5864 75.5178 62.4812 34.0479 30.9803 127.351 
lincRNA linc-CCDC54 DOWN I early 47.7848 106.422 260.851 109.27 86.8815 345.14 
lincRNA linc-LRCH2-1 DOWN I early 22.5481 53.0649 207.333 61.7038 111.306 158.297 
lincRNA linc-ATP6V1G3-2 DOWN I early 44.23 134.482 231.968 272.933 124.75 219.159 
lincRNA linc-GABRA5-5 DOWN I early 260.182 366.049 605.978 333.416 392.982 1247.93 
lincRNA linc-DR1 DOWN I early 25.5408 70.3441 130.219 47.8667 83.1226 107.544 
lincRNA linc-METAP1-2 DOWN II 
early-
mid 0.01 1.91409 46.3349 71.039 82.6442 150.429 
lincRNA linc-C3orf30-7 DOWN II early-mid 0.01 7.49809 41.6235 22.9576 55.0042 102.508 
lincRNA linc-ADAR DOWN II early-mid 0.01 11.0962 65.4625 21.2219 33.9282 93.4977 
lincRNA linc-GLA-1 DOWN II early-mid 2.66992 83.7508 203.948 105.987 229.239 400.242 
lincRNA linc-CBLB-4 DOWN II early-mid 10.8099 48.5368 327.209 169.662 339.979 637.365 
lincRNA linc-ID2-1 DOWN II early-mid 2.98224 16.7024 46.3857 24.7196 45.249 110.48 
lincRNA linc-GLRX3-2 DOWN II early-mid 1.88284 6.73503 46.4919 14.7538 23.5979 43.3583 
lincRNA linc-MKLN1-1 DOWN II early-mid 21.1187 31.8101 242.581 63.4316 66.3829 246.316 
lincRNA linc-C17orf87 DOWN II early-mid 13.0793 22.6122 205.503 59.1895 182.632 137.86 
lincRNA linc-ZNF674 DOWN II early-mid 10.2803 4.50661 21.8032 24.4728 21.6396 106.377 
lincRNA linc-PSMD11 DOWN II early-mid 4.48268 6.46583 28.8026 9.9306 12.3887 35.0797 
lincRNA linc-ZNF467-1 DOWN II early-mid 25.6669 26.4061 144.441 30.4965 25.9347 110.786 
lincRNA linc-GALNT10 DOWN III early-late 0.01 0.01 0.01 11.1392 10.4945 166.097 
lincRNA linc-S100B-2 DOWN III early-late 18650.5 12826.7 10703.6 47364.8 25523.3 90666.1 
   185 
lincRNA linc-PDE10A-1 DOWN IV late 0.01 0.01 20.3077 0.01 138.52 562.565 
lincRNA linc-SLC6A19-1 DOWN IV late 0.01 0.01 96.9263 0.01 93.0232 539.509 
lincRNA linc-P2RY1-2 DOWN IV late 0.01 0.01 1.88549 0.01 10.7693 259.635 
lincRNA linc-CLDN10-2 DOWN IV late 0.01 0.01 0.01 0.01 84.9703 110.013 
lincRNA linc-C15orf2-1 DOWN IV late 0.01 0.01 3.37162 0.01 15.6568 63.0937 
lincRNA linc-TGDS-1 DOWN IV late 0.01 0.01 0.01 0.01 103.75 37.7873 
lincRNA linc-PPDPF-3 DOWN IV late 0.01 0.01 0.01 0.01 8.33852 36.2504 
lincRNA linc-MRPS33-3 DOWN IV late 0.01 0.01 0.01 0.01 28.4757 35.7679 
lincRNA linc-YIPF5-3 DOWN IV late 0.01 0.01 0.405252 0.611163 17.6673 34.3327 
lincRNA linc-PPP1R3B-3 DOWN IV late 3.14017 52.5047 1.49652 2.42855 919.956 592.966 
lincRNA linc-RPL19-3 DOWN IV late 1.09166 3.00521 2.22939 1.57587 21.2074 66.0037 
lincRNA linc-FAM136B DOWN IV late 6.49027 4.94097 7.84233 11.2622 25.868 136.099 
lincRNA linc-BRD9-1 DOWN V InVivo-sp. 0.01 0.01 44.6191 0.01 392.605 2534.31 
lincRNA linc-RECK-3 DOWN V InVivo-sp. 0.01 113.535 99.5564 107.902 113.559 1133.08 
lincRNA linc-TMPRSS15-5 DOWN V 
InVivo-
sp. 0.01 0.01 0.01 0.01 0.01 844.018 
lincRNA linc-PHYHIPL DOWN V InVivo-sp. 0.01 0.01 0.01 0.01 0.01 571.452 
lincRNA linc-RAB23-1 DOWN V InVivo-sp. 0.01 0.01 0.01 0.01 0.01 473.072 
lincRNA linc-NEUROG3 DOWN V 
InVivo-
sp. 0.01 0.01 6.42298 11.0523 19.5966 411.785 
lincRNA linc-NAV3-1 DOWN V InVivo-sp. 0.01 0.01 5.51615 0.01 71.4462 348.146 
lincRNA linc-RSAD2-2 DOWN V InVivo-sp. 0.01 0.278525 1.68504 0.152923 8.62943 261.819 
lincRNA linc-KCNV1-1 DOWN V InVivo-sp. 0.01 0.01 0.01 0.01 0.01 244.522 
lincRNA linc-CEP110-14 DOWN V 
InVivo-
sp. 0.01 0.01 17.1866 0.01 23.8044 194.968 
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lincRNA linc-PARK2-4 DOWN V InVivo-sp. 0.01 0.01 0.01 0.01 12.2983 192.318 
lincRNA linc-SPACA3 DOWN V InVivo-sp. 0.01 0.01 0.01 1.62419 3.48003 184.172 
lincRNA linc-ZC3H12B-2 DOWN V 
InVivo-
sp. 0.01 0.01 0.01 0.01 2.84278 156.774 
lincRNA linc-TSPO2-2 DOWN V InVivo-sp. 0.01 0.01 0.01 0.01 0.01 150.053 
lincRNA linc-BCL2L10 DOWN V InVivo-sp. 0.01 27.4187 5.36229 8.71505 3.0106 145.873 
lincRNA linc-EMX2 DOWN V InVivo-sp. 0.01 0.01 0.01 0.01 9.85212 142.172 
lincRNA linc-ZC3H12B-3 DOWN V 
InVivo-
sp. 0.01 0.01 0.01 0.01 0.01 139.657 
lincRNA linc-GPC5-8 DOWN V InVivo-sp. 0.01 7.29959 9.60873 7.98632 1.76188 137.725 
lincRNA linc-DTHD1-3 DOWN V InVivo-sp. 0.01 0.01 0.01 0.01 0.01 137.367 
lincRNA linc-P2RX4 DOWN V InVivo-sp. 0.01 0.01 0.77723 3.81076 2.77833 132.047 
lincRNA linc-EIF2AK3-7 DOWN V 
InVivo-
sp. 0.01 0.01 0.01 0.01 0.01 108.788 
lincRNA linc-ERICH1-8 DOWN V InVivo-sp. 0.01 0.01 0.01 0.01 0.01 94.893 
lincRNA linc-CMPK2-2 DOWN V InVivo-sp. 0.01 0.01 1.54194 2.54255 2.77675 93.8576 
lincRNA linc-ABHD13-1 DOWN V 
InVivo-
sp. 0.01 0.01 0.01 0.01 0.01 89.2861 
lincRNA linc-CTTNBP2-1 DOWN V 
InVivo-
sp. 0.01 14.6551 11.3238 11.7786 6.98669 86.7669 
lincRNA linc-PAX9-5 DOWN V InVivo-sp. 0.01 0.01 0.01 0.01 0.01 79.756 
lincRNA linc-PARK2-6 DOWN V InVivo-sp. 0.01 6.6748 0.01 4.36368 0.01 75.3761 
lincRNA linc-ADAM12 DOWN V InVivo-sp. 0.01 0.01 0.01 0.01 0.01 70.0191 
lincRNA linc-CBR3-1 DOWN V InVivo-sp. 0.01 1.05335 0.830449 0.01 1.06494 66.4071 
lincRNA linc-PRDM9-8 DOWN V InVivo-sp. 0.01 0.01 0.01 0.01 0.01 61.3342 
lincRNA linc-FMR1 DOWN V InVivo-sp. 0.01 0.01 0.01 0.01 0.01 59.809 
lincRNA linc-PITRM1-4 DOWN V InVivo-sp. 0.01 0.01 0.01 0.01 0.01 57.1138 
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lincRNA linc-KCNN4 DOWN V InVivo-sp. 0.01 0.01 0.01 0.01 0.01 57.1106 
lincRNA linc-IGFL4 DOWN V InVivo-sp. 0.01 0.01 0.01 0.01 0.761637 54.1921 
lincRNA linc-CYP7B1-2 DOWN V InVivo-sp. 0.01 2.57199 3.29368 0.73573 0.01 53.2174 
lincRNA linc-COG6-2 DOWN V InVivo-sp. 0.01 0.792304 0.01 0.01 0.01 47.8983 
lincRNA linc-FAM120B-2 DOWN V 
InVivo-
sp. 0.01 0.01 8.2241 0.01 0.01 37.8895 
lincRNA linc-CLLU1-4 DOWN V InVivo-sp. 0.01 0.01 0.798681 0.01 1.06068 37.4126 
lincRNA linc-EDNRB-1 DOWN V InVivo-sp. 0.01 0.01 0.01 0.01 0.01 30.3656 
lincRNA linc-MMEL1-3 DOWN V InVivo-sp. 0.01 0.01 0.01 0.01 0.01 30.1776 
lincRNA linc-CBWD3-2 DOWN V InVivo-sp. 0.788404 0.01 3.5469 2.07191 0.706287 154.037 
lincRNA linc-SEPT7-1 DOWN V InVivo-sp. 3.71828 14.1418 17.2596 9.72931 43.1974 247.327 
lincRNA linc-ERICH1-7 DOWN V InVivo-sp. 18.409 0.01 18.8901 0.01 88.1585 1032.64 
lincRNA linc-RALGAPA1-4 DOWN V 
InVivo-
sp. 20.8549 68.1513 86.0433 41.4483 7.07914 1098.65 
lincRNA linc-PDE6B DOWN V InVivo-sp. 2.33586 0.01 0.01 0.01 7.73738 89.6723 
lincRNA linc-PICK1 DOWN V InVivo-sp. 2.4484 1.91901 15.3221 2.42278 3.38302 91.248 
lincRNA linc-SPANXB1-2 DOWN V 
InVivo-
sp. 7.27923 40.2681 57.8303 27.6662 51.6022 262.167 
lincRNA linc-CLRN2-1 DOWN V InVivo-sp. 67.5701 21.6818 34.8474 50.5977 62.4374 908.396 
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 MODEL I – UP 
 
# GO Processes pValue Ratio 
1 cellular macromolecular complex assembly 6.597E-10 30 484 
2 organelle organization 2.784E-09 70 2040 
3 cellular macromolecular complex subunit organization 3.875E-09 33 618 
4 cellular component organization or biogenesis 5.637E-09 117 4304 
5 cellular component organization or biogenesis at cellular level 5.848E-09 98 3367 
6 small molecule metabolic process 1.229E-08 77 2428 
7 macromolecular complex subunit organization 1.768E-08 46 1132 
8 cellular component organization 3.167E-08 112 4177 
9 mitotic cell cycle 4.057E-08 34 716 
10 macromolecular complex assembly 5.809E-08 41 984 
11 cell cycle phase 9.448E-08 37 851 
12 cellular component biogenesis 9.549E-08 56 1611 
13 cellular component organization at cellular level 1.680E-07 91 3253 
14 protein-DNA complex assembly 7.858E-07 13 143 
15 cell cycle 1.039E-06 45 1262 
16 protein-DNA complex subunit organization 1.460E-06 13 151 
17 translation 2.037E-06 22 417 
18 M phase 2.263E-06 25 521 
19 primary metabolic process 3.460E-06 184 8592 
20 cell cycle process 4.595E-06 37 1001 
21 mitosis 4.686E-06 19 341 
22 nuclear division 4.686E-06 19 341 
23 nucleosome assembly 5.569E-06 11 121 
24 M phase of mitotic cell cycle 6.535E-06 19 349 
25 organelle fission 8.329E-06 19 355 
26 mitochondrial membrane organization 8.542E-06 7 45 
27 chromatin assembly 8.883E-06 11 127 
28 cellular component assembly 9.006E-06 47 1458 
29 metabolic process 1.315E-05 200 9707 
30 M/G1 transition of mitotic cell cycle 1.401E-05 9 87 
31 small molecule biosynthetic process 1.612E-05 26 621 
32 cellular component assembly at cellular level 1.629E-05 36 1018 
33 glycerolipid catabolic process 1.805E-05 6 34 
34 nucleosome organization 1.825E-05 11 137 
35 catabolic process 2.207E-05 55 1875 
36 cellular metabolic process 2.209E-05 180 8579 
37 monosaccharide metabolic process 2.312E-05 16 284 
38 alcohol metabolic process 2.344E-05 25 597 
39 glucose metabolic process 2.521E-05 13 196 
40 chromatin assembly or disassembly 2.726E-05 11 143 
41 cellular process 2.777E-05 276 14653 
42 branching involved in mammary gland duct morphogenesis 2.992E-05 6 37 
43 organic ether metabolic process 3.102E-05 11 145 
44 DNA packaging 3.322E-05 12 173 
45 biosynthetic process 3.455E-05 106 4475 
46 nucleotide biosynthetic process 3.542E-05 14 232 
47 mitochondrial transport 3.665E-05 10 122 
48 cellular nitrogen compound biosynthetic process 4.093E-05 21 469 
49 heterocycle biosynthetic process 4.850E-05 16 302 
50 cellular biosynthetic process 5.397E-05 103 4362 
51 neutral lipid catabolic process 6.004E-05 5 26 
52 glycerol ether catabolic process 6.004E-05 5 26 
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53 acylglycerol catabolic process 6.004E-05 5 26 
54 DNA damage response, signal transduction by p53 class mediator 6.325E-05 9 105 
55 nucleoside metabolic process 6.813E-05 9 106 
56 signal transduction by p53 class mediator 7.332E-05 9 107 
57 nucleobase, nucleoside and nucleotide biosynthetic process 7.617E-05 14 249 
58 nucleobase, nucleoside, nucleotide and nucleic acid biosynthetic process 7.617E-05 14 249 
59 cell division 8.827E-05 19 422 
60 ribonucleoprotein complex biogenesis 1.023E-04 14 256 
61 neurological system process involved in regulation of systemic arterial blood pressure 1.041E-04 5 29 
62 nuclear-transcribed mRNA catabolic process, exonucleolytic 1.041E-04 5 29 
63 glucose catabolic process 1.089E-04 7 66 
64 ribonucleotide biosynthetic process 1.106E-04 10 139 
65 ribosome biogenesis 1.381E-04 11 171 
66 DNA conformation change 1.474E-04 12 202 
67 regulation of icosanoid secretion 1.488E-04 4 17 
68 protein import into mitochondrial outer membrane 1.504E-04 3 7 
69 meiotic spindle organization 1.504E-04 3 7 
70 mammary gland duct morphogenesis 1.523E-04 6 49 
71 cellular component biogenesis at cellular level 1.653E-04 14 268 
72 response to heat 1.663E-04 9 119 
73 cytokine production 1.825E-04 8 95 
74 protein secretion 1.907E-04 6 51 
75 mitotic prometaphase 1.963E-04 8 96 
76 ribonucleoside monophosphate biosynthetic process 1.970E-04 5 33 
77 monosaccharide biosynthetic process 2.063E-04 7 73 
78 cellular protein metabolic process 2.156E-04 73 2939 
79 triglyceride metabolic process 2.264E-04 8 98 
80 generation of precursor metabolites and energy 2.313E-04 21 531 
81 hexose metabolic process 2.321E-04 13 244 
82 icosanoid secretion 2.361E-04 4 19 
83 response to water 2.361E-04 4 19 
84 arachidonic acid secretion 2.361E-04 4 19 
85 outer mitochondrial membrane organization 2.377E-04 3 8 
86 ribose phosphate metabolic process 2.377E-04 3 8 
87 monocarboxylic acid transport 2.428E-04 8 99 
88 coenzyme biosynthetic process 2.428E-04 8 99 
89 cellular catabolic process 2.459E-04 45 1576 
90 one-carbon metabolic process 2.494E-04 15 313 
91 maintenance of blood-brain barrier 2.740E-04 2 2 
92 Golgi to plasma membrane CFTR protein transport 2.740E-04 2 2 
93 response to inorganic substance 2.741E-04 22 577 
94 cellular carbohydrate metabolic process 3.194E-04 21 544 
95 response to DNA damage stimulus 3.232E-04 23 624 
96 response to metal ion 3.380E-04 17 394 
97 cofactor metabolic process 3.452E-04 14 288 
98 positive regulation of endopeptidase activity 3.521E-04 3 9 
99 hexose biosynthetic process 3.536E-04 6 57 
100 multi-organism process 3.775E-04 41 1420 
101 glycerol ether metabolic process 3.823E-04 9 133 
102 hexose catabolic process 4.239E-04 7 82 
103 regulation of interleukin-1 beta secretion 4.285E-04 4 22 
104 alcohol biosynthetic process 4.390E-04 8 108 
105 alcohol catabolic process 4.390E-04 8 108 
106 signal transduction in response to DNA damage 4.504E-04 9 136 
107 D-ribose metabolic process 4.969E-04 3 10 
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108 brain renin-angiotensin system 4.969E-04 3 10 
109 icosanoid transport 5.120E-04 4 23 
110 regulation of interleukin-1 secretion 5.120E-04 4 23 
111 acylglycerol metabolic process 5.275E-04 8 111 
112 ribonucleoside monophosphate metabolic process 5.581E-04 5 41 
113 monosaccharide catabolic process 5.664E-04 7 86 
114 regulation of cell cycle process 5.751E-04 18 451 
115 neutral lipid metabolic process 5.942E-04 8 113 
116 triglyceride catabolic process 6.064E-04 4 24 
117 regulation of cellular carbohydrate catabolic process 6.250E-04 5 42 
118 regulation of carbohydrate catabolic process 6.250E-04 5 42 
119 regulation of interleukin-1 beta production 6.250E-04 5 42 
120 pyrimidine-containing compound biosynthetic process 6.250E-04 5 42 
121 chromosome segregation 6.484E-04 9 143 
122 cofactor biosynthetic process 6.484E-04 9 143 
123 cellular protein complex assembly 6.545E-04 12 238 
124 cholesterol homeostasis 6.631E-04 6 64 
125 sterol homeostasis 6.631E-04 6 64 
126 protein metabolic process 6.914E-04 82 3529 
127 hydrogen peroxide metabolic process 6.977E-04 5 43 
128 DNA integrity checkpoint 7.165E-04 9 145 
129 fatty acid transport 7.816E-04 6 66 
130 ncRNA metabolic process 7.854E-04 14 313 
131 nucleotide metabolic process 7.985E-04 27 837 
132 nucleoside phosphate metabolic process 7.985E-04 27 837 
133 dichotomous subdivision of terminal units involved in mammary gland duct morphogenesis 8.129E-04 2 3 
134 T-helper 17 cell chemotaxis 8.129E-04 2 3 
135 negative regulation of eosinophil degranulation 8.129E-04 2 3 
136 regulation of T cell extravasation 8.129E-04 2 3 
137 gamma-delta T cell activation 8.129E-04 2 3 
138 regulation of eosinophil degranulation 8.129E-04 2 3 
139 regulation of arachidonic acid secretion 8.129E-04 2 3 
140 T cell chemotaxis 8.129E-04 2 3 
141 positive regulation of arachidonic acid secretion 8.129E-04 2 3 
142 helper T cell chemotaxis 8.129E-04 2 3 
143 monocyte extravasation 8.129E-04 2 3 
144 urate biosynthetic process 8.129E-04 2 3 
145 positive regulation of T cell extravasation 8.129E-04 2 3 
146 regulation of Fc receptor mediated stimulatory signaling pathway 8.129E-04 2 3 
147 negative regulation of icosanoid secretion 8.129E-04 2 3 
148 regulation of fatty acid transport 8.312E-04 4 26 
149 cellular carbohydrate catabolic process 8.832E-04 8 120 
150 nucleoside diphosphate biosynthetic process 8.888E-04 3 12 
151 mammary gland morphogenesis 9.159E-04 6 68 
152 gluconeogenesis 9.541E-04 5 46 
153 exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay 9.631E-04 4 27 
154 parturition 9.631E-04 4 27 
155 tumor necrosis factor-mediated signaling pathway 9.631E-04 4 27 
156 motor axon guidance 9.631E-04 4 27 
157 regulation of interleukin-1 production 1.053E-03 5 47 
158 long-chain fatty acid transport 1.053E-03 5 47 
159 mitochondrion organization 1.081E-03 11 218 
160 heterocycle metabolic process 1.119E-03 31 1035 
161 response to hydroperoxide 1.141E-03 3 13 
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162 positive regulation of circadian sleep/wake cycle, sleep 1.141E-03 3 13 
163 small molecule catabolic process 1.149E-03 27 858 
164 chromosome organization 1.156E-03 24 728 
165 carbohydrate metabolic process 1.178E-03 24 729 
166 acid secretion 1.270E-03 4 29 
167 branching morphogenesis of a tube 1.315E-03 10 190 
168 positive regulation of ligase activity 1.386E-03 7 100 
169 regulation of glycogen catabolic process 1.435E-03 3 14 
170 nitric oxide mediated signal transduction 1.446E-03 4 30 
171 coenzyme metabolic process 1.495E-03 11 227 
172 organic substance transport 1.584E-03 19 534 
173 interspecies interaction between organisms 1.584E-03 19 534 
174 regulation of cellular ketone metabolic process 1.597E-03 10 195 
175 lysophospholipid transport 1.608E-03 2 4 
176 cell proliferation in hindbrain 1.608E-03 2 4 
177 regulation of metanephros size 1.608E-03 2 4 
178 regulation of immune complex clearance by monocytes and macrophages 1.608E-03 2 4 
179 response to lipid hydroperoxide 1.608E-03 2 4 
180 vasodilation by angiotensin involved in regulation of systemic arterial blood pressure 1.608E-03 2 4 
181 positive regulation of immune complex clearance by monocytes and macrophages 1.608E-03 2 4 
182 respiratory electron transport chain 1.632E-03 8 132 
183 nucleobase metabolic process 1.638E-03 6 76 
184 mammary gland epithelium development 1.638E-03 6 76 
185 pyrimidine nucleoside biosynthetic process 1.772E-03 3 15 
186 histamine secretion 1.772E-03 3 15 
187 low-density lipoprotein particle remodeling 1.772E-03 3 15 
188 glycolysis 1.818E-03 5 53 
189 interphase of mitotic cell cycle 1.846E-03 16 420 
190 protein-lipid complex subunit organization 1.849E-03 4 32 
191 plasma lipoprotein particle organization 1.849E-03 4 32 
192 mRNA metabolic process 1.850E-03 20 583 
193 response to abiotic stimulus 1.930E-03 26 845 
194 regulation of interphase of mitotic cell cycle 2.008E-03 9 168 
195 DNA damage checkpoint 2.063E-03 8 137 
196 pyrimidine nucleotide biosynthetic process 2.077E-03 4 33 
197 regulation of lipoprotein lipase activity 2.077E-03 4 33 
198 chromatin organization 2.077E-03 19 547 
199 carboxylic acid transport 2.099E-03 11 237 
200 mitotic cell cycle G1/S transition DNA damage checkpoint 2.131E-03 6 80 
201 cytokine secretion 2.154E-03 3 16 
202 lipid digestion 2.154E-03 3 16 
203 negative regulation of cAMP biosynthetic process 2.154E-03 3 16 
204 RNA catabolic process 2.160E-03 8 138 
205 interphase 2.178E-03 16 427 
206 nucleobase, nucleoside and nucleotide metabolic process 2.231E-03 27 899 
207 organic acid transport 2.241E-03 11 239 
208 cellular macromolecule catabolic process 2.253E-03 20 593 
209 negative regulation of catalytic activity 2.255E-03 23 722 
210 regulation of cell cycle arrest 2.311E-03 12 276 
211 glycerolipid metabolic process 2.452E-03 12 278 
212 regulation of mitotic cell cycle 2.490E-03 14 354 
213 mRNA catabolic process 2.521E-03 7 111 
214 negative regulation of nucleotide biosynthetic process 2.583E-03 3 17 
215 pentose metabolic process 2.583E-03 3 17 
216 histamine transport 2.583E-03 3 17 
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217 negative regulation of cyclic nucleotide biosynthetic process 2.583E-03 3 17 
218 negative regulation of cAMP metabolic process 2.583E-03 3 17 
219 positive regulation of metanephric glomerulus development 2.651E-03 2 5 
220 bombesin receptor signaling pathway 2.651E-03 2 5 
221 cellular chaperone-mediated protein complex assembly 2.651E-03 2 5 
222 positive regulation of metanephros development 2.651E-03 2 5 
223 sensory perception of sweet taste 2.651E-03 2 5 
224 positive regulation of cellular extravasation 2.651E-03 2 5 
225 T cell migration 2.651E-03 2 5 
226 positive regulation of somatostatin secretion 2.651E-03 2 5 
227 keratinocyte development 2.651E-03 2 5 
228 sebaceous gland development 2.651E-03 2 5 
229 multicellular organismal lipid catabolic process 2.651E-03 2 5 
230 stem cell differentiation 2.651E-03 7 112 
231 S phase of mitotic cell cycle 2.694E-03 8 143 
232 response to stress 2.727E-03 73 3216 
233 methylation 2.800E-03 11 246 
234 response to nicotine 2.925E-03 5 59 
235 negative regulation of cyclic nucleotide metabolic process 3.062E-03 3 18 
236 acute inflammatory response to antigenic stimulus 3.062E-03 3 18 
237 nucleoside monophosphate biosynthetic process 3.070E-03 6 86 
238 regulation of cellular amino acid metabolic process 3.148E-03 5 60 
239 nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay 3.148E-03 5 60 
240 negative regulation of lipid transport 3.183E-03 4 37 
241 electron transport chain 3.193E-03 9 180 
242 cellular aromatic compound metabolic process 3.266E-03 12 288 
243 cellular respiration 3.313E-03 9 181 
244 purine nucleotide biosynthetic process 3.313E-03 9 181 
245 negative regulation of kinase activity 3.313E-03 9 181 
246 carbohydrate catabolic process 3.327E-03 8 148 
247 S phase 3.327E-03 8 148 
248 protein polymerization 3.384E-03 5 61 
249 cellular carbohydrate biosynthetic process 3.385E-03 7 117 
250 regulation of cellular amine metabolic process 3.443E-03 6 88 
251 protein complex subunit organization 3.452E-03 25 837 
252 positive regulation of circadian rhythm 3.592E-03 3 19 
253 negative regulation of blood vessel endothelial cell migration 3.592E-03 3 19 
254 fructose metabolic process 3.592E-03 3 19 
255 peptidyl-lysine methylation 3.592E-03 3 19 
256 mitochondrial ATP synthesis coupled proton transport 3.592E-03 3 19 
257 epithelial cell development 3.642E-03 6 89 
258 regulation of ligase activity 3.718E-03 7 119 
259 positive regulation of cell cycle process 3.759E-03 8 151 
260 regulation of generation of precursor metabolites and energy 3.892E-03 5 63 
261 positive regulation of glomerulus development 3.932E-03 2 6 
262 activation of phospholipase A2 activity 3.932E-03 2 6 
263 germ-line stem cell maintenance 3.932E-03 2 6 
264 complement receptor mediated signaling pathway 3.932E-03 2 6 
265 renin-angiotensin regulation of aldosterone production 3.932E-03 2 6 
266 renal control of peripheral vascular resistance involved in regulation of systemic arterial blood pressure 3.932E-03 2 6 
267 positive regulation of circadian sleep/wake cycle, non-REM sleep 3.932E-03 2 6 
268 fructose 1,6-bisphosphate metabolic process 3.932E-03 2 6 
269 generation of ovulation cycle rhythm 3.932E-03 2 6 
270 regulation of blood vessel size by renin-angiotensin 3.932E-03 2 6 
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MODEL I – DOWN 
 
# GO Processes pValue Ratio 
1 nervous system development 5.463E-17 144 2143 
2 regulation of primary metabolic process 4.505E-15 255 4978 
3 regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 6.988E-15 215 3968 
4 regulation of cellular metabolic process 9.976E-15 255 5010 
5 regulation of metabolic process 2.635E-14 279 5690 
6 regulation of macromolecule metabolic process 3.352E-14 240 4667 
7 regulation of nitrogen compound metabolic process 8.374E-14 215 4061 
8 regulation of transcription, DNA-dependent 1.147E-13 184 3300 
9 regulation of RNA metabolic process 3.659E-13 185 3366 
10 regulation of cellular biosynthetic process 1.055E-12 204 3881 
11 regulation of cellular macromolecule biosynthetic process 2.899E-12 190 3568 
12 enzyme linked receptor protein signaling pathway 3.111E-12 68 819 
13 regulation of biosynthetic process 3.156E-12 204 3925 
14 neurogenesis 1.900E-11 96 1425 
15 transcription, DNA-dependent 2.196E-11 148 2614 
16 regulation of macromolecule biosynthetic process 2.667E-11 190 3657 
17 regulation of gene expression 3.942E-11 194 3775 
18 regulation of cellular process 4.798E-11 400 9537 
19 cell projection morphogenesis 5.536E-11 60 720 
20 intracellular signal transduction 5.686E-11 106 1673 
21 generation of neurons 1.123E-10 90 1342 
22 cell part morphogenesis 1.133E-10 60 733 
23 neuron differentiation 1.193E-10 76 1050 
24 neuron development 1.312E-10 68 891 
25 cell projection organization 2.223E-10 69 922 
26 behavior 2.230E-10 52 596 
27 system development 2.356E-10 197 3930 
28 RNA biosynthetic process 2.595E-10 148 2704 
29 neuron projection development 3.879E-10 59 737 
30 regulation of biological process 4.252E-10 415 10123 
31 negative regulation of cellular process 9.646E-10 158 3002 
32 cell morphogenesis 1.249E-09 65 879 
33 biological regulation 1.460E-09 429 10630 
34 neuron projection morphogenesis 1.499E-09 53 648 
35 locomotory behavior 1.651E-09 26 195 
36 multicellular organismal development 1.825E-09 219 4605 
37 cell morphogenesis involved in neuron differentiation 1.853E-09 52 633 
38 regulation of signaling 2.489E-09 121 2139 
39 nerve growth factor receptor signaling pathway 3.012E-09 31 275 
40 transmembrane receptor protein tyrosine kinase signaling pathway 3.346E-09 51 625 
41 developmental process 3.599E-09 233 5016 
42 intracellular protein kinase cascade 3.804E-09 48 571 
43 anatomical structure development 4.201E-09 207 4329 
44 cell morphogenesis involved in differentiation 4.242E-09 56 726 
45 MAPKKK cascade 6.775E-09 34 333 
46 cellular component morphogenesis 7.352E-09 66 940 
47 adult locomotory behavior 8.041E-09 17 92 
48 regulation of molecular function 8.820E-09 127 2330 
49 cellular macromolecule metabolic process 1.060E-08 276 6261 
50 response to inorganic substance 1.489E-08 47 577 
51 cell development 1.543E-08 90 1482 
52 positive regulation of cell death 1.599E-08 57 774 
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53 negative regulation of signaling 1.615E-08 50 636 
54 central nervous system development 1.850E-08 63 900 
55 negative regulation of cell communication 1.879E-08 50 639 
56 regulation of signal transduction 1.920E-08 103 1788 
57 anatomical structure morphogenesis 3.383E-08 117 2141 
58 negative regulation of biological process 4.132E-08 163 3296 
59 positive regulation of programmed cell death 4.165E-08 55 755 
60 regulation of cell death 5.018E-08 91 1543 
61 regulation of programmed cell death 5.806E-08 89 1502 
62 axonogenesis 6.004E-08 47 604 
63 cognition 6.025E-08 28 263 
64 macromolecule metabolic process 6.649E-08 294 6885 
65 death 7.043E-08 74 1171 
66 learning or memory 7.709E-08 27 250 
67 positive regulation of apoptosis 7.809E-08 54 749 
68 regulation of catalytic activity 8.998E-08 107 1939 
69 cellular macromolecule biosynthetic process 1.043E-07 169 3497 
70 macromolecule biosynthetic process 1.128E-07 170 3527 
71 cell death 1.174E-07 73 1164 
72 positive regulation of molecular function 1.291E-07 85 1437 
73 neuron recognition 1.302E-07 10 35 
74 regulation of apoptosis 1.545E-07 87 1489 
75 negative regulation of heart contraction 1.802E-07 9 28 
76 negative regulation of signal transduction 1.858E-07 45 588 
77 adult walking behavior 2.274E-07 11 46 
78 response to morphine 2.274E-07 11 46 
79 adult behavior 2.670E-07 20 157 
80 response to isoquinoline alkaloid 2.880E-07 11 47 
81 regulation of heart contraction 3.044E-07 19 144 
82 response to metal ion 4.051E-07 34 394 
83 regulation of transferase activity 4.468E-07 50 708 
84 regulation of protein phosphorylation 5.745E-07 59 904 
85 response to estradiol stimulus 5.810E-07 22 195 
86 regulation of phosphorylation 5.956E-07 62 970 
87 regulation of lipase activity 5.976E-07 23 211 
88 regulation of phosphorus metabolic process 7.608E-07 63 999 
89 regulation of phosphate metabolic process 7.608E-07 63 999 
90 cellular developmental process 7.933E-07 145 2981 
91 response to alkaloid 8.020E-07 20 168 
92 regulation of cell communication 1.027E-06 87 1557 
93 regulation of kinase activity 1.035E-06 48 687 
94 signaling 1.124E-06 233 5359 
95 positive regulation of myeloid cell differentiation 1.131E-06 14 88 
96 regulation of synaptic transmission, GABAergic 1.145E-06 9 34 
97 regulation of response to stimulus 1.168E-06 123 2441 
98 positive regulation of transferase activity 1.452E-06 37 474 
99 forebrain development 1.455E-06 31 361 
100 SMAD protein import into nucleus 1.519E-06 7 19 
101 protein import into nucleus 1.605E-06 17 131 
102 regulation of system process 1.687E-06 45 637 
103 regulation of multicellular organismal process 1.712E-06 106 2036 
104 lymphocyte proliferation 1.838E-06 13 79 
105 positive regulation of myeloid leukocyte differentiation 1.877E-06 11 56 
106 negative regulation of DNA binding 1.936E-06 9 36 
107 regulation of protein kinase activity 1.941E-06 46 661 
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108 regulation of hydrolase activity 2.008E-06 61 984 
109 positive regulation of kinase activity 2.095E-06 36 462 
110 cell differentiation 2.176E-06 140 2905 
111 nuclear import 2.206E-06 17 134 
112 negative regulation of systemic arterial blood pressure 2.270E-06 7 20 
113 protein phosphorylation 2.299E-06 57 900 
114 regulation of synaptic transmission 2.366E-06 27 297 
115 ephrin receptor signaling pathway 2.418E-06 8 28 
116 regulation of multicellular organismal development 2.445E-06 73 1262 
117 regulation of phospholipase activity 2.600E-06 20 181 
118 positive regulation of protein kinase activity 2.602E-06 35 447 
119 positive regulation of catalytic activity 2.744E-06 72 1243 
120 mononuclear cell proliferation 2.836E-06 13 82 
121 positive regulation of hydrolase activity 2.903E-06 46 671 
122 negative regulation of biosynthetic process 3.104E-06 66 1110 
123 regulation of cell differentiation 3.198E-06 66 1111 
124 leukocyte proliferation 3.262E-06 13 83 
125 primary metabolic process 3.270E-06 343 8592 
126 macromolecule modification 3.365E-06 116 2316 
127 circulatory system development 3.450E-06 52 803 
128 cardiovascular system development 3.450E-06 52 803 
129 protein modification process 3.602E-06 111 2194 
130 biosynthetic process 3.615E-06 198 4475 
131 regulation of transmission of nerve impulse 3.667E-06 28 322 
132 response to organic cyclic compound 3.759E-06 36 474 
133 inhibition of adenylate cyclase activity by G-protein signaling pathway 3.979E-06 12 72 
134 cellular metabolic process 4.011E-06 342 8579 
135 negative regulation of nitrogen compound metabolic process 4.460E-06 61 1009 
136 negative regulation of cellular biosynthetic process 4.501E-06 64 1077 
137 regulation of dephosphorylation 4.535E-06 11 61 
138 negative regulation of cellular macromolecule biosynthetic process 4.745E-06 61 1011 
139 anatomical structure formation involved in morphogenesis 4.850E-06 51 791 
140 regulation of transcription from RNA polymerase II promoter 4.937E-06 75 1334 
141 negative regulation of molecular function 4.975E-06 55 879 
142 regulation of neurological system process 5.088E-06 29 346 
143 cellular biosynthetic process 5.130E-06 193 4362 
144 vasculature development 5.477E-06 38 522 
145 positive regulation of phospholipase activity 5.962E-06 19 175 
146 signal transduction 6.048E-06 213 4921 
147 smooth muscle contraction 6.289E-06 11 63 
148 neural precursor cell proliferation 6.289E-06 11 63 
149 regulation of cardiac muscle contraction 6.581E-06 7 23 
150 brain development 6.824E-06 45 672 
151 positive regulation of biological process 7.140E-06 169 3736 
152 blood vessel development 7.538E-06 36 489 
153 regulation of myeloid cell differentiation 7.546E-06 18 162 
154 metabolic process 7.703E-06 378 9707 
155 positive regulation by host of viral transcription 7.827E-06 6 16 
156 negative regulation of response to stimulus 8.600E-06 49 764 
157 protein import 8.763E-06 20 196 
158 activation of phospholipase C activity 8.960E-06 18 164 
159 regulation of developmental process 9.052E-06 83 1548 
160 negative regulation of osteoblast differentiation 9.327E-06 8 33 
161 negative regulation of binding 9.383E-06 12 78 
162 negative regulation of macromolecule biosynthetic process 9.575E-06 62 1057 
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163 limbic system development 9.608E-06 14 105 
164 positive regulation of phospholipase C activity 9.752E-06 18 165 
165 programmed cell death 9.910E-06 59 990 
166 cellular component organization at cellular level 1.018E-05 150 3253 
167 negative regulation of RNA metabolic process 1.140E-05 56 927 
168 negative regulation of transmission of nerve impulse 1.140E-05 10 55 
169 RNA metabolic process 1.145E-05 156 3419 
170 two-component signal transduction system (phosphorelay) 1.176E-05 6 17 
171 negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic 
process 
1.186E-05 59 996 
172 cAMP-mediated signaling 1.233E-05 19 184 
173 negative regulation of transcription, DNA-dependent 1.348E-05 55 910 
174 cyclic nucleotide metabolic process 1.396E-05 12 81 
175 gene expression 1.434E-05 162 3593 
176 positive regulation of lipase activity 1.553E-05 19 187 
177 nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 1.574E-05 203 4713 
178 regulation of binding 1.587E-05 20 204 
179 regulation of membrane potential 1.588E-05 24 274 
180 modulation by host of symbiont transcription 1.619E-05 7 26 
181 modulation by host of viral transcription 1.619E-05 7 26 
182 telencephalon cell migration 1.685E-05 9 46 
183 positive regulation of action potential 1.703E-05 4 6 
184 negative regulation of adenylate cyclase activity 1.799E-05 12 83 
185 negative regulation of lyase activity 1.799E-05 12 83 
186 negative regulation of cyclase activity 1.799E-05 12 83 
187 regulation of DNA binding 1.799E-05 12 83 
188 cellular nitrogen compound metabolic process 1.845E-05 220 5196 
189 cellular component organization 1.862E-05 183 4177 
190 nucleic acid metabolic process 1.954E-05 172 3882 
191 modulation of transcription in other organism involved in symbiotic interaction 2.124E-05 7 27 
192 apoptosis 2.169E-05 57 971 
193 response to tropane 2.174E-05 10 59 
194 response to cocaine 2.174E-05 10 59 
195 positive regulation of cellular process 2.372E-05 153 3385 
196 negative regulation of synaptic transmission 2.417E-05 9 48 
197 transmembrane receptor protein serine/threonine kinase signaling pathway 2.552E-05 18 177 
198 regulation of osteoblast differentiation 2.618E-05 13 100 
199 phosphate metabolic process 2.793E-05 77 1451 
200 phosphorus metabolic process 2.859E-05 77 1452 
201 forebrain cell migration 2.875E-05 9 49 
202 cell proliferation 2.982E-05 47 757 
203 phosphorylation 3.316E-05 67 1219 
204 negative regulation of programmed cell death 3.400E-05 45 717 
205 negative regulation of neurological system process 3.403E-05 10 62 
206 organic alcohol transport 3.467E-05 8 39 
207 regulation of epithelial cell migration 3.523E-05 7 29 
208 vocalization behavior 3.628E-05 3 3 
209 positive regulation of developmental process 3.839E-05 48 787 
210 leading edge cell differentiation 3.869E-05 4 7 
211 activation of phospholipase C activity by muscarinic acetylcholine receptor signaling 
pathway 
3.869E-05 4 7 
212 protein localization to nucleus 3.886E-05 17 166 
213 regulation of vasoconstriction 3.960E-05 11 76 
214 regulation of nucleotide metabolic process 4.044E-05 38 571 
215 negative regulation of heart rate 4.070E-05 5 13 
216 cellular component organization or biogenesis at cellular level 4.091E-05 151 3367 
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217 membrane depolarization 4.120E-05 12 90 
218 regulation of growth 4.174E-05 41 636 
219 positive regulation of amine transport 4.209E-05 8 40 
220 negative regulation of cell death 4.279E-05 46 746 
221 negative regulation of developmental process 4.359E-05 38 573 
222 positive regulation of protein serine/threonine kinase activity 4.371E-05 23 273 
223 response to estrogen stimulus 4.467E-05 24 292 
224 regulation of locomotion 4.611E-05 33 470 
225 response to external stimulus 4.644E-05 79 1522 
226 nitrogen compound metabolic process 4.792E-05 222 5326 
227 gliogenesis 4.882E-05 17 169 
228 negative regulation of Wnt receptor signaling pathway 4.885E-05 13 106 
229 regulation of protein modification process 4.906E-05 61 1093 
230 angiogenesis 4.996E-05 25 313 
231 cAMP metabolic process 5.079E-05 8 41 
232 outflow tract morphogenesis 5.079E-05 8 41 
233 regulation of small GTPase mediated signal transduction 5.238E-05 30 412 
234 positive regulation of growth 5.303E-05 18 187 
235 memory 5.395E-05 13 107 
236 negative regulation of apoptosis 5.401E-05 44 709 
237 regulation of cell development 5.852E-05 38 581 
238 telencephalon development 6.072E-05 20 224 
239 positive regulation of epithelial cell migration 6.151E-05 6 22 
240 synaptic transmission 6.362E-05 42 670 
241 regulation of cell migration 6.813E-05 30 418 
242 axon guidance 6.845E-05 32 459 
243 multicellular organismal signaling 7.097E-05 46 762 
244 transmission of nerve impulse 7.097E-05 46 762 
245 protein targeting 7.147E-05 25 320 
246 cellular component organization or biogenesis 7.395E-05 184 4304 
247 positive regulation of phosphoprotein phosphatase activity 7.535E-05 4 8 
248 regulation of vascular smooth muscle contraction 7.535E-05 4 8 
249 axial mesoderm morphogenesis 7.535E-05 4 8 
250 positive regulation of MAP kinase activity 7.770E-05 20 228 
251 regulation of Ras protein signal transduction 7.897E-05 25 322 
252 negative regulation of catalytic activity 8.204E-05 44 722 
253 regulation of MAP kinase activity 8.423E-05 24 304 
254 response to lithium ion 8.623E-05 9 56 
255 interaction with symbiont 8.631E-05 8 44 
256 positive regulation of synaptic transmission, GABAergic 8.987E-05 5 15 
257 regulation of smooth muscle cell proliferation 9.050E-05 14 128 
258 negative regulation of transcription from RNA polymerase II promoter 9.156E-05 37 572 
259 response to hydrogen peroxide 9.738E-05 15 145 
260 positive regulation of epithelial cell proliferation 1.004E-04 16 162 
261 negative regulation of cell differentiation 1.023E-04 32 469 
262 modification by host of symbiont morphology or physiology 1.051E-04 7 34 
263 membrane hyperpolarization 1.051E-04 7 34 
264 regulation of the force of heart contraction 1.051E-04 7 34 
265 positive regulation of response to stimulus 1.058E-04 63 1171 
266 cell recognition 1.060E-04 12 99 
267 regulation of ossification 1.073E-04 17 180 
268 regulation of muscle system process 1.080E-04 16 163 
269 behavioral interaction between organisms 1.118E-04 10 71 
270 response to oxidative stress 1.126E-04 26 349 
271 cell communication 1.133E-04 73 1416 
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272 embryonic appendage morphogenesis 1.137E-04 15 147 
273 embryonic limb morphogenesis 1.137E-04 15 147 
274 regulation of blood vessel endothelial cell migration 1.199E-04 8 46 
275 regulation of cell motility 1.226E-04 30 432 
276 negative regulation of cell proliferation 1.229E-04 40 646 
277 glial cell migration 1.272E-04 5 16 
278 negative regulation of synaptic transmission, GABAergic 1.272E-04 5 16 
279 fat cell differentiation 1.363E-04 13 117 
280 blood vessel morphogenesis 1.365E-04 29 414 
281 regulation of phosphatidylinositol dephosphorylation 1.415E-04 3 4 
282 territorial aggressive behavior 1.415E-04 3 4 
283 Notch signaling pathway 1.418E-04 10 73 
284 regulation of cell proliferation 1.434E-04 73 1427 
285 tissue remodeling 1.486E-04 13 118 
286 regulation of anatomical structure morphogenesis 1.497E-04 38 608 
287 positive regulation of ion transmembrane transporter activity 1.540E-04 7 36 
288 positive regulation of transcription, DNA-dependent 1.618E-04 61 1141 
289 activation of protein kinase activity 1.621E-04 18 204 
290 regulation of synaptic transmission, glutamatergic 1.635E-04 8 48 
291 induction of programmed cell death 1.687E-04 32 482 
292 heart development 1.687E-04 32 482 
293 neural tube development 1.779E-04 15 153 
294 patterning of blood vessels 1.898E-04 8 49 
295 regulation of adenylate cyclase activity 1.912E-04 15 154 
296 positive regulation of GTPase activity 1.996E-04 23 302 
297 negative regulation of neuron apoptosis 2.079E-04 13 122 
298 cellular chemical homeostasis 2.104E-04 45 776 
299 regulation of phosphoprotein phosphatase activity 2.119E-04 6 27 
300 cellular ion homeostasis 2.138E-04 43 731 
301 aggressive behavior 2.144E-04 4 10 
302 axial mesoderm development 2.144E-04 4 10 
303 cellular response to potassium ion starvation 2.144E-04 4 10 
304 positive regulation of monocyte differentiation 2.144E-04 4 10 
305 regulation of angiogenesis 2.159E-04 16 173 
306 T cell proliferation 2.195E-04 8 50 
307 positive regulation of transcription from RNA polymerase II promoter 2.227E-04 45 778 
308 ion homeostasis 2.227E-04 45 778 
309 cyclic-nucleotide-mediated signaling 2.266E-04 19 228 
310 negative regulation of gene expression 2.270E-04 55 1012 
311 locomotion 2.299E-04 60 1132 
312 skeletal system development 2.304E-04 29 427 
313 protein localization to organelle 2.324E-04 24 325 
314 regulation of cAMP biosynthetic process 2.462E-04 16 175 
315 organ development 2.500E-04 128 2875 
316 vasodilation 2.529E-04 8 51 
317 regulation of cyclase activity 2.534E-04 15 158 
318 positive regulation of transporter activity 2.603E-04 7 39 
319 positive regulation of nitrogen compound metabolic process 2.722E-04 69 1359 
320 positive regulation of RNA metabolic process 2.798E-04 62 1189 
321 appendage development 2.801E-04 16 177 
322 limb development 2.801E-04 16 177 
323 muscle system process 2.877E-04 22 290 
324 regulation of lyase activity 2.905E-04 15 160 
325 regulation of muscle contraction 2.936E-04 14 143 
326 taxis 2.949E-04 40 674 
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327 regulation of cAMP metabolic process 2.985E-04 16 178 
328 regulation of protein serine/threonine kinase activity 3.019E-04 29 434 
329 osteoblast differentiation 3.059E-04 11 95 
330 social behavior 3.066E-04 7 40 
331 inositol phosphate metabolic process 3.117E-04 5 19 
332 negative regulation by host of viral transcription 3.117E-04 5 19 
333 induction of apoptosis 3.184E-04 31 478 
334 neurological system process involved in regulation of systemic arterial blood pressure 3.213E-04 6 29 
335 forebrain neuroblast division 3.280E-04 4 11 
336 neuroblast division 3.280E-04 4 11 
337 positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic 
process 
3.302E-04 67 1319 
338 regulation of blood vessel size 3.353E-04 11 96 
339 positive regulation of angiogenesis 3.353E-04 11 96 
340 cardiolipin biosynthetic process 3.451E-04 3 5 
341 regulation of mismatch repair 3.451E-04 3 5 
342 termination of signal transduction 3.451E-04 3 5 
343 brainstem development 3.451E-04 3 5 
344 male courtship behavior 3.451E-04 3 5 
345 inhibition of adenylate cyclase activity by muscarinic acetylcholine receptor signaling 
pathway 
3.451E-04 3 5 
346 phosphatidylglycerol biosynthetic process 3.451E-04 3 5 
347 norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial 
blood pressure 
3.451E-04 3 5 
348 regulation of anatomical structure size 3.469E-04 37 612 
349 regulation of neuron apoptosis 3.506E-04 19 236 
350 reproductive behavior 3.593E-04 7 41 
351 regulation of ion transmembrane transporter activity 3.671E-04 11 97 
352 regulation of Ras GTPase activity 3.783E-04 17 200 
353 positive regulation of neuron apoptosis 3.787E-04 8 54 
354 negative regulation of phosphorus metabolic process 3.891E-04 13 130 
355 negative regulation of phosphate metabolic process 3.891E-04 13 130 
356 multicellular organismal process 3.896E-04 265 6739 
357 regulation of synapse structure and activity 3.941E-04 9 68 
358 regulation of tube size 4.014E-04 11 98 
359 cAMP biosynthetic process 4.043E-04 5 20 
360 regulation of cellular component movement 4.160E-04 30 464 
361 positive regulation of muscle contraction 4.190E-04 7 42 
362 cellular protein metabolic process 4.243E-04 129 2939 
363 regulation of cellular protein metabolic process 4.261E-04 69 1381 
364 regulation of GTP catabolic process 4.303E-04 24 339 
365 mating 4.304E-04 8 55 
366 negative regulation of blood pressure 4.304E-04 8 55 
367 positive regulation of cell differentiation 4.492E-04 36 598 
368 chemical homeostasis 4.521E-04 53 993 
369 associative learning 4.548E-04 10 84 
370 stress-activated protein kinase signaling cascade 4.598E-04 15 167 
371 mating behavior 4.708E-04 6 31 
372 cellular response to calcium ion 4.708E-04 6 31 
373 pallium development 4.788E-04 14 150 
374 regulation of calcium ion transport via store-operated calcium channel activity 4.792E-04 4 12 
375 positive regulation of granulocyte differentiation 4.792E-04 4 12 
376 positive regulation of blood pressure by epinephrine-norepinephrine 4.792E-04 4 12 
377 response to calcium ion 4.852E-04 13 133 
378 regulation of receptor activity 4.904E-04 9 70 
379 negative regulation of cellular metabolic process 4.982E-04 68 1364 
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380 regulation of intracellular protein kinase cascade 5.153E-04 37 625 
381 negative regulation of viral transcription 5.162E-04 5 21 
382 microglial cell activation 5.162E-04 5 21 
383 response to organic substance 5.199E-04 107 2368 
384 circadian rhythm 5.214E-04 13 134 
385 positive regulation of cell proliferation 5.370E-04 46 834 
386 cellular response to peptide hormone stimulus 5.394E-04 26 386 
387 cellular process 5.412E-04 524 14653 
388 stem cell development 5.454E-04 9 71 
389 positive regulation of Ras GTPase activity 5.471E-04 14 152 
390 appendage morphogenesis 5.548E-04 15 170 
391 limb morphogenesis 5.548E-04 15 170 
392 regulation of sensory perception of pain 5.620E-04 7 44 
393 regulation of sensory perception 5.620E-04 7 44 
394 synaptic transmission, cholinergic 5.633E-04 6 32 
395 regulation of transmembrane transporter activity 5.665E-04 11 102 
396 regulation of cellular component organization 5.694E-04 66 1321 
397 second-messenger-mediated signaling 5.726E-04 28 430 
398 response to cytokine stimulus 6.065E-04 34 563 
399 cellular response to stimulus 6.304E-04 238 6009 
400 learning 6.440E-04 13 137 
401 muscle contraction 6.462E-04 19 248 
402 regulation of striated muscle contraction 6.468E-04 7 45 
403 positive regulation of cell migration 6.565E-04 20 268 
404 regulation of muscle adaptation 6.694E-04 6 33 
405 long-term memory 6.694E-04 6 33 
406 regulation of endothelial cell migration 6.705E-04 9 73 
407 positive regulation of endothelial cell proliferation 6.705E-04 9 73 
408 somatic recombination of T cell receptor gene segments 6.731E-04 3 6 
409 T cell receptor V(D)J recombination 6.731E-04 3 6 
410 phosphatidylglycerol metabolic process 6.731E-04 3 6 
411 cardiolipin metabolic process 6.731E-04 3 6 
412 baroreceptor response to increased systemic arterial blood pressure 6.731E-04 3 6 
413 branching morphogenesis of a nerve 6.731E-04 3 6 
414 somatic diversification of T cell receptor genes 6.731E-04 3 6 
415 adrenergic receptor signaling pathway 6.740E-04 4 13 
416 regulation of systemic arterial blood pressure by norepinephrine-epinephrine 6.740E-04 4 13 
417 positive regulation of protein dephosphorylation 6.740E-04 4 13 
418 regulation of catecholamine secretion 6.980E-04 8 59 
419 cerebral cortex development 7.225E-04 10 89 
420 chondrocyte differentiation 7.413E-04 7 46 
421 activation of immune response 7.876E-04 23 333 
422 central nervous system neuron differentiation 7.901E-04 13 140 
423 release of cytochrome c from mitochondria 7.904E-04 6 34 
424 response to iron ion 7.904E-04 6 34 
425 macrophage activation 7.904E-04 6 34 
426 regulation of dopamine secretion 7.904E-04 6 34 
427 positive regulation of smooth muscle contraction 7.904E-04 6 34 
428 negative regulation of phosphorylation 8.034E-04 12 123 
429 regulation of receptor recycling 8.080E-04 5 23 
430 positive regulation of organ growth 8.080E-04 5 23 
431 response to peptide hormone stimulus 8.088E-04 35 595 
432 immune response-activating signal transduction 8.219E-04 19 253 
433 regulation of purine nucleotide catabolic process 8.238E-04 25 376 
434 regulation of nucleotide catabolic process 8.238E-04 25 376 
   202 
435 regeneration 8.609E-04 17 215 
436 regulation of cyclic nucleotide biosynthetic process 8.611E-04 16 196 
437 regulation of nucleotide biosynthetic process 8.611E-04 16 196 
438 positive regulation of gene expression 8.848E-04 61 1219 
439 regulation of GTPase activity 8.889E-04 23 336 
440 regulation of organ growth 9.012E-04 9 76 
441 positive regulation of cell motility 9.041E-04 20 275 
442 regulation of protein metabolic process 9.077E-04 74 1547 
443 small GTPase mediated signal transduction 9.103E-04 29 465 
444 positive regulation of dephosphorylation 9.190E-04 4 14 
445 regulation of monocyte differentiation 9.190E-04 4 14 
446 negative regulation of protein autophosphorylation 9.190E-04 4 14 
447 regulation of epithelial cell proliferation 9.459E-04 19 256 
448 regulation of Wnt receptor signaling pathway 9.464E-04 15 179 
449 circulatory system process 9.625E-04 23 338 
450 regulation of cell growth 9.929E-04 25 381 
451 positive regulation of epithelial to mesenchymal transition 9.931E-04 5 24 
452 regulation of cardiac muscle hypertrophy 9.931E-04 5 24 
453 regulation of dopamine metabolic process 9.931E-04 5 24 
454 regulation of inhibitory postsynaptic membrane potential 9.931E-04 5 24 
455 regulation of peptide hormone secretion 1.012E-03 16 199 
456 chemotaxis 1.022E-03 38 672 
457 induction of apoptosis by extracellular signals 1.027E-03 13 144 
458 negative regulation of multicellular organismal process 1.051E-03 26 404 
459 nucleoside monophosphate metabolic process 1.066E-03 12 127 
460 regulation of cell morphogenesis involved in differentiation 1.067E-03 16 200 
461 embryonic morphogenesis 1.095E-03 33 560 
462 regulation of synaptic activity 1.097E-03 2 2 
463 negative regulation of heart rate involved in baroreceptor response to increased 
systemic arterial blood pressure 
1.097E-03 2 2 
464 thigmotaxis 1.097E-03 2 2 
465 negative regulation of the force of heart contraction involved in baroreceptor response to 
increased systemic arterial blood pressure 
1.097E-03 2 2 
466 jump response 1.097E-03 2 2 
467 regulation of chondrocyte development 1.097E-03 2 2 
468 odontoblast differentiation 1.097E-03 2 2 
469 cell-cell signaling 1.098E-03 54 1057 
470 regulation of cell size 1.102E-03 27 427 
471 positive regulation of adenylate cyclase activity 1.108E-03 10 94 
472 biological adhesion 1.118E-03 47 888 
473 response to reactive oxygen species 1.120E-03 15 182 
474 response to cAMP 1.141E-03 12 128 
475 epithelium development 1.145E-03 36 630 
476 forebrain ventricular zone progenitor cell division 1.149E-03 3 7 
477 regulation of hormone secretion 1.186E-03 18 241 
478 regulation of postsynaptic membrane potential 1.206E-03 8 64 
479 regulation of cell-cell adhesion 1.206E-03 8 64 
480 somatic stem cell division 1.208E-03 5 25 
481 paraxial mesoderm development 1.208E-03 5 25 
482 positive regulation of catecholamine secretion 1.208E-03 5 25 
483 regulation of muscle hypertrophy 1.208E-03 5 25 
484 response to lipopolysaccharide 1.214E-03 22 323 
485 negative regulation of synaptic transmission, glutamatergic 1.220E-03 4 15 
486 estrous cycle phase 1.220E-03 4 15 
487 anatomical structure regression 1.220E-03 4 15 
488 G-protein signaling, coupled to cAMP nucleotide second messenger 1.226E-03 14 165 
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489 cyclic nucleotide biosynthetic process 1.234E-03 7 50 
490 immune response-regulating signaling pathway 1.243E-03 19 262 
491 nucleocytoplasmic transport 1.243E-03 19 262 
492 regulation of peptide secretion 1.248E-03 16 203 
493 regulation of peptide transport 1.248E-03 16 203 
494 negative regulation of macromolecule metabolic process 1.288E-03 67 1389 
495 anti-apoptosis 1.305E-03 21 304 
496 regulation of myeloid leukocyte differentiation 1.333E-03 11 113 
497 regulation of striated muscle tissue development 1.333E-03 11 113 
498 fibroblast growth factor receptor signaling pathway 1.336E-03 8 65 
499 stem cell maintenance 1.336E-03 8 65 
500 regulation of transmembrane transport 1.374E-03 25 390 
501 positive regulation of locomotion 1.394E-03 20 285 
502 positive regulation of cyclase activity 1.411E-03 10 97 
503 regulation of transporter activity 1.432E-03 11 114 
504 regulation of phosphatase activity 1.450E-03 6 38 
505 positive regulation of blood vessel endothelial cell migration 1.455E-03 5 26 
506 B cell proliferation 1.455E-03 5 26 
507 muscarinic acetylcholine receptor signaling pathway 1.455E-03 5 26 
508 nuclear transport 1.482E-03 19 266 
509 tissue development 1.504E-03 65 1347 
510 regulation of cyclic nucleotide metabolic process 1.529E-03 16 207 
511 regulation of muscle organ development 1.538E-03 11 115 
512 calcium ion transport into cytosol 1.561E-03 7 52 
513 cellular homeostasis 1.576E-03 46 879 
514 reduction of cytosolic calcium ion concentration 1.585E-03 4 16 
515 mammary gland development 1.629E-03 14 170 
516 regulation of neuron differentiation 1.636E-03 25 395 
517 positive regulation of cellular component movement 1.646E-03 20 289 
518 regulation of multicellular organism growth 1.648E-03 10 99 
519 positive regulation of lyase activity 1.648E-03 10 99 
520 vascular process in circulatory system 1.649E-03 11 116 
521 release of sequestered calcium ion into cytosol 1.666E-03 6 39 
522 negative regulation of sequestering of calcium ion 1.666E-03 6 39 
523 cellular component maintenance 1.666E-03 6 39 
524 positive regulation of vasoconstriction 1.666E-03 6 39 
525 regulation of ion transmembrane transport 1.709E-03 18 249 
526 regulation of Rho protein signal transduction 1.722E-03 14 171 
527 cell adhesion 1.724E-03 46 883 
528 negative regulation of cell-cell adhesion 1.738E-03 5 27 
529 regulation of catecholamine metabolic process 1.738E-03 5 27 
530 dorsal/ventral neural tube patterning 1.738E-03 5 27 
531 motor axon guidance 1.738E-03 5 27 
532 sleep 1.738E-03 5 27 
533 response to stimulus 1.740E-03 301 7952 
534 regulation of excitatory postsynaptic membrane potential 1.748E-03 7 53 
535 activation of protein kinase C activity by G-protein coupled receptor protein signaling 
pathway 
1.748E-03 7 53 
536 regulation of heart rate 1.748E-03 7 53 
537 regulation of monocyte chemotaxis 1.793E-03 3 8 
538 intramembranous ossification 1.793E-03 3 8 
539 positive regulation of chronic inflammatory response 1.793E-03 3 8 
540 positive regulation of the force of heart contraction by epinephrine-norepinephrine 1.793E-03 3 8 
541 astrocyte cell migration 1.793E-03 3 8 
542 positive regulation of monocyte chemotaxis 1.793E-03 3 8 
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543 male mating behavior 1.793E-03 3 8 
544 regulation of amine transport 1.843E-03 9 84 
545 activation of MAPK activity 1.921E-03 14 173 
546 blood circulation 1.925E-03 22 335 
547 regulation of cellular component size 1.928E-03 31 534 
548 regulation of nervous system development 1.928E-03 31 534 
549 cytosolic calcium ion transport 1.952E-03 7 54 
550 regulation of skeletal muscle tissue development 1.971E-03 8 69 
551 pattern specification process 1.975E-03 28 467 
552 positive regulation of cardiac muscle hypertrophy 2.019E-03 4 17 
553 positive regulation of muscle hypertrophy 2.019E-03 4 17 
554 positive regulation of phosphatase activity 2.019E-03 4 17 
555 dentate gyrus development 2.019E-03 4 17 
556 suckling behavior 2.019E-03 4 17 
557 catecholamine transport 2.019E-03 4 17 
558 response to toxin 2.027E-03 14 174 
559 protein metabolic process 2.055E-03 146 3529 
560 regulation of epidermal growth factor receptor activity 2.058E-03 5 28 
561 central nervous system neuron axonogenesis 2.058E-03 5 28 
562 multicellular organismal reproductive behavior 2.058E-03 5 28 
563 organ morphogenesis 2.061E-03 50 989 
564 negative regulation of metabolic process 2.079E-03 70 1493 
565 leukocyte activation 2.100E-03 28 469 
566 macromolecule methylation 2.121E-03 13 156 
567 regulation of cellular catabolic process 2.164E-03 32 561 
568 regulation of sequestering of calcium ion 2.172E-03 6 41 
569 negative regulation of protein phosphorylation 2.172E-03 9 86 
570 positive regulation of smooth muscle cell proliferation 2.172E-03 9 86 
571 embryo development 2.189E-03 54 1091 
572 regulation of protein binding 2.219E-03 10 103 
573 positive regulation of signaling 2.287E-03 42 799 
574 cell activation 2.289E-03 41 775 
575 hippocampus development 2.353E-03 9 87 
576 positive regulation of Rho GTPase activity 2.367E-03 8 71 
577 cell surface receptor linked signaling pathway 2.370E-03 132 3156 
578 neuroblast proliferation 2.420E-03 5 29 
579 lymphocyte activation 2.444E-03 24 385 
580 forebrain generation of neurons 2.464E-03 6 42 
581 response to hypoxia 2.484E-03 22 342 
582 cyclic nucleotide catabolic process 2.528E-03 4 18 
583 chemosensory behavior 2.528E-03 4 18 
584 transcription from RNA polymerase II promoter 2.557E-03 27 453 
585 neuromuscular process 2.558E-03 10 105 
586 maintenance of DNA repeat elements 2.624E-03 3 9 
587 positive regulation of heart rate by epinephrine-norepinephrine 2.624E-03 3 9 
588 short-term memory 2.624E-03 3 9 
589 regulation of phospholipase A2 activity 2.624E-03 3 9 
590 positive regulation of the force of heart contraction by chemical signal 2.624E-03 3 9 
591 regulation of establishment of protein localization 2.645E-03 20 301 
592 synapse assembly 2.676E-03 7 57 
593 regulation of neurogenesis 2.750E-03 28 478 
594 negative regulation of locomotion 2.758E-03 12 142 
595 neural tube patterning 2.784E-03 6 43 
596 response to starvation 2.800E-03 11 124 
597 divalent metal ion transport 2.850E-03 18 261 
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598 response to hormone stimulus 2.901E-03 56 1156 
599 calcium ion transport 2.964E-03 16 221 
600 positive regulation of cell development 2.965E-03 15 201 
601 cellular response to hormone stimulus 3.045E-03 33 597 
602 negative regulation of canonical Wnt receptor signaling pathway 3.076E-03 8 74 
603 positive regulation of synaptic transmission 3.076E-03 8 74 
604 cellular response to endogenous stimulus 3.090E-03 39 740 
605 response to endogenous stimulus 3.099E-03 64 1363 
606 positive regulation of nervous system development 3.119E-03 4 19 
607 positive regulation of synaptogenesis 3.119E-03 4 19 
608 positive regulation of renal sodium excretion 3.119E-03 4 19 
609 positive regulation of synaptic transmission, glutamatergic 3.119E-03 4 19 
610 response to amphetamine 3.135E-03 6 44 
611 positive regulation of cellular metabolic process 3.215E-03 84 1886 
612 thymidine metabolic process 3.220E-03 2 3 
613 regulation of cell proliferation in bone marrow 3.220E-03 2 3 
614 T-helper 17 cell chemotaxis 3.220E-03 2 3 
615 negative regulation of eosinophil degranulation 3.220E-03 2 3 
616 muscle cell fate determination 3.220E-03 2 3 
617 regulation of apoptosis in bone marrow 3.220E-03 2 3 
618 regulation of eosinophil degranulation 3.220E-03 2 3 
619 T cell chemotaxis 3.220E-03 2 3 
620 helper T cell chemotaxis 3.220E-03 2 3 
621 amygdala development 3.220E-03 2 3 
622 terminal button organization 3.220E-03 2 3 
623 neurohypophysis development 3.220E-03 2 3 
624 monocyte extravasation 3.220E-03 2 3 
625 positive regulation of T cell extravasation 3.220E-03 2 3 
626 negative regulation of icosanoid secretion 3.220E-03 2 3 
627 positive regulation of cell proliferation in bone marrow 3.220E-03 2 3 
628 regulation of estrogen receptor binding 3.220E-03 2 3 
629 neutrophil differentiation 3.220E-03 2 3 
630 regulation of T cell extravasation 3.220E-03 2 3 
631 negative regulation of apoptosis in bone marrow 3.220E-03 2 3 
632 chondrocyte differentiation involved in endochondral bone morphogenesis 3.220E-03 2 3 
633 negative regulation of estrogen receptor binding 3.220E-03 2 3 
634 synaptic target recognition 3.220E-03 2 3 
635 formation of radial glial scaffolds 3.220E-03 2 3 
636 activation of MAPKK activity 3.262E-03 7 59 
637 positive regulation of macromolecule biosynthetic process 3.269E-03 62 1315 
638 cell proliferation in forebrain 3.279E-03 5 31 
639 positive regulation of cell morphogenesis involved in differentiation 3.279E-03 5 31 
640 cerebral cortex cell migration 3.279E-03 5 31 
641 response to molecule of bacterial origin 3.285E-03 22 350 
642 cilium morphogenesis 3.346E-03 8 75 
643 sensory perception of taste 3.346E-03 8 75 
644 divalent inorganic cation transport 3.349E-03 18 265 
645 positive regulation of defense response 3.349E-03 18 265 
646 feeding behavior 3.370E-03 11 127 
647 multi-organism process 3.400E-03 66 1420 
648 activation of adenylate cyclase activity 3.446E-03 9 92 
649 protein methylation 3.446E-03 9 92 
650 protein alkylation 3.446E-03 9 92 
651 regulation of homeostatic process 3.474E-03 19 287 
652 bone remodeling 3.518E-03 6 45 
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653 positive regulation of endothelial cell migration 3.518E-03 6 45 
654 positive regulation of cellular biosynthetic process 3.524E-03 67 1448 
655 cellular response to organic substance 3.557E-03 62 1320 
656 tube development 3.566E-03 29 510 
657 positive regulation of inflammatory response 3.592E-03 10 110 
658 positive regulation of adenylate cyclase activity by G-protein signaling pathway 3.633E-03 8 76 
659 regulation of adenylate cyclase activity involved in G-protein signaling pathway 3.633E-03 8 76 
660 activation of adenylate cyclase activity by G-protein signaling pathway 3.633E-03 8 76 
661 positive regulation of calcium ion transport via store-operated calcium channel activity 3.656E-03 3 10 
662 photoperiodism 3.656E-03 3 10 
663 regulation of systemic arterial blood pressure by carotid sinus baroreceptor feedback 3.656E-03 3 10 
664 positive regulation of macromolecule metabolic process 3.769E-03 81 1818 
665 stem cell division 3.782E-03 5 32 
666 Notch receptor processing 3.798E-03 4 20 
667 positive regulation of cellular component biogenesis 3.798E-03 4 20 
668 regulation of protein dephosphorylation 3.798E-03 4 20 
669 hypothalamus development 3.798E-03 4 20 
670 negative regulation of striated muscle tissue development 3.798E-03 4 20 
671 activation of protein kinase A activity 3.798E-03 4 20 
672 intracellular protein transport 3.822E-03 31 559 
673 regulation of insulin secretion 3.908E-03 14 187 
674 regulation of organic acid transport 3.935E-03 6 46 
675 negative regulation of hormone secretion 3.940E-03 8 77 
676 embryo development ending in birth or egg hatching 3.983E-03 36 679 
677 response to oxygen levels 4.004E-03 23 378 
678 ossification 4.020E-03 16 228 
679 response to mechanical stimulus 4.020E-03 16 228 
680 symbiosis, encompassing mutualism through parasitism 4.030E-03 11 130 
681 regulation of caspase activity 4.098E-03 14 188 
682 regulation of organelle organization 4.212E-03 27 470 
683 regulation of cytoskeleton organization 4.238E-03 17 250 
684 cellular response to organic cyclic compound 4.265E-03 8 78 
685 response to drug 4.266E-03 35 658 
686 myeloid cell differentiation 4.274E-03 15 209 
687 mesenchyme development 4.308E-03 12 150 
688 positive regulation of fibroblast proliferation 4.319E-03 7 62 
689 central nervous system neuron development 4.319E-03 7 62 
690 histone methylation 4.319E-03 7 62 
691 regulation of lipoprotein lipase activity 4.338E-03 5 33 
692 positive regulation of vasodilation 4.338E-03 5 33 
693 negative regulation of exocytosis 4.570E-03 4 21 
694 positive regulation of transmission of nerve impulse 4.612E-03 8 79 
695 mesenchymal cell differentiation 4.636E-03 10 114 
696 regulation of ion homeostasis 4.789E-03 12 152 
697 negative regulation of smooth muscle cell migration 4.904E-03 3 11 
698 choline transport 4.904E-03 3 11 
699 regulation of the force of heart contraction by chemical signal 4.904E-03 3 11 
700 behavioral response to cocaine 4.904E-03 3 11 
701 T cell receptor signaling pathway 4.931E-03 10 115 
702 positive regulation of multicellular organism growth 4.949E-03 5 34 
703 regulation of protein autophosphorylation 4.949E-03 5 34 
704 lysosome organization 4.949E-03 5 34 
705 leukocyte differentiation 5.016E-03 19 297 
706 regulation of endopeptidase activity 5.197E-03 19 298 
707 gland development 5.206E-03 22 364 
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708 positive regulation of multicellular organismal process 5.224E-03 32 595 
709 regulation of cellular component biogenesis 5.239E-03 20 320 
710 regulation of protein localization 5.239E-03 21 342 
711 regulation of endothelial cell proliferation 5.244E-03 9 98 
712 segmentation 5.244E-03 9 98 
713 positive regulation of biosynthetic process 5.288E-03 67 1474 
714 regulation of systemic arterial blood pressure mediated by a chemical signal 5.404E-03 6 49 
715 histone lysine methylation 5.404E-03 6 49 
716 negative regulation of muscle organ development 5.441E-03 4 22 
717 phasic smooth muscle contraction 5.441E-03 4 22 
718 morphogenesis of an epithelium 5.469E-03 23 388 
719 chordate embryonic development 5.500E-03 35 669 
720 positive regulation of cell communication 5.535E-03 40 791 
721 divalent inorganic cation homeostasis 5.544E-03 22 366 
722 homeostatic process 5.619E-03 63 1374 
723 positive regulation of cell-cell adhesion 5.620E-03 5 35 
724 astrocyte differentiation 5.620E-03 5 35 
725 regulation of synaptogenesis 5.620E-03 5 35 
726 receptor internalization 5.620E-03 5 35 
727 carbohydrate homeostasis 5.657E-03 11 136 
728 glucose homeostasis 5.657E-03 11 136 
729 regulation of calcium ion transport 5.673E-03 13 175 
730 regulation of MAPKKK cascade 5.720E-03 22 367 
731 cellular response to chemical stimulus 5.754E-03 76 1716 
732 response to steroid hormone stimulus 5.904E-03 33 624 
733 regulation of skeletal muscle fiber development 5.972E-03 6 50 
734 transforming growth factor beta receptor signaling pathway 5.982E-03 9 100 
735 positive regulation of cell growth 6.261E-03 10 119 
736 heart morphogenesis 6.272E-03 15 218 
737 regulation of metal ion transport 6.272E-03 15 218 
738 respiratory system development 6.289E-03 16 239 
739 optic placode formation 6.298E-03 2 4 
740 regulation of calcium-dependent cell-cell adhesion 6.298E-03 2 4 
741 PML body organization 6.298E-03 2 4 
742 negative regulation of interleukin-13 production 6.298E-03 2 4 
743 regulation of immune complex clearance by monocytes and macrophages 6.298E-03 2 4 
744 stress granule disassembly 6.298E-03 2 4 
745 forebrain radial glial cell differentiation 6.298E-03 2 4 
746 vasodilation by angiotensin involved in regulation of systemic arterial blood pressure 6.298E-03 2 4 
747 establishment of synaptic specificity at neuromuscular junction 6.298E-03 2 4 
748 negative regulation of Wnt receptor signaling pathway involved in dorsal/ventral axis 
specification 
6.298E-03 2 4 
749 relaxation of cardiac muscle 6.298E-03 2 4 
750 cell proliferation in hindbrain 6.298E-03 2 4 
751 regulation of cardiac muscle contraction by calcium ion signaling 6.298E-03 2 4 
752 regulation of metanephros size 6.298E-03 2 4 
753 pyrimidine deoxyribonucleoside metabolic process 6.298E-03 2 4 
754 inositol trisphosphate biosynthetic process 6.298E-03 2 4 
755 trachea submucosa development 6.298E-03 2 4 
756 hypothalamus cell differentiation 6.298E-03 2 4 
757 positive regulation of oocyte development 6.298E-03 2 4 
758 multicellular organismal iron ion homeostasis 6.298E-03 2 4 
759 trachea gland development 6.298E-03 2 4 
760 regulation of centromeric sister chromatid cohesion 6.298E-03 2 4 
761 positive regulation of immune complex clearance by monocytes and macrophages 6.298E-03 2 4 
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762 regulation of epithelial to mesenchymal transition 6.352E-03 5 36 
763 negative regulation of Ras protein signal transduction 6.352E-03 5 36 
764 Toll signaling pathway 6.379E-03 9 101 
765 regulation of systemic arterial blood pressure by baroreceptor feedback 6.379E-03 3 12 
766 positive regulation of release of cytochrome c from mitochondria 6.379E-03 3 12 
767 regulation of nerve growth factor receptor signaling pathway 6.379E-03 3 12 
768 histone H3 deacetylation 6.379E-03 3 12 
769 dopamine transport 6.379E-03 3 12 
770 positive regulation of receptor recycling 6.379E-03 3 12 
771 response to vitamin E 6.416E-03 4 23 
772 protein secretion 6.583E-03 6 51 
773 somitogenesis 6.630E-03 7 67 
774 negative regulation of cell migration 6.634E-03 10 120 
775 synapse organization 7.023E-03 10 121 
776 tissue morphogenesis 7.032E-03 29 536 
777 cellular response to insulin stimulus 7.056E-03 18 285 
778 negative regulation of small GTPase mediated signal transduction 7.148E-03 5 37 
779 phospholipid catabolic process 7.148E-03 5 37 
780 startle response 7.148E-03 5 37 
781 regulation of stress fiber assembly 7.148E-03 5 37 
782 modification of morphology or physiology of other organism involved in symbiotic 
interaction 
7.185E-03 7 68 
783 modification of morphology or physiology of other organism 7.185E-03 7 68 
784 dorsal/ventral pattern formation 7.235E-03 9 103 
785 heart process 7.238E-03 6 52 
786 pituitary gland development 7.238E-03 6 52 
787 G-protein signaling, coupled to cyclic nucleotide second messenger 7.319E-03 14 201 
788 negative regulation of cell motility 7.430E-03 10 122 
789 positive regulation of cell-matrix adhesion 7.501E-03 4 24 
790 regulation of respiratory gaseous exchange 7.501E-03 4 24 
791 positive regulation of heart rate 7.501E-03 4 24 
792 immune response-activating cell surface receptor signaling pathway 7.504E-03 12 161 
793 regulation of localization 7.550E-03 70 1577 
794 regulation of catabolic process 7.761E-03 33 636 
795 aging 7.762E-03 20 332 
796 glial cell differentiation 7.762E-03 11 142 
797 regulation of action potential 7.762E-03 11 142 
798 regulation of canonical Wnt receptor signaling pathway 7.855E-03 10 123 
799 amine transport 7.956E-03 14 203 
800 positive regulation of immune response 7.970E-03 25 447 
801 T cell activation 7.980E-03 15 224 
802 G-protein coupled purinergic receptor signaling pathway 8.011E-03 5 38 
803 regulation of erythrocyte differentiation 8.011E-03 5 38 
804 rhythmic process 8.081E-03 19 311 
805 positive regulation of circadian sleep/wake cycle, sleep 8.091E-03 3 13 
806 regulation of chronic inflammatory response 8.091E-03 3 13 
807 growth hormone receptor signaling pathway 8.091E-03 3 13 
808 positive regulation of mitochondrion organization 8.091E-03 3 13 
809 courtship behavior 8.091E-03 3 13 
810 interleukin-6-mediated signaling pathway 8.091E-03 3 13 
811 histone H4 deacetylation 8.091E-03 3 13 
812 toll-like receptor 3 signaling pathway 8.213E-03 8 87 
813 positive regulation of neurological system process 8.213E-03 8 87 
814 stress-activated MAPK cascade 8.397E-03 7 70 
815 negative regulation of insulin secretion 8.688E-03 6 54 
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816 regulation of mitochondrion organization 8.700E-03 4 25 
817 prepulse inhibition 8.700E-03 4 25 
818 regulation of establishment of protein localization in plasma membrane 8.700E-03 4 25 
819 cation homeostasis 8.748E-03 29 545 
820 mesoderm development 8.761E-03 10 125 
821 metal ion homeostasis 8.765E-03 26 474 
822 regulation of viral transcription 8.780E-03 8 88 
823 myeloid leukocyte differentiation 8.780E-03 8 88 
824 positive regulation of cellular component organization 8.924E-03 28 522 
825 positive regulation of intracellular protein kinase cascade 8.932E-03 24 428 
826 midbrain development 8.944E-03 5 39 
827 dendrite development 9.057E-03 7 71 
828 cellular component assembly at cellular level 9.126E-03 48 1018 
829 chromatin organization 9.172E-03 29 547 
830 neuron migration 9.208E-03 9 107 
831 mesenchymal cell development 9.208E-03 9 107 
832 cellular protein localization 9.338E-03 36 718 
833 MyD88-independent toll-like receptor signaling pathway 9.375E-03 8 89 
834 response to axon injury 9.375E-03 8 89 
835 axon regeneration 9.485E-03 6 55 
836 positive regulation of ossification 9.485E-03 6 55 
837 regulation of ion transport 9.486E-03 22 384 
838 positive regulation of reproductive process 9.745E-03 10 127 
839 positive regulation of cell size 9.745E-03 10 127 
840 immune response-regulating cell surface receptor signaling pathway 9.902E-03 12 167 
841 positive regulation of protein binding 9.950E-03 5 40 
842 regulation of nitric-oxide synthase activity 9.950E-03 5 40 
843 negative regulation of protein binding 9.950E-03 5 40 
844 nucleoside monophosphate catabolic process 1.002E-02 4 26 
845 ectodermal placode formation 1.002E-02 4 26 
846 ectodermal placode morphogenesis 1.002E-02 4 26 
847 regulation of granulocyte differentiation 1.002E-02 4 26 
848 ectodermal placode development 1.002E-02 4 26 
849 behavioral response to pain 1.002E-02 4 26 
850 G-protein coupled receptor internalization 1.005E-02 3 14 
851 adenosine receptor signaling pathway 1.005E-02 3 14 
852 regulation of focal adhesion assembly 1.005E-02 3 14 
853 granulocyte differentiation 1.005E-02 3 14 
854 regulation of growth hormone secretion 1.005E-02 3 14 
855 serine family amino acid catabolic process 1.005E-02 3 14 
856 positive regulation of dopamine secretion 1.005E-02 3 14 
857 axonal fasciculation 1.005E-02 3 14 
858 regulation of cell-substrate junction assembly 1.005E-02 3 14 
859 regulation of cellular localization 1.006E-02 35 697 
860 positive regulation of MAPKKK cascade 1.014E-02 14 209 
861 intestine smooth muscle contraction 1.027E-02 2 5 
862 positive regulation of metanephric glomerulus development 1.027E-02 2 5 
863 gastro-intestinal system smooth muscle contraction 1.027E-02 2 5 
864 bombesin receptor signaling pathway 1.027E-02 2 5 
865 olfactory placode development 1.027E-02 2 5 
866 positive regulation of cellular extravasation 1.027E-02 2 5 
867 nuclear body organization 1.027E-02 2 5 
868 peptidyl-proline hydroxylation to 4-hydroxy-L-proline 1.027E-02 2 5 
869 embryonic genitalia morphogenesis 1.027E-02 2 5 
870 regulation of oocyte development 1.027E-02 2 5 
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871 negative regulation of interleukin-5 production 1.027E-02 2 5 
872 axial mesoderm formation 1.027E-02 2 5 
873 4-hydroxyproline metabolic process 1.027E-02 2 5 
874 positive regulation of metanephros development 1.027E-02 2 5 
875 positive regulation of cardiac muscle contraction 1.027E-02 2 5 
876 radial glial cell differentiation 1.027E-02 2 5 
877 positive regulation of transcription of Notch receptor target 1.027E-02 2 5 
878 activation of store-operated calcium channel activity 1.027E-02 2 5 
879 regulation of Wnt receptor signaling pathway involved in dorsal/ventral axis specification 1.027E-02 2 5 
880 olfactory placode morphogenesis 1.027E-02 2 5 
881 T cell migration 1.027E-02 2 5 
882 positive regulation of somatostatin secretion 1.027E-02 2 5 
883 olfactory placode formation 1.027E-02 2 5 
884 cellular macromolecule localization 1.033E-02 36 723 
885 response to mineralocorticoid stimulus 1.033E-02 6 56 
886 JAK-STAT cascade 1.033E-02 6 56 
887 cilium assembly 1.033E-02 6 56 
888 negative regulation of peptide hormone secretion 1.033E-02 6 56 
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MODEL II – UP 
 
# GO Processes pValue Ratio 
1 nucleosome assembly 2.480E-20 12 121 
2 chromatin assembly 4.537E-20 12 127 
3 nucleosome organization 1.165E-19 12 137 
4 protein-DNA complex assembly 1.981E-19 12 143 
5 chromatin assembly or disassembly 1.981E-19 12 143 
6 protein-DNA complex subunit organization 3.885E-19 12 151 
7 DNA packaging 2.073E-18 12 173 
8 DNA conformation change 1.381E-17 12 202 
9 chromatin organization 6.712E-14 13 547 
10 chromosome organization 9.613E-14 14 728 
11 cellular macromolecular complex assembly 4.905E-13 12 484 
12 cellular macromolecular complex subunit organization 8.610E-12 12 618 
13 cellular component assembly at cellular level 1.663E-10 13 1018 
14 macromolecular complex assembly 1.818E-09 12 984 
15 organelle organization 7.954E-09 15 2040 
16 macromolecular complex subunit organization 8.827E-09 12 1132 
17 cellular component assembly 1.330E-08 13 1458 
18 cellular component biogenesis 4.383E-08 13 1611 
19 cellular component organization at cellular level 5.857E-07 16 3253 
20 cellular component organization or biogenesis at cellular level 9.466E-07 16 3367 
21 cellular component organization 1.772E-05 16 4177 
22 cellular component organization or biogenesis 2.632E-05 16 4304 
23 telomere maintenance 1.133E-04 3 70 
24 telomere organization 1.182E-04 3 71 
25 defense response to bacterium 1.543E-04 4 204 
26 regulation of gene silencing 2.082E-04 2 16 
27 DNA metabolic process 3.550E-04 6 728 
28 DNA fragmentation involved in apoptotic nuclear change 7.967E-04 2 31 
29 DNA catabolic process, endonucleolytic 7.967E-04 2 31 
30 cytokinesis, initiation of separation 1.349E-03 1 1 
31 assembly of actomyosin apparatus involved in cell cycle cytokinesis 1.349E-03 1 1 
32 cytokinesis, actomyosin contractile ring assembly 1.349E-03 1 1 
33 apoptotic nuclear change 1.393E-03 2 41 
34 response to stress 2.008E-03 11 3216 
35 multi-organism process 2.288E-03 7 1420 
36 glyoxylate cycle 2.697E-03 1 2 
37 protein localization to chromosome, centromeric region 2.697E-03 1 2 
38 anatomical structure homeostasis 2.739E-03 3 209 
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MODEL II – DOWN 
 
# GO Processes pValue Ratio 
1 regulation of lipid metabolic process 2.153E-06 13 254 
2 regulation of myotube differentiation 2.370E-06 5 22 
3 protein deacetylation 2.537E-06 6 39 
4 protein deacylation 2.960E-06 6 40 
5 phosphate metabolic process 4.188E-06 34 1451 
6 phosphorus metabolic process 4.251E-06 34 1452 
7 regulation of endothelial cell migration 9.382E-06 7 73 
8 positive regulation of synaptic transmission, GABAergic 1.298E-05 4 15 
9 protein modification process 1.808E-05 43 2194 
10 histone deacetylation 1.950E-05 5 33 
11 peptidyl-lysine deacetylation 2.026E-05 3 6 
12 regulation of striated muscle tissue development 2.051E-05 8 113 
13 regulation of synaptic transmission, GABAergic 2.268E-05 5 34 
14 regulation of muscle organ development 2.330E-05 8 115 
15 chromatin silencing 3.958E-05 5 38 
16 negative regulation of striated muscle tissue development 4.428E-05 4 20 
17 negative regulation of gene expression, epigenetic 6.490E-05 5 42 
18 macromolecule modification 6.535E-05 43 2316 
19 negative regulation of muscle organ development 6.580E-05 4 22 
20 positive regulation of endothelial cell migration 9.093E-05 5 45 
21 negative regulation of cell migration involved in sprouting angiogenesis 1.029E-04 2 2 
22 canonical Wnt receptor signaling pathway involved in positive regulation of 
wound healing 
1.029E-04 2 2 
23 negative regulation of cell volume 1.029E-04 2 2 
24 canonical Wnt receptor signaling pathway involved in positive regulation of 
cell-cell adhesion 
1.029E-04 2 2 
25 canonical Wnt receptor signaling pathway involved in positive regulation of 
endothelial cell migration 
1.029E-04 2 2 
26 dephosphorylation 1.153E-04 10 227 
27 central nervous system development 1.332E-04 22 900 
28 glutamate signaling pathway 1.373E-04 5 49 
29 negative regulation of protein complex assembly 1.437E-04 6 78 
30 regulation of skeletal muscle fiber development 1.513E-04 5 50 
31 protein localization in endoplasmic reticulum 1.517E-04 4 27 
32 sphingolipid metabolic process 1.579E-04 7 113 
33 actin cytoskeleton organization 1.629E-04 13 384 
34 intracellular signal transduction 1.782E-04 33 1673 
35 histone H3 deacetylation 2.130E-04 3 12 
36 membrane lipid metabolic process 2.291E-04 7 120 
37 nervous system development 2.314E-04 39 2143 
38 phospholipid dephosphorylation 2.749E-04 3 13 
39 negative regulation of myotube differentiation 2.749E-04 3 13 
40 germ cell migration 2.987E-04 4 32 
41 regulation of cellular component movement 2.998E-04 14 464 
42 cardiac muscle adaptation 3.066E-04 2 3 
43 muscle hypertrophy in response to stress 3.066E-04 2 3 
44 cardiac muscle hypertrophy in response to stress 3.066E-04 2 3 
45 chromatin silencing at telomere 3.066E-04 2 3 
46 negative regulation of biological process 3.431E-04 53 3296 
47 regulation of lipid biosynthetic process 3.736E-04 7 130 
48 negative regulation of synaptic transmission, glutamatergic 4.308E-04 3 15 
49 calcium-mediated signaling 4.512E-04 5 63 
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50 regulation of generation of precursor metabolites and energy 4.512E-04 5 63 
51 positive regulation of lipid biosynthetic process 4.512E-04 5 63 
52 second-messenger-mediated signaling 4.824E-04 13 430 
53 actin filament-based process 4.824E-04 13 430 
54 lipid modification 4.904E-04 7 136 
55 negative regulation of synaptic transmission, GABAergic 5.262E-04 3 16 
56 regulation of cardiac muscle contraction by calcium ion signaling 6.091E-04 2 4 
57 regulation of thyroid hormone mediated signaling pathway 6.091E-04 2 4 
58 response to muscle inactivity involved in regulation of muscle adaptation 6.091E-04 2 4 
59 response to denervation involved in regulation of muscle adaptation 6.091E-04 2 4 
60 negative regulation of striated muscle cell differentiation 6.342E-04 3 17 
61 regulation of localization 6.579E-04 30 1577 
62 regulation of muscle contraction 6.616E-04 7 143 
63 phosphorylation 6.661E-04 25 1219 
64 regulation of skeletal muscle tissue development 6.867E-04 5 69 
65 positive regulation of cellular component movement 7.830E-04 10 289 
66 negative regulation of cellular process 8.034E-04 48 3002 
67 negative regulation of blood vessel endothelial cell migration 8.903E-04 3 19 
68 positive regulation of synaptic transmission, glutamatergic 8.903E-04 3 19 
69 protein phosphorylation 8.995E-04 20 900 
70 positive regulation of synaptic transmission 9.448E-04 5 74 
71 cytoskeleton organization 9.856E-04 17 710 
72 regulation of striated muscle cell differentiation 1.004E-03 5 75 
73 positive regulation of female receptivity 1.008E-03 2 5 
74 regulation of protein complex assembly 1.009E-03 8 199 
75 chondroitin sulfate metabolic process 1.040E-03 3 20 
76 regulation of blood vessel endothelial cell migration 1.213E-03 4 46 
77 regulation of cell migration 1.235E-03 12 418 
78 positive regulation of transmission of nerve impulse 1.269E-03 5 79 
79 positive regulation of lipid metabolic process 1.318E-03 6 118 
80 viral genome replication 1.384E-03 3 22 
81 protein kinase B signaling cascade 1.384E-03 3 22 
82 regulation of muscle system process 1.422E-03 7 163 
83 regulation of synaptic transmission, glutamatergic 1.424E-03 4 48 
84 negative regulation of glycolysis 1.502E-03 2 6 
85 response to stimulus involved in regulation of muscle adaptation 1.502E-03 2 6 
86 negative regulation of RNA polymerase II transcriptional preinitiation complex 
assembly 
1.502E-03 2 6 
87 negative regulation of transcription initiation, DNA-dependent 1.502E-03 2 6 
88 interleukin-12 production 1.502E-03 2 6 
89 regulation of aldosterone metabolic process 1.502E-03 2 6 
90 positive regulation of myotube differentiation 1.502E-03 2 6 
91 response to muscle inactivity 1.502E-03 2 6 
92 regulation of synaptic vesicle fusion to presynaptic membrane 1.502E-03 2 6 
93 chondroitin sulfate proteoglycan metabolic process 1.579E-03 3 23 
94 regulation of cell motility 1.629E-03 12 432 
95 negative regulation of phosphorylation 1.630E-03 6 123 
96 regulation of cellular component biogenesis 1.681E-03 10 320 
97 gliogenesis 1.748E-03 7 169 
98 negative regulation of protein phosphorylation 1.852E-03 5 86 
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99 regulation of Rho protein signal transduction 1.869E-03 7 171 
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MODEL III – UP 
 
# GO Processes pValue Ratio 
1 cell cycle phase 8.787E-16 25 851 
2 cell cycle 1.302E-14 28 1262 
3 cell cycle process 3.578E-14 25 1001 
4 M phase 1.020E-13 19 521 
5 mitotic cell cycle 2.872E-13 21 716 
6 cell division 6.468E-12 16 422 
7 mitosis 5.416E-11 14 341 
8 nuclear division 5.416E-11 14 341 
9 M phase of mitotic cell cycle 7.359E-11 14 349 
10 organelle fission 9.214E-11 14 355 
11 organelle organization 1.279E-09 28 2040 
12 cellular component organization or biogenesis at cellular level 1.979E-09 36 3367 
13 chromosome segregation 4.653E-09 9 143 
14 regulation of cell cycle process 1.990E-08 13 451 
15 regulation of cell cycle 3.039E-08 17 864 
16 cellular component organization at cellular level 5.200E-08 33 3253 
17 DNA conformation change 9.346E-08 9 202 
18 regulation of mitotic cell cycle 1.272E-07 11 354 
19 DNA packaging 3.800E-07 8 173 
20 cellular component organization or biogenesis 4.048E-07 37 4304 
21 spindle organization 5.568E-07 6 77 
22 cell cycle checkpoint 8.388E-07 9 262 
23 regulation of cell cycle arrest 1.292E-06 9 276 
24 positive regulation of nuclease activity 1.982E-06 3 7 
25 mitotic cell cycle G2/M transition DNA damage checkpoint 4.731E-06 3 9 
26 cellular component organization 5.971E-06 34 4177 
27 mitotic cell cycle G2/M transition checkpoint 1.229E-05 3 12 
28 positive regulation of centrosome cycle 1.505E-05 2 2 
29 regulation of nuclease activity 1.593E-05 3 13 
30 base-excision repair 1.954E-05 4 41 
31 cellular process 2.141E-05 73 14653 
32 mitotic cell cycle checkpoint 3.222E-05 6 155 
33 microtubule cytoskeleton organization 3.433E-05 7 232 
34 G2/M transition of mitotic cell cycle 3.588E-05 6 158 
35 interphase of mitotic cell cycle 3.765E-05 9 420 
36 interphase 4.280E-05 9 427 
37 base-excision repair, DNA ligation 4.502E-05 2 3 
38 nuclear envelope reassembly 4.502E-05 2 3 
39 regulation of cyclin-dependent protein kinase activity 5.433E-05 5 104 
40 regulation of nuclear division 5.951E-05 5 106 
41 regulation of mitosis 5.951E-05 5 106 
42 organ regeneration 6.506E-05 5 108 
43 microtubule-based process 7.209E-05 8 354 
44 nucleus organization 8.325E-05 4 59 
45 regulation of cyclin-dependent protein kinase activity involved in G2/M 8.982E-05 2 4 
46 positive regulation of cyclin-dependent protein kinase activity involved in G2/M 8.982E-05 2 4 
47 chromosome organization 1.190E-04 11 728 
48 regulation of transcription involved in G1/S phase of mitotic cell cycle 1.396E-04 3 26 
49 active induction of host immune response by virus 1.493E-04 2 5 
50 induction of host immune response by virus 1.493E-04 2 5 
51 induction by symbiont of host defense response 1.493E-04 2 5 
52 positive regulation of megakaryocyte differentiation 1.493E-04 2 5 
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53 G2/M transition DNA damage checkpoint 1.566E-04 3 27 
54 positive regulation of cell cycle 2.136E-04 5 139 
55 induction by organism of defense response of other organism involved in symbiotic 
interaction 
2.234E-04 2 6 
56 adenine transport 2.234E-04 2 6 
57 DNA ligation involved in DNA repair 3.120E-04 2 7 
58 chromosome condensation 3.727E-04 3 36 
59 G2/M transition checkpoint 3.727E-04 3 36 
60 nucleobase, nucleoside, nucleotide and nucleic acid transport 3.860E-04 5 158 
61 spindle assembly checkpoint 4.044E-04 3 37 
62 cytoskeleton organization 4.331E-04 10 710 
63 organ morphogenesis 4.359E-04 12 989 
64 regulation of erythrocyte differentiation 4.379E-04 3 38 
65 cellular component disassembly involved in apoptosis 4.448E-04 4 91 
66 phosphatidylinositol-mediated signaling 4.636E-04 4 92 
67 embryonic skeletal system morphogenesis 4.830E-04 4 93 
68 inositol lipid-mediated signaling 4.830E-04 4 93 
69 spindle checkpoint 5.100E-04 3 40 
70 regulation of interphase of mitotic cell cycle 5.109E-04 5 168 
71 mitotic prometaphase 5.447E-04 4 96 
72 meiosis 5.837E-04 5 173 
73 M phase of meiotic cell cycle 5.837E-04 5 173 
74 regulation of G2/M transition of mitotic cell cycle 5.892E-04 3 42 
75 meiotic cell cycle 6.474E-04 5 177 
76 regulation of megakaryocyte differentiation 6.635E-04 2 10 
77 purine base transport 8.089E-04 2 11 
78 positive regulation by organism of defense response of other organism involved in 
symbiotic interaction 
1.141E-03 2 13 
79 positive regulation by symbiont of host defense response 1.141E-03 2 13 
80 modulation by organism of defense response of other organism involved in symbiotic 
interaction 
1.141E-03 2 13 
81 DNA topological change 1.141E-03 2 13 
82 DNA ligation 1.141E-03 2 13 
83 modulation by symbiont of host defense response 1.141E-03 2 13 
84 mitotic sister chromatid segregation 1.231E-03 3 54 
85 skeletal system morphogenesis 1.276E-03 5 206 
86 nucleosome assembly 1.294E-03 4 121 
87 nuclear envelope organization 1.328E-03 2 14 
88 nucleobase transport 1.328E-03 2 14 
89 spermatid nucleus differentiation 1.328E-03 2 14 
90 embryonic skeletal system development 1.334E-03 4 122 
91 ncRNA metabolic process 1.411E-03 6 313 
92 sister chromatid segregation 1.514E-03 3 58 
93 regeneration 1.541E-03 5 215 
94 chromatin assembly 1.547E-03 4 127 
95 G1/S transition of mitotic cell cycle 1.671E-03 5 219 
96 ventricular cardiac muscle cell development 1.970E-03 2 17 
97 nucleosome organization 2.041E-03 4 137 
98 DNA damage checkpoint 2.041E-03 4 137 
99 regulation of centrosome cycle 2.211E-03 2 18 
100 mitotic chromosome condensation 2.211E-03 2 18 
101 purine-containing compound transmembrane transport 2.211E-03 2 18 
102 cellular component disassembly at cellular level 2.358E-03 5 237 
103 chromatin assembly or disassembly 2.385E-03 4 143 
104 protein-DNA complex assembly 2.385E-03 4 143 
105 regulation of organelle organization 2.402E-03 7 470 
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106 immune system development 2.473E-03 8 605 
107 cellular component disassembly 2.490E-03 5 240 
108 DNA integrity checkpoint 2.508E-03 4 145 
109 response to host defenses 2.731E-03 2 20 
110 response to host 2.731E-03 2 20 
111 response to defenses of other organism involved in symbiotic interaction 2.731E-03 2 20 
112 cellular macromolecular complex subunit organization 2.818E-03 8 618 
113 cellular macromolecular complex assembly 2.828E-03 7 484 
114 protein-DNA complex subunit organization 2.903E-03 4 151 
115 response to DNA damage stimulus 2.989E-03 8 624 
116 ribonucleoprotein complex biogenesis 3.284E-03 5 256 
117 cellular component biogenesis 3.600E-03 14 1611 
118 positive chemotaxis 3.609E-03 2 23 
119 positive regulation of cyclin-dependent protein kinase activity 3.609E-03 2 23 
120 V(D)J recombination 3.609E-03 2 23 
121 positive regulation of mitotic centrosome separation 3.903E-03 1 1 
122 meiotic sister chromatid cohesion, centromeric 3.903E-03 1 1 
123 regulation of mitotic centrosome separation 3.903E-03 1 1 
124 endothelial cell fate specification 3.903E-03 1 1 
125 centromeric sister chromatid cohesion 3.903E-03 1 1 
126 positive regulation of deoxyribonuclease activity 3.903E-03 1 1 
127 positive regulation of centriole replication 3.903E-03 1 1 
128 DNA geometric change 3.928E-03 2 24 
129 cellular component biogenesis at cellular level 3.990E-03 5 268 
130 macromolecular complex subunit organization 4.411E-03 11 1132 
131 chordate embryonic development 4.548E-03 8 669 
132 embryonic organ development 4.586E-03 6 397 
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MODEL III – DOWN 
 
# GO Processes pValue Ratio 
1 synaptic transmission 1.287E-11 24 670 
2 multicellular organismal signaling 3.008E-11 25 762 
3 transmission of nerve impulse 3.008E-11 25 762 
4 regulation of neurotransmitter levels 1.045E-10 13 170 
5 neurotransmitter secretion 4.350E-10 11 120 
6 regulation of exocytosis 4.287E-09 10 114 
7 cell-cell adhesion 1.021E-08 16 402 
8 synaptic vesicle exocytosis 2.022E-08 7 46 
9 neurotransmitter transport 2.097E-08 11 173 
10 regulation of secretion 2.324E-08 18 549 
11 signal release 2.341E-08 12 218 
12 generation of a signal involved in cell-cell signaling 2.341E-08 12 218 
13 cell-cell signaling 2.455E-08 25 1057 
14 regulation of cellular localization 3.318E-08 20 697 
15 regulation of vesicle-mediated transport 5.508E-08 13 285 
16 homophilic cell adhesion 7.730E-08 10 154 
17 regulation of localization 1.057E-07 30 1577 
18 exocytosis 2.727E-07 12 273 
19 regulation of transport 4.986E-07 25 1238 
20 cell communication 4.988E-07 27 1416 
21 synaptic vesicle transport 6.396E-07 7 75 
22 phosphatidylinositol-mediated signaling 2.572E-06 7 92 
23 neurological system process 2.690E-06 32 2040 
24 inositol lipid-mediated signaling 2.766E-06 7 93 
25 secretion by cell 3.021E-06 14 472 
26 regulation of cell communication 3.081E-06 27 1557 
27 learning 3.590E-06 8 137 
28 regulation of signaling 7.288E-06 32 2139 
29 calcium ion-dependent exocytosis 1.029E-05 5 44 
30 glutamate secretion 1.460E-05 4 23 
31 synaptic vesicle endocytosis 1.743E-05 4 24 
32 system process 2.159E-05 34 2474 
33 cGMP catabolic process 2.296E-05 3 9 
34 regulation of biological quality 2.717E-05 38 2953 
35 second-messenger-mediated signaling 2.894E-05 12 430 
36 regulation of cell development 3.124E-05 14 581 
37 positive regulation of hydrolase activity 3.815E-05 15 671 
38 synaptic vesicle uncoating 4.326E-05 2 2 
39 maintenance of presynaptic active zone structure 4.326E-05 2 2 
40 vesicle uncoating 4.326E-05 2 2 
41 learning or memory 4.343E-05 9 250 
42 negative regulation of locomotion 4.440E-05 7 142 
43 calcium-dependent cell-cell adhesion 5.662E-05 4 32 
44 cognition 6.423E-05 9 263 
45 cell adhesion 7.351E-05 17 883 
46 biological adhesion 7.876E-05 17 888 
47 regulation of system process 8.397E-05 14 637 
48 negative regulation of transport 8.477E-05 10 338 
49 multicellular organismal process 9.183E-05 66 6739 
50 secretion 1.108E-04 14 654 
51 radial glia guided migration of Purkinje cell 1.292E-04 2 3 
52 regulation of multicellular organismal process 1.354E-04 28 2036 
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53 negative regulation of cell migration 1.462E-04 6 120 
54 cAMP catabolic process 1.480E-04 3 16 
55 negative regulation of cell motility 1.601E-04 6 122 
56 regulation of synaptic transmission 1.615E-04 9 297 
57 behavior 1.638E-04 13 596 
58 regulation of muscle cell differentiation 1.750E-04 6 124 
59 positive regulation of exocytosis 1.837E-04 4 43 
60 neuron-neuron synaptic transmission 1.883E-04 5 80 
61 positive regulation of catalytic activity 1.922E-04 20 1243 
62 cyclic nucleotide catabolic process 2.136E-04 3 18 
63 negative regulation of cellular component movement 2.170E-04 6 129 
64 positive regulation of developmental process 2.231E-04 15 787 
65 intracellular signal transduction 2.378E-04 24 1673 
66 regulation of insulin secretion 2.475E-04 7 187 
67 regulation of synapse structural plasticity 2.573E-04 2 4 
68 sensory perception of touch 2.573E-04 2 4 
69 negative regulation of endothelial cell differentiation 2.573E-04 2 4 
70 regulation of hydrolase activity 2.676E-04 17 984 
71 carbohydrate homeostasis 2.887E-04 6 136 
72 glucose homeostasis 2.887E-04 6 136 
73 regulation of locomotion 2.924E-04 11 470 
74 cell morphogenesis involved in neuron differentiation 2.936E-04 13 633 
75 regulation of transmission of nerve impulse 2.939E-04 9 322 
76 visual learning 3.058E-04 4 49 
77 response to electrical stimulus 3.058E-04 4 49 
78 cell morphogenesis involved in differentiation 3.240E-04 14 726 
79 signaling 3.252E-04 54 5359 
80 regulation of neurogenesis 3.374E-04 11 478 
81 regulation of peptide hormone secretion 3.608E-04 7 199 
82 positive regulation of cell development 3.832E-04 7 201 
83 regulation of peptide secretion 4.067E-04 7 203 
84 regulation of peptide transport 4.067E-04 7 203 
85 regulation of cellular component organization 4.239E-04 20 1321 
86 histone H3-K27 methylation 4.270E-04 2 5 
87 negative regulation of inclusion body assembly 4.270E-04 2 5 
88 activation of phospholipase C activity by metabotropic glutamate receptor 
signaling pathway 
4.270E-04 2 5 
89 peptidyl-cysteine methylation 4.270E-04 2 5 
90 synaptic transmission, GABAergic 4.525E-04 3 23 
91 cellular calcium ion homeostasis 4.653E-04 9 343 
92 visual behavior 4.775E-04 4 55 
93 positive regulation of molecular function 4.800E-04 21 1437 
94 regulation of neurological system process 4.954E-04 9 346 
95 generation of neurons 5.179E-04 20 1342 
96 regulation of myoblast differentiation 5.820E-04 3 25 
97 cellular divalent inorganic cation homeostasis 5.836E-04 9 354 
98 calcium ion homeostasis 5.836E-04 9 354 
99 regulation of cell motility 6.024E-04 10 432 
100 positive regulation of cell differentiation 6.190E-04 12 598 
101 synaptic vesicle priming 6.378E-04 2 6 
102 regulation of synaptic vesicle fusion to presynaptic membrane 6.378E-04 2 6 
103 ion homeostasis 6.434E-04 14 778 
104 nucleoside monophosphate catabolic process 6.547E-04 3 26 
105 neuromuscular process 6.632E-04 5 105 
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106 axonogenesis 6.755E-04 12 604 
107 positive regulation of neurogenesis 6.845E-04 6 160 
108 negative regulation of secretion 7.305E-04 6 162 
109 nervous system development 7.310E-04 27 2143 
110 divalent inorganic cation homeostasis 7.398E-04 9 366 
111 regulation of neurotransmitter secretion 7.537E-04 4 62 
112 calcium-mediated signaling 8.007E-04 4 63 
113 neuron development 8.144E-04 15 891 
114 dendrite morphogenesis 8.170E-04 3 28 
115 regulation of nervous system development 8.457E-04 11 534 
116 chemical homeostasis 8.668E-04 16 993 
117 type B pancreatic cell proliferation 8.890E-04 2 7 
118 hindbrain radial glia guided cell migration 8.890E-04 2 7 
119 smooth muscle contraction involved in micturition 8.890E-04 2 7 
120 brain morphogenesis 9.069E-04 3 29 
121 regulation of MAP kinase activity 9.451E-04 8 304 
122 regulation of transporter activity 9.617E-04 5 114 
123 cell projection morphogenesis 9.774E-04 13 720 
124 cation homeostasis 9.975E-04 11 545 
125 negative regulation of transporter activity 1.003E-03 3 30 
126 activation of MAPK activity 1.028E-03 6 173 
127 regulation of cellular component movement 1.038E-03 10 464 
128 regulation of cell differentiation 1.051E-03 17 1111 
129 neurogenesis 1.090E-03 20 1425 
130 neuromuscular synaptic transmission 1.105E-03 3 31 
131 regulation of hormone secretion 1.118E-03 7 241 
132 positive regulation of transport 1.138E-03 11 554 
133 cell part morphogenesis 1.149E-03 13 733 
134 regulation of response to stimulus 1.150E-03 29 2441 
135 regulation of inclusion body assembly 1.180E-03 2 8 
136 Rab protein signal transduction 1.180E-03 2 8 
137 positive regulation of long-term neuronal synaptic plasticity 1.180E-03 2 8 
138 phosphatidylinositol dephosphorylation 1.180E-03 2 8 
139 regulation of molecular function 1.195E-03 28 2330 
140 negative regulation of cell proliferation 1.206E-03 12 646 
141 neuron projection development 1.207E-03 13 737 
142 metal ion homeostasis 1.218E-03 10 474 
143 neuron projection morphogenesis 1.238E-03 12 648 
144 regulation of developmental process 1.245E-03 21 1548 
145 regulation of neurotransmitter transport 1.254E-03 4 71 
146 dendrite development 1.254E-03 4 71 
147 regulation of cellular catabolic process 1.258E-03 11 561 
148 optic nerve morphogenesis 1.511E-03 2 9 
149 cell migration in hindbrain 1.511E-03 2 9 
150 endothelial cell morphogenesis 1.511E-03 2 9 
151 synaptic vesicle maturation 1.511E-03 2 9 
152 urinary bladder smooth muscle contraction 1.511E-03 2 9 
153 cellular response to electrical stimulus 1.511E-03 2 9 
154 positive regulation of lipase activity 1.531E-03 6 187 
155 regulation of striated muscle cell differentiation 1.537E-03 4 75 
156 regulation of vasoconstriction 1.614E-03 4 76 
157 regulation of multicellular organismal development 1.645E-03 18 1262 
158 negative regulation of response to stimulus 1.663E-03 13 764 
159 positive regulation of muscle cell differentiation 1.694E-03 4 77 
160 regulation of cell migration 1.859E-03 9 418 
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161 protein depolymerization 1.880E-03 2 10 
162 urinary tract smooth muscle contraction 1.880E-03 2 10 
163 locomotory behavior 1.892E-03 6 195 
164 cell morphogenesis 2.046E-03 14 879 
165 regulation of gliogenesis 2.135E-03 4 82 
166 positive regulation of cell communication 2.254E-03 13 791 
167 positive regulation of protein serine/threonine kinase activity 2.274E-03 7 273 
168 growth hormone secretion 2.288E-03 2 11 
169 retinal cone cell development 2.288E-03 2 11 
170 negative regulation of smooth muscle cell migration 2.288E-03 2 11 
171 retinal cone cell differentiation 2.288E-03 2 11 
172 associative learning 2.331E-03 4 84 
173 hindbrain development 2.384E-03 5 140 
174 regulation of protein serine/threonine kinase activity 2.394E-03 9 434 
175 positive regulation of signaling 2.459E-03 13 799 
176 cGMP metabolic process 2.497E-03 3 41 
177 cAMP metabolic process 2.497E-03 3 41 
178 negative regulation of protein phosphorylation 2.540E-03 4 86 
179 multicellular organismal development 2.592E-03 45 4605 
180 regulation of protein phosphorylation 2.642E-03 14 904 
181 regulation of cell proliferation 2.660E-03 19 1427 
182 positive regulation of MAPKKK cascade 2.676E-03 6 209 
183 regulation of synaptic vesicle exocytosis 2.734E-03 2 12 
184 regulation of lipase activity 2.806E-03 6 211 
185 regulation of calcium ion-dependent exocytosis 2.864E-03 3 43 
186 cellular component assembly at cellular level 2.994E-03 15 1018 
187 synaptic transmission, glutamatergic 3.058E-03 3 44 
188 cerebellar cortex development 3.058E-03 3 44 
189 cell projection organization 3.154E-03 14 922 
190 phospholipid dephosphorylation 3.217E-03 2 13 
191 regulation of signal transduction 3.227E-03 22 1788 
192 protein methylation 3.242E-03 4 92 
193 protein alkylation 3.242E-03 4 92 
194 regulation of long-term neuronal synaptic plasticity 3.261E-03 3 45 
195 regulation of catabolic process 3.336E-03 11 636 
196 cellular ion homeostasis 3.349E-03 12 731 
197 cellular component assembly 3.372E-03 19 1458 
198 cellular metal ion homeostasis 3.520E-03 9 460 
199 regulation of nucleotide catabolic process 3.554E-03 8 376 
200 regulation of purine nucleotide catabolic process 3.554E-03 8 376 
201 camera-type eye morphogenesis 3.638E-03 4 95 
202 adherens junction organization 3.691E-03 3 47 
203 peptidyl-cysteine modification 3.737E-03 2 14 
204 regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate 
selective glutamate receptor activity 
3.737E-03 2 14 
205 cellular component morphogenesis 3.746E-03 14 940 
206 sensory perception of pain 3.777E-03 4 96 
207 response to abiotic stimulus 3.959E-03 13 845 
208 neuron differentiation 3.994E-03 15 1050 
209 cellular component organization 4.017E-03 41 4177 
210 regulation of catalytic activity 4.082E-03 23 1939 
211 homeostatic process 4.096E-03 18 1374 
212 positive regulation of MAP kinase activity 4.102E-03 6 228 
213 cell differentiation 4.141E-03 31 2905 
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214 positive regulation of insulin-like growth factor receptor signaling pathway 4.294E-03 2 15 
215 optic nerve development 4.294E-03 2 15 
216 respiratory system process 4.294E-03 2 15 
217 serotonin metabolic process 4.294E-03 2 15 
218 micturition 4.294E-03 2 15 
219 regulation of smooth muscle cell apoptosis 4.294E-03 2 15 
220 positive regulation of myoblast differentiation 4.294E-03 2 15 
221 regulation of vesicle fusion 4.294E-03 2 15 
222 regulation of skeletal muscle fiber development 4.398E-03 3 50 
223 vesicle-mediated transport 4.507E-03 14 960 
224 photoreceptor cell development 4.650E-03 3 51 
225 activation of phospholipase C activity 4.689E-03 5 164 
226 response to metal ion 4.700E-03 8 394 
227 developmental process 4.737E-03 47 5016 
228 positive regulation of phospholipase C activity 4.811E-03 5 165 
229 positive regulation of leukocyte degranulation 4.886E-03 2 16 
230 camera-type eye photoreceptor cell differentiation 4.886E-03 2 16 
231 regulation of endothelial cell differentiation 4.886E-03 2 16 
232 positive regulation of mast cell degranulation 4.886E-03 2 16 
233 positive regulation of mast cell activation involved in immune response 4.886E-03 2 16 
234 regulation of phosphorylation 4.932E-03 14 970 
235 response to inorganic substance 5.007E-03 10 577 
236 brain development 5.029E-03 11 672 
237 localization 5.164E-03 41 4235 
238 positive regulation of gliogenesis 5.181E-03 3 53 
239 cellular chemical homeostasis 5.366E-03 12 776 
240 negative regulation of insulin secretion 5.460E-03 3 54 
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MODEL IV – UP 
 
# GO Processes pValue Ratio 
1 DNA packaging 9.229E-11 10 173 
2 cellular macromolecular complex subunit organization 2.767E-10 15 618 
3 DNA conformation change 4.228E-10 10 202 
4 nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 2.029E-09 36 4713 
5 cellular nitrogen compound metabolic process 7.376E-09 37 5196 
6 nitrogen compound metabolic process 1.510E-08 37 5326 
7 macromolecular complex subunit organization 2.133E-08 17 1132 
8 nucleosome assembly 7.251E-08 7 121 
9 chromatin assembly 1.012E-07 7 127 
10 nucleosome organization 1.702E-07 7 137 
11 cellular macromolecular complex assembly 1.723E-07 11 484 
12 chromosome organization 1.862E-07 13 728 
13 protein-DNA complex assembly 2.280E-07 7 143 
14 chromatin assembly or disassembly 2.280E-07 7 143 
15 protein-DNA complex subunit organization 3.303E-07 7 151 
16 cellular component organization or biogenesis at cellular level 3.362E-07 27 3367 
17 nucleic acid metabolic process 4.320E-07 29 3882 
18 mitotic sister chromatid segregation 5.705E-07 5 54 
19 sister chromatid segregation 8.190E-07 5 58 
20 cell cycle phase 1.091E-06 13 851 
21 cellular component organization or biogenesis 1.103E-06 30 4304 
22 cellular component organization at cellular level 2.638E-06 25 3253 
23 M phase 3.040E-06 10 521 
24 cell cycle 3.281E-06 15 1262 
25 cellular macromolecule metabolic process 4.666E-06 36 6261 
26 macromolecular complex assembly 5.401E-06 13 984 
27 cell cycle process 6.502E-06 13 1001 
28 cellular component organization 7.304E-06 28 4177 
29 macromolecule metabolic process 1.643E-05 37 6885 
30 mitotic chromosome condensation 2.007E-05 3 18 
31 cellular metabolic process 2.358E-05 42 8579 
32 primary metabolic process 2.463E-05 42 8592 
33 cellular process 4.196E-05 57 14653 
34 mitotic cell cycle 4.765E-05 10 716 
35 cellular component biogenesis 5.960E-05 15 1611 
36 chromosome segregation 6.834E-05 5 143 
37 mitosis 6.886E-05 7 341 
38 nuclear division 6.886E-05 7 341 
39 organelle organization 6.933E-05 17 2040 
40 RNA metabolic process 7.307E-05 23 3419 
41 M phase of mitotic cell cycle 7.961E-05 7 349 
42 organelle fission 8.855E-05 7 355 
43 endocrine system development 1.196E-04 6 258 
44 viral infectious cycle 1.196E-04 5 161 
45 viral transcription 1.522E-04 4 90 
46 viral genome expression 1.522E-04 4 90 
47 chromosome condensation 1.690E-04 3 36 
48 translational termination 1.801E-04 4 94 
49 cellular component assembly at cellular level 1.910E-04 11 1018 
50 pancreas development 2.120E-04 5 182 
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51 chromatin organization 2.141E-04 8 547 
52 deoxyribonucleoside diphosphate metabolic process 2.431E-04 2 8 
53 metabolic process 2.672E-04 43 9707 
54 viral reproductive process 2.848E-04 5 194 
55 cellular component assembly 3.120E-04 13 1458 
56 cellular protein complex disassembly 3.177E-04 4 109 
57 protein complex disassembly 3.524E-04 4 112 
58 gene expression 4.537E-04 22 3593 
59 mitochondrial DNA replication 4.747E-04 2 11 
60 mitochondrial DNA metabolic process 5.685E-04 2 12 
61 cellular macromolecular complex disassembly 6.014E-04 4 129 
62 macromolecular complex disassembly 6.557E-04 4 132 
63 deoxyribonucleotide biosynthetic process 6.706E-04 2 13 
64 cellular component disassembly at cellular level 7.094E-04 5 237 
65 cellular component disassembly 7.507E-04 5 240 
66 protein heterotetramerization 7.809E-04 2 14 
67 protein complex subunit organization 8.058E-04 9 837 
68 cellular macromolecule biosynthetic process 8.453E-04 21 3497 
69 endocrine pancreas development 8.616E-04 4 142 
70 macromolecule biosynthetic process 9.475E-04 21 3527 
71 cellular biosynthetic process 1.102E-03 24 4362 
72 translational elongation 1.250E-03 4 157 
73 biosynthetic process 1.598E-03 24 4475 
74 nucleoside triphosphate metabolic process 1.736E-03 7 584 
75 meiosis 1.786E-03 4 173 
76 M phase of meiotic cell cycle 1.786E-03 4 173 
77 RNA biosynthetic process 1.912E-03 17 2704 
78 meiotic cell cycle 1.941E-03 4 177 
79 nucleobase, nucleoside and nucleotide interconversion 1.952E-03 2 22 
80 mitochondrial genome maintenance 2.134E-03 2 23 
81 regulation of cell cycle process 2.241E-03 6 451 
82 regulation of transcription involved in G1/S phase of mitotic cell cycle 2.725E-03 2 26 
83 S-adenosylhomocysteine catabolic process 2.988E-03 1 1 
84 regulation of mRNA stability involved in response to stress 2.988E-03 1 1 
85 nucleoside phosphate metabolic process 3.333E-03 8 837 
86 nucleotide metabolic process 3.333E-03 8 837 
87 positive regulation of DNA repair 3.862E-03 2 31 
88 regulation of cell cycle 4.038E-03 8 864 
89 microtubule-based process 4.101E-03 5 354 
90 energy coupled proton transport, down electrochemical gradient 4.368E-03 2 33 
91 ATP synthesis coupled proton transport 4.368E-03 2 33 
92 deoxyribonucleotide metabolic process 4.632E-03 2 34 
93 pyrimidine base metabolic process 4.904E-03 2 35 
94 microtubule cytoskeleton organization 5.114E-03 4 232 
95 nucleotide biosynthetic process 5.114E-03 4 232 
96 nucleobase, nucleoside and nucleotide metabolic process 5.120E-03 8 899 
97 proximal/distal pattern formation 5.761E-03 2 38 
98 nucleoside diphosphate metabolic process 5.761E-03 2 38 
99 DNA metabolic process 5.857E-03 7 728 
100 virion penetration into host cell 5.966E-03 1 2 
101 visceral motor neuron differentiation 5.966E-03 1 2 
102 viral envelope fusion with host membrane 5.966E-03 1 2 
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MODEL IV – DOWN 
 
# GO Processes pValue Ratio 
1 nervous system development 6.461E-15 94 2143 
2 neurogenesis 6.233E-13 69 1425 
3 generation of neurons 9.573E-12 64 1342 
4 multicellular organismal signaling 1.888E-11 45 762 
5 transmission of nerve impulse 1.888E-11 45 762 
6 system development 2.228E-11 130 3930 
7 neuron development 9.212E-11 48 891 
8 cell differentiation 1.411E-10 103 2905 
9 neuron differentiation 2.916E-10 52 1050 
10 cellular developmental process 6.149E-10 103 2981 
11 synaptic transmission 6.950E-10 39 670 
12 anatomical structure development 9.746E-10 134 4329 
13 multicellular organismal development 8.204E-09 137 4605 
14 cell development 5.806E-08 59 1482 
15 developmental process 9.762E-08 142 5016 
16 homophilic cell adhesion 2.746E-07 15 154 
17 cAMP catabolic process 3.166E-07 6 16 
18 cyclic nucleotide catabolic process 7.106E-07 6 18 
19 ethanolamine-containing compound metabolic process 7.627E-07 9 54 
20 cognition 8.022E-07 19 263 
21 calcium-dependent cell-cell adhesion 1.948E-06 7 32 
22 neuron projection development 2.128E-06 34 737 
23 cell-cell signaling 2.530E-06 43 1057 
24 cell projection organization 3.061E-06 39 922 
25 cell communication 4.259E-06 52 1416 
26 multicellular organismal process 4.395E-06 171 6739 
27 cellular biogenic amine metabolic process 5.056E-06 13 147 
28 phosphatidylcholine metabolic process 5.488E-06 7 37 
29 learning or memory 6.854E-06 17 250 
30 nucleoside monophosphate catabolic process 7.744E-06 6 26 
31 inner ear receptor cell development 1.122E-05 7 41 
32 synapse assembly 1.195E-05 8 57 
33 cell morphogenesis involved in neuron differentiation 1.388E-05 29 633 
34 cGMP catabolic process 1.525E-05 4 9 
35 axonogenesis 1.581E-05 28 604 
36 cellular component assembly 2.003E-05 51 1458 
37 synapse organization 2.076E-05 11 121 
38 regulation of fatty acid biosynthetic process 2.121E-05 7 45 
39 neuron projection morphogenesis 2.140E-05 29 648 
40 ovulation 2.285E-05 6 31 
41 central nervous system development 2.485E-05 36 900 
42 detection of calcium ion 2.504E-05 4 10 
43 long-chain fatty acid transport 2.845E-05 7 47 
44 response to methylmercury 3.019E-05 5 20 
45 regulation of lipid metabolic process 3.263E-05 16 254 
46 fatty acid transport 3.578E-05 8 66 
47 neuron migration 3.875E-05 10 107 
48 carnitine shuttle 3.875E-05 4 11 
49 cell adhesion 3.890E-05 35 883 
50 cell activation 3.893E-05 32 775 
51 regulation of localization 4.001E-05 53 1577 
52 platelet activation 4.050E-05 18 316 
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53 biological adhesion 4.361E-05 35 888 
54 cell projection morphogenesis 5.787E-05 30 720 
55 chemokine metabolic process 6.702E-05 3 5 
56 axon guidance 7.963E-05 22 459 
57 cell part morphogenesis 7.977E-05 30 733 
58 behavior 8.681E-05 26 596 
59 signaling 8.896E-05 136 5359 
60 synaptic vesicle transport 9.055E-05 8 75 
61 monocarboxylic acid transport 1.167E-04 9 99 
62 cAMP metabolic process 1.188E-04 6 41 
63 platelet activating factor biosynthetic process 1.321E-04 3 6 
64 negative regulation of cardiac muscle contraction 1.321E-04 3 6 
65 cellular component biogenesis 1.330E-04 52 1611 
66 cellular component morphogenesis 1.339E-04 35 940 
67 extracellular structure organization 1.494E-04 16 289 
68 regulation of microtubule polymerization or depolymerization 1.560E-04 6 43 
69 cell morphogenesis involved in differentiation 1.588E-04 29 726 
70 inner ear receptor cell differentiation 1.741E-04 7 62 
71 protein complex assembly 1.743E-04 29 730 
72 intracellular signal transduction 1.820E-04 53 1673 
73 protein complex biogenesis 1.867E-04 29 733 
74 anatomical structure morphogenesis 1.924E-04 64 2141 
75 positive regulation of lipid biosynthetic process 1.927E-04 7 63 
76 carnitine transport 1.981E-04 4 16 
77 cellular response to antibiotic 1.981E-04 4 16 
78 betaine transport 1.981E-04 4 16 
79 regulation of lipid biosynthetic process 1.995E-04 10 130 
80 associative learning 2.016E-04 8 84 
81 cellular component organization 2.177E-04 109 4177 
82 positive regulation of response to external stimulus 2.263E-04 12 184 
83 platelet activating factor metabolic process 2.280E-04 3 7 
84 response to calcium ion 2.402E-04 10 133 
85 localization 2.420E-04 110 4235 
86 intracellular protein kinase cascade 2.800E-04 24 571 
87 learning 3.052E-04 10 137 
88 mechanoreceptor differentiation 3.112E-04 7 68 
89 detection of temperature stimulus involved in sensory perception of pain 3.596E-04 3 8 
90 detection of temperature stimulus involved in sensory perception 3.596E-04 3 8 
91 female gonad development 3.631E-04 10 140 
92 regulation of iron ion transport 3.632E-04 2 2 
93 toluene-containing compound metabolic process 3.632E-04 2 2 
94 positive regulation of nucleoside transport 3.632E-04 2 2 
95 toluene metabolic process 3.632E-04 2 2 
96 cellular response to methylmercury 3.632E-04 2 2 
97 platelet-derived growth factor receptor-alpha signaling pathway 3.632E-04 2 2 
98 negative regulation of iron ion transport 3.632E-04 2 2 
99 regulation of nucleoside transport 3.632E-04 2 2 
100 regulation of cell adhesion 3.661E-04 16 313 
101 regulation of receptor activity 3.725E-04 7 70 
102 response to estradiol stimulus 3.848E-04 12 195 
103 cell morphogenesis 3.852E-04 32 879 
104 intracellular lipid transport 4.033E-04 4 19 
105 Leydig cell differentiation 4.033E-04 4 19 
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106 ovulation from ovarian follicle 4.033E-04 4 19 
107 regulation of vesicle-mediated transport 4.088E-04 15 285 
108 response to external stimulus 4.149E-04 48 1522 
109 regulation of transport 4.274E-04 41 1238 
110 glycerolipid catabolic process 4.351E-04 5 34 
111 positive regulation of lipid metabolic process 4.393E-04 9 118 
112 cellular component organization or biogenesis 4.541E-04 110 4304 
113 neurological system process 4.756E-04 60 2040 
114 regulation of microtubule polymerization 4.965E-04 4 20 
115 detection of abiotic stimulus 5.280E-04 9 121 
116 glycerophospholipid catabolic process 5.317E-04 3 9 
117 regulation of mucus secretion 5.317E-04 3 9 
118 synaptic vesicle maturation 5.317E-04 3 9 
119 regulation of fatty acid metabolic process 5.394E-04 8 97 
120 regulation of lipid catabolic process 5.540E-04 6 54 
121 regulation of catabolic process 5.652E-04 25 636 
122 response to wounding 6.159E-04 41 1261 
123 carboxylic acid transport 6.671E-04 13 237 
124 organic acid transport 7.212E-04 13 239 
125 negative regulation of lipid catabolic process 7.274E-04 4 22 
126 negative regulation of kinase activity 7.397E-04 11 181 
127 regulation of prostaglandin biosynthetic process 7.489E-04 3 10 
128 positive regulation of prostaglandin biosynthetic process 7.489E-04 3 10 
129 detection of temperature stimulus 7.489E-04 3 10 
130 system process 7.545E-04 69 2474 
131 development of primary female sexual characteristics 7.679E-04 10 154 
132 cell-cell adhesion 7.765E-04 18 402 
133 regulation of cellular component organization 8.236E-04 42 1321 
134 phosphatidylcholine biosynthetic process 8.674E-04 4 23 
135 synaptic transmission, GABAergic 8.674E-04 4 23 
136 energy reserve metabolic process 8.781E-04 12 214 
137 regulation of signaling 9.249E-04 61 2139 
138 sensory perception of mechanical stimulus 9.255E-04 11 186 
139 ion transport 9.936E-04 35 1049 
140 retina vasculature development in camera-type eye 1.015E-03 3 11 
141 CDP-choline pathway 1.015E-03 3 11 
142 negative regulation of striated muscle contraction 1.015E-03 3 11 
143 sensory perception of temperature stimulus 1.015E-03 3 11 
144 synaptic vesicle endocytosis 1.025E-03 4 24 
145 positive regulation of cell-matrix adhesion 1.025E-03 4 24 
146 locomotion 1.035E-03 37 1132 
147 wound healing 1.052E-03 28 778 
148 cellular response to endogenous stimulus 1.055E-03 27 740 
149 clustering of voltage-gated potassium channels 1.076E-03 2 3 
150 metanephric glomerulus vasculature morphogenesis 1.076E-03 2 3 
151 negative regulation of circadian sleep/wake cycle, non-REM sleep 1.076E-03 2 3 
152 negative regulation of neurotrophin production 1.076E-03 2 3 
153 negative regulation of mucus secretion 1.076E-03 2 3 
154 regulation of neurotrophin production 1.076E-03 2 3 
155 cell proliferation in midbrain 1.076E-03 2 3 
156 metanephric glomerular capillary formation 1.076E-03 2 3 
157 chemokine production 1.076E-03 2 3 
158 metanephric glomerulus morphogenesis 1.076E-03 2 3 
159 detection of external stimulus 1.099E-03 9 134 
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160 hemostasis 1.113E-03 24 630 
161 protein phosphorylation 1.168E-03 31 900 
162 negative regulation of transferase activity 1.198E-03 11 192 
163 estrogen metabolic process 1.202E-03 4 25 
164 alcohol metabolic process 1.213E-03 23 597 
165 brain development 1.228E-03 25 672 
166 chemotaxis 1.228E-03 25 672 
167 positive regulation of inflammatory response 1.235E-03 8 110 
168 female sex differentiation 1.242E-03 10 164 
169 regulation of protein phosphorylation 1.252E-03 31 904 
170 negative regulation of signaling 1.265E-03 24 636 
171 sensory organ development 1.267E-03 21 526 
172 taxis 1.280E-03 25 674 
173 retina development in camera-type eye 1.284E-03 9 137 
174 response to cadmium ion 1.308E-03 5 43 
175 neuronal ion channel clustering 1.335E-03 3 12 
176 negative regulation of cell communication 1.347E-03 24 639 
177 locomotory behavior 1.357E-03 11 195 
178 regulation of transmission of nerve impulse 1.414E-03 15 322 
179 behavioral fear response 1.453E-03 5 44 
180 regulation of body fluid levels 1.465E-03 27 757 
181 regulation of cell-substrate adhesion 1.468E-03 8 113 
182 regulation of signal transduction 1.494E-03 52 1788 
183 protein complex subunit organization 1.532E-03 29 837 
184 response to estrogen stimulus 1.543E-03 14 292 
185 regulation of microtubule-based process 1.572E-03 7 89 
186 innervation 1.619E-03 4 27 
187 regulation of neurotransmitter levels 1.625E-03 10 170 
188 negative regulation of protein kinase activity 1.625E-03 10 170 
189 phospholipid biosynthetic process 1.647E-03 9 142 
190 regulation of Ras GTPase activity 1.660E-03 11 200 
191 regulation of germinal center formation 1.710E-03 3 13 
192 positive regulation of protein dephosphorylation 1.710E-03 3 13 
193 amino acid transport 1.729E-03 9 143 
194 response to inorganic substance 1.752E-03 22 577 
195 behavioral defense response 1.778E-03 5 46 
196 glycerophospholipid biosynthetic process 1.788E-03 7 91 
197 response to organic nitrogen 1.797E-03 15 330 
198 regulation of synaptic transmission 1.807E-03 14 297 
199 glycerophospholipid metabolic process 1.850E-03 10 173 
200 dendrite morphogenesis 1.860E-03 4 28 
201 cGMP-mediated signaling 1.860E-03 4 28 
202 amine transport 1.867E-03 11 203 
203 response to hydrogen peroxide 1.902E-03 9 145 
204 cell cycle arrest 2.013E-03 10 175 
205 gonad development 2.026E-03 13 268 
206 ovum-producing ovary development 2.039E-03 8 119 
207 protein oligomerization 2.070E-03 16 369 
208 phospholipid metabolic process 2.093E-03 13 269 
209 regulation of multicellular organismal process 2.097E-03 57 2036 
210 regulation of protein kinase activity 2.102E-03 24 661 
211 regulation of cell projection organization 2.108E-03 14 302 
212 lysophospholipid transport 2.124E-03 2 4 
213 fractalkine metabolic process 2.124E-03 2 4 
214 maintenance of cell polarity 2.124E-03 2 4 
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215 glomerular capillary formation 2.124E-03 2 4 
216 glomerulus vasculature morphogenesis 2.124E-03 2 4 
217 cellular response to luteinizing hormone stimulus 2.124E-03 2 4 
218 positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid 
transport 
2.124E-03 2 4 
219 negative regulation of microtubule polymerization or depolymerization 2.126E-03 4 29 
220 protein kinase C signaling cascade 2.146E-03 3 14 
221 positive regulation of dephosphorylation 2.146E-03 3 14 
222 positive regulation of icosanoid secretion 2.146E-03 3 14 
223 negative regulation of glutamate secretion 2.146E-03 3 14 
224 positive regulation of prostaglandin secretion 2.146E-03 3 14 
225 regulation of prostaglandin secretion 2.146E-03 3 14 
226 negative regulation of synaptic transmission 2.153E-03 5 48 
227 regulation of fatty acid oxidation 2.153E-03 5 48 
228 regulation of response to stimulus 2.175E-03 66 2441 
229 cellular component assembly at cellular level 2.192E-03 33 1018 
230 negative regulation of transport 2.263E-03 15 338 
231 positive regulation of cell-substrate adhesion 2.343E-03 6 71 
232 positive regulation of fatty acid metabolic process 2.360E-03 5 49 
233 fear response 2.360E-03 5 49 
234 quaternary ammonium group transport 2.416E-03 4 30 
235 neuron maturation 2.416E-03 4 30 
236 sensory perception of pain 2.429E-03 7 96 
237 regulation of transferase activity 2.479E-03 25 708 
238 anion transport 2.483E-03 12 242 
239 regulation of protein localization 2.531E-03 15 342 
240 cochlea development 2.582E-03 5 50 
241 response to oxygen levels 2.630E-03 16 378 
242 regulation of circadian sleep/wake cycle, non-REM sleep 2.645E-03 3 15 
243 serotonin metabolic process 2.645E-03 3 15 
244 positive regulation of microtubule polymerization or depolymerization 2.645E-03 3 15 
245 cellular response to hormone stimulus 2.658E-03 22 597 
246 response to reactive oxygen species 2.680E-03 10 182 
247 phosphate metabolic process 2.748E-03 43 1451 
248 phosphorus metabolic process 2.783E-03 43 1452 
249 regulation of neurological system process 2.825E-03 15 346 
250 regulation of microtubule cytoskeleton organization 2.889E-03 6 74 
251 inner ear development 2.899E-03 10 184 
252 negative regulation of molecular function 3.122E-03 29 879 
253 negative regulation of synaptic transmission, GABAergic 3.210E-03 3 16 
254 cellular response to peptide hormone stimulus 3.229E-03 16 386 
255 regulation of metal ion transport 3.243E-03 11 218 
256 regulation of nervous system development 3.409E-03 20 534 
257 regulation of kinase activity 3.435E-03 24 687 
258 lipid localization 3.475E-03 11 220 
259 facial nucleus development 3.496E-03 2 5 
260 regulation of sphingolipid biosynthetic process 3.496E-03 2 5 
261 commissural neuron axon guidance 3.496E-03 2 5 
262 testosterone biosynthetic process 3.496E-03 2 5 
263 insecticide metabolic process 3.496E-03 2 5 
264 response to luteinizing hormone stimulus 3.496E-03 2 5 
265 regulation of ceramide biosynthetic process 3.496E-03 2 5 
266 cellular response to mercury ion 3.496E-03 2 5 
267 positive regulation of cell adhesion 3.540E-03 9 159 
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268 transport 3.618E-03 88 3513 
269 regulation of cell-matrix adhesion 3.623E-03 5 54 
270 regulation of biological quality 3.629E-03 76 2953 
271 response to temperature stimulus 3.645E-03 10 190 
272 regulation of phosphorylation 3.649E-03 31 970 
273 regulation of Ras protein signal transduction 3.753E-03 14 322 
274 negative regulation of MAPKKK cascade 3.760E-03 6 78 
275 relaxation of muscle 3.843E-03 3 17 
276 regulation of icosanoid secretion 3.843E-03 3 17 
277 positive regulation of fatty acid transport 3.843E-03 3 17 
278 luteinization 3.843E-03 3 17 
279 regulation of synaptic transmission, GABAergic 3.852E-03 4 34 
280 ion transmembrane transport 3.859E-03 20 540 
281 negative regulation of transmission of nerve impulse 3.924E-03 5 55 
282 response to metal ion 3.935E-03 16 394 
283 peptidyl-tyrosine dephosphorylation 4.011E-03 7 105 
284 regulation of neuron differentiation 4.032E-03 16 395 
285 glycerolipid biosynthetic process 4.052E-03 8 133 
286 organophosphate metabolic process 4.099E-03 13 291 
287 forebrain development 4.188E-03 15 361 
288 response to lithium ion 4.242E-03 5 56 
289 regulation of activated T cell proliferation 4.284E-03 4 35 
290 development of primary sexual characteristics 4.464E-03 13 294 
291 coagulation 4.486E-03 22 624 
292 blood coagulation 4.486E-03 22 624 
293 response to steroid hormone stimulus 4.486E-03 22 624 
294 cyclic nucleotide metabolic process 4.530E-03 6 81 
295 response to activity 4.530E-03 6 81 
296 positive regulation of macrophage derived foam cell differentiation 4.547E-03 3 18 
297 positive regulation of receptor activity 4.547E-03 3 18 
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MODEL V – UP 
 
# GO Processes pValue Ratio 
1 cell cycle process 1.581E-38 89 1001 
2 mitotic cell cycle 4.771E-37 75 716 
3 cell cycle 7.961E-37 97 1262 
4 cell cycle phase 3.493E-36 80 851 
5 cellular component organization or biogenesis 2.648E-28 168 4304 
6 cellular component organization 2.944E-28 165 4177 
7 M phase 3.031E-27 55 521 
8 cellular component organization or biogenesis at cellular level 1.002E-25 141 3367 
9 cellular component organization at cellular level 1.264E-25 138 3253 
10 cell division 2.947E-25 48 422 
11 M phase of mitotic cell cycle 4.813E-25 44 349 
12 regulation of cell cycle process 7.137E-25 49 451 
13 regulation of cell cycle 8.817E-24 65 864 
14 mitosis 1.547E-23 42 341 
15 nuclear division 1.547E-23 42 341 
16 cell cycle checkpoint 6.250E-23 37 262 
17 organelle fission 7.532E-23 42 355 
18 regulation of cell cycle arrest 3.978E-22 37 276 
19 interphase of mitotic cell cycle 9.203E-22 44 420 
20 interphase 1.780E-21 44 427 
21 cellular process 2.570E-21 329 14653 
22 organelle organization 4.549E-20 96 2040 
23 macromolecular complex subunit organization 7.588E-19 67 1132 
24 cellular macromolecule metabolic process 2.534E-18 188 6261 
25 DNA conformation change 2.156E-17 28 202 
26 organ development 7.591E-17 111 2875 
27 DNA metabolic process 9.915E-17 50 728 
28 macromolecule metabolic process 1.076E-16 196 6885 
29 developmental process 2.032E-16 158 5016 
30 nucleic acid metabolic process 3.224E-16 133 3882 
31 nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 3.566E-16 151 4713 
32 regulation of macromolecule metabolic process 3.637E-16 150 4667 
33 DNA packaging 4.299E-16 25 173 
34 S phase of mitotic cell cycle 5.980E-16 23 143 
35 cellular nitrogen compound metabolic process 9.778E-16 160 5196 
36 S phase 1.302E-15 23 148 
37 G1/S transition of mitotic cell cycle 1.643E-15 27 219 
38 multicellular organismal development 1.678E-15 147 4605 
39 nitrogen compound metabolic process 1.776E-15 162 5326 
40 cellular macromolecular complex subunit organization 2.251E-15 44 618 
41 regulation of metabolic process 5.908E-15 168 5690 
42 chromosome segregation 6.811E-15 22 143 
43 cellular metabolic process 9.084E-15 222 8579 
44 positive regulation of biological process 1.067E-14 126 3736 
45 primary metabolic process 1.101E-14 222 8592 
46 positive regulation of cellular process 1.119E-14 118 3385 
47 negative regulation of cellular process 1.220E-14 109 3002 
48 positive regulation of cell proliferation 2.183E-14 50 834 
49 regulation of cell proliferation 2.369E-14 68 1427 
50 anatomical structure development 2.625E-14 138 4329 
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51 negative regulation of biological process 2.742E-14 115 3296 
52 chromosome organization 4.055E-14 46 728 
53 anatomical structure morphogenesis 8.361E-14 86 2141 
54 system development 8.438E-14 128 3930 
55 cellular component disassembly at cellular level 9.208E-14 26 237 
56 cellular component disassembly 1.241E-13 26 240 
57 regulation of mitotic cell cycle 1.755E-13 31 354 
58 microtubule-based process 1.755E-13 31 354 
59 protein-DNA complex subunit organization 2.211E-13 21 151 
60 metabolic process 3.912E-13 237 9707 
61 regulation of cellular metabolic process 4.373E-13 149 5010 
62 cell proliferation 6.686E-13 45 757 
63 protein-DNA complex assembly 7.473E-13 20 143 
64 regulation of primary metabolic process 1.290E-12 147 4978 
65 positive regulation of metabolic process 1.796E-12 79 1984 
66 biosynthetic process 1.960E-12 136 4475 
67 cellular biosynthetic process 3.215E-12 133 4362 
68 nucleosome organization 3.297E-12 19 137 
69 nucleosome assembly 3.659E-12 18 121 
70 biological regulation 6.049E-12 249 10630 
71 macromolecule biosynthetic process 6.786E-12 114 3527 
72 viral infectious cycle 7.081E-12 20 161 
73 chromatin assembly or disassembly 7.170E-12 19 143 
74 chromatin assembly 8.494E-12 18 127 
75 positive regulation of macromolecule metabolic process 1.046E-11 73 1818 
76 macromolecular complex assembly 1.066E-11 50 984 
77 response to stress 1.634E-11 106 3216 
78 sister chromatid segregation 1.737E-11 13 58 
79 protein complex subunit organization 2.020E-11 45 837 
80 microtubule cytoskeleton organization 2.092E-11 23 232 
81 positive regulation of cellular metabolic process 2.184E-11 74 1886 
82 viral reproductive process 3.017E-11 21 194 
83 mitotic cell cycle checkpoint 3.032E-11 19 155 
84 regulation of cellular process 3.800E-11 228 9537 
85 regulation of biological process 3.868E-11 238 10123 
86 cellular macromolecule biosynthetic process 4.662E-11 111 3497 
87 regulation of gene expression 4.964E-11 117 3775 
88 cellular component biogenesis 5.420E-11 66 1611 
89 spindle organization 5.847E-11 14 77 
90 DNA integrity checkpoint 8.178E-11 18 145 
91 mitotic prometaphase 1.148E-10 15 96 
92 regulation of interphase of mitotic cell cycle 1.250E-10 19 168 
93 regulation of cellular protein metabolic process 1.361E-10 59 1381 
94 multi-organism process 1.430E-10 60 1420 
95 DNA replication 1.620E-10 22 234 
96 cellular response to stress 2.154E-10 52 1142 
97 positive regulation of molecular function 2.285E-10 60 1437 
98 negative regulation of cell differentiation 2.464E-10 31 469 
99 translation 2.940E-10 29 417 
100 response to DNA damage stimulus 3.629E-10 36 624 
101 regulation of protein kinase activity 4.711E-10 37 661 
102 regulation of protein metabolic process 5.589E-10 62 1547 
103 regulation of cellular component organization 5.764E-10 56 1321 
104 regulation of molecular function 7.720E-10 81 2330 
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105 anaphase-promoting complex-dependent proteasomal ubiquitin-dependent 
protein catabolic process 
8.024E-10 14 93 
106 cellular component assembly 1.095E-09 59 1458 
107 regulation of protein modification process 1.282E-09 49 1093 
108 regulation of kinase activity 1.358E-09 37 687 
109 viral reproduction 1.497E-09 30 476 
110 cellular protein metabolic process 1.804E-09 94 2939 
111 protein metabolic process 1.812E-09 107 3529 
112 mitotic sister chromatid segregation 1.914E-09 11 54 
113 DNA damage checkpoint 2.305E-09 16 137 
114 G2/M transition of mitotic cell cycle 2.594E-09 17 158 
115 regulation of transferase activity 3.063E-09 37 708 
116 regulation of catalytic activity 3.128E-09 70 1939 
117 tissue development 3.211E-09 55 1347 
118 regulation of cyclin-dependent protein kinase activity 3.618E-09 14 104 
119 regulation of developmental process 3.946E-09 60 1548 
120 regulation of DNA metabolic process 4.035E-09 20 229 
121 cellular protein complex disassembly 6.743E-09 14 109 
122 cellular macromolecular complex disassembly 7.797E-09 15 129 
123 regulation of protein phosphorylation 7.910E-09 42 904 
124 mammary gland development 7.951E-09 17 170 
125 negative regulation of developmental process 7.961E-09 32 573 
126 cellular macromolecular complex assembly 8.828E-09 29 484 
127 negative regulation of macromolecule metabolic process 9.384E-09 55 1389 
128 positive regulation of cell cycle process 9.568E-09 16 151 
129 protein complex disassembly 9.638E-09 14 112 
130 multicellular organismal process 9.836E-09 169 6739 
131 macromolecular complex disassembly 1.071E-08 15 132 
132 response to abiotic stimulus 1.107E-08 40 845 
133 regulation of macromolecule biosynthetic process 1.330E-08 107 3657 
134 regulation of phosphorus metabolic process 1.649E-08 44 999 
135 regulation of phosphate metabolic process 1.649E-08 44 999 
136 chromosome localization 1.818E-08 8 28 
137 establishment of chromosome localization 1.818E-08 8 28 
138 regulation of organelle organization 1.819E-08 28 470 
139 response to drug 1.835E-08 34 658 
140 regulation of phosphorylation 2.025E-08 43 970 
141 gene expression 2.079E-08 105 3593 
142 interspecies interaction between organisms 2.088E-08 30 534 
143 regulation of biosynthetic process 2.104E-08 112 3925 
144 positive regulation of cell cycle 2.174E-08 15 139 
145 embryo development 2.823E-08 46 1091 
146 positive regulation of biosynthetic process 2.833E-08 56 1474 
147 regulation of cellular macromolecule biosynthetic process 2.878E-08 104 3568 
148 positive regulation of catalytic activity 2.960E-08 50 1243 
149 organ morphogenesis 3.526E-08 43 989 
150 negative regulation of metabolic process 4.381E-08 56 1493 
151 regulation of multicellular organismal development 4.770E-08 50 1262 
152 reproductive process 5.220E-08 55 1461 
153 viral genome expression 5.343E-08 12 90 
154 viral transcription 5.343E-08 12 90 
155 regulation of cell death 5.489E-08 57 1543 
156 neurogenesis 5.665E-08 54 1425 
157 embryonic morphogenesis 5.991E-08 30 560 
158 positive regulation of organelle organization 6.633E-08 17 196 
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159 reproduction 6.851E-08 55 1473 
160 positive regulation of nitrogen compound metabolic process 7.607E-08 52 1359 
161 regulation of cellular biosynthetic process 8.471E-08 109 3881 
162 translational termination 8.751E-08 12 94 
163 positive regulation of chromosome segregation 9.108E-08 4 4 
164 regulation of biological quality 9.567E-08 89 2953 
165 regulation of apoptosis 9.785E-08 55 1489 
166 DNA recombination 1.106E-07 17 203 
167 cytoskeleton organization 1.143E-07 34 710 
168 response to mechanical stimulus 1.146E-07 18 228 
169 chromatin organization 1.251E-07 29 547 
170 regulation of programmed cell death 1.301E-07 55 1502 
171 pancreas development 1.345E-07 16 182 
172 response to stimulus 1.389E-07 187 7952 
173 positive regulation of macromolecule biosynthetic process 1.697E-07 50 1315 
174 positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid 
metabolic process 
1.861E-07 50 1319 
175 response to external stimulus 1.998E-07 55 1522 
176 regulation of protein serine/threonine kinase activity 2.042E-07 25 434 
177 positive regulation of cellular biosynthetic process 2.309E-07 53 1448 
178 regulation of nitrogen compound metabolic process 2.572E-07 111 4061 
179 chordate embryonic development 2.819E-07 32 669 
180 M/G1 transition of mitotic cell cycle 3.350E-07 11 87 
181 RNA metabolic process 3.787E-07 97 3419 
182 embryo development ending in birth or egg hatching 3.913E-07 32 679 
183 anti-apoptosis 4.407E-07 20 304 
184 anatomical structure formation involved in morphogenesis 4.827E-07 35 791 
185 regulation of multicellular organismal process 5.479E-07 66 2036 
186 regulation of G2/M transition of mitotic cell cycle 5.580E-07 8 42 
187 G1 phase of mitotic cell cycle 6.787E-07 9 58 
188 positive regulation of gene expression 6.914E-07 46 1219 
189 generation of neurons 7.514E-07 49 1342 
190 response to antibiotic 7.887E-07 9 59 
191 mitotic spindle organization 8.502E-07 7 31 
192 regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic 
process 
9.301E-07 107 3968 
193 wound healing 9.386E-07 34 778 
194 positive regulation of epithelial cell proliferation 1.009E-06 14 162 
195 apoptosis 1.177E-06 39 971 
196 response to inorganic substance 1.215E-06 28 577 
197 G1 phase 1.216E-06 9 62 
198 regeneration 1.279E-06 16 215 
199 endocrine pancreas development 1.282E-06 13 142 
200 cellular component assembly at cellular level 1.467E-06 40 1018 
201 cellular response to fatty acid 1.592E-06 6 22 
202 response to organic substance 1.659E-06 72 2368 
203 aging 1.741E-06 20 332 
204 posttranscriptional regulation of gene expression 1.784E-06 22 393 
205 G2 phase 1.802E-06 5 13 
206 G2 phase of mitotic cell cycle 1.802E-06 5 13 
207 organelle localization 1.819E-06 15 195 
208 positive regulation of cellular component organization 1.832E-06 26 522 
209 protein complex assembly 1.867E-06 32 730 
210 programmed cell death 1.884E-06 39 990 
211 skeletal system development 1.993E-06 23 427 
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212 protein complex biogenesis 2.035E-06 32 733 
213 cellular macromolecule catabolic process 2.065E-06 28 593 
214 regulation of cell differentiation 2.111E-06 42 1111 
215 metaphase plate congression 2.123E-06 6 23 
216 chromosome condensation 2.504E-06 7 36 
217 G2/M transition checkpoint 2.504E-06 7 36 
218 muscle structure development 2.619E-06 25 499 
219 negative regulation of cellular metabolic process 2.757E-06 48 1364 
220 negative regulation of epithelial cell differentiation 2.789E-06 6 24 
221 regulation of epithelial cell proliferation 2.859E-06 17 256 
222 organ regeneration 2.979E-06 11 108 
223 positive regulation of cellular protein metabolic process 3.280E-06 27 573 
224 translational elongation 3.955E-06 13 157 
225 cellular response to lipid 4.100E-06 8 54 
226 positive regulation of protein metabolic process 4.111E-06 29 650 
227 cellular component disassembly involved in apoptosis 4.226E-06 10 91 
228 organelle assembly 4.226E-06 10 91 
229 regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle 4.226E-06 10 91 
230 positive regulation of protein kinase activity 4.275E-06 23 447 
231 regulation of RNA metabolic process 4.280E-06 92 3366 
232 positive regulation of peptidase activity 4.470E-06 12 135 
233 regulation of epidermal cell differentiation 4.632E-06 6 26 
234 phosphatidylinositol-mediated signaling 4.669E-06 10 92 
235 positive regulation of RNA metabolic process 4.879E-06 43 1189 
236 cell differentiation 5.057E-06 82 2905 
237 circulatory system development 5.085E-06 33 803 
238 cardiovascular system development 5.085E-06 33 803 
239 embryonic skeletal system morphogenesis 5.151E-06 10 93 
240 inositol lipid-mediated signaling 5.151E-06 10 93 
241 positive regulation of attachment of spindle microtubules to kinetochore 5.264E-06 3 3 
242 spindle checkpoint 5.267E-06 7 40 
243 response to lithium ion 5.430E-06 8 56 
244 astrocyte cell migration 6.031E-06 4 8 
245 positive regulation of vesicle fusion 6.031E-06 4 8 
246 macromolecule catabolic process 6.534E-06 30 702 
247 cell death 6.713E-06 42 1164 
248 gland development 6.963E-06 20 364 
249 positive regulation of kinase activity 7.339E-06 23 462 
250 death 7.766E-06 42 1171 
251 negative regulation of apoptosis 7.924E-06 30 709 
252 negative regulation of cell death 7.982E-06 31 746 
253 proteasomal ubiquitin-dependent protein catabolic process 8.400E-06 14 194 
254 translational initiation 8.556E-06 9 78 
255 gliogenesis 8.864E-06 13 169 
256 proteasomal protein catabolic process 8.909E-06 14 195 
257 lactation 9.205E-06 8 60 
258 response to wounding 9.251E-06 44 1261 
259 response to ionizing radiation 9.345E-06 12 145 
260 positive regulation of transcription, DNA-dependent 9.617E-06 41 1141 
261 embryonic skeletal system development 9.752E-06 11 122 
262 negative regulation of programmed cell death 9.842E-06 30 717 
263 mitotic cell cycle G1/S transition DNA damage checkpoint 1.055E-05 9 80 
264 positive regulation of transferase activity 1.110E-05 23 474 
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265 regulation of transcription, DNA-dependent 1.113E-05 89 3300 
266 mitotic metaphase plate congression 1.116E-05 5 18 
267 mitotic chromosome condensation 1.116E-05 5 18 
268 DNA replication-independent nucleosome assembly 1.126E-05 6 30 
269 DNA replication-independent nucleosome organization 1.126E-05 6 30 
270 CenH3-containing nucleosome assembly at centromere 1.126E-05 6 30 
271 regulation of epidermis development 1.189E-05 7 45 
272 nervous system development 1.263E-05 64 2143 
273 endocrine system development 1.324E-05 16 258 
274 cellular developmental process 1.345E-05 82 2981 
275 response to nutrient 1.386E-05 22 447 
276 muscle organ development 1.399E-05 19 350 
277 RNA biosynthetic process 1.446E-05 76 2704 
278 regulation of chromosome segregation 1.494E-05 5 19 
279 regulation of keratinocyte differentiation 1.494E-05 5 19 
280 DNA-dependent DNA replication 1.576E-05 9 84 
281 regulation of mitosis 1.662E-05 10 106 
282 regulation of nuclear division 1.662E-05 10 106 
283 chromatin remodeling at centromere 1.669E-05 6 32 
284 DNA repair 1.721E-05 21 420 
285 negative regulation of epidermal cell differentiation 1.760E-05 4 10 
286 regulation of prostaglandin biosynthetic process 1.760E-05 4 10 
287 DNA unwinding involved in replication 1.760E-05 4 10 
288 positive regulation of prostaglandin biosynthetic process 1.760E-05 4 10 
289 negative regulation of gene expression 1.854E-05 37 1012 
290 protein import into nucleus 1.918E-05 11 131 
291 response to glucocorticoid stimulus 1.931E-05 16 266 
292 negative regulation of monocyte differentiation 2.078E-05 3 4 
293 regulation of attachment of spindle microtubules to kinetochore 2.078E-05 3 4 
294 'de novo' IMP biosynthetic process 2.078E-05 3 4 
295 response to vitamin B3 2.078E-05 3 4 
296 nuclear import 2.372E-05 11 134 
297 tissue morphogenesis 2.666E-05 24 536 
298 cellular process involved in reproduction 2.706E-05 22 467 
299 embryonic organ morphogenesis 2.723E-05 15 244 
300 establishment of organelle localization 2.724E-05 11 136 
301 regulation of body fluid levels 2.749E-05 30 757 
302 regulation of caspase activity 2.764E-05 13 188 
303 positive regulation of protein modification process 2.795E-05 22 468 
304 DNA strand elongation involved in DNA replication 2.861E-05 6 35 
305 response to biotic stimulus 2.978E-05 32 837 
306 intracellular signal transduction 3.310E-05 52 1673 
307 muscle cell differentiation 3.341E-05 17 309 
308 negative regulation of cellular component organization 3.362E-05 19 373 
309 histone exchange 3.383E-05 6 36 
310 regulation of ubiquitin-protein ligase activity 3.387E-05 10 115 
311 homeostatic process 3.476E-05 45 1374 
312 regulation of cell development 3.493E-05 25 581 
313 regulation of epithelial cell differentiation 3.591E-05 8 72 
314 positive regulation of caspase activity 3.650E-05 10 116 
315 regulation of neurogenesis 3.839E-05 22 478 
316 DNA strand elongation 3.979E-05 6 37 
317 mitotic cell cycle G1/S transition checkpoint 4.252E-05 9 95 
318 body fluid secretion 4.252E-05 9 95 
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319 regulation of ligase activity 4.546E-05 10 119 
320 G1/S transition checkpoint 4.620E-05 9 96 
321 response to corticosteroid stimulus 4.647E-05 16 286 
322 mitotic cell cycle spindle checkpoint 4.656E-05 6 38 
323 response to chemical stimulus 4.714E-05 101 4020 
324 negative regulation of myeloid cell differentiation 4.837E-05 8 75 
325 regulation of cell migration 5.055E-05 20 418 
326 T cell migration 5.129E-05 3 5 
327 L-serine biosynthetic process 5.129E-05 3 5 
328 negative regulation of cell cycle 5.376E-05 17 321 
329 activation of caspase activity 5.439E-05 9 98 
330 regulation of DNA replication 5.624E-05 10 122 
331 regulation of localization 5.779E-05 49 1577 
332 positive regulation of protein phosphorylation 5.948E-05 16 292 
333 microtubule-based movement 6.312E-05 11 149 
334 response to metal ion 7.007E-05 19 394 
335 skeletal system morphogenesis 7.118E-05 13 206 
336 cellular response to abiotic stimulus 7.124E-05 11 151 
337 nuclear transport 7.305E-05 15 266 
338 cellular response to external stimulus 7.560E-05 16 298 
339 regulation of cell motility 7.950E-05 20 432 
340 skeletal muscle organ development 7.973E-05 12 180 
341 regulation of G1/S transition of mitotic cell cycle 8.038E-05 9 103 
342 ATP-dependent chromatin remodeling 8.342E-05 6 42 
343 response to other organism 8.350E-05 28 727 
344 response to cAMP 8.441E-05 10 128 
345 tube morphogenesis 8.752E-05 17 334 
346 neuron differentiation 9.034E-05 36 1050 
347 parturition 9.245E-05 5 27 
348 protein oligomerization 9.373E-05 18 369 
349 negative regulation of cellular macromolecule biosynthetic process 9.400E-05 35 1011 
350 regulation of mitotic spindle organization 1.012E-04 3 6 
351 IMP biosynthetic process 1.012E-04 3 6 
352 protein targeting to plasma membrane 1.012E-04 3 6 
353 platelet activating factor biosynthetic process 1.012E-04 3 6 
354 small molecule biosynthetic process 1.013E-04 25 621 
355 negative regulation of macromolecule biosynthetic process 1.031E-04 36 1057 
356 regulation of vesicle fusion 1.067E-04 4 15 
357 nucleobase, nucleoside, nucleotide and nucleic acid transport 1.071E-04 11 158 
358 response to steroid hormone stimulus 1.092E-04 25 624 
359 positive regulation of ubiquitin-protein ligase activity involved in mitotic cell 
cycle 
1.186E-04 8 85 
360 response to extracellular stimulus 1.208E-04 26 666 
361 striated muscle tissue development 1.242E-04 16 311 
362 angiogenesis 1.337E-04 16 313 
363 positive regulation of developmental process 1.340E-04 29 787 
364 neuron fate commitment 1.354E-04 7 65 
365 vasculature development 1.385E-04 22 522 
366 positive regulation of fever generation 1.404E-04 4 16 
367 glial cell migration 1.404E-04 4 16 
368 ribosomal large subunit biogenesis 1.404E-04 4 16 
369 cellular protein catabolic process 1.493E-04 18 383 
370 blood vessel development 1.515E-04 21 489 
371 regulation of microtubule-based process 1.639E-04 8 89 
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372 protein localization to nucleus 1.658E-04 11 166 
373 chemokine-mediated signaling pathway 1.749E-04 3 7 
374 regulation of spindle organization 1.749E-04 3 7 
375 IMP metabolic process 1.749E-04 3 7 
376 platelet activating factor metabolic process 1.749E-04 3 7 
377 central nervous system neuron differentiation 1.776E-04 10 140 
378 protein import 1.783E-04 12 196 
379 response to fatty acid 1.787E-04 6 48 
380 cellular response to oxygen levels 1.803E-04 7 68 
381 negative regulation of epidermis development 1.810E-04 4 17 
382 negative regulation of cellular protein metabolic process 1.880E-04 17 356 
383 regulation of response to stimulus 1.886E-04 66 2441 
384 regulation of nervous system development 1.907E-04 22 534 
385 response to lipopolysaccharide 1.914E-04 16 323 
386 striated muscle cell differentiation 1.964E-04 13 228 
387 cell migration 1.999E-04 25 649 
388 cell development 2.000E-04 45 1482 
389 regulation of cellular component movement 2.066E-04 20 464 
390 skeletal muscle tissue development 2.149E-04 11 171 
391 cellular catabolic process 2.160E-04 47 1576 
392 signal transduction involved in mitotic cell cycle checkpoint 2.164E-04 7 70 
393 DNA damage response, signal transduction by p53 class mediator resulting 
in cell cycle arrest 
2.164E-04 7 70 
394 signal transduction involved in DNA damage checkpoint 2.164E-04 7 70 
395 signal transduction involved in mitotic cell cycle G1/S checkpoint 2.164E-04 7 70 
396 signal transduction involved in mitotic cell cycle G1/S transition DNA 
damage checkpoint 
2.164E-04 7 70 
397 signal transduction involved in DNA integrity checkpoint 2.164E-04 7 70 
398 positive regulation of phosphorylation 2.199E-04 16 327 
399 nucleocytoplasmic transport 2.211E-04 14 262 
400 virus-host interaction 2.248E-04 6 50 
401 positive regulation of heat generation 2.296E-04 4 18 
402 regulation of fever generation 2.296E-04 4 18 
403 purine-containing compound transmembrane transport 2.296E-04 4 18 
404 embryonic organ development 2.319E-04 18 397 
405 cellular response to chemical stimulus 2.325E-04 50 1716 
406 muscle tissue development 2.355E-04 16 329 
407 positive regulation of cell death 2.364E-04 28 774 
408 signal transduction involved in G1/S transition checkpoint 2.365E-04 7 71 
409 signal transduction involved in cell cycle checkpoint 2.365E-04 7 71 
410 meiosis 2.377E-04 11 173 
411 M phase of meiotic cell cycle 2.377E-04 11 173 
412 regulation of locomotion 2.443E-04 20 470 
413 regulation of endopeptidase activity 2.542E-04 15 298 
414 positive regulation of transcription from RNA polymerase II promoter 2.570E-04 28 778 
415 negative regulation of cell migration 2.586E-04 9 120 
416 negative regulation of biosynthetic process 2.664E-04 36 1110 
417 positive regulation of DNA metabolic process 2.751E-04 9 121 
418 negative regulation of keratinocyte differentiation 2.762E-04 3 8 
419 positive regulation of mammary gland epithelial cell proliferation 2.762E-04 3 8 
420 centromere complex assembly 2.762E-04 3 8 
421 mitotic metaphase 2.762E-04 3 8 
422 pentose biosynthetic process 2.762E-04 3 8 
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423 luteolysis 2.762E-04 3 8 
424 traversing start control point of mitotic cell cycle 2.762E-04 3 8 
425 maternal process involved in parturition 2.762E-04 3 8 
426 positive regulation of ubiquitin-protein ligase activity 2.770E-04 8 96 
427 positive regulation of cytoskeleton organization 2.770E-04 8 96 
428 neural tube formation 2.770E-04 8 96 
429 icosanoid secretion 2.868E-04 4 19 
430 arachidonic acid secretion 2.868E-04 4 19 
431 spindle assembly 2.883E-04 5 34 
432 appendage development 2.896E-04 11 177 
433 meiotic cell cycle 2.896E-04 11 177 
434 limb development 2.896E-04 11 177 
435 negative regulation of cell motility 2.926E-04 9 122 
436 diadenosine tetraphosphate biosynthetic process 3.034E-04 2 2 
437 cerebral cortex GABAergic interneuron fate commitment 3.034E-04 2 2 
438 positive regulation of retroviral genome replication 3.034E-04 2 2 
439 regulation of transcription from RNA polymerase II promoter involved in 
forebrain neuron fate commitment 
3.034E-04 2 2 
440 diadenosine tetraphosphate metabolic process 3.034E-04 2 2 
441 response to DDT 3.034E-04 2 2 
442 bis(5'-nucleosidyl) oligophosphate biosynthetic process 3.034E-04 2 2 
443 cellular response to iron(III) ion 3.034E-04 2 2 
444 T cell extravasation 3.034E-04 2 2 
445 mitotic spindle elongation 3.034E-04 2 2 
446 spindle elongation 3.034E-04 2 2 
447 regulation of ribonuclease activity 3.034E-04 2 2 
448 cellular response to iron ion 3.034E-04 2 2 
449 regulation of mitotic anaphase 3.034E-04 2 2 
450 mitotic chromosome movement towards spindle pole 3.034E-04 2 2 
451 diadenosine polyphosphate biosynthetic process 3.034E-04 2 2 
452 helper T cell extravasation 3.034E-04 2 2 
453 regulation of chromosome condensation 3.034E-04 2 2 
454 regulation of endoribonuclease activity 3.034E-04 2 2 
455 regulation of microtubule cytoskeleton organization 3.061E-04 7 74 
456 negative regulation of cellular biosynthetic process 3.129E-04 35 1077 
457 positive regulation of phosphorus metabolic process 3.181E-04 16 338 
458 positive regulation of phosphate metabolic process 3.181E-04 16 338 
459 response to bacterium 3.210E-04 21 517 
460 positive regulation of apoptosis 3.225E-04 27 749 
461 negative regulation of cell development 3.302E-04 9 124 
462 regulation of mRNA processing 3.316E-04 5 35 
463 maternal placenta development 3.316E-04 5 35 
464 positive regulation of bone mineralization 3.316E-04 5 35 
465 neural tube closure 3.326E-04 7 75 
466 regulation of peptidase activity 3.444E-04 17 375 
467 regulation of heat generation 3.536E-04 4 20 
468 negative regulation of cell-matrix adhesion 3.536E-04 4 20 
469 proteolysis involved in cellular protein catabolic process 3.551E-04 17 376 
470 tube closure 3.609E-04 7 76 
471 neural tube development 3.639E-04 10 153 
472 positive regulation of programmed cell death 3.651E-04 27 755 
473 positive regulation of ligase activity 3.660E-04 8 100 
474 response to oxygen levels 3.773E-04 17 378 
475 cell fate commitment 3.785E-04 13 244 
476 positive regulation of ossification 3.811E-04 6 55 
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477 blood vessel morphogenesis 3.836E-04 18 414 
478 negative regulation of cell adhesion 3.915E-04 8 101 
479 L-serine metabolic process 4.089E-04 3 9 
480 B cell lineage commitment 4.089E-04 3 9 
481 negative regulation of myeloid leukocyte differentiation 4.207E-04 6 56 
482 cell redox homeostasis 4.234E-04 7 78 
483 DNA duplex unwinding 4.308E-04 4 21 
484 positive regulation of biomineral tissue development 4.327E-04 5 37 
485 negative regulation of cellular component movement 4.420E-04 9 129 
486 primary neural tube formation 4.577E-04 7 79 
487 regulation of signaling 4.577E-04 58 2139 
488 response to molecule of bacterial origin 4.664E-04 16 350 
489 negative regulation of neurogenesis 4.770E-04 8 104 
490 protein catabolic process 4.809E-04 18 422 
491 proximal/distal pattern formation 4.912E-04 5 38 
492 positive regulation of cell cycle arrest 4.942E-04 7 80 
493 morphogenesis of an epithelium 5.075E-04 17 388 
494 regulation of protein stability 5.086E-04 8 105 
495 negative regulation of protein modification process 5.111E-04 12 220 
496 cellular response to stimulus 5.116E-04 134 6009 
497 response to vitamin 5.165E-04 14 285 
498 nucleobase, nucleoside and nucleotide interconversion 5.194E-04 4 22 
499 protein destabilization 5.194E-04 4 22 
500 negative regulation of glial cell differentiation 5.194E-04 4 22 
501 cellular response to mechanical stimulus 5.330E-04 7 81 
502 protein targeting 5.379E-04 15 320 
503 negative regulation of organelle organization 5.523E-04 11 191 
504 protein phosphorylation 5.603E-04 30 900 
505 regulation of hydrolase activity 5.605E-04 32 984 
506 ubiquitin-dependent protein catabolic process 5.606E-04 16 356 
507 response to hormone stimulus 5.665E-04 36 1156 
508 regulation of gliogenesis 5.742E-04 7 82 
509 chorio-allantoic fusion 5.767E-04 3 10 
510 cerebellar granular layer development 5.767E-04 3 10 
511 mesenchymal cell development 5.770E-04 8 107 
512 response to UV 5.770E-04 8 107 
513 regulation of transcription from RNA polymerase II promoter 5.892E-04 40 1334 
514 regulation of signal transduction 5.981E-04 50 1788 
515 cellular response to hypoxia 6.119E-04 6 60 
516 cellular component movement 6.127E-04 28 822 
517 response to radiation 6.151E-04 18 431 
518 icosanoid transport 6.201E-04 4 23 
519 protein localization to organelle 6.310E-04 15 325 
520 response to nutrient levels 6.428E-04 23 623 
521 positive regulation of lymphocyte proliferation 6.492E-04 9 136 
522 chemical homeostasis 6.532E-04 32 993 
523 coagulation 6.569E-04 23 624 
524 blood coagulation 6.569E-04 23 624 
525 multicellular organismal metabolic process 6.688E-04 6 61 
526 modification-dependent protein catabolic process 6.707E-04 16 362 
527 positive regulation of mononuclear cell proliferation 6.844E-04 9 137 
528 apoptotic nuclear change 7.027E-04 5 41 
529 negative regulation of protein metabolic process 7.133E-04 17 400 
530 modification-dependent macromolecule catabolic process 7.323E-04 16 365 
531 purine nucleoside monophosphate biosynthetic process 7.340E-04 4 24 
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532 purine ribonucleoside monophosphate biosynthetic process 7.340E-04 4 24 
533 DNA geometric change 7.340E-04 4 24 
534 response to organic nitrogen 7.375E-04 15 330 
535 epithelium development 7.475E-04 23 630 
536 hemostasis 7.475E-04 23 630 
537 macromolecule localization 7.503E-04 46 1622 
538 positive regulation of leukocyte proliferation 7.595E-04 9 139 
539 phosphorylation 7.619E-04 37 1219 
540 localization of cell 7.636E-04 25 711 
541 cell motility 7.636E-04 25 711 
542 ribonucleoside metabolic process 7.648E-04 7 86 
543 negative regulation of protein phosphorylation 7.648E-04 7 86 
544 interaction with host 7.648E-04 7 86 
545 locomotion 7.675E-04 35 1132 
546 forebrain neuron fate commitment 7.827E-04 3 11 
547 wound healing involved in inflammatory response 7.827E-04 3 11 
548 forebrain generation of neurons 7.864E-04 5 42 
549 regulation of mitotic metaphase/anaphase transition 7.864E-04 5 42 
550 epithelial tube morphogenesis 7.924E-04 13 264 
551 cellular homeostasis 8.120E-04 29 879 
552 positive regulation of multicellular organismal process 8.221E-04 22 595 
553 negative regulation of cell cycle process 8.279E-04 8 113 
554 regulation of striated muscle tissue development 8.279E-04 8 113 
555 limb morphogenesis 8.300E-04 10 170 
556 appendage morphogenesis 8.300E-04 10 170 
557 ribosomal small subunit biogenesis 8.619E-04 4 25 
558 mammary gland epithelial cell proliferation 8.619E-04 4 25 
559 cholesterol homeostasis 8.645E-04 6 64 
560 sterol homeostasis 8.645E-04 6 64 
561 ribosome biogenesis 8.682E-04 10 171 
562 heart development 8.752E-04 19 482 
563 mesenchymal cell differentiation 8.771E-04 8 114 
564 negative regulation of locomotion 8.845E-04 9 142 
565 mitotic cell cycle G2/M transition decatenation checkpoint 8.998E-04 2 3 
566 cellular response to prostaglandin D stimulus 8.998E-04 2 3 
567 mitotic cell cycle DNA replication checkpoint 8.998E-04 2 3 
568 spindle stabilization 8.998E-04 2 3 
569 chromosome movement towards spindle pole 8.998E-04 2 3 
570 M phase specific microtubule process 8.998E-04 2 3 
571 glycine biosynthetic process from serine 8.998E-04 2 3 
572 formation of translation preinitiation complex 8.998E-04 2 3 
573 ribosomal large subunit export from nucleus 8.998E-04 2 3 
574 mitotic spindle stabilization 8.998E-04 2 3 
575 response to prostaglandin D stimulus 8.998E-04 2 3 
576 regulation of muscle organ development 9.287E-04 8 115 
577 regulation of binding 9.512E-04 11 204 
578 catabolic process 9.765E-04 51 1875 
579 positive regulation of stress fiber assembly 1.005E-03 4 26 
580 cell aging 1.018E-03 6 66 
581 nucleoside diphosphate phosphorylation 1.030E-03 3 12 
582 surfactant homeostasis 1.030E-03 3 12 
583 establishment of protein localization in plasma membrane 1.030E-03 3 12 
584 chemical homeostasis within a tissue 1.030E-03 3 12 
585 positive regulation of penile erection 1.030E-03 3 12 
586 response to water deprivation 1.030E-03 3 12 
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587 protein maturation 1.039E-03 8 117 
588 regulation of protein localization 1.057E-03 15 342 
589 lipid homeostasis 1.070E-03 7 91 
590 placenta development 1.081E-03 10 176 
591 regulation of anatomical structure morphogenesis 1.086E-03 22 608 
592 embryonic epithelial tube formation 1.098E-03 8 118 
593 macromolecule modification 1.129E-03 60 2316 
594 embryonic limb morphogenesis 1.130E-03 9 147 
595 embryonic appendage morphogenesis 1.130E-03 9 147 
596 epithelial tube formation 1.160E-03 8 119 
597 positive regulation of fatty acid biosynthetic process 1.163E-03 4 27 
598 G2/M transition DNA damage checkpoint 1.163E-03 4 27 
599 central nervous system development 1.167E-03 29 900 
600 developmental process involved in reproduction 1.172E-03 21 572 
601 mammary gland morphogenesis 1.191E-03 6 68 
602 regulation of glial cell differentiation 1.191E-03 6 68 
603 purine base metabolic process 1.197E-03 5 46 
604 collagen metabolic process 1.197E-03 5 46 
605 cellular localization 1.224E-03 46 1661 
606 response to lipid 1.224E-03 8 120 
607 digestive system development 1.242E-03 9 149 
608 regulation of ossification 1.281E-03 10 180 
609 pallium development 1.302E-03 9 150 
610 long-chain fatty acid transport 1.321E-03 5 47 
611 establishment of protein localization in membrane 1.322E-03 3 13 
612 DNA demethylation 1.322E-03 3 13 
613 negative regulation of leukocyte migration 1.322E-03 3 13 
614 negative regulation of survival gene product expression 1.322E-03 3 13 
615 DNA replication checkpoint 1.322E-03 3 13 
616 cellular response to oxidative stress 1.361E-03 8 122 
617 negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid 
metabolic process 
1.379E-03 31 996 
618 negative regulation of translation 1.385E-03 6 70 
619 negative regulation of phosphorylation 1.434E-03 8 123 
620 regulation of I-kappaB kinase/NF-kappaB cascade 1.450E-03 10 183 
621 nucleobase, nucleoside and nucleotide biosynthetic process 1.497E-03 12 249 
622 nucleobase, nucleoside, nucleotide and nucleic acid biosynthetic process 1.497E-03 12 249 
623 regulation of muscle cell differentiation 1.511E-03 8 124 
624 pattern specification process 1.523E-03 18 467 
625 cellular extravasation 1.532E-03 4 29 
626 acid secretion 1.532E-03 4 29 
627 serine family amino acid metabolic process 1.532E-03 4 29 
628 DNA-dependent DNA replication initiation 1.532E-03 4 29 
629 negative regulation of gliogenesis 1.532E-03 4 29 
630 decidualization 1.532E-03 4 29 
631 regulation of intracellular protein kinase cascade 1.540E-03 22 625 
632 regulation of cytoskeleton organization 1.548E-03 12 250 
633 phosphate metabolic process 1.572E-03 41 1451 
634 phosphorus metabolic process 1.592E-03 41 1452 
635 response to endogenous stimulus 1.637E-03 39 1363 
636 regulation of monocyte differentiation 1.661E-03 3 14 
637 purine base biosynthetic process 1.661E-03 3 14 
638 metaphase 1.661E-03 3 14 
639 serine family amino acid biosynthetic process 1.661E-03 3 14 
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640 negative regulation of G2/M transition of mitotic cell cycle 1.661E-03 3 14 
641 tube formation 1.672E-03 8 126 
642 cellular response to organic substance 1.687E-03 38 1320 
643 negative regulation of nitrogen compound metabolic process 1.688E-03 31 1009 
644 positive regulation of hydrolase activity 1.710E-03 23 671 
645 positive regulation of actin filament bundle assembly 1.743E-03 4 30 
646 positive regulation of reproductive process 1.758E-03 8 127 
647 negative regulation of centrosome duplication 1.779E-03 2 4 
648 diadenosine polyphosphate metabolic process 1.779E-03 2 4 
649 5-phosphoribose 1-diphosphate metabolic process 1.779E-03 2 4 
650 ribosomal small subunit export from nucleus 1.779E-03 2 4 
651 positive regulation of centrosome duplication 1.779E-03 2 4 
652 negative regulation of nuclear mRNA splicing, via spliceosome 1.779E-03 2 4 
653 bis(5'-nucleosidyl) oligophosphate metabolic process 1.779E-03 2 4 
654 5-phosphoribose 1-diphosphate biosynthetic process 1.779E-03 2 4 
655 apoptotic chromosome condensation 1.779E-03 2 4 
656 regulation of immune complex clearance by monocytes and macrophages 1.779E-03 2 4 
657 ATP transport 1.779E-03 2 4 
658 positive regulation of immune complex clearance by monocytes and 
macrophages 
1.779E-03 2 4 
659 establishment of synaptic specificity at neuromuscular junction 1.779E-03 2 4 
660 negative regulation of RNA metabolic process 1.816E-03 29 927 
661 purine ribonucleotide biosynthetic process 1.848E-03 8 128 
662 multicellular organismal macromolecule metabolic process 1.911E-03 5 51 
663 positive regulation of sequence-specific DNA binding transcription factor 
activity 
1.916E-03 10 190 
664 localization 1.916E-03 97 4235 
665 regulation of translation 1.939E-03 11 223 
666 response to estrogen stimulus 1.961E-03 13 292 
667 regulation of protein ubiquitination 1.991E-03 10 191 
668 telencephalon development 2.008E-03 11 224 
669 regulation of cellular response to stress 2.015E-03 12 258 
670 regionalization 2.033E-03 14 329 
671 symbiosis, encompassing mutualism through parasitism 2.037E-03 8 130 
672 negative regulation of phosphorus metabolic process 2.037E-03 8 130 
673 negative regulation of phosphate metabolic process 2.037E-03 8 130 
674 DNA dealkylation 2.049E-03 3 15 
675 GTP biosynthetic process 2.049E-03 3 15 
676 regulation of penile erection 2.049E-03 3 15 
677 UTP biosynthetic process 2.049E-03 3 15 
678 UTP metabolic process 2.049E-03 3 15 
679 lymphocyte chemotaxis 2.049E-03 3 15 
680 heart valve development 2.049E-03 3 15 
681 CTP metabolic process 2.049E-03 3 15 
682 CTP biosynthetic process 2.049E-03 3 15 
683 regulation of estrogen receptor signaling pathway 2.049E-03 3 15 
684 positive regulation of lymphocyte activation 2.082E-03 13 294 
685 positive regulation of acute inflammatory response 2.084E-03 5 52 
686 cytokinesis 2.117E-03 6 76 
687 muscle cell development 2.120E-03 9 161 
688 purine-containing compound biosynthetic process 2.149E-03 10 193 
689 protein processing 2.194E-03 7 103 
690 regulation of myeloid cell differentiation 2.211E-03 9 162 
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691 purine ribonucleoside monophosphate metabolic process 2.226E-03 4 32 
692 purine nucleoside monophosphate metabolic process 2.226E-03 4 32 
693 tRNA aminoacylation 2.269E-03 5 53 
694 amino acid activation 2.269E-03 5 53 
695 tRNA aminoacylation for protein translation 2.269E-03 5 53 
696 response to estradiol stimulus 2.317E-03 10 195 
697 DNA damage response, signal transduction by p53 class mediator 2.447E-03 7 105 
698 macrophage chemotaxis 2.490E-03 3 16 
699 cellular response to antibiotic 2.490E-03 3 16 
700 pyrimidine ribonucleoside triphosphate metabolic process 2.490E-03 3 16 
701 glycine metabolic process 2.490E-03 3 16 
702 pyrimidine ribonucleoside triphosphate biosynthetic process 2.490E-03 3 16 
703 positive regulation of cardiac muscle cell proliferation 2.490E-03 3 16 
704 protein localization 2.491E-03 38 1350 
705 negative regulation of cell-substrate adhesion 2.498E-03 4 33 
706 ribonucleoside monophosphate biosynthetic process 2.498E-03 4 33 
707 positive regulation of I-kappaB kinase/NF-kappaB cascade 2.503E-03 9 165 
708 lymphocyte proliferation 2.578E-03 6 79 
709 nucleoside metabolic process 2.581E-03 7 106 
710 heterocycle biosynthetic process 2.627E-03 13 302 
711 carbohydrate homeostasis 2.699E-03 8 136 
712 glucose homeostasis 2.699E-03 8 136 
713 signal transduction in response to DNA damage 2.699E-03 8 136 
714 signal transduction by p53 class mediator 2.722E-03 7 107 
715 proteolysis 2.783E-03 28 911 
716 response to iron ion 2.793E-03 4 34 
717 response to hypoxia 2.890E-03 14 342 
718 response to iron(III) ion 2.930E-03 2 5 
719 positive regulation of mitotic metaphase/anaphase transition 2.930E-03 2 5 
720 regulation of endodeoxyribonuclease activity 2.930E-03 2 5 
721 anterior neuropore closure 2.930E-03 2 5 
722 ribosomal subunit export from nucleus 2.930E-03 2 5 
723 purine ribonucleotide transport 2.930E-03 2 5 
724 kinetochore assembly 2.930E-03 2 5 
725 active induction of host immune response by virus 2.930E-03 2 5 
726 rRNA-containing ribonucleoprotein complex export from nucleus 2.930E-03 2 5 
727 establishment of ribosome localization 2.930E-03 2 5 
728 positive regulation of tooth mineralization 2.930E-03 2 5 
729 induction of host immune response by virus 2.930E-03 2 5 
730 regulation of retroviral genome replication 2.930E-03 2 5 
731 keratinocyte development 2.930E-03 2 5 
732 adenine nucleotide transport 2.930E-03 2 5 
733 induction by symbiont of host defense response 2.930E-03 2 5 
734 ribosome localization 2.930E-03 2 5 
735 ribonucleoprotein complex export from nucleus 2.930E-03 2 5 
736 neuropore closure 2.930E-03 2 5 
737 mammary gland specification 2.930E-03 2 5 
738 digestive tract development 2.953E-03 8 138 
739 lymphocyte migration 2.985E-03 3 17 
740 negative regulation of JAK-STAT cascade 2.985E-03 3 17 
741 pentose metabolic process 2.985E-03 3 17 
742 ventricular cardiac muscle cell development 2.985E-03 3 17 
743 transcription, DNA-dependent 3.035E-03 64 2614 
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744 ribonucleotide biosynthetic process 3.087E-03 8 139 
745 mononuclear cell proliferation 3.109E-03 6 82 
746 glucose transport 3.109E-03 6 82 
747 positive regulation of calcium ion transport into cytosol 3.111E-03 4 35 
748 apoptotic mitochondrial changes 3.129E-03 5 57 
749 positive regulation of NF-kappaB transcription factor activity 3.178E-03 7 110 
750 positive regulation of protein ubiquitination 3.226E-03 8 140 
751 regulation of cell communication 3.236E-03 42 1557 
752 regulation of fibroblast proliferation 3.303E-03 6 83 
753 hexose transport 3.303E-03 6 83 
754 leukocyte proliferation 3.303E-03 6 83 
755 regulation of blood coagulation 3.376E-03 5 58 
756 regulation of lymphocyte activation 3.394E-03 15 386 
757 regulation of S phase 3.452E-03 4 36 
758 mitotic cell cycle spindle assembly checkpoint 3.452E-03 4 36 
759 multicellular organismal catabolic process 3.452E-03 4 36 
760 monosaccharide transport 3.506E-03 6 84 
761 pyrimidine nucleoside triphosphate biosynthetic process 3.536E-03 3 18 
762 nucleobase biosynthetic process 3.536E-03 3 18 
763 protein localization in plasma membrane 3.536E-03 3 18 
764 histone phosphorylation 3.536E-03 3 18 
765 regulation of cell adhesion 3.563E-03 13 313 
766 regulation of bone mineralization 3.637E-03 5 59 
767 negative regulation of signal transduction 3.653E-03 20 588 
768 regulation of myeloid leukocyte differentiation 3.690E-03 7 113 
769 cell cycle arrest 3.704E-03 9 175 
770 brain development 3.715E-03 22 672 
771 cellular nitrogen compound biosynthetic process 3.815E-03 17 469 
772 phospholipid catabolic process 3.818E-03 4 37 
773 regulation of stress fiber assembly 3.818E-03 4 37 
774 spindle assembly checkpoint 3.818E-03 4 37 
775 negative regulation of mitotic metaphase/anaphase transition 3.818E-03 4 37 
776 regulation of leukocyte migration 3.940E-03 6 86 
777 regulation of leukocyte activation 4.020E-03 16 432 
778 multicellular organismal reproductive process 4.042E-03 27 892 
779 multicellular organism reproduction 4.042E-03 27 892 
780 negative regulation of signaling 4.120E-03 21 636 
781 positive regulation of circadian rhythm 4.145E-03 3 19 
782 response to water 4.145E-03 3 19 
783 cardiac atrium morphogenesis 4.145E-03 3 19 
784 protein localization in membrane 4.145E-03 3 19 
785 ovulation from ovarian follicle 4.145E-03 3 19 
786 hippocampus development 4.171E-03 6 87 
787 positive regulation of leukocyte activation 4.178E-03 13 319 
788 regulation of neuron differentiation 4.197E-03 15 395 
789 tissue regeneration 4.201E-03 5 61 
790 protein maturation by peptide bond cleavage 4.201E-03 5 61 
791 nucleoside diphosphate metabolic process 4.210E-03 4 38 
792 morphogenesis of embryonic epithelium 4.337E-03 8 147 
793 commitment of multipotent stem cells to neuronal lineage in forebrain 4.345E-03 2 6 
794 response to UV-A 4.345E-03 2 6 
795 protein localization to kinetochore 4.345E-03 2 6 
796 STAT protein import into nucleus 4.345E-03 2 6 
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797 ribose phosphate biosynthetic process 4.345E-03 2 6 
798 positive regulation of mRNA 3'-end processing 4.345E-03 2 6 
799 activation of phospholipase A2 activity 4.345E-03 2 6 
800 D-ribose biosynthetic process 4.345E-03 2 6 
801 stress-induced premature senescence 4.345E-03 2 6 
802 rRNA transport 4.345E-03 2 6 
803 positive regulation of mRNA processing 4.345E-03 2 6 
804 adenine transport 4.345E-03 2 6 
805 negative regulation of mRNA processing 4.345E-03 2 6 
806 ribonucleoprotein complex localization 4.345E-03 2 6 
807 re-entry into mitotic cell cycle 4.345E-03 2 6 
808 induction by organism of defense response of other organism involved in 
symbiotic interaction 
4.345E-03 2 6 
809 rRNA export from nucleus 4.345E-03 2 6 
810 kinetochore organization 4.345E-03 2 6 
811 regulation of deoxyribonuclease activity 4.345E-03 2 6 
812 viral genome transport in host cell 4.345E-03 2 6 
813 cardiac muscle cell development 4.627E-03 4 39 
814 positive regulation of vasoconstriction 4.627E-03 4 39 
815 regulation of survival gene product expression 4.627E-03 4 39 
816 forebrain development 4.657E-03 14 361 
817 positive regulation of response to stimulus 4.659E-03 33 1171 
818 I-kappaB kinase/NF-kappaB cascade 4.663E-03 6 89 
819 regulation of cell morphogenesis 4.758E-03 12 287 
820 regulation of mammary gland epithelial cell proliferation 4.814E-03 3 20 
821 cardiac atrium development 4.814E-03 3 20 
822 response to methylmercury 4.814E-03 3 20 
823 labyrinthine layer morphogenesis 4.814E-03 3 20 
824 positive regulation of lipid biosynthetic process 4.826E-03 5 63 
825 mesenchyme development 4.895E-03 8 150 
826 positive regulation of homeostatic process 4.924E-03 6 90 
827 extracellular structure organization 5.024E-03 12 289 
828 collagen fibril organization 5.072E-03 4 40 
829 embryonic cranial skeleton morphogenesis 5.072E-03 4 40 
830 positive regulation of mitotic cell cycle 5.072E-03 4 40 
831 negative regulation of protein binding 5.072E-03 4 40 
832 establishment of localization in cell 5.075E-03 39 1456 
833 positive regulation of cell activation 5.128E-03 13 327 
834 regulation of biomineral tissue development 5.161E-03 5 64 
835 negative regulation of transcription, DNA-dependent 5.255E-03 27 910 
836 neuron projection development 5.405E-03 23 737 
837 ribonucleoprotein complex biogenesis 5.523E-03 11 256 
838 positive regulation of blood coagulation 5.544E-03 3 21 
839 pyrimidine nucleoside triphosphate metabolic process 5.544E-03 3 21 
840 cellular response to drug 5.544E-03 3 21 
841 retinal ganglion cell axon guidance 5.544E-03 3 21 
842 regulation of nuclear mRNA splicing, via spliceosome 5.544E-03 3 21 
843 cellular response to monosaccharide stimulus 5.544E-03 4 41 
844 cellular response to hexose stimulus 5.544E-03 4 41 
845 ribonucleoside monophosphate metabolic process 5.544E-03 4 41 
846 cellular response to glucose stimulus 5.544E-03 4 41 
847 activation of pro-apoptotic gene products 5.544E-03 4 41 
848 response to protein stimulus 5.591E-03 12 293 
849 regulation of lymphocyte proliferation 5.696E-03 9 187 
850 regulation of intracellular protein transport 5.721E-03 8 154 
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851 intracellular protein kinase cascade 5.730E-03 19 571 
852 cardiac muscle cell differentiation 5.774E-03 6 93 
853 negative regulation of transcription from RNA polymerase II promoter 5.835E-03 19 572 
854 fatty acid transport 5.882E-03 5 66 
855 regulation of coagulation 5.882E-03 5 66 
856 regulation of mononuclear cell proliferation 5.893E-03 9 188 
857 regulation of response to stress 5.903E-03 24 786 
858 protein modification process 5.914E-03 54 2194 
859 positive regulation of phospholipase A2 activity 6.013E-03 2 7 
860 pathogenesis 6.013E-03 2 7 
861 hindbrain radial glia guided cell migration 6.013E-03 2 7 
862 positive regulation of nitric-oxide synthase biosynthetic process 6.013E-03 2 7 
863 cellular response to cell-matrix adhesion 6.013E-03 2 7 
864 positive regulation of keratinocyte differentiation 6.013E-03 2 7 
865 connective tissue replacement involved in inflammatory response wound 
healing 
6.013E-03 2 7 
866 glycine biosynthetic process 6.013E-03 2 7 
867 purine nucleotide transport 6.013E-03 2 7 
868 regulation of cell activation 6.028E-03 16 451 
869 regulation of actin filament bundle assembly 6.045E-03 4 42 
870 purine-containing compound metabolic process 6.132E-03 23 745 
871 epithelial cell proliferation 6.267E-03 5 67 
872 branching morphogenesis of a tube 6.303E-03 9 190 
873 regulation of DNA damage response, signal transduction by p53 class 
mediator 
6.338E-03 3 22 
874 protein localization to chromosome 6.338E-03 3 22 
875 meiotic chromosome segregation 6.338E-03 3 22 
876 osteoblast differentiation 6.396E-03 6 95 
877 response to hyperoxia 6.575E-03 4 43 
878 regulation of plasma lipoprotein particle levels 6.575E-03 4 43 
879 ventricular cardiac muscle cell differentiation 6.575E-03 4 43 
880 cardiac cell development 6.575E-03 4 43 
881 regulation of leukocyte proliferation 6.735E-03 9 192 
882 cardiac muscle tissue development 6.900E-03 8 159 
883 morphogenesis of a branching structure 6.944E-03 10 228 
884 female gamete generation 6.952E-03 7 127 
885 double-strand break repair 7.066E-03 6 97 
886 axon guidance 7.086E-03 16 459 
887 centrosome organization 7.135E-03 4 44 
888 regulation of DNA repair 7.135E-03 4 44 
889 cerebellar cortex development 7.135E-03 4 44 
890 regulation of leukocyte apoptosis 7.135E-03 4 44 
891 somatic stem cell maintenance 7.135E-03 4 44 
892 regulation of nucleocytoplasmic transport 7.156E-03 8 160 
893 cellular senescence 7.195E-03 3 23 
894 positive regulation of cyclin-dependent protein kinase activity 7.195E-03 3 23 
895 V(D)J recombination 7.195E-03 3 23 
896 regulation of protein import into nucleus 7.248E-03 7 128 
897 regulation of cell growth 7.373E-03 14 381 
898 regulation of cellular ketone metabolic process 7.426E-03 9 195 
899 chemotaxis 7.573E-03 21 672 
900 cellular component biogenesis at cellular level 7.692E-03 11 268 
901 regulation of fatty acid biosynthetic process 7.725E-03 4 45 
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902 neutrophil chemotaxis 7.725E-03 4 45 
903 taxis 7.819E-03 21 674 
904 cellular protein localization 7.905E-03 22 718 
905 response to parathyroid hormone stimulus 7.926E-03 2 8 
906 resolution of meiotic recombination intermediates 7.926E-03 2 8 
907 regulation of stem cell maintenance 7.926E-03 2 8 
908 cellular response to prostaglandin stimulus 7.926E-03 2 8 
909 axial mesoderm morphogenesis 7.926E-03 2 8 
910 cerebellar granule cell differentiation 7.926E-03 2 8 
911 ribose phosphate metabolic process 7.926E-03 2 8 
912 carbon catabolite regulation of transcription 7.926E-03 2 8 
913 cerebellar granular layer formation 7.926E-03 2 8 
914 positive regulation of epidermal cell differentiation 7.926E-03 2 8 
915 neurotransmitter receptor metabolic process 7.926E-03 2 8 
916 collagen biosynthetic process 7.926E-03 2 8 
917 regulation of transcription by glucose 7.926E-03 2 8 
918 positive regulation of exit from mitosis 7.926E-03 2 8 
919 nucleotide transport 7.926E-03 2 8 
920 skin development 7.987E-03 5 71 
921 anterior/posterior pattern formation 8.033E-03 10 233 
922 cellular response to cAMP 8.118E-03 3 24 
923 ribosome assembly 8.118E-03 3 24 
924 nucleotide phosphorylation 8.118E-03 3 24 
925 oocyte maturation 8.118E-03 3 24 
926 cellular response to biotic stimulus 8.253E-03 8 164 
927 negative regulation of axonogenesis 8.347E-03 4 46 
928 response to corticosterone stimulus 8.347E-03 4 46 
929 nucleobase, nucleoside and nucleotide metabolic process 8.387E-03 26 899 
930 heterocycle metabolic process 8.397E-03 29 1035 
931 regulation of growth 8.472E-03 20 636 
932 cellular response to extracellular stimulus 8.504E-03 10 235 
933 cellular macromolecule localization 8.532E-03 22 723 
934 tube development 8.571E-03 17 510 
935 response to oxidative stress 8.657E-03 13 349 
936 regulation of cell morphogenesis involved in differentiation 8.694E-03 9 200 
937 regulation of neuron apoptosis 8.748E-03 10 236 
938 positive regulation of protein serine/threonine kinase activity 8.770E-03 11 273 
939 rhythmic process 8.798E-03 12 311 
940 gland morphogenesis 8.865E-03 7 133 
941 negative regulation of cell communication 8.893E-03 20 639 
942 second-messenger-mediated signaling 8.914E-03 15 430 
943 regulation of wound healing 8.959E-03 5 73 
944 histone H4 acetylation 9.001E-03 4 47 
945 somatic diversification of immune receptors via germline recombination 
within a single locus 
9.001E-03 4 47 
946 negative regulation of nuclear division 9.001E-03 4 47 
947 negative regulation of mitosis 9.001E-03 4 47 
948 somatic cell DNA recombination 9.001E-03 4 47 
949 pyrimidine ribonucleotide biosynthetic process 9.108E-03 3 25 
950 positive regulation of cell differentiation 9.160E-03 19 598 
951 RNA transport 9.218E-03 7 134 
952 establishment of RNA localization 9.218E-03 7 134 
953 nucleic acid transport 9.218E-03 7 134 
954 ncRNA metabolic process 9.228E-03 12 313 
955 regulation of protein binding 9.379E-03 6 103 
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956 response to organic cyclic compound 9.470E-03 16 474 
957 regulation of reproductive process 9.531E-03 9 203 
958 intracellular protein transport 9.713E-03 18 559 
959 negative regulation of cell proliferation 9.943E-03 20 646 
960 negative regulation of ubiquitin-protein ligase activity involved in mitotic cell 
cycle 
1.001E-02 5 75 
961 regulation of transcription factor import into nucleus 1.001E-02 5 75 
962 regulation of nitric-oxide synthase biosynthetic process 1.007E-02 2 9 
963 cerebellar granular layer morphogenesis 1.007E-02 2 9 
964 regulation of stem cell differentiation 1.007E-02 2 9 
965 cell migration in hindbrain 1.007E-02 2 9 
966 glycerophospholipid catabolic process 1.007E-02 2 9 
967 platelet dense granule organization 1.007E-02 2 9 
968 regulation of tooth mineralization 1.007E-02 2 9 
969 positive regulation of estrogen receptor signaling pathway 1.007E-02 2 9 
970 regulation of phospholipase A2 activity 1.007E-02 2 9 
971 positive regulation of histone phosphorylation 1.007E-02 2 9 
972 attachment of spindle microtubules to kinetochore 1.007E-02 2 9 
973 negative regulation of RNA splicing 1.007E-02 2 9 
974 regulation of mRNA 3'-end processing 1.007E-02 2 9 
975 immunoglobulin V(D)J recombination 1.007E-02 2 9 
976 pyrimidine ribonucleotide metabolic process 1.016E-02 3 26 
977 positive regulation of coagulation 1.016E-02 3 26 
978 regulation of cardiac muscle cell proliferation 1.016E-02 3 26 
979 hydrogen peroxide catabolic process 1.016E-02 3 26 
980 cellular response to UV 1.016E-02 3 26 
981 limbic system development 1.026E-02 6 105 
982 neuron projection morphogenesis 1.026E-02 20 648 
983 microtubule organizing center organization 1.041E-02 4 49 
984 muscle filament sliding 1.041E-02 4 49 
985 positive regulation of fatty acid metabolic process 1.041E-02 4 49 
986 response to gamma radiation 1.041E-02 4 49 
987 nucleobase metabolic process 1.057E-02 5 76 
988 peripheral nervous system development 1.057E-02 5 76 
989 odontogenesis of dentine-containing tooth 1.057E-02 5 76 
990 negative regulation of Wnt receptor signaling pathway 1.072E-02 6 106 
991 maintenance of location 1.073E-02 7 138 
992 response to interferon-gamma 1.114E-02 7 139 
993 positive regulation of muscle cell differentiation 1.114E-02 5 77 
994 actin-myosin filament sliding 1.116E-02 4 50 
995 ER-nucleus signaling pathway 1.116E-02 4 50 
996 T cell proliferation 1.116E-02 4 50 
997 cellular response to carbohydrate stimulus 1.116E-02 4 50 
998 neuron migration 1.119E-02 6 107 
999 secretion 1.126E-02 20 654 
1000 macromolecular complex remodeling 1.129E-02 3 27 
1001 plasma lipoprotein particle remodeling 1.129E-02 3 27 
1002 centrosome cycle 1.129E-02 3 27 
1003 protein-lipid complex remodeling 1.129E-02 3 27 
1004 sleep 1.129E-02 3 27 
1005 cell projection organization 1.136E-02 26 922 
1006 regulation of anatomical structure size 1.150E-02 19 612 
1007 RNA localization 1.156E-02 7 140 
1008 hindbrain development 1.156E-02 7 140 
1009 negative regulation of molecular function 1.171E-02 25 879 
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1010 regulation of vesicle-mediated transport 1.184E-02 11 285 
1011 cellular glucose homeostasis 1.195E-02 4 51 
1012 regulation of sequence-specific DNA binding transcription factor activity 1.200E-02 13 364 
1013 positive regulation of cell communication 1.203E-02 23 791 
1014 cellular response to reactive oxygen species 1.236E-02 5 79 
1015 in utero embryonic development 1.238E-02 15 447 
1016 regulation of homeostatic process 1.242E-02 11 287 
1017 glial cell differentiation 1.242E-02 7 142 
1018 chromosome separation 1.245E-02 2 10 
1019 positive regulation of transcription during mitosis 1.245E-02 2 10 
1020 negative regulation of astrocyte differentiation 1.245E-02 2 10 
1021 regulation of transcription during mitosis 1.245E-02 2 10 
1022 axial mesoderm development 1.245E-02 2 10 
1023 replicative senescence 1.245E-02 2 10 
1024 embryonic cleavage 1.245E-02 2 10 
1025 thrombin receptor signaling pathway 1.245E-02 2 10 
1026 positive regulation of steroid hormone receptor signaling pathway 1.245E-02 2 10 
1027 tyrosine phosphorylation of STAT protein 1.245E-02 2 10 
1028 meiotic chromosome separation 1.245E-02 2 10 
1029 regulation of transcription from RNA polymerase II promoter, mitotic 1.245E-02 2 10 
1030 mammary gland formation 1.245E-02 2 10 
1031 positive regulation of transcription from RNA polymerase II promoter during 
mitosis 
1.245E-02 2 10 
1032 D-ribose metabolic process 1.245E-02 2 10 
1033 sequestering of actin monomers 1.245E-02 2 10 
1034 regulation of transcription involved in cell fate commitment 1.245E-02 2 10 
1035 ephrin receptor signaling pathway 1.248E-02 3 28 
1036 collagen catabolic process 1.248E-02 3 28 
1037 regulation of viral genome replication 1.248E-02 3 28 
1038 transmembrane receptor protein serine/threonine kinase signaling pathway 1.270E-02 8 177 
1039 cell chemotaxis 1.271E-02 6 110 
1040 regulation of steroid hormone receptor signaling pathway 1.277E-02 4 52 
1041 purine ribonucleoside metabolic process 1.277E-02 4 52 
1042 purine nucleoside metabolic process 1.277E-02 4 52 
1043 positive regulation of B cell proliferation 1.277E-02 4 52 
1044 icosanoid biosynthetic process 1.277E-02 4 52 
1045 regulation of MAPKKK cascade 1.277E-02 13 367 
1046 regulation of muscle contraction 1.287E-02 7 143 
1047 regulation of cellular component size 1.305E-02 17 534 
1048 establishment of localization 1.330E-02 79 3573 
1049 positive regulation of signaling 1.342E-02 23 799 
1050 extracellular matrix organization 1.351E-02 8 179 
1051 regulation of Wnt receptor signaling pathway 1.351E-02 8 179 
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MODEL V – DOWN 
 
# GO Processes pValue Ratio 
1 multicellular organismal signaling 1.202E-67 175 762 
2 transmission of nerve impulse 1.202E-67 175 762 
3 synaptic transmission 2.592E-59 154 670 
4 cell communication 3.649E-49 213 1416 
5 cell-cell signaling 5.980E-49 180 1057 
6 regulation of system process 5.588E-46 133 637 
7 regulation of transport 1.149E-43 188 1238 
8 nervous system development 8.408E-42 258 2143 
9 regulation of localization 5.925E-40 210 1577 
10 regulation of neurological system process 2.634E-38 89 346 
11 regulation of transmission of nerve impulse 7.715E-36 83 322 
12 regulation of synaptic transmission 3.386E-35 79 297 
13 regulation of multicellular organismal process 7.392E-34 233 2036 
14 regulation of biological quality 6.663E-32 293 2953 
15 localization 3.131E-31 374 4235 
16 regulation of membrane potential 6.176E-31 71 274 
17 system process 2.950E-30 256 2474 
18 regulation of secretion 1.988E-29 100 549 
19 establishment of localization 2.232E-29 327 3573 
20 multicellular organismal process 2.367E-29 515 6739 
21 transport 5.730E-29 322 3513 
22 regulation of ion transport 1.945E-28 81 384 
23 behavior 1.013E-27 102 596 
24 signaling 1.118E-27 431 5359 
25 neurogenesis 3.206E-27 172 1425 
26 regulation of neurotransmitter levels 1.084E-26 52 170 
27 cellular ion homeostasis 1.096E-26 113 731 
28 ion homeostasis 1.533E-26 117 778 
29 neurotransmitter transport 2.756E-26 52 173 
30 neurological system process 1.097E-25 214 2040 
31 regulation of cell communication 2.137E-25 178 1557 
32 response to wounding 2.623E-25 155 1261 
33 generation of neurons 3.771E-25 161 1342 
34 cellular chemical homeostasis 5.481E-25 114 776 
35 regulation of nucleotide metabolic process 6.450E-25 95 571 
36 regulation of cellular localization 1.761E-24 106 697 
37 generation of a signal involved in cell-cell signaling 1.997E-24 56 218 
38 signal release 1.997E-24 56 218 
39 system development 3.647E-24 334 3930 
40 chemical homeostasis 1.083E-23 130 993 
41 secretion by cell 1.712E-23 83 472 
42 regulation of cyclic nucleotide biosynthetic process 1.790E-23 52 196 
43 regulation of nucleotide biosynthetic process 1.790E-23 52 196 
44 regulation of signaling 2.188E-23 215 2139 
45 neurotransmitter secretion 2.202E-23 41 120 
46 neuron differentiation 2.256E-23 134 1050 
47 cell development 4.161E-23 167 1482 
48 positive regulation of transport 2.579E-22 89 554 
49 regulation of cyclic nucleotide metabolic process 2.760E-22 52 207 
50 neuron development 5.942E-22 118 891 
51 regulation of synaptic plasticity 7.860E-22 43 144 
52 wound healing 1.003E-21 108 778 
   252 
53 ion transport 1.545E-21 130 1049 
54 cellular homeostasis 1.840E-21 116 879 
55 central nervous system development 4.192E-21 117 900 
56 multicellular organismal development 6.482E-21 364 4605 
57 metal ion transport 8.578E-21 93 627 
58 anatomical structure development 9.265E-21 347 4329 
59 regulation of ion transmembrane transport 1.208E-20 55 249 
60 regulation of metal ion transport 2.124E-20 51 218 
61 cell differentiation 3.048E-20 257 2905 
62 membrane depolarization 3.498E-20 33 90 
63 secretion 4.790E-20 94 654 
64 regulation of transmembrane transport 7.503E-20 69 390 
65 regulation of adenylate cyclase activity 1.064E-19 42 154 
66 cyclic-nucleotide-mediated signaling 1.734E-19 51 228 
67 locomotory behavior 1.817E-19 47 195 
68 cellular developmental process 2.411E-19 259 2981 
69 cell projection organization 2.542E-19 115 922 
70 regulation of cyclase activity 3.051E-19 42 158 
71 regulation of neuronal synaptic plasticity 3.134E-19 29 72 
72 regulation of lyase activity 5.095E-19 42 160 
73 developmental process 5.730E-19 381 5016 
74 cAMP-mediated signaling 5.812E-19 45 184 
75 platelet activation 5.948E-19 60 316 
76 cognition 9.169E-19 54 263 
77 regulation of action potential 1.665E-18 39 142 
78 neuron projection development 1.837E-18 98 737 
79 regulation of exocytosis 1.888E-18 35 114 
80 cell activation 2.212E-18 101 775 
81 regulation of body fluid levels 3.870E-18 99 757 
82 neuron projection morphogenesis 9.661E-18 89 648 
83 learning or memory 1.147E-17 51 250 
84 regulation of calcium ion transport 1.830E-17 42 175 
85 regulation of cAMP biosynthetic process 1.830E-17 42 175 
86 exocytosis 2.538E-17 53 273 
87 coagulation 2.870E-17 86 624 
88 blood coagulation 2.870E-17 86 624 
89 negative regulation of adenylate cyclase activity 3.077E-17 29 83 
90 negative regulation of lyase activity 3.077E-17 29 83 
91 negative regulation of cyclase activity 3.077E-17 29 83 
92 regulation of cAMP metabolic process 3.558E-17 42 178 
93 homeostatic process 4.307E-17 144 1374 
94 cation transport 4.972E-17 96 749 
95 hemostasis 5.190E-17 86 630 
96 multicellular organismal response to stress 5.622E-17 30 91 
97 regulation of calcium ion transport via voltage-gated calcium channel 
activity 
6.642E-17 26 67 
98 regulation of heart contraction 1.386E-16 37 144 
99 regulation of excitatory postsynaptic membrane potential 2.125E-16 23 53 
100 cell morphogenesis involved in neuron differentiation 2.163E-16 85 633 
101 regulation of postsynaptic membrane potential 2.184E-16 25 64 
102 regulation of synaptic transmission, glutamatergic 2.276E-16 22 48 
103 positive regulation of catalytic activity 3.717E-16 132 1243 
104 regulation of nervous system development 3.734E-16 76 534 
105 synaptic transmission, glutamatergic 3.877E-16 21 44 
106 fear response 3.933E-16 22 49 
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107 regulation of amine transport 4.444E-16 28 84 
108 G-protein signaling, coupled to cAMP nucleotide second messenger 4.511E-16 39 165 
109 regulation of molecular function 5.756E-16 206 2330 
110 G-protein signaling, coupled to cyclic nucleotide second messenger 6.917E-16 43 201 
111 ion transmembrane transport 6.954E-16 76 540 
112 regulation of action potential in neuron 7.519E-16 32 113 
113 regulation of vesicle-mediated transport 7.779E-16 52 285 
114 transmembrane transport 8.552E-16 116 1040 
115 regulation of peptide secretion 1.010E-15 43 203 
116 regulation of peptide transport 1.010E-15 43 203 
117 calcium ion transport 1.037E-15 45 221 
118 cell morphogenesis involved in differentiation 1.379E-15 91 726 
119 cyclic nucleotide metabolic process 1.489E-15 27 81 
120 divalent metal ion transport 1.661E-15 49 261 
121 positive regulation of molecular function 1.924E-15 144 1437 
122 cell projection morphogenesis 2.361E-15 90 720 
123 intracellular signal transduction 2.709E-15 160 1673 
124 second-messenger-mediated signaling 2.973E-15 65 430 
125 divalent inorganic cation transport 3.107E-15 49 265 
126 axonogenesis 3.758E-15 80 604 
127 calcium ion transmembrane transport 3.846E-15 32 119 
128 cell part morphogenesis 6.991E-15 90 733 
129 cellular calcium ion homeostasis 9.197E-15 56 343 
130 cellular divalent inorganic cation homeostasis 9.833E-15 57 354 
131 neuron-neuron synaptic transmission 9.982E-15 26 80 
132 regulation of long-term neuronal synaptic plasticity 1.108E-14 20 45 
133 regulation of catalytic activity 1.172E-14 176 1939 
134 regulation of peptide hormone secretion 1.285E-14 41 199 
135 regulation of transmembrane transporter activity 1.522E-14 29 102 
136 negative regulation of transport 1.850E-14 55 338 
137 synaptic vesicle exocytosis 1.868E-14 20 46 
138 behavioral defense response 1.868E-14 20 46 
139 response to stimulus 1.869E-14 524 7952 
140 positive regulation of hydrolase activity 1.958E-14 84 671 
141 regulation of ion transmembrane transporter activity 2.830E-14 28 97 
142 positive regulation of secretion 2.859E-14 48 270 
143 cell morphogenesis 2.864E-14 100 879 
144 regulation of hormone secretion 2.932E-14 45 241 
145 regulation of multicellular organismal development 3.589E-14 128 1262 
146 calcium ion homeostasis 3.669E-14 56 354 
147 divalent inorganic cation homeostasis 4.303E-14 57 366 
148 response to external stimulus 4.332E-14 146 1522 
149 synapse organization 4.418E-14 31 121 
150 learning 4.600E-14 33 137 
151 regulation of transporter activity 5.230E-14 30 114 
152 regulation of developmental process 7.895E-14 147 1548 
153 negative regulation of multicellular organismal process 7.932E-14 60 404 
154 vesicle-mediated transport 8.115E-14 105 960 
155 positive regulation of phospholipase C activity 8.483E-14 36 165 
156 adult behavior 9.508E-14 35 157 
157 behavioral fear response 9.851E-14 19 44 
158 regulation of sensory perception of pain 9.851E-14 19 44 
159 regulation of sensory perception 9.851E-14 19 44 
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160 muscle system process 1.162E-13 49 290 
161 cellular component morphogenesis 1.274E-13 103 940 
162 locomotion 1.424E-13 117 1132 
163 regulation of blood vessel size 1.645E-13 27 96 
164 regulation of insulin secretion 1.895E-13 38 187 
165 vasodilation 2.023E-13 20 51 
166 regulation of cellular component organization 2.072E-13 130 1321 
167 regulation of organic acid transport 2.635E-13 19 46 
168 regulation of tube size 2.853E-13 27 98 
169 activation of phospholipase C activity 3.748E-13 35 164 
170 regulation of hydrolase activity 3.929E-13 105 984 
171 biological regulation 4.506E-13 655 10630 
172 brain development 4.560E-13 81 672 
173 regulation of lipase activity 4.772E-13 40 211 
174 inhibition of adenylate cyclase activity by G-protein signaling pathway 5.239E-13 23 72 
175 positive regulation of phospholipase activity 5.562E-13 36 175 
176 positive regulation of transmission of nerve impulse 5.673E-13 24 79 
177 establishment of localization in cell 5.944E-13 138 1456 
178 positive regulation of neurological system process 7.617E-13 25 87 
179 regulation of cell development 9.047E-13 73 581 
180 positive regulation of lipase activity 9.266E-13 37 187 
181 cation homeostasis 9.460E-13 70 545 
182 metal ion homeostasis 9.862E-13 64 474 
183 glutamate signaling pathway 1.034E-12 19 49 
184 nucleoside monophosphate metabolic process 1.127E-12 30 127 
185 sensory perception of pain 1.216E-12 26 96 
186 regulation of synapse structure and activity 1.253E-12 22 68 
187 negative regulation of secretion 1.346E-12 34 162 
188 synaptic vesicle transport 1.382E-12 23 75 
189 regulation of neurotransmitter secretion 1.473E-12 21 62 
190 positive regulation of cell communication 1.537E-12 89 791 
191 regulation of phospholipase activity 1.600E-12 36 181 
192 membrane hyperpolarization 1.723E-12 16 34 
193 regulation of vasoconstriction 1.888E-12 23 76 
194 signal transduction 2.186E-12 348 4921 
195 cellular localization 2.306E-12 150 1661 
196 synapse assembly 2.358E-12 20 57 
197 cellular metal ion homeostasis 2.435E-12 62 460 
198 positive regulation of signaling 2.687E-12 89 799 
199 positive regulation of developmental process 2.912E-12 88 787 
200 activation of adenylate cyclase activity 3.036E-12 25 92 
201 myelination 3.331E-12 24 85 
202 regulation of neurotransmitter transport 3.359E-12 22 71 
203 vascular process in circulatory system 3.624E-12 28 116 
204 cGMP metabolic process 4.443E-12 17 41 
205 positive regulation of adenylate cyclase activity 5.129E-12 25 94 
206 regulation of cellular process 5.932E-12 594 9537 
207 regulation of gamma-aminobutyric acid secretion 6.499E-12 11 15 
208 neuron cell-cell adhesion 6.499E-12 11 15 
209 positive regulation of protein kinase activity 6.604E-12 60 447 
210 regulation of short-term neuronal synaptic plasticity 6.842E-12 10 12 
211 cytosolic calcium ion homeostasis 7.241E-12 40 229 
212 positive regulation of synaptic transmission 8.509E-12 22 74 
213 cellular cation homeostasis 8.968E-12 64 498 
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214 positive regulation of transferase activity 8.975E-12 62 474 
215 ensheathment of neurons 9.878E-12 24 89 
216 axon ensheathment 9.878E-12 24 89 
217 positive regulation of synaptic transmission, glutamatergic 1.048E-11 12 19 
218 positive regulation of cyclase activity 1.095E-11 25 97 
219 regulation of synapse organization 1.149E-11 19 55 
220 regulation of response to external stimulus 1.257E-11 56 407 
221 regulation of glutamate secretion 1.617E-11 15 33 
222 positive regulation of lyase activity 1.783E-11 25 99 
223 memory 1.813E-11 26 107 
224 positive regulation of nucleotide biosynthetic process 2.367E-11 19 57 
225 positive regulation of cyclic nucleotide biosynthetic process 2.367E-11 19 57 
226 muscle contraction 2.426E-11 41 248 
227 positive regulation of kinase activity 2.636E-11 60 462 
228 blood circulation 2.741E-11 49 335 
229 regulation of muscle contraction 2.833E-11 30 143 
230 regulation of neurogenesis 3.739E-11 61 478 
231 response to stress 3.775E-11 243 3216 
232 circulatory system process 3.788E-11 49 338 
233 regulation of muscle system process 3.956E-11 32 163 
234 cell adhesion 4.604E-11 92 883 
235 biological adhesion 6.239E-11 92 888 
236 regulation of catabolic process 6.882E-11 73 636 
237 extracellular structure organization 7.531E-11 44 289 
238 negative regulation of synaptic transmission 8.864E-11 17 48 
239 positive regulation of biological process 9.338E-11 272 3736 
240 positive regulation of cellular process 1.099E-10 251 3385 
241 negative regulation of transmission of nerve impulse 1.125E-10 18 55 
242 regulation of neuron differentiation 1.157E-10 53 395 
243 negative regulation of smooth muscle contraction 1.167E-10 12 22 
244 negative regulation of neurological system process 1.248E-10 19 62 
245 associative learning 1.341E-10 22 84 
246 elevation of cytosolic calcium ion concentration 1.404E-10 35 200 
247 positive regulation of organic acid transport 1.504E-10 13 27 
248 positive regulation of cyclic nucleotide metabolic process 1.702E-10 19 63 
249 regulation of purine nucleotide catabolic process 1.762E-10 51 376 
250 regulation of nucleotide catabolic process 1.762E-10 51 376 
251 regulation of response to stimulus 1.782E-10 193 2441 
252 positive regulation of nucleotide metabolic process 2.306E-10 19 64 
253 negative regulation of muscle contraction 2.426E-10 14 33 
254 regulation of biological process 2.453E-10 615 10123 
255 response to ethanol 2.829E-10 35 205 
256 regulation of cell projection organization 3.219E-10 44 302 
257 anatomical structure morphogenesis 3.755E-10 173 2141 
258 regulation of kinase activity 3.860E-10 75 687 
259 regulation of the force of heart contraction 3.930E-10 14 34 
260 regulation of synaptic transmission, GABAergic 3.930E-10 14 34 
261 regulation of catecholamine secretion 4.164E-10 18 59 
262 neuromuscular process 4.210E-10 24 105 
263 positive regulation of ion transport 5.182E-10 24 106 
264 regulation of cellular catabolic process 5.327E-10 65 561 
265 positive regulation of locomotion 5.693E-10 42 285 
266 positive regulation of cGMP biosynthetic process 6.313E-10 11 20 
267 regulation of transferase activity 6.365E-10 76 708 
268 positive regulation of cell motility 6.388E-10 41 275 
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269 regulation of ion homeostasis 6.565E-10 29 152 
270 nitric oxide mediated signal transduction 7.779E-10 13 30 
271 positive regulation of adenylate cyclase activity by G-protein signaling 
pathway 
8.422E-10 20 76 
272 regulation of adenylate cyclase activity involved in G-protein signaling 
pathway 
8.422E-10 20 76 
273 activation of adenylate cyclase activity by G-protein signaling pathway 8.422E-10 20 76 
274 positive regulation of cellular component movement 8.795E-10 42 289 
275 positive regulation of multicellular organismal process 9.577E-10 67 595 
276 positive regulation of cell migration 9.991E-10 40 268 
277 positive regulation of response to external stimulus 1.013E-09 32 184 
278 regulation of amino acid transport 1.264E-09 11 21 
279 startle response 1.493E-09 14 37 
280 regulation of blood pressure 1.507E-09 33 197 
281 purine nucleotide metabolic process 1.754E-09 74 697 
282 cyclic nucleotide biosynthetic process 1.779E-09 16 50 
283 negative regulation of biological process 1.858E-09 240 3296 
284 gliogenesis 2.032E-09 30 169 
285 cellular response to stimulus 2.252E-09 393 6009 
286 taxis 2.252E-09 72 674 
287 regulation of protein kinase activity 2.313E-09 71 661 
288 receptor clustering 2.473E-09 12 27 
289 gamma-aminobutyric acid signaling pathway 2.544E-09 17 58 
290 regulation of phosphorus metabolic process 2.842E-09 95 999 
291 regulation of phosphate metabolic process 2.842E-09 95 999 
292 response to abiotic stimulus 3.229E-09 84 845 
293 energy reserve metabolic process 3.518E-09 34 214 
294 axon guidance 3.528E-09 55 459 
295 regulation of protein phosphorylation 3.709E-09 88 904 
296 response to inorganic substance 4.174E-09 64 577 
297 regulation of cGMP biosynthetic process 4.410E-09 11 23 
298 chemotaxis 4.647E-09 71 672 
299 regulation of cell differentiation 4.673E-09 102 1111 
300 positive regulation of amine transport 4.916E-09 14 40 
301 positive regulation of protein serine/threonine kinase activity 5.739E-09 39 273 
302 regulation of phosphorylation 5.850E-09 92 970 
303 positive regulation of amino acid transport 6.395E-09 8 11 
304 synaptic vesicle docking involved in exocytosis 6.395E-09 8 11 
305 positive regulation of gamma-aminobutyric acid secretion 6.395E-09 8 11 
306 positive regulation of cGMP metabolic process 7.767E-09 11 24 
307 regulation of inhibitory postsynaptic membrane potential 7.767E-09 11 24 
308 negative regulation of catalytic activity 8.053E-09 74 722 
309 regulation of locomotion 8.198E-09 55 470 
310 visual behavior 8.445E-09 16 55 
311 negative regulation of synaptic transmission, glutamatergic 8.526E-09 9 15 
312 positive regulation of synaptic transmission, GABAergic 8.526E-09 9 15 
313 cGMP biosynthetic process 1.067E-08 12 30 
314 response to organic cyclic compound 1.105E-08 55 474 
315 response to chemical stimulus 1.135E-08 278 4020 
316 visual learning 1.138E-08 15 49 
317 telencephalon development 1.159E-08 34 224 
318 purine-containing compound metabolic process 1.369E-08 75 745 
319 cell-cell adhesion 1.460E-08 49 402 
320 negative regulation of ion transport 1.493E-08 16 57 
321 response to toxin 1.651E-08 29 174 
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322 regulated secretory pathway 1.660E-08 12 31 
323 response to defense-related nitric oxide production by other organism 
involved in symbiotic interaction 
1.732E-08 6 6 
324 response to defense-related host nitric oxide production 1.732E-08 6 6 
325 myeloid leukocyte activation 1.761E-08 21 98 
326 negative regulation of synaptic transmission, GABAergic 1.860E-08 9 16 
327 nucleotide metabolic process 2.074E-08 81 837 
328 nucleoside phosphate metabolic process 2.074E-08 81 837 
329 activation of phospholipase C activity by G-protein coupled receptor protein 
signaling pathway coupled to IP3 second messenger 
2.129E-08 21 99 
330 behavioral response to pain 2.188E-08 11 26 
331 response to drug 2.392E-08 68 658 
332 developmental maturation 2.436E-08 31 198 
333 cellular membrane organization 2.490E-08 67 645 
334 calcium ion transport into cytosol 2.803E-08 15 52 
335 forebrain development 2.891E-08 45 361 
336 membrane organization 2.982E-08 67 648 
337 regulation of neuron projection development 3.328E-08 36 256 
338 regulation of GTP catabolic process 3.533E-08 43 339 
339 positive regulation of response to stimulus 3.592E-08 103 1171 
340 regulation of heart rate 3.726E-08 15 53 
341 purine nucleotide biosynthetic process 4.070E-08 29 181 
342 cytosolic calcium ion transport 4.917E-08 15 54 
343 receptor metabolic process 4.967E-08 19 86 
344 nucleoside monophosphate biosynthetic process 4.967E-08 19 86 
345 glial cell differentiation 5.240E-08 25 142 
346 regulation of smooth muscle contraction 5.450E-08 18 78 
347 negative regulation of heart contraction 5.533E-08 11 28 
348 mast cell activation 5.533E-08 11 28 
349 dopamine receptor signaling pathway 5.596E-08 12 34 
350 positive regulation of signal transduction 5.817E-08 72 729 
351 nitrogen compound transport 5.983E-08 34 239 
352 regulation of behavior 6.009E-08 26 153 
353 response to pain 6.774E-08 13 41 
354 smooth muscle contraction 7.077E-08 16 63 
355 glutamate secretion 7.080E-08 10 23 
356 regulation of growth 7.436E-08 65 636 
357 regulation of GTPase activity 7.714E-08 42 336 
358 anion transport 8.148E-08 34 242 
359 endocytosis 8.195E-08 43 349 
360 membrane invagination 8.195E-08 43 349 
361 rhythmic synaptic transmission 9.200E-08 7 10 
362 regulation of signal transduction 9.349E-08 141 1788 
363 adenosine receptor signaling pathway 1.014E-07 8 14 
364 inositol phosphate-mediated signaling 1.048E-07 21 108 
365 chloride transport 1.206E-07 23 128 
366 regulation of cell migration 1.306E-07 48 418 
367 positive regulation of calcium ion transport via voltage-gated calcium 
channel activity 
1.307E-07 9 19 
368 regulation of cell motility 1.414E-07 49 432 
369 adult locomotory behavior 1.556E-07 19 92 
370 positive regulation of nitric oxide biosynthetic process 1.618E-07 14 51 
371 myeloid cell activation involved in immune response 1.640E-07 12 37 
372 negative regulation of molecular function 1.693E-07 81 879 
373 response to carbohydrate stimulus 1.699E-07 30 204 
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374 activation of protein kinase activity 1.699E-07 30 204 
375 purine-containing compound biosynthetic process 1.700E-07 29 193 
376 calcium ion-dependent exocytosis 1.730E-07 13 44 
377 response to amphetamine 1.730E-07 13 44 
378 oligodendrocyte differentiation 1.784E-07 15 59 
379 prepulse inhibition 1.842E-07 10 25 
380 regulation of cGMP metabolic process 1.894E-07 11 31 
381 vesicle docking involved in exocytosis 1.894E-07 11 31 
382 positive regulation of MAP kinase activity 1.995E-07 32 228 
383 regulation of cellular component movement 2.121E-07 51 464 
384 nucleobase, nucleoside and nucleotide metabolic process 2.177E-07 82 899 
385 regulation of cell death 2.257E-07 124 1543 
386 positive regulation of cellular component biogenesis 2.269E-07 9 20 
387 G-protein coupled purinergic receptor signaling pathway 2.286E-07 12 38 
388 purinergic receptor signaling pathway 2.320E-07 13 45 
389 cell surface receptor linked signaling pathway 2.439E-07 221 3156 
390 positive regulation of GTPase activity 2.691E-07 38 302 
391 negative regulation of calcium ion transport 2.754E-07 11 32 
392 neuromuscular process controlling balance 2.865E-07 15 61 
393 response to endogenous stimulus 3.078E-07 112 1363 
394 enzyme linked receptor protein signaling pathway 3.134E-07 76 819 
395 regulation of MAPKKK cascade 3.373E-07 43 367 
396 histone H3-T6 phosphorylation 3.413E-07 5 5 
397 positive regulation of behavior 3.730E-07 19 97 
398 negative regulation of cellular process 3.788E-07 211 3002 
399 glial cell development 3.825E-07 18 88 
400 vesicle docking 3.941E-07 11 33 
401 negative regulation of ossification 3.941E-07 11 33 
402 axon ensheathment in central nervous system 3.965E-07 8 16 
403 central nervous system myelination 3.965E-07 8 16 
404 response to alkaloid 4.064E-07 26 168 
405 positive regulation of the force of heart contraction by epinephrine-
norepinephrine 
4.438E-07 6 8 
406 localization of cell 4.508E-07 68 711 
407 cell motility 4.508E-07 68 711 
408 phosphorylation 4.697E-07 102 1219 
409 amine transport 5.058E-07 29 203 
410 regulation of multicellular organism growth 5.197E-07 19 99 
411 positive regulation of calcium ion transport 5.454E-07 17 81 
412 relaxation of vascular smooth muscle 5.547E-07 7 12 
413 regulation of dopamine secretion 5.558E-07 11 34 
414 sodium ion transmembrane transport 5.613E-07 15 64 
415 cAMP metabolic process 5.787E-07 12 41 
416 regulation of homeostatic process 5.952E-07 36 287 
417 cellular component organization 6.029E-07 277 4177 
418 phasic smooth muscle contraction 6.124E-07 9 22 
419 striated muscle contraction 6.557E-07 17 82 
420 relaxation of muscle 7.154E-07 8 17 
421 ionotropic glutamate receptor signaling pathway 7.154E-07 8 17 
422 phosphate metabolic process 7.500E-07 116 1451 
423 negative regulation of signaling 7.687E-07 62 636 
424 phosphorus metabolic process 7.761E-07 116 1452 
425 response to organic substance 7.789E-07 172 2368 
426 positive regulation of chemotaxis 7.858E-07 17 83 
427 protein phosphorylation 8.657E-07 80 900 
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428 negative regulation of cell communication 9.011E-07 62 639 
429 nucleotide biosynthetic process 9.161E-07 31 232 
430 response to metal ion 9.343E-07 44 394 
431 positive regulation of MAPKKK cascade 9.351E-07 29 209 
432 response to dietary excess 9.606E-07 9 23 
433 positive regulation of organ growth 9.606E-07 9 23 
434 regulation of anatomical structure size 9.621E-07 60 612 
435 positive regulation of exocytosis 1.022E-06 12 43 
436 regulation of calcium ion-dependent exocytosis 1.022E-06 12 43 
437 regulation of cellular protein metabolic process 1.027E-06 111 1381 
438 inorganic anion transport 1.135E-06 25 166 
439 response to tropane 1.136E-06 14 59 
440 response to cocaine 1.136E-06 14 59 
441 MAPKKK cascade 1.189E-06 39 333 
442 negative regulation of organic acid transport 1.230E-06 8 18 
443 negative regulation of cell death 1.248E-06 69 746 
444 neuronal signal transduction 1.274E-06 6 9 
445 positive regulation of the force of heart contraction by chemical signal 1.274E-06 6 9 
446 regulation of G-protein coupled receptor protein signaling pathway 1.356E-06 20 115 
447 regulation of protein modification process 1.382E-06 92 1093 
448 response to hormone stimulus 1.452E-06 96 1156 
449 nucleobase, nucleoside and nucleotide biosynthetic process 1.462E-06 32 249 
450 nucleobase, nucleoside, nucleotide and nucleic acid biosynthetic process 1.462E-06 32 249 
451 regulation of dopamine metabolic process 1.467E-06 9 24 
452 inflammatory response 1.561E-06 50 482 
453 leukocyte activation 1.617E-06 49 469 
454 regulation of potassium ion transport 1.889E-06 10 31 
455 transmembrane receptor protein tyrosine kinase signaling pathway 1.909E-06 60 625 
456 regulation of sodium ion transport 1.937E-06 11 38 
457 positive regulation of heart growth 1.961E-06 5 6 
458 vasodilation by norepinephrine-epinephrine involved in regulation of 
systemic arterial blood pressure 
1.961E-06 5 6 
459 histone-threonine phosphorylation 1.961E-06 5 6 
460 regulation of synaptic vesicle fusion to presynaptic membrane 1.961E-06 5 6 
461 positive regulation of nervous system development 2.030E-06 8 19 
462 positive regulation of synaptogenesis 2.030E-06 8 19 
463 regulation of developmental growth 2.058E-06 20 118 
464 elevation of cytosolic calcium ion concentration involved in G-protein 
signaling coupled to IP3 second messenger 
2.189E-06 9 25 
465 regulation of synapse maturation 2.196E-06 7 14 
466 response to immune response of other organism involved in symbiotic 
interaction 
2.196E-06 7 14 
467 negative regulation of glutamate secretion 2.196E-06 7 14 
468 response to host immune response 2.196E-06 7 14 
469 adult walking behavior 2.251E-06 12 46 
470 regulation of blood vessel endothelial cell migration 2.251E-06 12 46 
471 regulation of protein serine/threonine kinase activity 2.273E-06 46 434 
472 renal system process 2.301E-06 16 80 
473 regulation of MAP kinase activity 2.345E-06 36 304 
474 regulation of programmed cell death 2.399E-06 117 1502 
475 activation of MAPK activity 2.458E-06 25 173 
476 positive regulation of vasoconstriction 2.574E-06 11 39 
   260 
477 oligodendrocyte development 2.574E-06 11 39 
478 response to light stimulus 2.617E-06 33 268 
479 cellular component movement 2.728E-06 73 822 
480 positive regulation of inflammatory response 2.752E-06 19 110 
481 negative regulation of blood pressure 2.868E-06 13 55 
482 organic substance transport 2.880E-06 53 534 
483 negative regulation of response to stimulus 2.884E-06 69 764 
484 cell migration 3.112E-06 61 649 
485 regulation of fatty acid transport 3.197E-06 9 26 
486 nucleoside monophosphate catabolic process 3.197E-06 9 26 
487 regulation of nitric oxide biosynthetic process 3.222E-06 14 64 
488 response to host defenses 3.232E-06 8 20 
489 negative regulation of systemic arterial blood pressure 3.232E-06 8 20 
490 response to defenses of other organism involved in symbiotic interaction 3.232E-06 8 20 
491 response to host 3.232E-06 8 20 
492 regulation of endothelial cell migration 3.327E-06 15 73 
493 membrane docking 3.388E-06 11 40 
494 regulation of protein metabolic process 3.588E-06 119 1547 
495 long-term memory 3.591E-06 10 33 
496 positive regulation of sodium ion transport 3.936E-06 7 15 
497 regulation of acetylcholine secretion 3.936E-06 7 15 
498 negative regulation of calcium ion transport via voltage-gated calcium 
channel activity 
3.936E-06 7 15 
499 activation of adenylate cyclase activity by dopamine receptor signaling 
pathway 
3.936E-06 7 15 
500 serotonin metabolic process 3.936E-06 7 15 
501 regulation of intracellular protein kinase cascade 3.942E-06 59 625 
502 regulation of chemotaxis 4.213E-06 18 103 
503 regulation of apoptosis 4.406E-06 115 1489 
504 regulation of catecholamine metabolic process 4.579E-06 9 27 
505 regulation of urine volume 4.579E-06 9 27 
506 protein complex assembly 4.581E-06 66 730 
507 forebrain cell migration 4.633E-06 12 49 
508 monovalent inorganic cation transport 4.835E-06 41 379 
509 negative regulation of developmental process 5.127E-06 55 573 
510 protein complex biogenesis 5.247E-06 66 733 
511 potassium ion transport 5.285E-06 24 169 
512 cellular component organization or biogenesis 5.322E-06 278 4304 
513 response to hexose stimulus 5.861E-06 24 170 
514 negative regulation of urine volume 6.411E-06 6 11 
515 gamma-aminobutyric acid transport 6.411E-06 6 11 
516 regulation of the force of heart contraction by chemical signal 6.411E-06 6 11 
517 cGMP-mediated signaling 6.444E-06 9 28 
518 neuron recognition 6.489E-06 10 35 
519 neurotransmitter metabolic process 6.489E-06 10 35 
520 negative regulation of gamma-aminobutyric acid secretion 6.574E-06 5 7 
521 feeding behavior 6.582E-06 20 127 
522 negative regulation of hormone secretion 6.668E-06 15 77 
523 positive regulation of neurotransmitter transport 6.689E-06 7 16 
524 negative regulation of cAMP biosynthetic process 6.689E-06 7 16 
525 positive regulation of the force of heart contraction by norepinephrine 6.719E-06 4 4 
526 positive regulation of the force of heart contraction by epinephrine 6.719E-06 4 4 
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527 response to progesterone stimulus 6.859E-06 14 68 
528 pallium development 7.612E-06 22 150 
529 response to steroid hormone stimulus 7.614E-06 58 624 
530 response to monosaccharide stimulus 7.952E-06 24 173 
531 positive regulation of intracellular protein kinase cascade 8.229E-06 44 428 
532 regulation of inflammatory response 8.430E-06 29 233 
533 regulation of positive chemotaxis 8.576E-06 10 36 
534 peptidyl-threonine phosphorylation 8.576E-06 10 36 
535 positive regulation of ion transmembrane transporter activity 8.576E-06 10 36 
536 positive regulation of cell death 8.602E-06 68 774 
537 positive regulation of cell differentiation 8.770E-06 56 598 
538 negative regulation of response to external stimulus 9.555E-06 21 141 
539 G-protein coupled receptor protein signaling pathway 9.875E-06 117 1548 
540 rhythmic process 1.003E-05 35 311 
541 negative regulation of nucleotide biosynthetic process 1.087E-05 7 17 
542 negative regulation of cyclic nucleotide biosynthetic process 1.087E-05 7 17 
543 negative regulation of cAMP metabolic process 1.087E-05 7 17 
544 activation of protein kinase C activity by G-protein coupled receptor protein 
signaling pathway 
1.109E-05 12 53 
545 positive regulation of phosphatidylinositol 3-kinase cascade 1.122E-05 10 37 
546 nerve growth factor receptor signaling pathway 1.206E-05 32 275 
547 regulation of macrophage cytokine production 1.227E-05 6 12 
548 positive regulation of odontogenesis 1.227E-05 6 12 
549 positive regulation of neurotransmitter secretion 1.227E-05 6 12 
550 positive regulation of blood pressure by epinephrine-norepinephrine 1.227E-05 6 12 
551 cellular component assembly 1.239E-05 111 1458 
552 negative regulation of apoptosis 1.299E-05 63 709 
553 hormone secretion 1.313E-05 16 91 
554 calcium-mediated signaling 1.416E-05 13 63 
555 positive regulation of cellular component organization 1.446E-05 50 522 
556 hormone transport 1.485E-05 17 102 
557 glycerolipid metabolic process 1.506E-05 32 278 
558 positive regulation of hormone secretion 1.515E-05 16 92 
559 heterocycle metabolic process 1.595E-05 84 1035 
560 regulation of small GTPase mediated signal transduction 1.608E-05 42 412 
561 positive regulation of excitatory postsynaptic membrane potential 1.679E-05 5 8 
562 positive regulation of peptide secretion 1.695E-05 13 64 
563 cyclic nucleotide catabolic process 1.701E-05 7 18 
564 negative regulation of cyclic nucleotide metabolic process 1.701E-05 7 18 
565 positive regulation of muscle organ development 1.701E-05 7 18 
566 positive regulation of G-protein coupled receptor protein signaling pathway 1.701E-05 7 18 
567 positive regulation of striated muscle tissue development 1.701E-05 7 18 
568 sodium ion transport 1.834E-05 21 147 
569 negative regulation of programmed cell death 1.834E-05 63 717 
570 release of sequestered calcium ion into cytosol 1.866E-05 10 39 
571 positive regulation of transporter activity 1.866E-05 10 39 
572 negative regulation of sequestering of calcium ion 1.866E-05 10 39 
573 peptidyl-threonine modification 1.866E-05 10 39 
574 response to mineralocorticoid stimulus 2.016E-05 12 56 
575 L-amino acid import 2.180E-05 6 13 
576 negative regulation of heart rate 2.180E-05 6 13 
577 adrenergic receptor signaling pathway 2.180E-05 6 13 
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578 regulation of systemic arterial blood pressure by norepinephrine-
epinephrine 
2.180E-05 6 13 
579 leukocyte degranulation 2.208E-05 8 25 
580 negative regulation of peptide secretion 2.436E-05 12 57 
581 positive regulation of programmed cell death 2.554E-05 65 755 
582 positive regulation of renal sodium excretion 2.574E-05 7 19 
583 regulation of smooth muscle cell proliferation 2.627E-05 19 128 
584 response to corticosteroid stimulus 2.664E-05 32 286 
585 positive regulation of developmental growth 2.801E-05 11 49 
586 nucleobase, nucleoside, nucleotide and nucleic acid catabolic process 2.836E-05 53 579 
587 nucleobase, nucleoside and nucleotide catabolic process 2.836E-05 53 579 
588 positive regulation of heart contraction 2.857E-05 9 33 
589 regulation of sequestering of calcium ion 2.998E-05 10 41 
590 cellular component organization at cellular level 3.034E-05 214 3253 
591 regulation of establishment of protein localization 3.035E-05 33 301 
592 phenol-containing compound metabolic process 3.088E-05 15 87 
593 hippocampus development 3.088E-05 15 87 
594 carboxylic acid transport 3.147E-05 28 237 
595 phosphatidylinositol metabolic process 3.198E-05 17 108 
596 protein oligomerization 3.215E-05 38 369 
597 musculoskeletal movement, spinal reflex action 3.223E-05 4 5 
598 positive regulation of skeletal muscle tissue growth 3.223E-05 4 5 
599 positive regulation of cell growth involved in cardiac muscle cell 
development 
3.223E-05 4 5 
600 regulation of cell growth involved in cardiac muscle cell development 3.223E-05 4 5 
601 positive regulation of cardiac muscle tissue growth 3.223E-05 4 5 
602 heterocycle biosynthetic process 3.245E-05 33 302 
603 nucleotide catabolic process 3.286E-05 51 553 
604 defense response 3.468E-05 93 1201 
605 diet induced thermogenesis 3.619E-05 5 9 
606 positive regulation of heart rate by epinephrine-norepinephrine 3.619E-05 5 9 
607 regulation of somatostatin secretion 3.619E-05 5 9 
608 gamma-aminobutyric acid secretion 3.619E-05 5 9 
609 organ development 3.639E-05 192 2875 
610 amino acid import 3.650E-05 6 14 
611 protein heterotetramerization 3.650E-05 6 14 
612 organic acid transport 3.665E-05 28 239 
613 response to dexamethasone stimulus 3.711E-05 9 34 
614 dopamine metabolic process 3.711E-05 9 34 
615 grooming behavior 3.786E-05 7 20 
616 metabotropic glutamate receptor signaling pathway 3.786E-05 7 20 
617 negative regulation of nucleotide metabolic process 3.786E-05 7 20 
618 intracellular protein kinase cascade 3.856E-05 52 571 
619 aging 4.022E-05 35 332 
620 negative regulation of cellular component organization 4.069E-05 38 373 
621 response to calcium ion 4.522E-05 19 133 
622 regulation of protein secretion 4.610E-05 18 122 
623 regulation of synaptogenesis 4.771E-05 9 35 
624 positive regulation of positive chemotaxis 4.771E-05 9 35 
625 regulation of dephosphorylation 4.972E-05 12 61 
626 positive regulation of peptide hormone secretion 4.972E-05 12 61 
627 response to extracellular stimulus 5.029E-05 58 666 
628 response to nutrient 5.117E-05 43 447 
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629 regulation of hormone levels 5.230E-05 32 296 
630 regulation of anatomical structure morphogenesis 5.408E-05 54 608 
631 response to oxygen levels 5.425E-05 38 378 
632 desensitization of G-protein coupled receptor protein signaling pathway 5.536E-05 8 28 
633 regulation of renal sodium excretion 5.536E-05 8 28 
634 negative adaptation of signaling pathway 5.536E-05 8 28 
635 adaptation of signaling pathway 5.536E-05 8 28 
636 negative regulation of amine transport 5.536E-05 8 28 
637 regulation of endocytosis 5.540E-05 22 170 
638 regulation of dendritic spine development 5.820E-05 6 15 
639 regulation of vesicle fusion 5.820E-05 6 15 
640 mast cell degranulation 5.820E-05 6 15 
641 positive regulation of membrane potential 5.820E-05 6 15 
642 mast cell activation involved in immune response 5.820E-05 6 15 
643 response to estradiol stimulus 5.889E-05 24 195 
644 positive regulation of immune effector process 6.011E-05 21 159 
645 purine-containing compound catabolic process 6.093E-05 49 537 
646 cellular nitrogen compound catabolic process 6.161E-05 54 611 
647 response to growth factor stimulus 6.593E-05 21 160 
648 negative regulation of amino acid transport 6.933E-05 5 10 
649 positive regulation of synapse maturation 6.933E-05 5 10 
650 neural precursor cell proliferation 6.934E-05 12 63 
651 neutrophil chemotaxis 7.086E-05 10 45 
652 positive regulation of endothelial cell migration 7.086E-05 10 45 
653 immune response-activating cell surface receptor signaling pathway 7.225E-05 21 161 
654 glycerophospholipid metabolic process 7.225E-05 22 173 
655 regulation of glucose import 7.286E-05 11 54 
656 regulation of lipid catabolic process 7.286E-05 11 54 
657 regulation of protein localization 7.370E-05 35 342 
658 negative regulation of ion transmembrane transporter activity 7.614E-05 7 22 
659 negative regulation of lipid catabolic process 7.614E-05 7 22 
660 cellular component assembly at cellular level 7.619E-05 80 1018 
661 purinergic nucleotide receptor signaling pathway 7.668E-05 9 37 
662 positive regulation of multicellular organismal metabolic process 7.668E-05 9 37 
663 negative regulation of catabolic process 7.816E-05 15 94 
664 response to glucose stimulus 7.910E-05 21 162 
665 negative regulation of growth 8.123E-05 27 237 
666 response to organic nitrogen 8.136E-05 34 330 
667 telencephalon cell migration 8.645E-05 10 46 
668 regulation of phosphatidylinositol 3-kinase cascade 8.645E-05 10 46 
669 response to morphine 8.645E-05 10 46 
670 purine nucleotide catabolic process 8.664E-05 48 530 
671 regulation of calcium ion transport into cytosol 8.692E-05 11 55 
672 cAMP catabolic process 8.911E-05 6 16 
673 mast cell mediated immunity 8.911E-05 6 16 
674 calcium ion-dependent exocytosis of neurotransmitter 9.276E-05 4 6 
675 positive regulation of saliva secretion 9.276E-05 4 6 
676 positive regulation of cardiac muscle tissue development 9.276E-05 4 6 
677 regulation of skeletal muscle tissue growth 9.276E-05 4 6 
678 regulation of neuron maturation 9.276E-05 4 6 
679 synaptic vesicle priming 9.276E-05 4 6 
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680 positive regulation of odontogenesis of dentine-containing tooth 9.276E-05 4 6 
681 small molecule biosynthetic process 9.422E-05 54 621 
682 negative regulation of transporter activity 9.519E-05 8 30 
683 G-protein coupled purinergic nucleotide receptor signaling pathway 9.519E-05 8 30 
684 peptide hormone secretion 9.529E-05 12 65 
685 response to estrogen stimulus 9.537E-05 31 292 
686 regulation of phosphatase activity 9.596E-05 9 38 
687 response to radiation 9.703E-05 41 431 
688 protein localization 9.808E-05 100 1350 
689 tissue remodeling 1.005E-04 17 118 
690 regulation of cellular component biogenesis 1.011E-04 33 320 
691 response to nutrient levels 1.024E-04 54 623 
692 negative regulation of peptide hormone secretion 1.032E-04 11 56 
693 synaptic transmission, GABAergic 1.047E-04 7 23 
694 response to isoquinoline alkaloid 1.048E-04 10 47 
695 response to temperature stimulus 1.074E-04 23 190 
696 regulation of lipid metabolic process 1.074E-04 28 254 
697 cellular process 1.105E-04 800 14653 
698 regulation of organ growth 1.119E-04 13 76 
699 leukocyte migration 1.157E-04 27 242 
700 positive regulation of smooth muscle cell migration 1.192E-04 9 39 
701 lipid phosphorylation 1.192E-04 9 39 
702 phospholipid metabolic process 1.210E-04 29 269 
703 L-glutamate import 1.218E-04 5 11 
704 activation of phospholipase C activity by dopamine receptor signaling 
pathway 
1.218E-04 5 11 
705 elastic fiber assembly 1.218E-04 5 11 
706 amino acid transport 1.224E-04 19 143 
707 vasoconstriction 1.226E-04 8 31 
708 immune response-regulating cell surface receptor signaling pathway 1.228E-04 21 167 
709 response to lipid 1.242E-04 17 120 
710 regulation of multicellular organismal metabolic process 1.264E-04 10 48 
711 positive regulation of cardiac muscle hypertrophy 1.318E-04 6 17 
712 positive regulation of muscle hypertrophy 1.318E-04 6 17 
713 positive regulation of fatty acid transport 1.318E-04 6 17 
714 positive regulation of plasma membrane long-chain fatty acid transport 1.321E-04 3 3 
715 cerebellum maturation 1.321E-04 3 3 
716 vestibular nucleus development 1.321E-04 3 3 
717 negative regulation of neuron maturation 1.321E-04 3 3 
718 cellular response to histamine 1.321E-04 3 3 
719 spinal cord oligodendrocyte cell fate specification 1.321E-04 3 3 
720 cerebellar molecular layer development 1.321E-04 3 3 
721 positive regulation of smooth muscle cell chemotaxis 1.321E-04 3 3 
722 spinal cord oligodendrocyte cell differentiation 1.321E-04 3 3 
723 detection of abiotic stimulus 1.377E-04 17 121 
724 positive regulation of cAMP biosynthetic process 1.469E-04 9 40 
725 regulation of calcium-mediated signaling 1.469E-04 9 40 
726 positive regulation of ERK1 and ERK2 cascade 1.470E-04 13 78 
727 peptide secretion 1.497E-04 12 68 
728 regulation of cell adhesion 1.502E-04 32 313 
729 regulation of systemic arterial blood pressure mediated by a chemical 
signal 
1.517E-04 10 49 
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730 response to electrical stimulus 1.517E-04 10 49 
731 regulation of vasodilation 1.517E-04 10 49 
732 negative regulation of neuron apoptosis 1.526E-04 17 122 
733 microspike assembly 1.562E-04 8 32 
734 regulation of excretion 1.562E-04 8 32 
735 detection of external stimulus 1.589E-04 18 134 
736 leukocyte activation involved in immune response 1.602E-04 15 100 
737 cell activation involved in immune response 1.602E-04 15 100 
738 regulation of cell morphogenesis 1.618E-04 30 287 
739 regulation of bone mineralization 1.687E-04 11 59 
740 small molecule metabolic process 1.734E-04 162 2428 
741 macromolecule localization 1.753E-04 115 1622 
742 heterocycle catabolic process 1.754E-04 52 606 
743 negative regulation of cell adhesion 1.794E-04 15 101 
744 positive regulation of catecholamine secretion 1.876E-04 7 25 
745 regulation of norepinephrine secretion 1.876E-04 7 25 
746 regulation of neuron apoptosis 1.883E-04 26 236 
747 actin filament-based process 1.884E-04 40 430 
748 neurotransmitter uptake 1.892E-04 6 18 
749 phosphatidylinositol 3-kinase cascade 1.892E-04 6 18 
750 carbohydrate homeostasis 1.920E-04 18 136 
751 glucose homeostasis 1.920E-04 18 136 
752 regulation of striated muscle tissue development 1.956E-04 16 113 
753 positive regulation of vasodilation 1.971E-04 8 33 
754 response to yeast 2.000E-04 5 12 
755 regulation of synaptic vesicle exocytosis 2.000E-04 5 12 
756 positive regulation of penile erection 2.000E-04 5 12 
757 cellular response to lipoteichoic acid 2.077E-04 4 7 
758 regulation of cardiac muscle cell differentiation 2.077E-04 4 7 
759 involuntary skeletal muscle contraction 2.077E-04 4 7 
760 regulation of melanocyte differentiation 2.077E-04 4 7 
761 diaphragm contraction 2.077E-04 4 7 
762 regulation of saliva secretion 2.077E-04 4 7 
763 positive regulation of mucus secretion 2.077E-04 4 7 
764 desensitization of G-protein coupled receptor protein signaling pathway by 
arrestin 
2.077E-04 4 7 
765 response to lipoteichoic acid 2.077E-04 4 7 
766 regulation of pigment cell differentiation 2.077E-04 4 7 
767 response to histamine 2.077E-04 4 7 
768 positive regulation of apoptosis 2.111E-04 61 749 
769 cellular protein localization 2.115E-04 59 718 
770 negative regulation of G-protein coupled receptor protein signaling pathway 2.185E-04 9 42 
771 positive regulation of cAMP metabolic process 2.185E-04 9 42 
772 positive regulation of growth 2.270E-04 22 187 
773 regulation of dendrite development 2.287E-04 12 71 
774 response to glucocorticoid stimulus 2.347E-04 28 266 
775 regulation of immune response 2.354E-04 57 690 
776 regulation of muscle organ development 2.403E-04 16 115 
777 cellular component organization or biogenesis at cellular level 2.412E-04 214 3367 
778 positive regulation of blood vessel endothelial cell migration 2.455E-04 7 26 
779 phosphatidylinositol phosphorylation 2.463E-04 8 34 
780 positive regulation of lipid transport 2.463E-04 8 34 
781 mononuclear cell proliferation 2.463E-04 13 82 
782 small GTPase mediated signal transduction 2.482E-04 42 465 
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783 negative regulation of neurogenesis 2.496E-04 15 104 
784 regulation of Ras protein signal transduction 2.516E-04 32 322 
785 cellular macromolecule localization 2.534E-04 59 723 
786 negative regulation of blood vessel endothelial cell migration 2.646E-04 6 19 
787 G-protein signaling, coupled to cGMP nucleotide second messenger 2.646E-04 6 19 
788 response to fungicide 2.646E-04 6 19 
789 vesicle organization 2.658E-04 16 116 
790 hindbrain development 2.768E-04 18 140 
791 actin filament organization 2.768E-04 18 140 
792 limbic system development 2.777E-04 15 105 
793 leukocyte proliferation 2.787E-04 13 83 
794 positive regulation of phosphorus metabolic process 2.809E-04 33 338 
795 positive regulation of phosphate metabolic process 2.809E-04 33 338 
796 negative regulation of signal transduction 2.872E-04 50 588 
797 positive regulation of I-kappaB kinase/NF-kappaB cascade 2.895E-04 20 165 
798 multicellular organismal homeostasis 2.895E-04 20 165 
799 protein complex subunit organization 2.922E-04 66 837 
800 catechol metabolic process 2.992E-04 10 53 
801 catecholamine metabolic process 2.992E-04 10 53 
802 diol metabolic process 2.992E-04 10 53 
803 positive regulation of bone mineralization 3.051E-04 8 35 
804 regulation of heart growth 3.051E-04 8 35 
805 benzene-containing compound metabolic process 3.085E-04 15 106 
806 regulation of axon regeneration 3.113E-04 5 13 
807 peristalsis 3.113E-04 5 13 
808 regulation of neuron projection regeneration 3.113E-04 5 13 
809 positive regulation of skeletal muscle tissue development 3.113E-04 5 13 
810 positive regulation of potassium ion transport 3.113E-04 5 13 
811 negative regulation of myeloid cell apoptosis 3.113E-04 5 13 
812 positive regulation of protein secretion 3.146E-04 13 84 
813 negative regulation of endothelial cell migration 3.170E-04 7 27 
814 positive regulation of systemic arterial blood pressure 3.170E-04 7 27 
815 sleep 3.170E-04 7 27 
816 acidic amino acid transport 3.170E-04 7 27 
817 tissue homeostasis 3.239E-04 16 118 
818 homophilic cell adhesion 3.241E-04 19 154 
819 cell death 3.297E-04 86 1164 
820 negative regulation of locomotion 3.302E-04 18 142 
821 digestion 3.306E-04 17 130 
822 actin cytoskeleton organization 3.335E-04 36 384 
823 negative regulation of lipid metabolic process 3.406E-04 12 74 
824 response to hypoxia 3.474E-04 33 342 
825 regulation of ossification 3.499E-04 21 180 
826 negative regulation of insulin secretion 3.506E-04 10 54 
827 organ growth 3.506E-04 10 54 
828 regulation of acute inflammatory response 3.543E-04 13 85 
829 regulation of biomineral tissue development 3.553E-04 11 64 
830 positive regulation of nitric-oxide synthase activity 3.618E-04 6 20 
831 regulation of ATPase activity 3.749E-04 8 36 
832 response to peptide hormone stimulus 3.776E-04 50 595 
833 temperature homeostasis 3.785E-04 9 45 
834 regulation of protein transport 3.815E-04 28 274 
835 cell maturation 3.924E-04 18 144 
836 receptor-mediated endocytosis 3.941E-04 14 97 
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837 positive regulation of phosphoprotein phosphatase activity 3.986E-04 4 8 
838 striated muscle myosin thick filament assembly 3.986E-04 4 8 
839 skeletal muscle myosin thick filament assembly 3.986E-04 4 8 
840 regulation of plasma membrane long-chain fatty acid transport 3.986E-04 4 8 
841 death 3.988E-04 86 1171 
842 ribonucleotide metabolic process 4.027E-04 51 612 
843 regulation of lipid kinase activity 4.042E-04 7 28 
844 purine ribonucleotide metabolic process 4.078E-04 50 597 
845 positive regulation of blood pressure 4.083E-04 11 65 
846 positive regulation of ossification 4.092E-04 10 55 
847 regulation of systemic arterial blood pressure 4.386E-04 12 76 
848 positive regulation of cell proliferation 4.433E-04 65 834 
849 positive regulation of biomineral tissue development 4.572E-04 8 37 
850 organophosphate metabolic process 4.586E-04 29 291 
851 protein kinase C signaling cascade 4.640E-04 5 14 
852 skeletal myofibril assembly 4.640E-04 5 14 
853 pons development 4.640E-04 5 14 
854 response to folic acid 4.640E-04 5 14 
855 glycosphingolipid biosynthetic process 4.640E-04 5 14 
856 regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate 
selective glutamate receptor activity 
4.640E-04 5 14 
857 extracellular matrix assembly 4.640E-04 5 14 
858 regulation of growth hormone secretion 4.640E-04 5 14 
859 axonal fasciculation 4.640E-04 5 14 
860 positive regulation of glutamate secretion 4.640E-04 5 14 
861 positive regulation of tumor necrosis factor biosynthetic process 4.640E-04 5 14 
862 protein targeting 4.838E-04 31 320 
863 response to fluid shear stress 4.848E-04 6 21 
864 regulation of lipid transport 4.958E-04 12 77 
865 positive regulation of muscle cell differentiation 4.958E-04 12 77 
866 protein heterooligomerization 5.045E-04 18 147 
867 negative regulation of synapse maturation 5.084E-04 3 4 
868 regulation of smooth muscle cell chemotaxis 5.084E-04 3 4 
869 regulation of digestive system process 5.096E-04 7 29 
870 positive regulation of Ras protein signal transduction 5.096E-04 7 29 
871 insulin secretion 5.312E-04 9 47 
872 energy derivation by oxidation of organic compounds 5.397E-04 36 394 
873 regulation of immune effector process 5.420E-04 29 294 
874 germ cell development 5.437E-04 21 186 
875 positive regulation of protein transport 5.476E-04 18 148 
876 negative regulation of neuron projection development 5.535E-04 8 38 
877 musculoskeletal movement 5.535E-04 8 38 
878 positive regulation of glucose import 5.535E-04 8 38 
879 multicellular organismal movement 5.535E-04 8 38 
880 positive regulation of chemokine production 5.535E-04 8 38 
881 cellular nitrogen compound biosynthetic process 5.679E-04 41 469 
882 regulation of cell morphogenesis involved in differentiation 5.808E-04 22 200 
883 regulation of cell growth 5.811E-04 35 381 
884 positive regulation of cell development 6.216E-04 22 201 
885 lymphocyte proliferation 6.294E-04 12 79 
886 neuron maturation 6.357E-04 7 30 
887 indolalkylamine metabolic process 6.357E-04 7 30 
888 indole-containing compound metabolic process 6.357E-04 7 30 
889 regulation of cell size 6.362E-04 38 427 
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890 regulation of phosphatidylinositol 3-kinase activity 6.381E-04 6 22 
891 cellular component biogenesis 6.544E-04 111 1611 
892 plasma membrane organization 6.656E-04 8 39 
893 negative regulation of multicellular organism growth 6.669E-04 5 15 
894 macrophage activation involved in immune response 6.669E-04 5 15 
895 respiratory system process 6.669E-04 5 15 
896 histamine secretion 6.669E-04 5 15 
897 neurotransmitter biosynthetic process 6.669E-04 5 15 
898 vascular smooth muscle contraction 6.669E-04 5 15 
899 tolerance induction 6.669E-04 5 15 
900 regulation of penile erection 6.669E-04 5 15 
901 purine ribonucleoside triphosphate metabolic process 6.687E-04 47 564 
902 regulation of axonogenesis 6.792E-04 15 114 
903 cGMP catabolic process 6.885E-04 4 9 
904 plasma membrane repair 6.885E-04 4 9 
905 regulation of mucus secretion 6.885E-04 4 9 
906 artery smooth muscle contraction 6.885E-04 4 9 
907 tonic smooth muscle contraction 6.885E-04 4 9 
908 short-term memory 6.885E-04 4 9 
909 bleb assembly 6.885E-04 4 9 
910 positive regulation of protein maturation by peptide bond cleavage 6.885E-04 4 9 
911 synaptic vesicle maturation 6.885E-04 4 9 
912 sperm ejaculation 6.885E-04 4 9 
913 potassium ion transmembrane transport 6.939E-04 13 91 
914 cellular potassium ion transport 6.939E-04 13 91 
915 cell junction organization 6.955E-04 23 216 
916 positive regulation of phosphorylation 6.960E-04 31 327 
917 regulation of cell proliferation 6.973E-04 100 1427 
918 phagocytosis 7.309E-04 14 103 
919 regulation of neural precursor cell proliferation 7.310E-04 9 49 
920 blood vessel remodeling 7.310E-04 9 49 
921 regulation of cellular response to stress 7.469E-04 26 258 
922 ribonucleoside triphosphate metabolic process 7.487E-04 47 567 
923 regulation of cardiac muscle tissue growth 7.853E-04 7 31 
924 ERK1 and ERK2 cascade 7.853E-04 7 31 
925 regulation of myeloid leukocyte mediated immunity 7.953E-04 8 40 
926 regulation of nitric-oxide synthase activity 7.953E-04 8 40 
927 purine nucleoside triphosphate metabolic process 8.066E-04 47 569 
928 regulation of cardiac muscle contraction 8.263E-04 6 23 
929 T cell proliferation 8.518E-04 9 50 
930 cellular response to carbohydrate stimulus 8.518E-04 9 50 
931 leukocyte chemotaxis 8.553E-04 13 93 
932 positive T cell selection 9.296E-04 5 16 
933 reduction of cytosolic calcium ion concentration 9.296E-04 5 16 
934 regulation of membrane depolarization 9.296E-04 5 16 
935 regulation of feeding behavior 9.296E-04 5 16 
936 positive regulation of establishment of protein localization in plasma 
membrane 
9.296E-04 5 16 
937 eating behavior 9.445E-04 8 41 
938 positive regulation of calcium-mediated signaling 9.615E-04 7 32 
939 positive regulation of small GTPase mediated signal transduction 9.615E-04 7 32 
940 metencephalon development 1.047E-03 13 95 
941 cerebellar Purkinje cell layer development 1.055E-03 6 24 
942 positive regulation of heart rate 1.055E-03 6 24 
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943 positive regulation of striated muscle cell differentiation 1.055E-03 6 24 
944 regulation of cardiac muscle hypertrophy 1.055E-03 6 24 
945 establishment of protein localization 1.094E-03 78 1077 
946 regulation of I-kappaB kinase/NF-kappaB cascade 1.095E-03 20 183 
947 muscle fiber development 1.100E-03 12 84 
948 response to aluminum ion 1.101E-03 4 10 
949 inhibition of adenylate cyclase activity by metabotropic glutamate receptor 
signaling pathway 
1.101E-03 4 10 
950 positive regulation of dendritic spine development 1.101E-03 4 10 
951 negative regulation of neuroblast proliferation 1.101E-03 4 10 
952 positive regulation of inositol phosphate biosynthetic process 1.101E-03 4 10 
953 microglial cell activation involved in immune response 1.101E-03 4 10 
954 L-amino acid transport 1.115E-03 8 42 
955 regulation of production of molecular mediator of immune response 1.120E-03 11 73 
956 cellular response to molecule of bacterial origin 1.161E-03 15 120 
957 regulation of muscle adaptation 1.167E-03 7 33 
958 negative regulation of cell adhesion mediated by integrin 1.223E-03 3 5 
959 intestine smooth muscle contraction 1.223E-03 3 5 
960 gastro-intestinal system smooth muscle contraction 1.223E-03 3 5 
961 oligodendrocyte cell fate specification 1.223E-03 3 5 
962 glial cell fate specification 1.223E-03 3 5 
963 peptidyl-cysteine methylation 1.223E-03 3 5 
964 hindbrain maturation 1.223E-03 3 5 
965 negative regulation of serotonin secretion 1.223E-03 3 5 
966 NFAT protein import into nucleus 1.223E-03 3 5 
967 exploration behavior 1.223E-03 3 5 
968 negative regulation of macrophage cytokine production 1.223E-03 3 5 
969 negative regulation of axon regeneration 1.223E-03 3 5 
970 central nervous system maturation 1.223E-03 3 5 
971 negative regulation of inclusion body assembly 1.223E-03 3 5 
972 regulation of phagocytosis 1.238E-03 10 63 
973 positive regulation of lipid biosynthetic process 1.238E-03 10 63 
974 glycolipid biosynthetic process 1.262E-03 5 17 
975 histamine transport 1.262E-03 5 17 
976 positive regulation of phosphatase activity 1.262E-03 5 17 
977 regulation of icosanoid secretion 1.262E-03 5 17 
978 regulation of ERK1 and ERK2 cascade 1.274E-03 13 97 
979 protein localization to organelle 1.286E-03 30 325 
980 myeloid leukocyte mediated immunity 1.310E-03 8 43 
981 positive regulation of glucose transport 1.310E-03 8 43 
982 regulation of smooth muscle cell migration 1.314E-03 9 53 
983 positive regulation of phagocytosis 1.314E-03 9 53 
984 circadian rhythm 1.324E-03 16 134 
985 positive regulation of monooxygenase activity 1.328E-03 6 25 
986 regulation of establishment of protein localization in plasma membrane 1.328E-03 6 25 
987 regulation of muscle hypertrophy 1.328E-03 6 25 
988 sensory perception of mechanical stimulus 1.338E-03 20 186 
989 negative regulation of cell proliferation 1.343E-03 51 646 
990 nucleoside triphosphate metabolic process 1.383E-03 47 584 
991 cell chemotaxis 1.404E-03 14 110 
992 regulation of striated muscle cell differentiation 1.406E-03 11 75 
993 regulation of meiotic cell cycle 1.406E-03 7 34 
994 B cell receptor signaling pathway 1.406E-03 7 34 
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995 sodium ion export 1.406E-03 7 34 
996 immune effector process 1.409E-03 28 298 
997 small molecule catabolic process 1.480E-03 64 858 
998 response to cold 1.507E-03 9 54 
999 regeneration 1.512E-03 22 215 
1000 anatomical structure maturation 1.531E-03 8 44 
1001 cerebellar cortex development 1.531E-03 8 44 
1002 multicellular organismal reproductive process 1.536E-03 66 892 
1003 multicellular organism reproduction 1.536E-03 66 892 
1004 cell recognition 1.540E-03 13 99 
1005 peripheral nervous system development 1.569E-03 11 76 
1006 growth 1.583E-03 39 464 
1007 negative regulation of cell development 1.622E-03 15 124 
1008 positive regulation of ATPase activity 1.653E-03 6 26 
1009 myosin filament assembly 1.661E-03 4 11 
1010 regulation of epinephrine secretion 1.661E-03 4 11 
1011 detection of mechanical stimulus involved in sensory perception of pain 1.661E-03 4 11 
1012 cardiac muscle hypertrophy 1.661E-03 4 11 
1013 cerebral cortex GABAergic interneuron differentiation 1.661E-03 4 11 
1014 myosin filament organization 1.661E-03 4 11 
1015 striated muscle hypertrophy 1.661E-03 4 11 
1016 regulation of inositol phosphate biosynthetic process 1.661E-03 4 11 
1017 cardiac muscle fiber development 1.661E-03 4 11 
1018 cellular response to growth factor stimulus 1.672E-03 14 112 
1019 positive regulation of urine volume 1.675E-03 5 18 
1020 reflex 1.675E-03 5 18 
1021 histone phosphorylation 1.675E-03 5 18 
1022 astrocyte differentiation 1.681E-03 7 35 
1023 regulation of cardiac muscle tissue development 1.681E-03 7 35 
1024 positive regulation of calcium ion transport into cytosol 1.681E-03 7 35 
1025 regulation of humoral immune response 1.681E-03 7 35 
1026 intracellular protein transport 1.721E-03 45 559 
1027 mating 1.722E-03 9 55 
1028 bone remodeling 1.780E-03 8 45 
1029 regulation of striated muscle contraction 1.780E-03 8 45 
1030 positive regulation of cellular metabolic process 1.822E-03 124 1886 
1031 peptide transport 1.832E-03 12 89 
1032 leukocyte mediated immunity 1.843E-03 20 191 
1033 purine ribonucleotide catabolic process 1.861E-03 41 499 
1034 regulation of response to stress 1.932E-03 59 786 
1035 regulation of cell adhesion mediated by integrin 1.997E-03 7 36 
1036 response to vitamin D 1.999E-03 10 67 
1037 peptidyl-serine modification 2.018E-03 12 90 
1038 detection of mechanical stimulus involved in sensory perception 2.035E-03 6 27 
1039 response to gravity 2.035E-03 6 27 
1040 regulation of phosphoprotein phosphatase activity 2.035E-03 6 27 
1041 response to corticosterone stimulus 2.060E-03 8 46 
1042 response to fungus 2.060E-03 8 46 
1043 protein localization to nucleus 2.071E-03 18 166 
1044 central nervous system neuron differentiation 2.095E-03 16 140 
1045 positive regulation of protein phosphorylation 2.135E-03 27 292 
1046 cell proliferation 2.135E-03 57 757 
1047 regulation of cellular component size 2.142E-03 43 534 
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1048 ribonucleotide catabolic process 2.153E-03 41 503 
1049 ameboidal cell migration 2.156E-03 11 79 
1050 cellular lipid metabolic process 2.168E-03 62 839 
1051 positive regulation of neutrophil chemotaxis 2.178E-03 5 19 
1052 response to herbicide 2.178E-03 5 19 
1053 glutamate metabolic process 2.178E-03 5 19 
1054 positive regulation of humoral immune response 2.178E-03 5 19 
1055 negative regulation of neural precursor cell proliferation 2.178E-03 5 19 
1056 positive regulation of metabolic process 2.202E-03 129 1984 
1057 respiratory gaseous exchange 2.225E-03 9 57 
1058 response to protein stimulus 2.241E-03 27 293 
1059 positive regulation of defense response 2.337E-03 25 265 
1060 cellular response to temperature stimulus 2.353E-03 3 6 
1061 complement receptor mediated signaling pathway 2.353E-03 3 6 
1062 positive regulation of acetylcholine secretion 2.353E-03 3 6 
1063 renal control of peripheral vascular resistance involved in regulation of 
systemic arterial blood pressure 
2.353E-03 3 6 
1064 frontal suture morphogenesis 2.353E-03 3 6 
1065 regulation of NAD(P)H oxidase activity 2.353E-03 3 6 
1066 transcription factor import into nucleus 2.353E-03 3 6 
1067 renin-angiotensin regulation of aldosterone production 2.353E-03 3 6 
1068 negative regulation of neuron projection regeneration 2.353E-03 3 6 
1069 regulation of alkaline phosphatase activity 2.353E-03 3 6 
1070 regulation of blood vessel size by renin-angiotensin 2.353E-03 3 6 
1071 astrocyte activation 2.353E-03 3 6 
1072 regulation of interleukin-1 production 2.373E-03 8 47 
1073 positive regulation of digestive system process 2.391E-03 4 12 
1074 negative regulation of glucose import 2.391E-03 4 12 
1075 regulation of nerve growth factor receptor signaling pathway 2.391E-03 4 12 
1076 induction of programmed cell death in response to chemical stimulus 2.391E-03 4 12 
1077 N-glycan processing 2.391E-03 4 12 
1078 neuronal ion channel clustering 2.391E-03 4 12 
1079 regulation of cAMP-mediated signaling 2.391E-03 4 12 
1080 blood vessel morphogenesis 2.433E-03 35 414 
1081 response to ATP 2.480E-03 6 28 
1082 cellular response to dexamethasone stimulus 2.480E-03 6 28 
1083 positive regulation of lipid catabolic process 2.480E-03 6 28 
1084 multicellular organismal reproductive behavior 2.480E-03 6 28 
1085 cellular protein complex assembly 2.525E-03 23 238 
1086 lymphocyte activation 2.566E-03 33 385 
1087 regulation of sprouting of injured axon 2.597E-03 2 2 
1088 tolerance induction to nonself antigen 2.597E-03 2 2 
1089 enteric smooth muscle cell differentiation 2.597E-03 2 2 
1090 regulation of collateral sprouting of intact axon in response to injury 2.597E-03 2 2 
1091 tolerance induction dependent upon immune response 2.597E-03 2 2 
1092 glutamate decarboxylation to succinate 2.597E-03 2 2 
1093 cell surface pattern recognition receptor signaling pathway 2.597E-03 2 2 
1094 regulation of axon extension involved in regeneration 2.597E-03 2 2 
1095 negative regulation of growth hormone secretion 2.597E-03 2 2 
1096 substantia nigra development 2.597E-03 2 2 
1097 lung connective tissue development 2.597E-03 2 2 
1098 cytotoxic T cell differentiation 2.597E-03 2 2 
1099 synaptonemal complex disassembly 2.597E-03 2 2 
1100 negative regulation of alkaline phosphatase activity 2.597E-03 2 2 
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1101 axonogenesis involved in innervation 2.597E-03 2 2 
1102 phenylethylamine metabolic process 2.597E-03 2 2 
1103 negative regulation of cortisol secretion 2.597E-03 2 2 
1104 immune response-activating signal transduction 2.630E-03 24 253 
1105 positive regulation of immune response 2.669E-03 37 447 
1106 response to fatty acid 2.723E-03 8 48 
1107 positive regulation of lipid metabolic process 2.740E-03 14 118 
1108 response to amine stimulus 2.768E-03 24 254 
1109 negative regulation of steroid biosynthetic process 2.784E-03 5 20 
1110 regulation of tumor necrosis factor biosynthetic process 2.784E-03 5 20 
1111 serotonin receptor signaling pathway 2.784E-03 5 20 
1112 regulation of receptor activity 2.787E-03 10 70 
1113 protein import into nucleus 2.792E-03 15 131 
1114 defense response to Gram-positive bacterium 2.838E-03 9 59 
1115 activation of MAPKK activity 2.838E-03 9 59 
1116 protein transport 2.936E-03 74 1050 
1117 neurological system process involved in regulation of systemic arterial 
blood pressure 
2.994E-03 6 29 
1118 regulation of leukocyte degranulation 2.994E-03 6 29 
1119 response to purine-containing compound 2.994E-03 6 29 
1120 macromolecular complex assembly 3.010E-03 70 984 
1121 positive regulation of leukocyte migration 3.099E-03 10 71 
1122 behavioral interaction between organisms 3.099E-03 10 71 
1123 neuron migration 3.104E-03 13 107 
1124 positive regulation of cellular catabolic process 3.104E-03 13 107 
1125 positive regulation of nitrogen compound metabolic process 3.144E-03 92 1359 
1126 response to mechanical stimulus 3.151E-03 22 228 
1127 regulation of Ras GTPase activity 3.160E-03 20 200 
1128 membrane lipid metabolic process 3.202E-03 14 120 
1129 response to biotic stimulus 3.202E-03 61 837 
1130 generation of precursor metabolites and energy 3.309E-03 42 531 
1131 cerebellar Purkinje cell differentiation 3.316E-03 4 13 
1132 activation of transmembrane receptor protein tyrosine kinase activity 3.316E-03 4 13 
1133 cerebellar Purkinje cell layer formation 3.316E-03 4 13 
1134 cerebellar Purkinje cell layer morphogenesis 3.316E-03 4 13 
1135 positive regulation of fatty acid beta-oxidation 3.316E-03 4 13 
1136 positive thymic T cell selection 3.316E-03 4 13 
1137 positive regulation of protein dephosphorylation 3.316E-03 4 13 
1138 negative regulation of potassium ion transport 3.316E-03 4 13 
1139 negative regulation of glucose transport 3.316E-03 4 13 
1140 antigen receptor-mediated signaling pathway 3.436E-03 16 147 
1141 regulation of cytokine secretion 3.438E-03 10 72 
1142 nuclear import 3.473E-03 15 134 
1143 striated muscle cell development 3.473E-03 15 134 
1144 epidermal growth factor receptor signaling pathway 3.484E-03 12 96 
1145 cerebral cortex neuron differentiation 3.502E-03 5 21 
1146 lipoprotein transport 3.502E-03 5 21 
1147 negative regulation of exocytosis 3.502E-03 5 21 
1148 insemination 3.502E-03 5 21 
1149 heat generation 3.502E-03 5 21 
1150 cellular aromatic compound metabolic process 3.528E-03 26 288 
1151 regulation of chemokine production 3.542E-03 8 50 
1152 tissue regeneration 3.577E-03 9 61 
1153 negative regulation of angiogenesis 3.577E-03 9 61 
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1154 muscle cell development 3.582E-03 17 161 
1155 filopodium assembly 3.584E-03 6 30 
1156 regulation of odontogenesis 3.584E-03 6 30 
1157 T cell selection 3.584E-03 6 30 
1158 response to other organism 3.655E-03 54 727 
1159 lipid metabolic process 3.659E-03 80 1161 
1160 neuron death 3.736E-03 7 40 
1161 positive regulation of leukocyte activation 3.757E-03 28 319 
1162 positive regulation of adaptive immune response 3.796E-03 12 97 
1163 negative regulation of cell projection organization 3.796E-03 12 97 
1164 protein tetramerization 3.862E-03 11 85 
1165 cerebellum development 3.862E-03 11 85 
1166 positive regulation of proteolysis 3.862E-03 11 85 
1167 negative regulation of cell size 3.952E-03 19 190 
1168 cerebral cortex GABAergic interneuron migration 3.961E-03 3 7 
1169 cellular response to manganese ion 3.961E-03 3 7 
1170 negative regulation of nerve growth factor receptor signaling pathway 3.961E-03 3 7 
1171 oligodendrocyte cell fate commitment 3.961E-03 3 7 
1172 regulation of retinal cell programmed cell death 3.961E-03 3 7 
1173 smooth muscle contraction involved in micturition 3.961E-03 3 7 
1174 positive regulation of macrophage cytokine production 3.961E-03 3 7 
1175 interneuron migration from the subpallium to the cortex 3.961E-03 3 7 
1176 embryonic neurocranium morphogenesis 3.961E-03 3 7 
1177 inhibition of adenylate cyclase activity by dopamine receptor signaling 
pathway 
3.961E-03 3 7 
1178 regulation of serotonin secretion 3.961E-03 3 7 
1179 regulation of Rap GTPase activity 3.961E-03 3 7 
1180 cerebral cortex GABAergic interneuron development 3.961E-03 3 7 
1181 central nervous system neuron development 3.999E-03 9 62 
1182 neuromuscular junction development 4.017E-03 8 51 
1183 regulation of monooxygenase activity 4.017E-03 8 51 
1184 fluid transport 4.017E-03 8 51 
1185 immune response-regulating signaling pathway 4.112E-03 24 262 
1186 spinal cord development 4.130E-03 12 98 
1187 intracellular transport 4.131E-03 71 1014 
1188 cell junction assembly 4.185E-03 19 191 
1189 purine ribonucleoside triphosphate catabolic process 4.227E-03 39 491 
1190 regulation of leukocyte migration 4.229E-03 11 86 
1191 positive regulation of smooth muscle cell proliferation 4.229E-03 11 86 
1192 interaction with host 4.229E-03 11 86 
1193 regulation of circadian sleep/wake cycle 4.255E-03 6 31 
1194 regulation of circadian sleep/wake cycle, sleep 4.255E-03 6 31 
1195 neuromuscular synaptic transmission 4.255E-03 6 31 
1196 retina development in camera-type eye 4.283E-03 15 137 
1197 cardiac muscle contraction 4.311E-03 7 41 
1198 regulation of muscle cell differentiation 4.316E-03 14 124 
1199 cellular response to biotic stimulus 4.326E-03 17 164 
1200 protein kinase B signaling cascade 4.344E-03 5 22 
1201 positive regulation of epithelial cell migration 4.344E-03 5 22 
1202 regulation of interleukin-1 beta secretion 4.344E-03 5 22 
1203 positive regulation of T-helper cell differentiation 4.344E-03 5 22 
1204 regulation of filopodium assembly 4.344E-03 5 22 
1205 ribonucleoside triphosphate catabolic process 4.373E-03 39 492 
1206 positive regulation of cytokine production 4.375E-03 21 220 
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1207 negative regulation of cell growth 4.401E-03 18 178 
1208 positive regulation of dephosphorylation 4.457E-03 4 14 
1209 negative regulation of production of molecular mediator of immune 
response 
4.457E-03 4 14 
1210 peptidyl-cysteine modification 4.457E-03 4 14 
1211 regulation of cholesterol esterification 4.457E-03 4 14 
1212 platelet degranulation 4.488E-03 12 99 
1213 purine nucleoside triphosphate catabolic process 4.523E-03 39 493 
1214 positive regulation of endocytosis 4.614E-03 13 112 
1215 regulation of oxidoreductase activity 4.635E-03 10 75 
1216 muscle cell differentiation 4.650E-03 27 309 
1217 positive regulation of Ras GTPase activity 4.772E-03 16 152 
1218 regulation of leukocyte activation 4.796E-03 35 432 
1219 regulation of cytokine production involved in immune response 4.950E-03 7 42 
1220 regulation of interleukin-1 beta production 4.950E-03 7 42 
1221 glycolipid metabolic process 4.950E-03 7 42 
1222 positive regulation of oxidoreductase activity 4.950E-03 7 42 
1223 cellular response to lipopolysaccharide 4.977E-03 13 113 
1224 sphingolipid metabolic process 4.977E-03 13 113 
1225 detection of mechanical stimulus 5.015E-03 6 32 
1226 regulation of type 2 immune response 5.015E-03 6 32 
1227 regulation of release of sequestered calcium ion into cytosol 5.015E-03 6 32 
1228 positive regulation of immune system process 5.018E-03 50 673 
1229 positive regulation of adaptive immune response based on somatic 
recombination of immune receptors built from immunoglobulin superfamily 
domains 
5.047E-03 11 88 
1230 striated muscle tissue development 5.066E-03 27 311 
1231 cellular response to chemical stimulus 5.211E-03 111 1716 
1232 positive regulation of cell activation 5.270E-03 28 327 
1233 regulation of cellular metabolic process 5.274E-03 291 5010 
1234 regulation of neutrophil chemotaxis 5.322E-03 5 23 
1235 regulation of interleukin-1 secretion 5.322E-03 5 23 
1236 astrocyte development 5.322E-03 5 23 
1237 regulation of insulin secretion involved in cellular response to glucose 
stimulus 
5.322E-03 5 23 
1238 L-glutamate transport 5.322E-03 5 23 
1239 positive regulation of cyclin-dependent protein kinase activity 5.322E-03 5 23 
1240 positive regulation of cell size 5.342E-03 14 127 
1241 T cell activation 5.375E-03 21 224 
1242 regulation of cell activation 5.399E-03 36 451 
1243 cerebral cortex development 5.501E-03 11 89 
1244 angiogenesis 5.513E-03 27 313 
1245 nucleoside triphosphate catabolic process 5.518E-03 39 499 
1246 protein import 5.526E-03 19 196 
1247 response to reactive oxygen species 5.544E-03 18 182 
1248 monovalent inorganic cation homeostasis 5.600E-03 10 77 
1249 peptidyl-serine phosphorylation 5.600E-03 10 77 
1250 positive regulation of interleukin-6 production 5.658E-03 7 43 
1251 transition metal ion transport 5.725E-03 14 128 
1252 digestive system process 5.741E-03 8 54 
1253 negative regulation of cell differentiation 5.830E-03 37 469 
1254 low-density lipoprotein particle remodeling 5.835E-03 4 15 
1255 receptor guanylyl cyclase signaling pathway 5.835E-03 4 15 
1256 estrous cycle phase 5.835E-03 4 15 
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1257 regulation of developmental pigmentation 5.835E-03 4 15 
1258 regulation of odontogenesis of dentine-containing tooth 5.835E-03 4 15 
1259 negative regulation of catecholamine secretion 5.835E-03 4 15 
1260 regulation of lipoprotein lipase activity 5.870E-03 6 33 
1261 regulation of oligodendrocyte differentiation 5.870E-03 6 33 
1262 phospholipid biosynthetic process 5.972E-03 15 142 
1263 positive regulation of homeostatic process 5.986E-03 11 90 
1264 cellular response to metal ion 5.986E-03 11 90 
1265 response to vitamin 5.998E-03 25 285 
1266 regulation of kidney size 6.099E-03 3 8 
1267 regulation of inclusion body assembly 6.099E-03 3 8 
1268 Rab protein signal transduction 6.099E-03 3 8 
1269 positive regulation of Rho protein signal transduction 6.099E-03 3 8 
1270 negative regulation of calcium ion transport into cytosol 6.099E-03 3 8 
1271 negative regulation of hormone metabolic process 6.099E-03 3 8 
1272 positive regulation of T-helper 1 cell differentiation 6.099E-03 3 8 
1273 negative regulation of fatty acid transport 6.099E-03 3 8 
1274 positive regulation of long-term neuronal synaptic plasticity 6.099E-03 3 8 
1275 negative regulation of hormone biosynthetic process 6.099E-03 3 8 
1276 negative regulation of cAMP-mediated signaling 6.099E-03 3 8 
1277 gap junction assembly 6.099E-03 3 8 
1278 menstrual cycle phase 6.099E-03 3 8 
1279 manganese ion transmembrane transport 6.099E-03 3 8 
1280 histamine production involved in inflammatory response 6.099E-03 3 8 
1281 response to iron(II) ion 6.099E-03 3 8 
1282 positive regulation of norepinephrine secretion 6.099E-03 3 8 
1283 histamine secretion by mast cell 6.099E-03 3 8 
1284 regulation of Rap protein signal transduction 6.099E-03 3 8 
1285 neuronal action potential propagation 6.099E-03 3 8 
1286 histamine secretion involved in inflammatory response 6.099E-03 3 8 
1287 negative regulation of cellular component movement 6.129E-03 14 129 
1288 cell growth 6.129E-03 14 129 
1289 brown fat cell differentiation 6.439E-03 7 44 
1290 sphingolipid biosynthetic process 6.439E-03 7 44 
1291 synaptic vesicle endocytosis 6.444E-03 5 24 
1292 negative regulation of osteoclast differentiation 6.444E-03 5 24 
1293 regulation of respiratory gaseous exchange 6.444E-03 5 24 
1294 regulation of myeloid cell apoptosis 6.444E-03 5 24 
1295 negative regulation of steroid metabolic process 6.444E-03 5 24 
1296 spinal cord motor neuron differentiation 6.444E-03 5 24 
1297 thymic T cell selection 6.444E-03 5 24 
1298 regulation of stress-activated MAPK cascade 6.444E-03 5 24 
1299 regulation of immune system process 6.493E-03 72 1051 
1300 regulation of lipid biosynthetic process 6.556E-03 14 130 
1301 skeletal muscle tissue development 6.562E-03 17 171 
1302 positive regulation of protein metabolic process 6.578E-03 48 650 
1303 blood vessel development 6.681E-03 38 489 
1304 activation of immune response 6.714E-03 28 333 
1305 response to iron ion 6.827E-03 6 34 
1306 neural retina development 6.827E-03 6 34 
1307 macrophage activation 6.827E-03 6 34 
1308 circadian sleep/wake cycle process 6.827E-03 6 34 
1309 glycosphingolipid metabolic process 6.827E-03 6 34 
1310 response to cortisol stimulus 6.827E-03 6 34 
1311 positive regulation of smooth muscle contraction 6.827E-03 6 34 
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1312 response to oxidative stress 6.897E-03 29 349 
1313 organic anion transport 7.056E-03 11 92 
1314 peptidyl-tyrosine dephosphorylation 7.183E-03 12 105 
1315 water transport 7.297E-03 7 45 
1316 regulation of receptor-mediated endocytosis 7.297E-03 7 45 
1317 regulation of intracellular transport 7.302E-03 18 187 
1318 circulatory system development 7.325E-03 57 803 
1319 cardiovascular system development 7.325E-03 57 803 
1320 regulation of angiogenesis 7.349E-03 17 173 
1321 positive regulation of transmembrane transport 7.411E-03 9 68 
1322 regulation of glial cell differentiation 7.411E-03 9 68 
1323 cytokine secretion 7.470E-03 4 16 
1324 glial cell migration 7.470E-03 4 16 
1325 regulation of endothelial cell differentiation 7.470E-03 4 16 
1326 positive regulation of stress-activated MAPK cascade 7.470E-03 4 16 
1327 macrophage chemotaxis 7.470E-03 4 16 
1328 negative regulation of meiotic cell cycle 7.526E-03 2 3 
1329 detection of hypoxia 7.526E-03 2 3 
1330 germ-line stem cell division 7.526E-03 2 3 
1331 male germ-line stem cell division 7.526E-03 2 3 
1332 ossification involved in bone remodeling 7.526E-03 2 3 
1333 T-helper 17 cell chemotaxis 7.526E-03 2 3 
1334 negative regulation of eosinophil degranulation 7.526E-03 2 3 
1335 nipple morphogenesis 7.526E-03 2 3 
1336 negative regulation of release of sequestered calcium ion into cytosol 7.526E-03 2 3 
1337 detection of fungus 7.526E-03 2 3 
1338 regulation of eosinophil degranulation 7.526E-03 2 3 
1339 nipple development 7.526E-03 2 3 
1340 T cell chemotaxis 7.526E-03 2 3 
1341 helper T cell chemotaxis 7.526E-03 2 3 
1342 negative regulation of acetylcholine secretion 7.526E-03 2 3 
1343 D-aspartate transport 7.526E-03 2 3 
1344 regulation of catagen 7.526E-03 2 3 
1345 monocyte extravasation 7.526E-03 2 3 
1346 protein localization to juxtaparanode region of axon 7.526E-03 2 3 
1347 activation of phospholipase A2 activity by calcium-mediated signaling 7.526E-03 2 3 
1348 positive regulation of T cell extravasation 7.526E-03 2 3 
1349 negative regulation of icosanoid secretion 7.526E-03 2 3 
1350 regulation of atrial cardiomyocyte membrane depolarization 7.526E-03 2 3 
1351 activation of adenylate cyclase activity by serotonin receptor signaling 
pathway 
7.526E-03 2 3 
1352 positive regulation of catagen 7.526E-03 2 3 
1353 regulation of T cell extravasation 7.526E-03 2 3 
1354 glutamine biosynthetic process 7.526E-03 2 3 
1355 ammonia assimilation cycle 7.526E-03 2 3 
1356 thymine catabolic process 7.526E-03 2 3 
1357 posterior midgut development 7.526E-03 2 3 
1358 positive regulation of mismatch repair 7.526E-03 2 3 
1359 cellular response to magnesium starvation 7.526E-03 2 3 
1360 negative regulation of gastric acid secretion 7.526E-03 2 3 
1361 positive regulation of NAD(P)H oxidase activity 7.526E-03 2 3 
1362 thymine metabolic process 7.526E-03 2 3 
1363 D-aspartate import 7.526E-03 2 3 
1364 AMP catabolic process 7.526E-03 2 3 
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1365 positive regulation of cell growth 7.665E-03 13 119 
1366 production of molecular mediator involved in inflammatory response 7.724E-03 5 25 
1367 skeletal muscle contraction 7.724E-03 5 25 
1368 positive regulation of neurogenesis 7.768E-03 16 160 
1369 cerebellum morphogenesis 7.891E-03 6 35 
1370 positive regulation of epidermal growth factor receptor signaling pathway 7.891E-03 6 35 
1371 positive regulation of tumor necrosis factor production 7.891E-03 6 35 
1372 receptor internalization 7.891E-03 6 35 
1373 defense response to virus 7.976E-03 8 57 
1374 regulation of skeletal muscle tissue development 8.147E-03 9 69 
1375 cellular biogenic amine metabolic process 8.161E-03 15 147 
1376 regulation of cytokine production 8.197E-03 33 416 
1377 negative regulation of cell migration 8.207E-03 13 120 
1378 membrane lipid biosynthetic process 8.237E-03 7 46 
1379 regulation of adaptive immune response 8.667E-03 15 148 
1380 regulation of gliogenesis 8.701E-03 10 82 
1381 fibroblast migration 8.804E-03 3 9 
1382 negative regulation of circadian rhythm 8.804E-03 3 9 
1383 urinary bladder smooth muscle contraction 8.804E-03 3 9 
1384 aspartate transport 8.804E-03 3 9 
1385 activation of phospholipase D activity 8.804E-03 3 9 
1386 regulation of uterine smooth muscle contraction 8.804E-03 3 9 
1387 negative regulation of phosphatase activity 8.804E-03 3 9 
1388 positive regulation of uterine smooth muscle contraction 8.804E-03 3 9 
1389 negative regulation of circadian sleep/wake cycle, sleep 8.804E-03 3 9 
1390 regulation of defense response 8.842E-03 39 514 
1391 cytokine production 8.935E-03 11 95 
1392 regulation of glucose transport 8.935E-03 11 95 
1393 actin filament-based movement 8.938E-03 9 70 
1394 cell-cell junction organization 9.060E-03 14 135 
1395 regulation of protein maturation by peptide bond cleavage 9.169E-03 5 26 
1396 positive regulation of branching involved in ureteric bud morphogenesis 9.169E-03 5 26 
1397 cerebellar cortex morphogenesis 9.169E-03 5 26 
1398 copulation 9.169E-03 5 26 
1399 cell differentiation in spinal cord 9.263E-03 7 47 
1400 two-component signal transduction system (phosphorelay) 9.380E-03 4 17 
1401 dentate gyrus development 9.380E-03 4 17 
1402 suckling behavior 9.380E-03 4 17 
1403 catecholamine transport 9.380E-03 4 17 
1404 regulation of respiratory gaseous exchange by neurological system process 9.380E-03 4 17 
1405 glial cell fate commitment 9.380E-03 4 17 
1406 drinking behavior 9.380E-03 4 17 
1407 positive regulation of filopodium assembly 9.380E-03 4 17 
1408 negative regulation of cell motility 9.382E-03 13 122 
1409 regulation of metabolic process 9.545E-03 324 5690 
1410 positive regulation of angiogenesis 9.641E-03 11 96 
1411 response to nicotine 9.793E-03 8 59 
1412 hormone metabolic process 1.022E-02 19 208 
1413 regulation of adaptive immune response based on somatic recombination 
of immune receptors built from immunoglobulin superfamily domains 
1.025E-02 14 137 
1414 nerve development 1.026E-02 10 84 
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1415 positive regulation of NF-kappaB transcription factor activity 1.028E-02 12 110 
1416 circadian sleep/wake cycle 1.037E-02 6 37 
1417 positive regulation of biosynthetic process 1.038E-02 95 1474 
1418 positive regulation of insulin secretion 1.038E-02 7 48 
1419 muscle tissue development 1.040E-02 27 329 
1420 detection of light stimulus 1.069E-02 9 72 
1421 anatomical structure homeostasis 1.072E-02 19 209 
1422 skeletal muscle organ development 1.072E-02 17 180 
1423 negative regulation of cell-cell adhesion 1.079E-02 5 27 
1424 positive regulation of Rac GTPase activity 1.079E-02 5 27 
1425 regulation of protein processing 1.079E-02 5 27 
1426 parturition 1.079E-02 5 27 
1427 response to magnesium ion 1.079E-02 5 27 
1428 digestive tract development 1.089E-02 14 138 
1429 programmed cell death 1.094E-02 67 990 
1430 acylglycerol metabolic process 1.101E-02 12 111 
1431 positive regulation of T cell differentiation 1.111E-02 10 85 
1432 triglyceride metabolic process 1.118E-02 11 98 
1433 ribonucleotide biosynthetic process 1.156E-02 14 139 
1434 acute inflammatory response to antigenic stimulus 1.158E-02 4 18 
1435 regulation of respiratory system process 1.158E-02 4 18 
1436 chemosensory behavior 1.158E-02 4 18 
1437 muscle hypertrophy 1.158E-02 4 18 
1438 neural nucleus development 1.158E-02 4 18 
1439 positive regulation of cell division 1.159E-02 7 49 
1440 muscle filament sliding 1.159E-02 7 49 
1441 positive regulation of fatty acid metabolic process 1.159E-02 7 49 
1442 response to osmotic stress 1.166E-02 9 73 
1443 excretion 1.166E-02 9 73 
1444 regulation of systemic arterial blood pressure by hormone 1.180E-02 6 38 
1445 retina morphogenesis in camera-type eye 1.180E-02 6 38 
1446 positive regulation of cellular protein metabolic process 1.185E-02 42 573 
1447 response to testosterone stimulus 1.190E-02 8 61 
1448 post-Golgi vesicle-mediated transport 1.201E-02 10 86 
1449 atrial cardiac muscle tissue morphogenesis 1.211E-02 3 10 
1450 positive regulation of triglyceride biosynthetic process 1.211E-02 3 10 
1451 parental behavior 1.211E-02 3 10 
1452 calcium ion import 1.211E-02 3 10 
1453 urinary tract smooth muscle contraction 1.211E-02 3 10 
1454 brain renin-angiotensin system 1.211E-02 3 10 
1455 epithelial structure maintenance 1.211E-02 3 10 
1456 protein-cofactor linkage 1.211E-02 3 10 
1457 negative regulation of astrocyte differentiation 1.211E-02 3 10 
1458 maternal behavior 1.211E-02 3 10 
1459 negative regulation of epinephrine secretion 1.211E-02 3 10 
1460 atrial cardiac muscle tissue development 1.211E-02 3 10 
1461 regulation of mitochondrial depolarization 1.211E-02 3 10 
1462 detection of calcium ion 1.211E-02 3 10 
1463 positive regulation of cellular biosynthetic process 1.216E-02 93 1448 
1464 GTP metabolic process 1.221E-02 24 287 
1465 regulation of primary metabolic process 1.229E-02 285 4978 
1466 GTP catabolic process 1.234E-02 23 272 
1467 negative regulation of immune system process 1.235E-02 19 212 
1468 neutral lipid metabolic process 1.259E-02 12 113 
1469 regulation of mast cell activation 1.260E-02 5 28 
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1470 dendrite morphogenesis 1.260E-02 5 28 
1471 bone resorption 1.260E-02 5 28 
1472 regulation of branching involved in ureteric bud morphogenesis 1.260E-02 5 28 
1473 negative regulation of homeostatic process 1.260E-02 5 28 
1474 positive regulation vascular endothelial growth factor production 1.260E-02 5 28 
1475 thyroid hormone metabolic process 1.260E-02 5 28 
1476 response to insulin stimulus 1.280E-02 29 366 
1477 acute inflammatory response 1.290E-02 11 100 
1478 actin-myosin filament sliding 1.290E-02 7 50 
1479 heart contraction 1.290E-02 7 50 
1480 positive regulation of alpha-beta T cell differentiation 1.290E-02 7 50 
1481 anti-apoptosis 1.300E-02 25 304 
1482 striated muscle cell differentiation 1.301E-02 20 228 
1483 cellular response to glucagon stimulus 1.307E-02 8 62 
1484 cytoskeleton organization 1.320E-02 50 710 
1485 hindbrain morphogenesis 1.336E-02 6 39 
1486 purine ribonucleotide biosynthetic process 1.371E-02 13 128 
1487 regulation of cellular amine metabolic process 1.399E-02 10 88 
1488 inositol phosphate metabolic process 1.409E-02 4 19 
1489 synaptonemal complex organization 1.409E-02 4 19 
1490 regulation of appetite 1.409E-02 4 19 
1491 dicarboxylic acid transport 1.409E-02 4 19 
1492 insulin-like growth factor receptor signaling pathway 1.409E-02 4 19 
1493 long-chain fatty-acyl-CoA metabolic process 1.409E-02 4 19 
1494 cerebellar cortex formation 1.409E-02 4 19 
1495 SMAD protein import into nucleus 1.409E-02 4 19 
1496 positive regulation of triglyceride metabolic process 1.409E-02 4 19 
1497 long-chain fatty-acyl-CoA biosynthetic process 1.409E-02 4 19 
1498 cellular response to hormone stimulus 1.449E-02 43 597 
1499 regulation of synapse structural plasticity 1.454E-02 2 4 
1500 positive regulation of chemokine (C-X-C motif) ligand 2 production 1.454E-02 2 4 
1501 smooth muscle cell proliferation 1.454E-02 2 4 
1502 activation of phospholipase D activity by G-protein coupled receptor protein 
signaling pathway 
1.454E-02 2 4 
1503 positive regulation of melanocyte differentiation 1.454E-02 2 4 
1504 positive regulation of catecholamine metabolic process 1.454E-02 2 4 
1505 subthalamus development 1.454E-02 2 4 
1506 regulation of phosphatidylinositol dephosphorylation 1.454E-02 2 4 
1507 regulation of immune complex clearance by monocytes and macrophages 1.454E-02 2 4 
1508 Tie receptor signaling pathway 1.454E-02 2 4 
1509 cellular response to peptidoglycan 1.454E-02 2 4 
1510 regulation of cyclin-dependent protein kinase activity involved in G2/M 1.454E-02 2 4 
1511 vasodilation by angiotensin involved in regulation of systemic arterial blood 
pressure 
1.454E-02 2 4 
1512 endothelial cell activation 1.454E-02 2 4 
1513 paranodal junction assembly 1.454E-02 2 4 
1514 positive regulation of complement activation 1.454E-02 2 4 
1515 positive regulation of dopamine receptor signaling pathway 1.454E-02 2 4 
1516 cell proliferation in hindbrain 1.454E-02 2 4 
1517 protein targeting to Golgi 1.454E-02 2 4 
1518 positive regulation of dopamine metabolic process 1.454E-02 2 4 
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1519 positive regulation of protein activation cascade 1.454E-02 2 4 
1520 regulation of metanephros size 1.454E-02 2 4 
1521 establishment of meiotic spindle localization 1.454E-02 2 4 
1522 regulation of gastric acid secretion 1.454E-02 2 4 
1523 catagen 1.454E-02 2 4 
1524 positive regulation of cyclin-dependent protein kinase activity involved in 
G2/M 
1.454E-02 2 4 
1525 inhibition of adenylate cyclase activity by serotonin receptor signaling 
pathway 
1.454E-02 2 4 
1526 locomotory exploration behavior 1.454E-02 2 4 
1527 cellular response to purine-containing compound 1.454E-02 2 4 
1528 regulation of cortisol secretion 1.454E-02 2 4 
1529 positive regulation of oocyte development 1.454E-02 2 4 
1530 response to blue light 1.454E-02 2 4 
1531 positive regulation of pigment cell differentiation 1.454E-02 2 4 
1532 regulation of chemokine (C-X-C motif) ligand 2 production 1.454E-02 2 4 
1533 establishment of protein localization in Golgi 1.454E-02 2 4 
1534 deoxyribonucleoside diphosphate biosynthetic process 1.454E-02 2 4 
1535 minus-end-directed organelle transport along microtubule 1.454E-02 2 4 
1536 positive regulation of immune complex clearance by monocytes and 
macrophages 
1.454E-02 2 4 
1537 positive regulation of catabolic process 1.457E-02 14 143 
1538 neuroblast proliferation 1.460E-02 5 29 
1539 monoamine transport 1.460E-02 5 29 
1540 regulation of epithelial cell migration 1.460E-02 5 29 
1541 cellular response to peptide hormone stimulus 1.471E-02 30 386 
1542 regulation of lymphocyte activation 1.471E-02 30 386 
1543 response to lipopolysaccharide 1.477E-02 26 323 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
